var title_f33_40_34432="Junctional EB Herlitz 5";
var content_f33_40_34432=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Junctional epidermolysis bullosa (JEB) Herlitz",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 471px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHXAdIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzmduTVXdlqtXA5NUs/NXmn0sS/b9BVodKqQHpVrNBMhetOUGmjrUijNJkMco55qRRSItTKtSIVRTm4FGKbIQBTQ0iOR9tUpZc9KdM/OKhUEnmqHaxGwLU5ISSM1OkfrU6gAUBcZFHtFSE7RSZ54oKlqAvcjZs0zYxqwsYzUgj4oAqiOpFSp9mKULk8UDIkTmplj9qkSOp1SgpFYRc9KlWKrCoPSpAnFAXKuym7asstHl0ElfZRsqzso2UFFfZmmlKtbKawoGU3Q1A4q644qs45oHYpuKjK1YdcmmsmBTHykBXNRSR1O3WmkZoIcSjJF7VUmjHpWrIvHSqkqdapMylAyJ4uDxVNoyCeOK2ZYwRVSSKqTOepTTM6ipJU25qOmcko2Fpy00c05aTJJF6U9RTVp46UgDpUUrYqRjxiq0p4NMBofJrSsFLMKyYsl639MXpQ9hG9p8Q2qa1kQcVSsV+UVpIKzGKEp4UU5cYp2Km7AjIGKbtzUjCkUc0xSEVal20oGKWlcBuKKdkUUXA424+8ao/xVoXHOaoEfNTPbiy3AelWwapwDFW1pMTJUFTIKhSp0FSQyRKkHWkUYpwHNAIUnAzVOeTmrFw+1cVmuxZqaKsKPmapUSkjWpselUS3cb04p8aE06NMkZqyEAHFAiFYu9OKACpsHFNxQUiNU5p4WpESnbKAI9lKqCpCMUq9aBgq1Kq80IOKkXr0oKQgXFOxTwuadtxQKw0Jml2Ypy09RQFiMRZo8qraqKQrQIq+XUTx1d21E68GgpMoulVJlrRcdapS9aDQospBpWUkVOUyc0u2gZSMfNIUq75YpjrTJZSdMiq0seK0WTioJE5oTItcy5UqrIlaskfFVZEqkzOUDImjqnImOla8sdVJY8VSOacLlEDFPUUkindTlFNo5HFrceo4pw6ULTjUk3IpDgZqnK3Wrc5wMVnynmqQrktry4zXRaYOlc9a9RXQWHy4qZDR0tmQAtaKc1k2jcCtSE5AFZgTinjpSAcUpOBSuAjdaRetBOaVBk0XESpzTiKVBgUNUgJsoo3UUAchcL1qg6/NWlKM5NU5F5zVnsJ2HRDFWV6Cq8fSpx2pMV7snQc1ZjFV061Zj6VI2SilZgBSVFOfloKSuV7qSq8aktRINz1YhXAFUhyaQ9FxU8cdEaZqygApmQ1VA7U8DJoHWg8GgaENCjvR1NSKKChQKXFKRgUL15oKSDbQq80/OaVRQOyFXjinqKQcU5eaAsO6U7rTSDn2pw6UBYO9OU80w5pwyKALCtTgM1CuamTNBmDDAqvJwDVphkVWkWgcSq/NVmT5quleaiaPnig2RX8qgx4q0sdPaMAUAzOl+QVXZ1NW7uMspxWasDhsnNBpGKaJSMio3XjNWAjYwRxSOny0GTVmZ0y9aqumc1ozR8cVA8ZxTRLVzNlSqcyVqyJVWWPNWmjCcTHkTk1EvBxWhNHiqMqkGqOSpEkXkUpHFRRvxUjHikczKs7daoSHJq7cnrWeeTTRLLlqORW5aN0rGtR0rWtj0qZDRv2j9K1rdulYVq3IrYt26VmM00PFDVEh4qTORUsBjcGpoqhcZqaEdKQiyo+WmN2p65xio3OKBjuPSimAiigRyzciq0gqznioH61Z6pGnHWp1Oag71LHSY0y3D1q0g4qtD1q0nSpLQ4VWnbg1ZzgGqc5yeKEh3sQquWzVyFM1XiHNXYjgVSRDJUUDrS7sVG8oFV3nJ6GmItlwDTWl54qp5hanDpQUkTeZzipFfFVlHNToOKC0TLJmpA1MReKkxxQMUMKmjGagVOasxcCgY5hgZpFp5wRzSIATQUh3anADFIOtSKuaCRFQGn7BinBcU5uKBEY461IrLTCM00LigmxPvWoXYE0mDSFeaCkkNJFREHtUzLgU3bQWtCIA55pxzjmn4pGHFAtyLAOQaY8YxwKkORTWPHNBV2VyoxUTICKnIyfakK9aBNFKRMdKgkXjpV5xVaRaZNijKgqrKgrQkWq8iUGckZM6e1Z88fWtuWM+lUJo/atEznkrmSRtapM5WnTpzUO7AOaNzjqQaZWuyeaor96rd0c5qmM7qpGDNK0rVtxWVaA4Fa8A4FRIpGnbnBFalu/SsaMnPNXoJOnNZjNyNsj3qdc4rOt5enNX0filYBQfmqxD1qv1birMAqRFhsbagPLc1K33agY4bigZIAKKj3migRyStxSPjFRhuKdnIqz1LjD3p0bYpjUIeeaQXNCE1aVsCqEDciriGpNExZHOOtV2Oalk5qLHSmhk0S9KkZgopinatQyvuPWqEDSFmx2pVjojTmrCrQBGq8U4CpAtLtoGOjXI5FTKoHao0qdaBpjlHpT8HApBgClDUDWo4LUqLTFOamQ4oKEZfSlVak60gUg0DuMUNnip0zgZoUgClHWgQ7cfSlHPWlUU7bQTcaSB1oUbqSQUsANAXAoc0FanI4pu2gm5AVyKYVwas7aRl4oKuV9tBUkVLt4ppBoC5XZKidKuEc1C45xQUmU8EUc+tWTH3xTCtBTZXZOKgdB6VbYZFQyIcUEtlKZBiq0gFXZVqq6U0xNXKsqjpiqM0ftWo8RqtLFVXMnEw7mI81nzJjNbtxFwazLiPnpTUjnqQuYlwTyKrx8tVy9iIJI4qtAv7wVZwTVmatmvArVhGBWfZrwK04hwKh7giVc1NGeah7inrUMZpW8o4q/FN05rFibBxVyKTkc0gubELhmrQgIrGtW+YVrQNxUiLEg4qq4NTs1VmbDc0hjgvFFKDxRQI4VZKkD5FUVkqUPV2PSuWSc0mcEVEHzQW6UWAvQNyKvqc4rIgbmtKJqh7msWSyUxaGamjrTRQ56RV5p1FUIepp6tUeKcnWgaROtSIM1HU8S9KB2sOCYFPUU8DilxRcLDTTGpxoAzQUtB0fSrC/dqKMYqZaBtkyDIqTb2qsG2mrMT5WghiMuBQg+elY5oi+9SuUiyF4owKUH5ajamQtQkWlhXioWapovu0rjasTBeKNtC8cU6mSRhetIy8VLTGOKB3I9tIy8VN1FRsMUAiEjC1FjJqRzualHAoLInGBVc/MatMN1IYe9AFcJjmo5KtsmBmoJRQBnyrURib0q6UpGWgZQaOoJY+DWg61BJHTIasY88XWs25jHNb08fWs2eLk00ZSic/dxbgaoLDh63bmHOaoMmGq7nJWp3JrVelX1GMVUtxjFXFOKTOaw+lHWmZzRnFQwsTKcNU8b4NVVqRTzSCxq28vArWgl6Vztu/NaUEtKwjXMmVqP71Vll96mieiw7lgJx1ooEnFFSI8y34p4l4poiOaXy/atDtuSLLT/ADMiogtLjFAXLEMuGrWt3yBWEpwa0rWTpUtFxnY0HOTTlqJDmpaLG6d0PzSrUYqRaZSHU9QPWm4PpTlWgpImQCrKcAVBGKmWgpIl3UoOajp69KAaHKMmpBHgZqNOTxVhelBDGAYNB609qZjrQNA2cZFSQSHpTAe1NU7ZKCi2TUsAzUP3gDVq3XilYluxIOBTGWpSOKjamRFkDLU0fA4qJvvVNH90VJciQHinJTcCnY7iqJFNRmnEnHSm59aBADj3qGWTPFOd+w4qEIWOTQMKNpPNTKgA5FD/AHelA7kOGzUqKcdaRAaeRgUBcgmGBVbqaszMTxUapQURtH7VAy1dbgVAy/NQFyqy1HIPlqwV+aopFpiepQlXrVCdK05gBmqE5HPNFxNGZPD1NZk8YBNa079QKzbgE84NUmYzXQrRHaauxvnFZzhs8VPbyEcMaGcM4W1Lmck09elMXnmpV6VJkFOzxTaRulAFiFttXopPlrLQ4FWI3pWEaiy1PC7Z61lrJ71agloA0g5xRUIkGOtFKw9Dl/s+e1H2bFafkY5oEfPFM6jM+zZpDbegrVMRPWkMVFwMh7epbdCpq8YhSLGBSuOO4+IcDNS9KavFO70zshqhR1qRQKRVp4FBaQ9OelSqtMjGKmUYoKsPVcdalXFNxQDQWoj+BTgQR0qMdeelBOOlAOJKvFSK3vVcMc1IhOaCWrE4PHNNJpM0mc0CSG85oY9PWndqgkbBoDqaFu24AVfh4FZVoc4rVhPAoIkSmonFS1G/BoJiVmHzVNGOBUT8mpkNSWyTBpy9KOoFITiqJFJAqGRx2pWaoGbmpuFh+N1SIuBzSRnpTywp3BjTmkHPWnmm96YDlAFK4GKO1RyfWgCFxluKUDinKtJIcCgdyOQVE44qUEHrUErgDrQNEDtg81XmfAPNNnly3ymoDk96BkMrktVeRSx6VcKjPNNeMYpkszHhHU1XlgB7VqsgNRPFx0oIkYMtuOeKqOhU8CtyWMc1QnjHNUtjCSuRQSZ4Jq2CKyySjZFXreTeAe9KxyTjZk1IeopCcUmelIyJVGTUmCOlRxnmpsigBMmp4XIqrzUkbUgLwkOKKg3GigVjSkjA6VXYc1oXC8mqL9am51XI6KDQTihsLjGFMqRjkVGemaEaUtXqKvWpUGahX71Woh0qjsjohyjFPC804LTXdV6nFBcVd2JFFSAE1XgcE9auL0pNmvLYRc96kC02hTzzSuWxxHFIVNOHPTmlxzg00IjxipE5oI9qaeDxTE7sl61JGuaiQ5qVTg0Gb0HMAKpzjHNWXbNVJzxQSieybJrWhHFYVk+HrZgfigUkWwabJzTd1KWBFBC0ImU1LDg9ajJzSocHFSVctcYNQSHqB1p5PFVpXwaomOoxn5pyDjmo1G41aQADmlYpuwgGKAaSQgd6h83B4NFiSyWFJkZqAS56mlDjPWmBZyMVG55pvmAd6jkl9DQBJmoJmNMMwA5NVJrjJODxQUkTvKFXFUZZSelMZ2Y0g96Cthmz5smpNtM3Uu+gTBxVeRjUrt1qs55pkj1OBzSOQetM3cYoPPeiwmV5VHNUZUyTWjICarunXinqZMypoBjpzVdN0b89K13QFTWfcpiqRjUimiQHctKBUED54qc8dKVjjasSxjFSVChOBmn5qQAnNCGm5qRcUCJMmiiigDorjqaz261euTyaoFuTWZuMPWkagtzSFqQxDTT0xSkikHLCmjaiiaCPIBq7GlRQY2irAqzqSYOPlrOulLvxWixyKYqDcMikzen7ruQWkJHWtFV4xSqo7DFSKp9KSNZS5ncZt5oIHIqUjjpUZBz0oYLUYp2nrxU42sM96rsD6UilgcdqLjsTk1EQc1IBuxjrTnTAouS9BinFSjpUQHNPJGOtNESGyHiqdw4ANTTOAKzLmTrzTIiixZvmWtmF8VzdhJ+961uRN70CkaAfIpwbJ61UV8UolG6gVi8vHfNO71VNxHEm6Vwi+rVTn120jbCbpPpUEtN7Gu5wvWqMr/NWXNr+77tu2PrVePXIS+ZUdB607lKm7HQwkAc1I8ir3rPgvYJowYZFb8aZPcZ74ouTbXUmmuOarNPz1qjLPyeaqyXPvTTHY2BcgdTT1uVJ64rnmvQvemi/HXcaYcp0hul6ZqN7gY4Nc8L0seDU0U7OcDk0r2Gos1GnJyAahaRV5dgPxqII7jngVG9uO+PxpXNVTbJvt1sv/LQflThcwt92Raz5LbBP9Krtb/7NFynRNZ5lJ+U1E0+OKyGjkj+45pjTTp97ketNMzdJo1mnI+lRNLuPWs4XYPDEiniQHoQatGb0L4b3pQ3vVISY4zUM12qDrzVIyeppNKAOtVXuAc4rNFw8pPpUqDPWi5JJJOe1U5mLA5q2UFRSoMcUGclcoISsnXitBPmHFVJVxzT7abnb3pHNUjYuLTqRRxnvT8VJkR05GpD70AYoES5opnHrRQM37lzziqLtg1PcSdeaz5JPmPNZGlyUvTS9VjL70xpuaYalsNlhVqNOhqnajewNasScc00dtGNkKimp16DNKi4oYiqOpK41zinpzio3FPi7UG0VYl5HSp0b1qNacR6UnoUiXOaUKDUUeR1qUe1IojkAFRnFSyqahI9aQAG2nOamRt45qttJOD0qVBsHFNEyHPxULvwakkfIqnI4Gaoztcjnfisy5fGatzuCD61mXLdaBbEthJ+9roIGyK5fTz++610kJAUUESLDSYyarTXZHywglvXtTZnJO1evUmqt1Osa4yB64qZSsXCFxsgLuGnkJbvnpUbSwr8qKp+vJrIvbqaZ/Ktnwp6vUsabVRAxJAHz1hKr2OlU7I0Xm3DA2r9BVaUkd1NAuhCpTG71LU+KSCRcMWyacZ3NIw8imu6Jt0TbT7VoQ6i0ibZPvjvVaeHbkYIbPHuKqlSDnnitTOpSUtS7NPyeapS3BpsjFgezCs+SQ85po5JRcWTyTnPWojcEd6qtJk9aauWPPSrE2acEpkcBep6V0tjB5UYL9TWBoUPmXG4jIWunkban1qGbUo3V2DttcImSxqWeBYoDJK5z3FX9N0yQoLiVSCe2OlZeul0j+8QM9Kzk7FKSnPlRX8yM/wCrbJPak8otnkVkqx35NbFk+ApbBpKVzqnT5SMwZB4qB4TjpW0sInHycVFJbFTyK2RzOS2MCW1DA5FVJLdozlSRXRtDnORVW4gyOnNO5lKKZz8ksoGMZqmWd2+YYrdlteuRVSW0Hpj6U0zGcOxTjbAAqzG/vVaSF0PAqMTFTjFUtTCSaNUMKHwRWct2c/MKnS6QimZiyrxVJvkkBrRDo/1qOaIMpx1oJkkyW1lDqKsZrIiY28uD0NaUbh1zmlY5ZKw5+abSkg0mRRYgdRRxRRYCxPccnmqck2T1qtNNk5zUAclqySLctC00tCAu1RwxM5rSt7cgjimxwTky9YRYArVjXA561Wto9qiri9KR6kFZWAnioWzmpiOKZjig6IDDk1LEpplWIe1NGg9QR1pwyKXHFOA4oY0KFyKegxSjpS9BUjGSc1XfrVk9Kj2Z5xQBFg0E8YqTHUUxhjNCJZWlYjpVGZiauz9KzZTgmncRBK2BVGc5UmrUpyaqzfdpkMZp5PnCuliOEyemK5qw/wBePrXRE4gH1pkPcbNIEjJPU96zUgm1G7FraDeXO0t6VdlhM0m0uAmeg64qaC5jsLhRbIc45NYTd3Y3U1HRFqTQo4gbZnAkX5WZehNaFtpMaaRKCESQn88d6rPqIn2MgOfU9q0bW5WSFlkX52GOP51rGER807HA38JE7exxzUVuCrbSflbit/W7ZRO+0dO9ZIh+UjH0qHGx3xd4mosUk0O1yoZBgH1rP8hmbYo5zzV61dvJUnlsYNQy7kdj/epmGzsZs0XzH1X9ay7yBsF069xW+F9qgnhyapGNSFzmkVj1FThcVdntsZKjmqbHnmqucM04nQ+GFHlSk9ScVr3AxKoHOeK5/wAN3AWWWNjjPI963pXUSoUz1zms5ux1U37p10OqJHaiPbyABkn2rA194pIPm5Y+lVb67WKJiCcmueeeWaQszHn37Vm5XHhqDcuYkdAretXbRgByOlUgau2wyVxzSSselNaGpZylXX3rVlt8wCZfmTOD9ayIl+Yc10mlqzW21Rk+ldETzK2mqMaSFQ2RwD2qB4ea27q3UsQoIX1PrVJ4cdKZkp3RjzQdeKpSwnPSt2WPjpVOWP2oBu5hywZzkVny2wzwK6CSLOeKqyQ+1MzZhvbcZxUBiKtW48OAeKpyQ9eKpGMkimi5781MAyjrkUhiKnNSLQQ0VpMnPFSWsuDtNSOpNVpV2ndTOepG5fPPSio4XynvUlI5x1FNyaKBGbgt2q3a2pbkirUFnwK0YYNqjis7lRiVooNq9KuQDmlcYBFPtuSKR001qX4V+WpwtNjXAqULnikej0I2HFMPAq4sYC/NVedQQQKDWJEpVqmhIBxVMKytUwcr2oLtc0VAIp23C1WguBUjSfL3pitYehyaeRVdH5qaNuRSGxyLnrT9mKaW2nNPWQGgTGNFxmq0ikVfPIqtOuDmgDOmHFZs45Nas68Vl3IxmgCkRkmq03erYGQaq3PANUiHuRWH+vH1rflz5C4571z+nnE/NbxfEdN7GXN7xhveEXhZ2bjgCrMbnJkz96pJ7dJefL5/vA1WWOWF9rKSlc2p3U6afvGjZhn4JyfYVfdngOXJHYVDpUyxzrHIuC1XdZVQg+YZPSqUilfm5SrNIsw9TiqxiwenWlt+TVtUzWho3yjbeH5TjvRcRhm+grRsoGLk7cqBkinPbCTJUcZ4osc/tPeMFoSD04pGjPpWzJalR6n1qrJGRxQU5GNcW+RkVi3tsVyyiuqlhwPrWdcw/LnGaadjOUFJWOahma3lEq53LXVWdyl5BlSN2Ocda5i/t2iJdRxmoLO9ktJg0Zwp61TjdGEJeydmdZdRM33c49+tVTCR1H51Pp+oRXSh1wT3BPIrQUK4wyg5rHksd9OoktDKWNvStCzyi9MVZSzU/dJq1FYlVX7v50WsOVW6Etl3MtdFp7eXCdxI+lZdrAqn1PtWlGcAcgfWtUcNWV0SSkOSDx/Kq8iAnA7dafu5OeR7UwtnP9KZktitPGB0NUZlxmtJuc561UmGc0DM51GPrUDx5OKuOtMC4yfQUyWZ8kftVSWLnitHG5h9agZcsBQRIzHi4qAqVIrTkiPNVZY+lUYyIKrT/wAQ7VbZcVUn70zKQlm3GKt1n2rbZqvUM5JbkmBRTM0UhHQpb7QKGXBq7IBtqjM2M4rA3K8h61JZnJqtM/FTWEnzUzWlubUQyKmQVFEQMZqUPgnFI9BK49zgVXfkU52zUTMcUGyVhu35qkMe5aSPk1N0FX0C9io0bLTvNZV2tU7fNUEiDFQaJ3GCX5qsxy5FUJFKnimrKyH2poDTkk6ULLVIzblqJJsPigDajl4prvuFVVlyBigyYFUiWEpyDWZcjOauSNwTVN/mbpTE9iAr8tZt5wDW26YT8Kxr/hTQYsraecS5rUkfIAHWsizOHrVt13uDTIY5CysAehq6oWVcN+fpSyQq8JU8Ecg1Xgk8t9j9R0qOU6qVS6sJdJIpzt5H3XWkJlm2lnZq0UbeuD0pyW8ZbI+XFTynRGp/MV7WJs1p29sS+Sce9LbxgdOta9rGrAAD5qqJhUqCWluZHEMZCiQgHNW5rLyFKqytjjI9qt2YECuh/wBaepHYUy6lDFVG44GAT61Ry82piTxAtkcL3FUposE569q150Ctkn5j1AqnOqgcUmbRkY86fKc1RdM5FbEy5BrMePaxI5qTaLMu5tQ4Oa5jUrQwNkfdruCgas++sxKjKRVKViJw51Y4aK4e2lDxtj29a6jR9dSYiOY7JP51japprwEsi5Xv7VjklW6lSOQa0tzI5FOdHQ9XtJ9wUhq0o5eP4a8x0bX2gZY7gkp/erttP1GOdFaNwwqOWx0qaqK6OiV17VIrfWs6CWrAloM5KxbDHPJ4pA2DUIkGOaYz+vNBJKzAtzVeYgninlyeBUON5Kj8T6UAQtyDjoKjlOIwPWpJWXoOUH6mqc8h6DqeKZDCJfmdj0Wogu1snsDVlPkiwagcZH1qkTIruMjNVJl4q9jAIqpcdDQYyKj/AHapTDirTVXmpxMpFO3/AOPitKs+Nf8ASFrSC80SOafxCUU/bRSIOheTIqhcFiTjNaggz1FRzwDBFYnSjAkY7uTU+nv8/wCNNu49rHHSorN8S0Fx3OrhwVFS4qrbPmMVaQ5FI9GOyArTNmakNIHCtz0po2WwKm0CnEDFDSg9BUMjt2FMnqPC0/yvlqmZmWkF0wXmgrXoTyQiqVxHjOKm+2ZHPWopZ1YEcUWuLVGe0hjJGaj8/wCbOaS6IyeaoSuRRY0vc3YJsr1qyHyOa5y2uyGCk1qrPlRzTRLLUjYFJbLl8moVYuQK07aEYBpoznIgnUBDXNaocZrpb2SNQRvXI965jUd8jEIpYZ6im2ZxTK+nqXkrobWPaozVDS7UKmT1rUyFXigl6D2YDvVK7APzL96llkK1SknPrSHHQ0bSXco56da0IHGa5qG4WOUHPynrW3aybsc+9QdUZc0TWicbuBzWhBLtPH6Vkxt6HkVcgbOM9qCZRNVJ2wQCCT1oZy46gfrVRWIHFTocjJUY75pmNhHfaACD/vetQyKp54yfWpyO+SB7VA4XqM++abBGbcAgkcYqmwFX7lck4NVjGMetI2T0KrJ3HNRFAeoOav7BUZQdaAcjKu7QOpBAIIrkdY0koWeEfhXfugK1n3dsGU5A6U02tiJJSVmeWSK6EhlINWdP1O4sXDRMwH908iul1HTFbLKvP0rHezAOCBmtVJPQ5ZQlB+6dZoniOC7VUdvLl9Ca6OGcFc7q8oNttbco2sOhBrV03W7mzOyfLx1Lp9S41HtI9JSXnFL5hzxisOw1WO6jDRsOavLLuHWoRpo9i8WwMg80wvtUqD97qRVbf/tU3zNuSTxTIY524zkcdqrx5ebJ6CggynIPy+tS7doAWmS9hzHceajkOeB2pT8inByTULHAHc1SIBjzVC4YAVYmfaMDrVKV8mmZPchz3qvP96rD1BIep71RjIrJ/wAfK1pLWdZrvuMnpWkF5qZHNPcWil20UhHXFOKhm6EVcIqGWMnPpWB0HPXa8ms9fkkB961r9MZ4rHc/MPrT6FpnSWTZjFXkbisnTnJQCtROlI9GEroVmOajJJPtT3qOmbp6EuQelI1IvFPwMU0Q9CGRAahdRVtlqvIKbC5Qm/KqcpPZquXFUZjgGhF3Kk0jDqapvNlsZq1Lhs1RnQc4pibGiXa4Oa1bafdjmudldwcAE/StjSoHaMM4I+tD2End2NuO4EZHGWqSSe4mX5nIT0HFV0VI8fxP6VPHHNczCMDHck9BWfMaKMU9SPyVPJ25+tNdBjINOuAsMxjeYe3FVpS8TYdgVPQjpS5kbxghcspyrEVIbo4+fkjoahfOM9jUTMOhNFxzoRnoOu5j8rE8kVmS3Bq9Ooktyp+8DlaxbrdEcOCK0ucU6bgSPOR3rW0a/wB4CNwwrm92SOetWIXMbKyHkU+UzjNxPQLeTJBHPHNXYXyxI4rmNIvxKgPRhwRW5HKCAQeak6b3RsQuT7j61L5hyOckVmxzYHFSCfPBGaEZuBoGTLHjj+VRyOSOcYqqr56g04uBjNMhoZIueScDtUYACk9amJJyR17CkjTBJbrTHeyGKhK4Aphi52jk1YyFyakCAKSepoFzGcyDFV5YwQa0pI+KrOgzQF7mRcQBlxgVjXtgCMhea6aaMZqrLECMGkF0cTLbtG/OcfSoZIwwIxzXV3NoGzmsi5s9hJArRSM5RXQxoTNaSeZASD/drpNM1qOdVVyEkHGD3rHkhIP3aqTW+WyowRRuZczid+swKdRTkCkAk59q4K01a4sm2S/OnvXSWOrQ3Sgqwz6UOLD2qe5vF8LgVGXOMHiqyzgnihpc1IpTJy+ahlfjFRlzgioHYiqRnzBI1VpCc09n9aiZt3FMiUhpbOar3B4461ZZgq4HWm21uZX3sDgVRhKQljF5aZI5q6o5qdYR2HFOMGOlQ3cxIMUVJtoqrEnXMvFRM3arLDIqu6ZNclzqMvUI8oTXPToVY11N0mVIrEu4gMmqAk0psgVtIcCsXSxhselbQ6Cmd9J3iO600jmnDpSHrQdMWAHFHIpR2p5X5aaCTIHYiq0smKnlOKo3BwM5qhIr3EhJqhOTg0+4mAPWqUtwCDzQMZIxzTGkBHzrn6VG0gJqF5PSmhMt2tk90+/bsiBzkjBNbyBIUG8ZwMAVQ0ot5JZ2LfWuh0+KNrYzNFllG75hUTehd0lqSWcNrFAJJz+9cZUHt71qrBbW1ugiBbPJJ/izWFp8Sy3Pn3WcNngdB7VPdagFlPO0JwF9KyjrqKzbMXX0RL5mPTOQPSs6S43suMhR0q5q0nmtuPJPNZkasHyPyokkejTSUVc24JGkhQ3KqY8YBJwarXcABLRNvXsabw0Khnbg8DHFSxrvjlCdB2zUQlrZias7spKT0NRzxrImHGRRMrxn2pFcdDW4pQUivf2EflxyWMZ2quH7nNZ3QVuxyNC+9D8w/Ws2+UvM8m0AtyQOlXFnm1aNtitDO8EodDz6V0+mags6Ag8965Jic+9S2dybefcPunrVON9iYVOXRnoMMgIxmrcZ6VgafdCRAynIPetiF8jntWZ03ujQUkYyKV8AZ6H0qFG3Y2k1YWNcZckmixiyNCT0GPenBgAQDnnk0ONxAQc9qWKMRsGk5PYVQmyWCL5C8nC9s/xU5ie9KZN6A5GB2qInJ4yBQQEi5HFQslWOT2ppGAQRzQFyjMmRVWRR6VouvGKqSLQK5RlQGqU0W7PArTdahKDNMGzDmtA2fWs25tWjauoaMZPFVLm3VgaFczk0zkriDeDxis5Y5LeUMhIINdJdQbSRWc8ILVqmclaPVFix1WRQFkHPrWtHfK/TqaxktuB0/KrEcO3FDSMVVa0Zqm4BHWonn44NV1i96f5YFSP2wbyeaekbyHCCnwouRmtS22LjAovYl1Lla209iQ0tXfLCjAHFWS4IxRGobvU3IbZFEO5xSzGrZhwmcVQuG2n1oimTchJGaKj3+1FbWEdqw4ppWp2XFJtrgOoy7mM8kc1iXwKkgiukuc4OBWDfIWJJqkMrWBw+a2U6DmsW2JVsYrVibimdlD4SfpxSHmk3ZpryBVyao6EyZVJ57VDc3KouM1Smu5GyE4FUm3NncaEUk3uWp77jjms65nZxxUvl+1RMn0p3K5TNmDNVaSNutaksdVpI+2KaYWMqRXB4qAswOCK1HQDtULRjOSKaZEkdFpVv5ogjzjIBNdPfSxx2zQwuBhcHuaw9IX9wsg+8RxTdVuBGrttIOOvvWEt7Ev3pJIpfb9pKq33eMVTlu975PB9u9ZpfdIWOeT1qZCC1NaaHpQppF8OGUlhSxx5G4HimRDeMGrsY+TaMelOxUpW0If7wCgrjkY6URTRo4wcDtg8U+a8htLW4HmlZ2+VUAzkVyrX8kTPG7fKedpqPZu90c1Suk+U6q8iYsSFJUcms6WMg5XlasafqIltlS4xkD5Tnr9aimJR8KMZ9ORWidty4zIw+OtJLyM1JJDIF3NHge1Qk4wP51VxtqRWvYYTbmRQVmB5A6EVlt1rZkG7LDB9RWbd27Al16VcWcVanZ+6WdG1AwSiKQ/LniuztpQw9jXmjud2cnNdF4e1bOIZj8w6fSiUbamdOrrZnf2zAIMED2q5GV75596xrWUMAcnHtWpGwx1FSayJzkfdwtNzg5JzTlwR1pyoN2cAn3oIbIkHcjipBg5LdOwoPByeTQM9SQfrQS2C46mkfr04pwUsOOnrQ3yjHWgm5C4FVJRxmrEpqvI3GKYXKz1E1TOPSomHNAm0REVDMOKnYYqGbpmqRmzHvUBB4rJkXB/Gtu55zWXOMZpmVTYlhAKDipAoFQ27EpU+eKDie4gp1IBS4p2IYqHmrsBNU061ajOBUsEXVckVZtic1RhwWrUt1GAakdyd3xHWPcklulaVweMVT2bnrSKEVBG2KK1Bb8UVqB1jiojUrg1ExGPevOOorzKCDWHegAkGt2Q8GsTUB81NAZyL84q8hwKqEbWFTxtkc1R1YdlgkgZFVpst1qcHIqNwKo60VStLtHepG4zTPvZBpGqGY9qjZPapzxTWbigpIqOgOarSJV58Yqu4z0pp2GomfKtV3GOa0JUJqsyc9Kdx8hp6JeCKWNZHVYyMEntU2rRGYhFkSRHOQc9KwB8hx2qwhLrtDEg9iazn3EqaT5iKW1WN2R1YOp7cirVpYF8EFSByc8GopN8YMiksB/ATyKijv5IyCyMpz6VMX3NnPQ044fmwox9TTb50hVRuB5+YjtVaTUC2GzjuMGs2S68+XEmVQnk+tXe5hOpZXG3bwmZpDJsXHDdaxSFmnGwkg9Se1XHV5Jm8tA0Y/vHGKntYFaNhNhI2PLjk59APStY2S1OFvmlcYLhIJBhkcAY61Ya7luZFNqpTA5yeDUa2kXnKoK59QOFHvTL+6hQrFGDJEp5IGKTjcuVblHyTXEbhZHcc7uTSpctLIM44qo0xKfNlgT8rZ6H0p0GPNw4A9alqxpCsmaSyruxjNOcBuR+VQyIglVY23AjNPQ4XaT8wpam0ZKRl31jJ80kGXA5IA5rJWZ4ZlYbldTyDXZx5Uh4+COuO9ZPiGxM832tABvwGAFbxd9zlr02tYm54c1hbiEZb5hxiurtpgwzxXkNnI9nOHTPHUV3mkaiJY1IPXtUyjYKcuZWOwjl9KnEmf/rVkwXAKjNW0kBqSmXMk/SlDLnmq6sW4zgetPUjHrQQyxv4AHT0qOVuOKYSOMUxmANMkZK3c1WlIC5J4qWU7qqyYBwDmgVw4pDikPynnmmucA1SQmROeSKglPFPkJHTvVdjuPtTJZVnHJzWXc961bnjmse5OWIppGU2OtQStWajtF+WpmAzSOOW4gpaTvS45qkQ2PjHNTc4xUaDBqYCpYE1qMkVrwZC1mWqncK1lGE96m2oLQhnOTikgGWpsgLNVyzh5FbpWAlCcdKKvCDgUUwL5cNVWVsHihXpkjDFecdFxC2Uyaxb9ssc1rl8pWNqIxzVIZSZl696fHIBxmqTn5iKdE4U1SNqErOzNRGzSscioIXBFP3UHoxEfHemDApJGFQtLig6FG4+R6hZxionl5qIyCg0SLDMDxTcVDu706OQlqVykkOKZqvLEfSr8fI+7SyRgg8c4pi0MOWM5pikgcVoXMDqM44qGzjRmk8wHGw8+hoJk0iONgR2BA71Vv5JFIOdykc4qVvkbFKAHOW+6Ov0oaFKKauUnu8xiLYuexPU1TmeRQMgKpb7zVrTwwpJjbuVSCGx2qldbHlOwHAPAFCdjklC5AtuSol3YBbp9KtX0oKxogUDGR6insPlDtkgDoRUESiYNK2Aqnr3rRanNJpETSOihYycnsOmKWGz3QlpOB0NXYNqozbQSxyfmwAKgkmklZhGu2EdRurVKxzyncqx2awXI3HdCTg89KTUlSO58y3YsD1FXET5cSBgrg54rGnjAchWIC4460mrkRdjQ+YRqXGAehHerk7gQQygEdmqhG+6NVL7h/KtGO1MqtGG/dkZBPrWDR305liA7414xmrJgT7GsvmA7ztMeOlRQBJLaPGQyrgnsTmpYOUnQ/wAI3ChNnVuc9qVhtJeIfKe1VtOu3tJwWyF6YrqCgkTBHFYuo6cGyUGGrVPSxzSppO6Oo068EiqQ2QRWxDMDivOdLvJLKQRyZ2V2NhdrKqsrcGk0FzfjfJwTVjdgdc1mJJyO9TrJzxUiZdL5UcVC7g/WmbiR2qNiMnHWmQPdzkBjxUbdcj8qTdk46e5o/i/rVJCuMKktgHk9/So2Pb071OWGNidKhk+UcdT+lMTZBIN5A7VC/B47U9mzkCopmVFwDmgiTKV4+Aax5CWkHvV+6fcTk1UijLvnHFUtjnm9C7AuEGKVhg0+IY4occ1N9TnewxRmjPPpR0FOAzVED0GTVhBzUca81ZQDipYy3aIOuOauudqcVVtThabcXG0/eFCV2D0Joxuatiyj5XisvT8SHrXQ2sOAOK3sJO5MFGKKm8uigZieb2zTtwI5ql5maPMxXn2NyyzAdDWVqTHBq20mQaztRfg/SmkO5mM+PeoTLtYVXmlwxFRB+aq1gU7O5t282RU5l4rHimwQKsNP8tI9ajJSSJppuagklyMVWll+aoZZcjC9aDuRYkmVepqs12F6c1nzzMeKjtN0suAGapeozetrlQpLr9M1MkoyTiqsdszEbunarDQ5/AYpcpnZ3L1s/wAoLHHpV5YvOj3DAx6msNkIwNzCgPOv3XJUc4q07FOLsbUtoWRS5XYOuKxdSuydyRKsKfd4Xk0s2qSs2JRhQMCqN86vhlNPcyUbbkMbb1KluV5BPegPleM574qmzZzUttMN23uKLFRlbQ2I44Z7IxDKuw4J9awNkkNxscZZT6cGr4klSQbT8p7VDqkm5A/8a9alLU563u7DzeQLHIsnPy8AdjWeku5fLTCo/BY+tZdxMS+R92oFujGwPat4RseVWnY6AyRx4jB4HUmpT5aI8olY8cL0BNZMF0LgjchK55IFPuTDvYJJIwx9xxjFbWOe7EluZZiuZOTxsQ1DIpgDibiQ9BSBJt+YsADqw45qszs87O7bnzipasXF3djUtVJiG3qetXZZZVtGAPJOBjtVW1Hl2pc/e7Uy3kkuXEfbOTisHsd9K8mdLp0D/wBnIx4j2hlz35xRBgSS7j1Q1N5gS2jiUYIGPpiqUxzJ8vSpjqd6XQtWo3YXuafNCCDkD0osIycsf4Rmpl6DNUZSMO7sFkByPxqCzlksZMMS0f1reljzmqU1sD1xTIdjUs7tZUDA8YrQjlHFcnGHtXyh+X0rWs75WwCcH0oJZvKwbvSg47iqCTjtT/PpohlsgHkk4prNnp0qt53+1RuZvu1SJbJWlVPumoizSdOhpMbWO6mvJgHFAmJM4UY6VnzSZ4FOmfJNUpZsHFBlORFMcttHNTxptUAdabDFnnGSavQW5JG5eanmOWTuxkSE9Bk05om3cjitaGyG0EjFJJEqnFJEvYyZIwoqPoQKs3QAziqwGRmtTMniOasxruYVUiGKvWzDIpAWGAiiJJrnNSvQs21TWxqlwIoSBXIsGubvPvWlBe9qRVemh2vhyXzNtd3aL8i1xPhm18tVrvLNdqLXRUSJi2P8uirNFYmx5uJ8HrQbjNZbS0glxXDY2uaZnNULycYOTioJrjCHmsi7u9xIyaqMRXFnlG44NV1l5qq82e9RNNz1q1EVzVjmw1WPOyKwhPirMN3kYJFDideGrcr5WXXl5qtLKRzTZHyKrjdJKqJklj0rOx7CmuhcsrZrxjnhV5Zq3Le2SMbY1xTrK3W3t1QDB7mp1cDoKk1jdj0iU9BmlYBTjFOSRgcpuyfSpFzj5h8xPOe1BdrFckY61ExxznFSSq2WAKH0xVd87OeopNpFppiSqso+YfjWTewOoJXpWg24AMD8p6VGW3ZBNUtNTOcLo515SDg9RTFmKncOorR1CyV0LR8GsC4d4mKscfhWqdzjleB0MM6zoMfeFOJywLfSsGDUkgTCxZJ6tmtS1uUuEDIenUUpRFGpGasQ3liEYyBSyHk1SENm86FdwA6hq6AuksRUr2rCvodpYKD1pxlbc4a2HTJb+5W2QizT5GwM4wDVH7dPwfLXAOOlNRplQptyvUZ7UrwTSODjAAzkDvW/MjhdOSEMzFm52BuSM9akjtX3gn7o5p9vauZPMmG32zmtey2mRJPvMvRD0NZTn2NqVJx1ZdGmtb6WJZ+A3yqB3zVRIViu1EA4RfmfuWqTU7uWWdEZizjnaOgPapbSAohV1bfnJ96zPQw8NbstRFzG8kgJZjjJpVzKUA7DAo5VQD19OwqzbAZBwBQdb0J0+WNY0XGOSfWnhOlOReTUoXA5pnJN2ZXdM5qAp1q444NQMtOxFymyDJzVSaHDbl61oyrxUDLTSsSyvBetCcScD1rSguYpV+VuTWZcRqyHPWsuYSwHdExA9KZm5WOwQrUwk21xEOuyQZ8zkVP/AMJNCPvZoszN1onWSS/3aqyzBeWauTufFXaFD+NZNzrF1dvt3kA1Si+pnKvFaHWXeooW2RnJqSwtpLlgzDPNUPDemvcAO4yTXo2l6akMQ+XtUSdtDPmctTNs9Nbb9ytSG2RMB1rSjiKDIXikJTfhgOayb1JZRu40CfuhismZjuIbqK2L1NuSpyPasWZwQfWriS3oVLjlaqocGpp34wTUC1qZ3H7ulW4WwpqnGMsBVmRhHEc0gTuZGtT84p+gWyyMGPrWfqLmWbg8VueGxt2+tddFqS0M5xaZ2ulW+xVrordeKx9N+6tbtuPlpT1KiSeXRUmfeisy7niRk560x5cDrWZNdlCeapTai3Y1zqNzRyNC6usd6yp7j5uDVWe7Zu9VHmPrVqJDZcaX3qMy+9UmnPrUbTGqSJbLrz4PWkF0VIINZ5ck80hJJ61VhczN62vQ42sea19EjEl2XbovNcXE5RwQa7Dw3cbopG78VlUjZXPUwWI9o1FnSNJ37elCHJXFQRB5BkEKPerduEiB3HNctz2lUSVieMkHcxCjso7Uy6u2djjAwfzqCSb5jzx2qEEuTmna5Kk29Srcu5bILde1EEpAYHuce9TSx7iMcD1qK58uJN3LEenFTNLYudWMUaKWE7wIUbeoBJGOlZ9whRs45FaWj6w1mfJKnypR1bnFQ6gVknc4wc9KcdNGY0qrm7GcpyCDjJrM1CxWVGwBu7VpNlWNPCblHrWkWXVjdHBTxPDIQ4P1qW0uXgfch+o9a6DVrJZs8c+1YbWhVyK3UrnmSpuEro37S5SaPcnUdqvvFDNGuwZlxyprlIhJBJuUkEV0OjXC3E0YPEoOayqR0ujWNRTVnuPWzO795Ew5xwM0skcsIKor7O+RWjfLJb3AaJj+89T0NMaV5EVLiRgo/ujrWOpfs0zLSOIttmYBf1qWBZPNP2OI7f7zjtVpRbRHMaMT71K1wW/1abOPWr5S/Yq9yvFaxQZd5S05OfpUibmYFc5zyxp8cDSNuc1K2B8qDp3qjZWQAAvheQetXYo9oAA5qG2XHJFW4gByTTsZ1Jj4xtGTwc09iNvJ5NBHemk8c07HHLcQjIqJhUoP5Uxx1IpktldxUMi1YeoJOlMSKsgqldp8jH2q+4NUr8hYW+lBnLZnJ3p2uwHSs9ias3j7pWqtW62PNdr3GmtTQ7B7y5GBxVS0gM0oQDOa9R8GaBiMSFeTUylYIxuzW8N6UYIl4yMc11sERxjAptrCYFChe1WI0ZDk8iuNu7ub2sQMdgIIGKqXQVo8oOavTtGynB5rAu7po5Cg6UJCkyB59rFWNZd6wRzjoafduQ+4nmq10/mKK1SMWypIc0DpTnXmgAZFaEj4uuar6pMVhOKuRLxUV3ZmYYGcGnGNx7HLRzF5jnkZrqvD4LMuAQKjsvD+6TODXYaLoohCnFddNRhHQyk5N3NnS4SVWtuNMLVa3hESjFWlaolY0Wg7bRRvHrRUWLPn7XLJkY7FNcvLkMc5Fet6zp24N8vNec6zYtDMxxxmsISuXONzDY+9RlqklUg8ioa1MWNbrSGnNTaYhMUYp1J0oAVRzW/4dlxvTPJPSsAHnNX9JnEN7G3Zjg1FT4WdGGnyVEzurY5ILHgdqmeViMngVSWRUVXVgUPr2pBeI77SwFeen3Pevd3LWdwJ7UgkGdufyqKeJo4g7OAp6cdadEYo1VuCx9a05rIfPYnO9CHZCR3HtVe8MDRvL1TGAAe9JealJKuGlVgnQDg1izs1xG0cTABzknPAogru7OetUuy7BM10VVHdguOT/KtTzhLIBwWPAqr4csWRioYbcfeNPuGSK5BTllPPFKTuzfCrUJVHJHY4NCZxT2y7szjG/wCbFQx8n8a0R2boJI8g1l3Nrlsgc1uMMgVE8QIqkckzBltsrkDmo7GZrG8jmC7th5B9K3Xt/lJ71n3Fv14Gau+hg43Opt4LfV7RbmzmDSIvzRk8r+FVjBJEu2Vcj3FctbzT6fcia3co/cjuK6qHWpNQhQPs3DrxUtWCMpRI/KjxnbTQiDoP0q0qh15p4jWpNedlTaSOOKlig496sBVHQU76U7BzibAAAKenBpAfzoHrTsZPUlYluBUR44PWlV8ZqNz+ZpmbJFPakcikUHbzSH8KZk3qNbBFV39KnwcGomAPSgL2KsgrJ1p/Ltm9SK15eTgVy3ie4+YRqaaV2ZVZWic7I2WOaRVLMMDrQASc11PhvRBeOrlTWzlyo89K7NDwhoLSMsrKT9a9Z0a3W3jROhqn4f04W0CJwBXRKqIy/Jx61xynzM6IqwrCRcELlaZPMpXA4PerNyWCAoeKwb1xEWYtUoGzPvrgwzEisLVLwAZ3DNS61dqyM4Iri5r2SW4K5yBW1OBhORsNe+aeTVjfuUEVyc1w8c4HQVvadIZUFauNtTNSLxyVpYlJapgoKe9Ot4zu/GkUWbaHdjitezsgzDNQWcXHSugsYOBxzVLQq1yexskXHyitiGFUHFQQDGOKtKau7sFgdQF4qu7hasyn5ay7qTGTT3CxY80etFZBuRn71FAuYZqFuHVsgZrgfEOn7ieM16ldw5yMVzepWayMRjtXBGTTOi1zxrU7FowTjisZlIr07XtNXynAXtXnt5b+VMRiuqMrmM42KWKaRUzoQabiqIGAcUYp1FMBuKehKtkYpQKMUDWjujotJuhIgMpz2IqzcQ/Mv2baC3v0rnrSZopOvBrY3blDIeneuWdOzuexh6ntI2b1HCadmCSzH5eBnmnSM2QELMx7saaCrkb0w3cg1LEzRg/JuB4Gazubcj2EhtsM24/NjqelWl0h2t4ySvzHovpTrbT3uWZiWQEVo29sbRAHmLei0nNon2V2TRgafaKqr8/RazY1chi+csefWrbzEuGlJwvSkjv4yxJj46ZxSt1O2lHlIWd2lQkkgDFJH149aeRk7l6GmRKQxGO9Wmb3LgX5aesYIoToBUoGKpHJMheMYIqlNEMdK0scmoJkzTuZmNcQhlwRVGHzLSbcpNbksdVLiIMuCKrcmRoWV2Jk681fVwQDmuVh3W8mRkD0rYtLjeuB19M0rEXNYc9KXFVo5Mkdql8zmnYXMS7cd6QkDrTd9Ge+aBc41sbsrTgM9aAQepoOewoIch5YAU0ANyRSKfWkZ9p4NBDFfkEAYqBjjPepA2c96imKxIXc4FMRSvZ1ggd34OOK4TUJ2ubgt15rW17UDdSmOM/IKi0fTGuJlOMirWmrOSpLmdkSaDobXjqSpxXrPhnRRbIoCcVV8MaUII1yv6V2VrCVChTisKk2xRjZEiWqgrnj2q3NiKNQFznuae8SiIF+o71RuLkjhRlR61kguVLu5eNjlvlrnNWuQys26rOr3G8thq4nXNT2fKrZx71tTptu5lKRU1e5lkGxTVKwtyZSXHWktrj7RMA3Qmuhht40UN+tdVrGO7MDU7ZFcHHetXRlzEBWfq7B5wqnoa1tHXbGKcnoTG1zRVSMCrlrDyDSRRbsVr2FsWIGOKyRvYsWEBznFdHbRDHTFQWdnhQSK0UTaOlaDG7cCnKwFO2nFV5zt70AOmk+WsLUJwqtzUt5d7VPzdK5LXNV2q2DVESkTtfjcee9FcY2qHcee/rRTsYcx71cx5U8Vg3duSW4rqXXdVG4txk8V5p6JwGs2mUYY7VwGsaXkkha9g1W035woxXJ6lp4BOQK1hOwmrnlF1beTxiqZTBrsNc045JUflXNvAQxyOa2UrmTjYpFabtzVl46jK4qkybEQHFO2+9OxS4phYYfSr1jclDsc5Wqe2nY9qUtUXTqOnK6Oig2Ofm6GrTK6KApBUVlW9zGyxoeCBWjETt68VzOFj3KVWM1cv216YyMgfgKU3KvLvUbfc1UAyOODRsGalxOpRRNIS7lmcHJ6CpIiiqQEznuahQY6VKoZjgcU7Gmi1HnAXCnrT4Y27inxwHjirsUfFFjOc10I40P4VKQO1P24OO1KFyc1Ryudxm2o5Fqzio5BQTzFCVKrSJV91zUDrk4ouK5nSRZ61VcvA+UOK12X2qndRjGaoyk0hbO/Eh2sea0kkHBBzXJXQMbZTIPtUllq0kZ2yDIFVynO6qW51fmUvm8c1kR6lE+Md6spOrDK81LTKU0y8JRnpT95PfFU1Yn+E5qdC+OENTcOZEpbAoVe7Gomk2qdwxVK5vyAVUU0S5pItXN9Hbr1GfSuZ1W/muDtXIWlnDyybjmpYoWfAK5rRHPKbexS0uy82QK4ySa9F8OaJEmDt/Cs/RNKUlW2132l2ghjyoycVjUm9hRVieztvLQBBitYW42KznBqGKJpE6bcVNNLsVVc/lWSG2Q3dxs+VufesLVbvYmV/Gr2rS7Y8oM1x2q3jBGyTVxjdmcnYbchryXyYDuY9cVzPiHQprUlmz681p6Jqy2N0zyjqetdTpUcfi7UfJJCRKMsa6k3HYhJSPIIzJCwO04BrWt9TLJtY4rs/HvhWPSnRLQb93TArgxpk0eWcEY/Cq509yZQa2LdtCbmdSOea6e2t/LUDGK5DT79be5CH1rtrRxcRqw6Yoeq0IirGhaKOtdFpsanBrAtxjH0rodMPC0kjU34MBBxTJnwDzTox8nFV7g8HJqhjhLheTVC+uVAJqO6m2oa5rV7/ywcsaqxEpWI9Zv1VWw1ef6xfmSQgE81b1fUTISATg1z75d8k1UYnPKYu40UbaKsyuz6oZSDVeWMtWg6gnio9nNeQeuYt1b8YxXN6ragqeOa7e5jG33rGuoAVJYVS0A88vrRWVgRXC6pbFJ2wOM16xqdtgsQK4jWrQZYgYOa1jITVzinj64FV3jrXuIwp6d6pOvtWyZlaxS8vim7TVwpTRGSeBRewFfZS7asiEjqKEhLHFFxFfH51ds74xELKPl9aY1uQOlQshBwaG0zSFRw2Olt5I5VBUjmrPlDAIxXMWpkiIMZ/Cti1vw2FfhqyaPQp4u5pqg71YiUDtVWOUNjHSrKMM1NrHS6t0XEAxzUowFJFVBJUisW+lNIi7HKNzd6n6DBpFKgU0sM0hXFPXio5OlP3VHIeTQK5ERxUR61OSMVCxFBNyJhVS5FW2PGao3L1RlKRk3qbicVVWDPUc1psm405LYt2quY4p6yKEFsSw4NdFp9piMFhTbOz5BIrZhQKMGplIFoLGiBR8vNOJXBwKa2QeKryybT1qBkN4gZay5IOelaMswYc1W3jPNNCKYgJbpV2xtt0qripII975HWuh0y1UkNt5pylZDSNfRbVFiUbea6K3hboBjAqpYWv7sY4rTjRlJye1YN3Y2OLsI9lVrzCxAk5IqViojPOayL662/JjIppXJbM6/viQVxgVxWt3YBIzk10OqyZ3YNcRrJwGYHmuqlE55tsy7m+LSkAnrXQeGNautKl+02z4YDHPcVxqwtI5cnqa0YrkRwBOc10NaELQ9G0zxDN4i1mKK8K7ncIPavXde+HOj2nhqa5kfMqoWdzwBXzjoSSownjLKyncDW74p8ea3qWnfYLm9c264GwcZ+tZ8t2Xz2WpxdxCP7TdYjkByBjvzXomiQstogPpXLeGtKe5uBI6cZr0a3tdkagDpVNWVhQTbuQxpgjitrT8jGarw23tWjDGEwelJGppI/wAnJqhezbQfSpGcKnWsLWLwIh+aqsRKVijqmpiNSCa4rV9U8xmANJrl8XZgrVzjbnfknmqjG5z1JDpHLtkmlVaAuKetWY3G7aKkooA+qJOBTFGetOLbhTa8dHriNHkc1n3MR5HatIPUUihhzVCOc1CyDqeK4rWtP2uSAa9LnTKkVzmqWu4HIzVJ2BOx5JqdkwfIHFZJtznpXeapZ4YjH51zlxblScAVqpD5bmN5HqKekQXtWgIxjkHNMZB6U3IXKUni9hQkJB4q2FB7Gl20uYOUqvHwartbZ5xWjt9BmgIc4xRzDUTOWBhzTJYjkcc1rBe2KQxgnkZo5hqNipZ3DxYVwTiteC4Vuc1S+z57UgtnQ7lJA9qNzaE2tGbSOMZFSrIe1ZEc7pw4NWorlD1OKTN1NdDRViadnFVknTH3qUzrjrmkHMTlqjZuaga5QdTUMl4v8NAcxZd8VA0g9aqPcu3amwhpW9KDOUyaSUt9wVUfcXw1acVm0Q3dRSraGWUHFUc1SpfYoQ27E52nmtK0tMjJFaMFuI0+YZ+tRSv5bfIMj0oMyVYVRRwKTABqI3DhcyLgetVZLzkgdanlGXJWwKzriTn1qI3rl8N0q1DavcMCOhpWGZ7ZJ4FT29q8jZrcGhHYCTzV2zsVjYKw5pc9hpFbStO28sM+1dLp1tjHGKdbW20ZA4rWhgU4OccVm3comtkCqOcmpiyjOeOKjXYi5BqC6kBhLChGbKd3cLESFzg1jX9xkfKMVPc3O5SMc1jXVwQdtXFXZEjO1KbCNk1yeoBp1OwE11dxALhSAarR6WfLcbfpXZTVkYu/Q4UuyDaRg5qexsnuGBAzzXRroDSTnK8Zrq9H0FIwMpj8Kpuwkm9zL0TSX8jYQQavW/glZ5/MkyRnOK7G000Io2rWxbQ7ABilcvkT3MC00SKyjCxrg/SrKW2W6VszJiqmcNQUlbYiFvtHSoZjsBzV5pQF561jahcBVPNUhN2K1/fiJeoriNc1USFgG/Wp9f1EgEBs1xc8rSyHPTNNRMKkhZ5TK2aRAPSkVccU/FaHPJiUuMUU6ggbRTsUUFn1Eg706qkM/wAoqdZd3FeOj2BTUUhqwOB9aRlBxmqEUWXjNUrm33DNa0igDiqsgwDQBxes2O4k7a5W7tBk5GBXo1/F5hrl9VtAoyOtWhnISW6qDjpVVrfILVsvFk4NMWNRkFabdhmVDb89KFtvm+atVItpy3WhId5YtUuQGYloOaRIBvIrSSLdLj7uKcYlZ8Dr3pXuBnvbDjZ1pptOnHNa7QgPgdakEQUgnrQNGULQjGVqZbXj7taQh38nqKtRxFh0+tF7DMJ7BSR8tI2lKVz0rp/JQR8Lz3p6W6bMletLnsNHJjS2HSm/2e49a7aOxGwsRj0qVNMVx0zxRzBzHAnT235YHFE1iEAIWu2fTgG4Wq0unCQkdCKOYrmOOFvkH5aEhaI7q3201g7CoHsmUbWWnzElVbgGPa1PhnCNwvFJ5DK33ad9nPYVpzEcpbe+ieLb0NVI5o1kyelSx6aW5pJtMbctHMTyksstvLEe59Ky/sDsxkVflrUh0s4HeteK3KwbAtTzAonN2umiRxuWui0+yEW0basW1jkjjBragtQkeTzWcpl8qWxALcFBnipBZoVJXrUpfcpVRxmrEKxog3d+azTuwbshlrGxQKVzVxdsfVaTcBjyqrNPgsD1rRENk8s0RjO371ZEs7KWB6Gid3R9zVl3tySCc1SVyW7Fe8kZJN2Rism5LSNuq1cN5opLeBjWsVYxepXgjZea2LJA6/MtLbWm7FbNlY8CtFfoNKxXt7FWIO2tuytFUDinxW+wCrsSccVSv1GSJGqqKlTbUDkgc1XefBrVAWbhhzisuZ8E0+a4+U1jX16EBJOKCW7Et1dBEJJxXI63q6qWw1Ra5re3cFauIvruS4kb5uM01ExnPQl1C7a4Y896qIM80IM4zzT8Voc0pBnFFGKcFoIG0tFFBQlFGKKBn0LBcZAwKuxT8iiivHPYL6NuSkwc8UUUAKw45qCYcYoopoTKE6DaawtQi3DFFFUJHLXtuEkJ96rkBjyOlFFWUMkYErxTsgr0oopMGIzJwAOaeNjLxwRRRUgPCptD85pYk83LN1HSiigB8bFjkdqmjcucpxg0UUDLRm2pjv3qzDKhjBOaKKzkNF61j81SCTitCPAxGPSiikthPcetuiL8/JqFrQSZPT3oopgVJLNN2P4vWoLrTSdvSiigoqyaWjLuHWo/7OC9hRRVXGWFtFVBwKkNqhXJFFFAiUW6JHwOtSxRARDAFFFSSWYIQFG4DJ4qxJbgJjPXpRRQ9gIljKDAAzSYxkMKKKimtRSehAbnYSBkVVnl2tuyaKK3M2VbycyJmsqQ+YMGiitYkMIYRg1ftoBRRWgGzaWuccCtWCAKKKKqIMtKnAp6fLRRWiAJPm4rLu/lbNFFMlmZd3G1DnNcV4h1ErvwTRRQlqZz2OHuZ3nlbJ4poj4zRRWqOSQ9aU9aKKCBpPNPU/LRRQULTGoooGJRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nail erosions with periungual granulomatous tissue and incipient onycholysis in JEB Herlitz.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_40_34432=[""].join("\n");
var outline_f33_40_34432=null;
var title_f33_40_34433="Patient information: Priapism (The Basics)";
var content_f33_40_34433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/24/386\">",
"         Patient information: Sex problems in men (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/8/4227\">",
"         Patient information: Sickle cell anemia (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Priapism (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/priapism-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29306317\">",
"      <span class=\"h1\">",
"       What is priapism?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Priapism is an erection that lasts 2 to 4 hours or longer and can be very painful. It is not related to having sex or wanting to have sex. Priapism can be a very serious problem. An erection that lasts more than 4 hours can cause long-term damage to the penis. It can lead to a condition called &ldquo;erectile dysfunction&rdquo; (also called &ldquo;impotence&rdquo;), which is when you have problems getting or keeping an erection.",
"     </p>",
"     <p>",
"      There are 2 main types of priapism:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Ischemic",
"        </strong>",
"        &ndash; This type of priapism happens when blood stays trapped in the penis. It can be caused by many things, including certain medicines, blood diseases (such as sickle cell anemia), cocaine use, spider bites, and spinal cord injury.",
"        <strong>",
"        </strong>",
"        <br/>",
"        <br/>",
"        Priapism that happens again and again, also called &ldquo;stuttering&rdquo; priapism, is a type of ischemic priapism. It can happen in men or boys with sickle cell anemia. It begins with brief erections that often start during sleep and continue when the person wakes up. As time goes on, this begins to happen more often and the erection lasts longer.",
"       </li>",
"       <li>",
"        <strong>",
"         Nonischemic",
"        </strong>",
"        &ndash; This type of priapism happens when blood keeps flowing into the penis, keeping it erect, but not always fully hard. It is often due to an injury of some kind and is usually not as painful as ischemic priapism.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29306339\">",
"      <span class=\"h1\">",
"       What are the symptoms of priapism?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms depend on the kind of priapism. The symptoms of ischemic priapism are a very hard erection that is often painful. Nonischemic priapism is less painful and the erection is often not as hard.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29306354\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes! See your doctor or nurse right away if you have any erection that lasts longer than 2 to 4 hours. This can be a serious medical emergency.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29306369\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your doctor or nurse can tell if you have priapism by learning about your symptoms and doing an exam. But he or she might need to do tests to find out which kind of priapism you have. These tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood gas analysis &ndash; In this test, the doctor takes a sample of blood from your penis and checks the blood to see how much oxygen is in it. The blood looks black if it has little or no oxygen in it. This occurs with ischemic priapism. The blood looks red in nonischemic priapism.",
"       </li>",
"       <li>",
"        Doppler ultrasound &ndash; In this test the doctor uses sound waves to look at how the blood is moving in your penis. If the blood is flowing slowly or not at all, it is probably an ischemic priapism. If the blood is flowing normally, it is most likely a nonischemic priapism.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29306384\">",
"      <span class=\"h1\">",
"       How is priapism treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The treatment depends on the type of priapism you have.",
"     </p>",
"     <p>",
"      If you have ischemic priapism and your erection has lasted longer than 4 hours, your doctor will probably use a needle to drain some of the blood from your penis. Then he or she will inject a medicine into your penis that will make the erection go down. The doctor might need to repeat the injection until the erection is fully gone.",
"     </p>",
"     <p>",
"      Your doctor will also treat the pain from your ischemic priapism. If you have severe pain, he or she can prescribe a strong pain medicine.",
"     </p>",
"     <p>",
"      If these treatments do not work, your doctor might recommend surgery. There are different types of surgery available. Your doctor will talk to you about which is best for you.",
"     </p>",
"     <p>",
"      Nonischemic priapism often goes away on its own without treatment, even though it might last hours or days. If you have a nonischemic priapism that does not go away, your doctor might do a procedure called &ldquo;arterial embolization.&rdquo; During this procedure, the doctor inserts a thin tube into an artery in the leg and threads it up to the penis. Then he or she uses tiny pieces of foam or metal coils to close off the point where there is bleeding in the penis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29306399\">",
"      <span class=\"h1\">",
"       Can priapism be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Priapism caused by sickle cell anemia can sometimes be prevented. If you have sickle cell anemia, your doctor will work with you to find the best treatment for your situation.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29306416\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/24/386?source=see_link\">",
"       Patient information: Sex problems in men (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/8/4227?source=see_link\">",
"       Patient information: Sickle cell anemia (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/40/34433?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17232 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-41.78.124.10-AF412BCB0E-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_40_34433=[""].join("\n");
var outline_f33_40_34433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29306317\">",
"      What is priapism?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29306339\">",
"      What are the symptoms of priapism?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29306354\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29306369\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29306384\">",
"      How is priapism treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29306399\">",
"      Can priapism be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29306416\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/24/386?source=related_link\">",
"      Patient information: Sex problems in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/8/4227?source=related_link\">",
"      Patient information: Sickle cell anemia (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_40_34434="Septic cavernous sinus MRI";
var content_f33_40_34434=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Septic cavernous sinus MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These T1-weighted MRI scans with contrast show multiple irregular defects within the enhancing cavernous sinus on the left side (arrowhead). Panel A) Axial view. Panel B) Coronal view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yoshida, T, Kasai, T, Kondo, M, et al. Septic cavernous sinus thrombosis caused by penicillin-resistant Streptococcus. Infections in Medicine 2008; 25(115):20. Copyright &copy;2008, Infections in Medicine, CMPMedica. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_40_34434=[""].join("\n");
var outline_f33_40_34434=null;
var title_f33_40_34435="Trace metals: Drug information";
var content_f33_40_34435=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trace metals: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/32/6659?source=see_link\">",
"    see \"Trace metals: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/41/1686?source=see_link\">",
"    see \"Trace metals: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Multitrace&reg;-4;",
"     </li>",
"     <li>",
"      Multitrace&reg;-4 Concentrate;",
"     </li>",
"     <li>",
"      Multitrace&reg;-4 Neonatal;",
"     </li>",
"     <li>",
"      Multitrace&reg;-4 Pediatric;",
"     </li>",
"     <li>",
"      Multitrace&reg;-5;",
"     </li>",
"     <li>",
"      Multitrace&reg;-5 Concentrate;",
"     </li>",
"     <li>",
"      Trace Elements 4 Pediatric",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F229574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Trace Element, Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F229571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:left;display:inline\">",
"     <b>",
"      Recommended daily parenteral dosage:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chromium: 10-15 mcg; use caution in renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Copper: 0.5-1.5 mg; decrease dose or omit in patients with severe liver dysfunction and/or biliary tract obstruction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Manganese: 150-800 mcg;  decrease dose or omit in patients with severe liver dysfunction and/or biliary tract obstruction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Selenium: 20-40 mcg; decrease dose or omit in patients with renal dysfunction and/or gastrointestinal malfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Zinc: 2.5-4 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Aluminum: Trace element injection contains aluminum. Toxicity from aluminum accumulation may occur in renal dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F229573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/41/1686?source=see_link\">",
"      see \"Trace metals: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption>",
"      Recommended Daily Parenteral Dosage",
"     </caption>",
"     <col align=\"left\" width=\"140\">",
"     </col>",
"     <col align=\"center\" width=\"180\">",
"     </col>",
"     <col align=\"center\" width=\"180\">",
"     </col>",
"     <thead valign=\"bottom\">",
"      <tr>",
"       <th align=\"center\" valign=\"middle\">",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Infants",
"        </p>",
"       </th>",
"       <th align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Children",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;text-align:left;\">",
"         <b>",
"          Notes:",
"         </b>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Chromium: Use caution in renal dysfunction.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\" valign=\"middle\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         Copper: Decrease dose or omit in patients with severe liver dysfunction and/or biliary tract obstruction.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\" valign=\"middle\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         Manganese:  Decrease dose or omit in patients with severe liver dysfunction and/or biliary tract obstruction.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         Selenium: Decrease dose  or omit in patients with renal dysfunction and/or gastrointestinal malfunction.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\" valign=\"middle\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         Aluminum: Trace element injection contains aluminum. Toxicity from aluminum accumulation may occur in renal dysfunction or in premature neonates.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Chromium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (see Notes)",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.14-0.2 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         0.14-0.2 mcg/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Copper",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (see Notes)",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         20 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         20 mcg/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Manganese",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (see Notes)",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2-10 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         2-10 mcg/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Selenium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (see Notes)",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         3 mcg/kg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Zinc",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         Preterm, &le;3 kg: 300 mcg/kg",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         Full term: 100 mcg/kg",
"        </p>",
"       </td>",
"       <td align=\"center\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         100 mcg/kg",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F229572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F229564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [combination products]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multitrace&reg;-4: Chromium 4 mcg, copper 0.4 mg, manganese 0.1 mg, and zinc 1 mg per 1 mL (10 mL) [contains aluminum, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multitrace&reg;-4 Concentrate: Chromium 10 mcg, copper 1 mg, manganese 0.5 mg, and zinc 5 mg per 1 mL (1 mL) [contains aluminum]; chromium 10 mcg, copper 1 mg, manganese 0.5 mg, and zinc 5 mg per 1 mL (10 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multitrace&reg;-4 Neonatal: Chromium 0.85 mcg, copper 0.1 mg, manganese 0.025 mg, and zinc 1.5 mg per 1 mL (2 mL) [contains aluminum]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multitrace&reg;-5: Chromium 4 mcg, copper 0.4 mg, manganese 0.1 mg, selenium 20 mcg, and zinc 1 mg per 1 mL (10 mL) [contains aluminum, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multitrace&reg;-5 Concentrate: Chromium 10 mcg, copper 1 mg, manganese 0.5 mg, selenium 60 mcg, and zinc 5 mg per 1 mL (1 mL) [contains aluminum]; chromium 10 mcg, copper 1 mg, manganese 0.5 mg, selenium 60 mcg, and zinc 5 mg per 1 mL (10 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trace Elements 4 Pediatric: Chromium 1 mcg, copper 0.1 mg, manganese 0.03 mg, and zinc 0.5 mg per 1 mL (10 mL) [contains aluminum, benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [combination products, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Multitrace&reg;-4 Pediatric: Chromium 1 mcg, copper 0.1 mg, manganese 0.025 mg, and zinc 1 mg per 1 mL (3 mL) [contains aluminum]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F229556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F229566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Must be diluted prior to use and infused as component of parenteral nutrition or parenteral solutions",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F229565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and correction of trace metal deficiencies",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F229569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Decreased absorption of oral zinc when administered with bran products, protein, and phytates.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F229561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual elements for requirements in pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14287125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual elements for requirements while breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Chromium Picolinate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (60): $7.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (CrM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (100): $8.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Divista Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (60): $61.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Chromium Chloride Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mcg/mL (10 mL): $4.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Multitrace-4 Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-400-100-1000 mcg/mL (10 mL): $5.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Multitrace-4 Neonatal Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-25-1500 mcg/mL (2 mL): $4.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Multitrace-4 Pediatric Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-100-25-1000 mcg/mL (3 mL): $4.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Multitrace-5 Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-400-100-20 mcg/mL (10 mL): $7.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Trace Elements 4/Pediatric Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-100-30-500 mcg/mL (10 mL): $5.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Chromium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (100): $2.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Chromium Picolinate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mcg (90): $8.11",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10293 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-EFD95E538C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_40_34435=[""].join("\n");
var outline_f33_40_34435=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229570\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229574\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229571\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229573\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229572\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229564\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229556\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229566\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229565\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229569\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229561\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287124\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287125\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324006\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10293\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10293|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/32/6659?source=related_link\">",
"      Trace metals: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/41/1686?source=related_link\">",
"      Trace metals: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_40_34436="Apixaban: Patient drug information";
var content_f33_40_34436=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Apixaban: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     see \"Apixaban: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15881499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Eliquis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14471661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Eliquis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F14481372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700437",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       People who have had recent spinal anesthesia, epidurals, or spinal taps are more likely to have bleeding problems when started on this drug. This bleeding rarely happens, but can be very bad. Tell your doctor if you have had any spinal care. Do not take any other blood-thinner drugs including nonsteroidal anti-inflammatory drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F14481374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin the blood so that clots will not form.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F14481373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3808043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to apixaban or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703718",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have bleeding problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F14481378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F14481379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F14481380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fall or crash when you hit your head. Talk with your doctor even if you feel fine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F14481376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F14481377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose, brand, or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F14481381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F14481382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85643 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-7AD06D259D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_40_34436=[""].join("\n");
var outline_f33_40_34436=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881499\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471661\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14481372\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14481374\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14481373\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14481378\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14481379\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14481380\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14481376\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14481377\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14481381\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14481382\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=related_link\">",
"      Apixaban: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_40_34437="Inflammatory cells surrounding non-necrotic myofiber in IBM";
var content_f33_40_34437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F64343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F64343&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Inflammatory cells surrounding non-necrotic myofiber in IBM",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammatory cells surrounding and invading a non-necrotic myofiber in inclusion body myositis seen in a hematoxylin and eosin stained section.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Seven A Greenberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_40_34437=[""].join("\n");
var outline_f33_40_34437=null;
var title_f33_40_34438="ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias";
var content_f33_40_34438=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/40/34438/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/40/34438/contributors\">",
"     Jordan M Prutkin, MD, MHS, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/40/34438/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/40/34438/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/40/34438/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/40/34438/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/40/34438/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H94002758\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supraventricular rhythms appear on an electrocardiogram (ECG) as narrow complex rhythms, which may be regular or irregular. They may have a normal rate, tachycardia, or bradycardia depending on the underlying arrhythmia mechanism and presence of atrioventricular (AV) nodal block. Bundle branch blocks may be present, either at baseline or due to rate-related aberrancy, which can make the QRS complex wide, though they are typically narrow complex. When evaluating the rhythm, the most important step is to evaluate for the presence of P waves, and determine if the morphology, axis, and duration matches the normal sinus rhythm P wave.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     ESCAPE ATRIAL BEATS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Escape atrial beats or rhythm may occur after a long sinus pause, usually resulting from sinus node exit block or sinus node arrest (",
"    <a class=\"graphic graphic_waveform graphicRef52704 \" href=\"mobipreview.htm?36/61/37847\">",
"     waveform 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38756?source=see_link\">",
"     \"Sinoatrial nodal pause, arrest, and exit block\"",
"    </a>",
"    .) If the pause is long enough, there will be an escape atrial rhythm at a rate correlating with the intrinsic automaticity of the atrial focus. This may be a single atrial beat, multiple atrial complexes, or a sustained atrial rhythm due to an accelerated or ectopic pacemaker.",
"   </p>",
"   <p>",
"    The rate of the atrial rhythm is slower than that of the sinus node (since it is an escape rhythm) and the P wave morphology differs from that of the sinus P wave, depending upon the location of the ectopic atrial focus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ECTOPIC ATRIAL RHYTHM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ectopic atrial rhythm occurs when the dominant pacemaker is an ectopic focus in the atrium (",
"    <a class=\"graphic graphic_waveform graphicRef65515 \" href=\"mobipreview.htm?15/38/15975\">",
"     waveform 2",
"    </a>",
"    ). This may result from sinus node failure and the development of an escape atrial rhythm (generally at a rate of 30 to 60 beats per minute) or the acceleration of an ectopic atrial focus, as with sympathetic nervous system activation. If the rate of this focus exceeds that of the sinus node, an atrial rhythm will be present at a rate faster than the intrinsic sinus rate. In such cases, sinus node impulse generation is suppressed.",
"   </p>",
"   <p>",
"    The direction of atrial activation may be altered when an atrial rhythm is present since the pacemaker focus is within the atrial myocardium. The P wave morphology, axis, and duration vary based on the location the signal originates within the atrium. The QRS complexes of an ectopic atrial rhythm resemble those seen during sinus rhythm since myocardial activation is via the His Purkinje system. However, since atrial activation is abnormal and no longer via the normal intra-atrial pathways, right and left atrial abnormalities (hypertrophy or conduction abnormality) cannot be reliably diagnosed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ATRIAL TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the ectopic atrial rhythm is at a rate &gt;100 beats per minute, it is termed atrial tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21864?source=see_link\">",
"     \"Focal atrial tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atrial tachycardia with 1:1 conduction is a supraventricular tachyarrhythmia that has a rate of 140 to 220 beats per minute (",
"    <a class=\"graphic graphic_waveform graphicRef75232 \" href=\"mobipreview.htm?18/12/18629\">",
"     waveform 3",
"    </a>",
"    ). The QRS complexes occur at regular intervals (there is constant RR cycle length), and there is a P wave with a uniform morphology and the same PR interval. The baseline between successive P waves (if AV block is present) is flat and isoelectric on the electrocardiogram. The QRS complexes are similar to those seen during sinus rhythm since activation of the ventricular myocardium is unaltered and is via the His-Purkinje system. Commonly, there is a warm up phase at the onset of the tachycardia, during which gradual rate acceleration or progressive shortening of the PP cycle length between the first several beats occurs. There may also be a cool down phase at the end of the tachycardia, during which the rate gradually decelerates, with progressive lengthening of the PP cycle length.",
"   </p>",
"   <p>",
"    Although all of the P waves are the same, they have a different morphology than the sinus P wave, depending on the site of origin. The best lead for determining whether the location is from the left or right atrium is V1. A negative or biphasic",
"    <span class=\"nowrap\">",
"     positive/negative",
"    </span>",
"    P wave in V1 was 100 percent specific in one study for predicting a right atrial location. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21864?source=see_link&amp;anchor=H189482685#H189482685\">",
"     \"Focal atrial tachycardia\", section on 'Localization of AT focus'",
"    </a>",
"    .) Similarly, a positive or biphasic",
"    <span class=\"nowrap\">",
"     negative/positive",
"    </span>",
"    P wave in V1 was 100 percent sensitive for a left atrial location.",
"   </p>",
"   <p>",
"    In general, there is prolongation of the PR interval as a result of decremental conduction through the AV node. In other words, there is a progressive slowing of the rate of impulse conduction through the AV node as the atrial rate increases. On occasion the PR interval may be shorter than that seen during sinus rhythm if the ectopic atrial focus is close to the AV node and bypasses intra-atrial conduction.",
"   </p>",
"   <p>",
"    Since the ectopic focus is within the atrial myocardium and not affected by the vagus nerve, activation of the parasympathetic nervous system (as produced by carotid sinus pressure) does not alter the atrial rate of the tachycardia. However, increased parasympathetic nervous activity (or adenosine) may block the AV node and result in slowing of the ventricular rate, unmasking the atrial activity (",
"    <a class=\"graphic graphic_waveform graphicRef68731 \" href=\"mobipreview.htm?10/18/10536\">",
"     waveform 4",
"    </a>",
"    ). In this situation, sequential non-conducted P waves are seen, and there is an isoelectric baseline between the P waves. An increase in circulating catecholamines will cause an acceleration of the atrial rate by directly enhancing the automaticity of the ectopic atrial focus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146591646\">",
"    <span class=\"h2\">",
"     Atrial tachycardia with atrioventricular block",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the atrial rate is faster than the capability of the AV node to conduct each impulse, some of the impulses do not traverse through the node and are nonconducted to the ventricle, resulting in block (",
"    <a class=\"graphic graphic_waveform graphicRef68731 \" href=\"mobipreview.htm?10/18/10536\">",
"     waveform 4",
"    </a>",
"    ). The ventricular rate may be variable or occur in a repeating pattern, such as 2:1, 3:1, 4:1, or Wenckebach. AV nodal block may occur because of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal AV nodal decremental properties",
"     </li>",
"     <li>",
"      Increased vagal tone to the AV node (such as with digitalis or carotid sinus pressure)",
"     </li>",
"     <li>",
"      Intrinsic nodal disease",
"     </li>",
"     <li>",
"      Drugs that depress nodal function (such as calcium channel blockers and beta-blockers)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     WANDERING ATRIAL PACEMAKER",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wandering atrial pacemaker (also termed multifocal atrial rhythm) is present when there are three or more ectopic foci within the atrial myocardium that serve as the dominant pacemaker (",
"    <a class=\"graphic graphic_waveform graphicRef54943 \" href=\"mobipreview.htm?9/37/9815\">",
"     waveform 5",
"    </a>",
"    ). Since they discharge in random fashion, the pacemaker location is continuously shifting and may be located anywhere in the atrial myocardium. As a result, there is a changing vector of atrial activation that causes a changing P wave morphology and PR interval duration. A dominant P wave (sinus or atrial) cannot be identified. The rate is less than 100 beats per minute.",
"   </p>",
"   <p>",
"    The QRS intervals have variable cycle lengths since the ectopic foci exhibit differences in automaticity and rates of impulse generation. The rhythm is therefore irregularly irregular, and it can be confused with atrial fibrillation. However, in contrast to atrial fibrillation, distinct P waves are present. Sinus arrhythmia may also be irregularly irregular; however, one P wave morphology and PR interval are seen in this situation. This arrhythmia may also be confused with sinus rhythm with multifocal premature atrial contractions, although in this situation a dominant sinus P wave can be identified and there are periods of RR interval regularity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MULTIFOCAL ATRIAL TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multifocal atrial tachycardia is similar to a wandering atrial pacemaker in that there are three or more independent ectopic foci, except that the heart rate is rapid (greater than 100 beats per minute) (",
"    <a class=\"graphic graphic_waveform graphicRef77728 \" href=\"mobipreview.htm?21/61/22486\">",
"     waveform 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/20/38216?source=see_link\">",
"     \"Multifocal atrial tachycardia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This arrhythmia usually occurs when there is damage to and distension of the atrial myocardium. Within such a myocardium, there is the potential for multiple independent ectopic foci that generate impulses at variable rates. If the automaticity of these foci is increased, as with sympathetic nervous system activation, the rate at which these foci generate an action potential increases, resulting in an increase in the heart rate.",
"   </p>",
"   <p>",
"    Since these foci are located in multiple areas of the atrial myocardium, there is great variability of the P wave morphology and axis, the PR intervals, and the cycle lengths of the QRS complexes. The QRS complexes are unchanged and are similar to sinus rhythm since ventricular activation is normal.",
"   </p>",
"   <p>",
"    Since the rhythm is rapid and irregularly irregular, it is often confused with atrial fibrillation. However, with atrial fibrillation, there is no distinct or organized atrial waveform (P wave) seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREMATURE ATRIAL CONTRACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature atrial contractions (PACs), also known as atrial premature beats (APBs), premature atrial depolarizations (PAD), or premature atrial beats (PAB), occur when there is premature or early activation of the atrial myocardium as a result of an impulse generated by an ectopic focus within the atrial myocardium rather than the sinus node (",
"    <a class=\"graphic graphic_waveform graphicRef50512 \" href=\"mobipreview.htm?25/58/26534\">",
"     waveform 7",
"    </a>",
"    ). The interval between the last sinus beat and the ectopic beat is shorter than the interval between two sinus beats (ie, it is premature). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/441?source=see_link\">",
"     \"Supraventricular premature beats\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PACs can be unifocal or multifocal. The P waves of the premature complexes exhibit identical morphology in unifocal PACs and variable morphology in multifocal PACs. Atrial bigeminy and trigeminy refer to rhythms in which every other beat (bigeminy) or every third beat (trigeminy) is a PAC. Apart from the repeating pattern, there is no clinical significance to this finding.",
"   </p>",
"   <p>",
"    The P wave morphology differs from that of sinus rhythm and its axis and amplitude depend upon the atrial location of the ectopic focus. The PR interval is often longer than that of the sinus beat, a result of decremental conduction, though this finding may be subtle. However, the PR interval may be shorter if the ectopic focus is near the AV node and does not occur too prematurely. Since activation of the ventricular myocardium occurs in a normal fashion, the QRS complex is unchanged from that of sinus rhythm.",
"   </p>",
"   <p>",
"    Premature activation of the atrial myocardium by an ectopic focus results in a transient and variable affect on sinus nodal function and impulse generation. These findings can be reproduced in the electrophysiology lab during testing of the sinoatrial conduction time (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9064?source=see_link&amp;anchor=H17557871#H17557871\">",
"     \"Diagnosis and evaluation of the sick sinus syndrome\", section on 'Sinoatrial conduction time'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the sinus node is depressed and reset, it activates the atrium after an interval identical to the usual sinus cycle length. In this setting, there is less than a full compensatory pause. In other words, the cycle length measured between the last P wave before and the first P wave after the premature beat is less than twice the cycle length of two sinus P waves.",
"     </li>",
"     <li>",
"      If the premature beat collides with the sinus node impulse in the sinoatrial junction, the sinus node activity is not suppressed and there is a true compensatory pause seen. The cycle length between the sinus beat just prior to and the first beat after the ectopic beat is twice the cycle length of two successive sinus beats.",
"     </li>",
"     <li>",
"      If the PAC is appropriately timed such that it only results in a slowing of impulse conduction through the sinoatrial junction, as opposed to block, there is a delay in atrial activation of the next sinus beat, and the compensatory pause will have a cycle length greater than two sinus beat cycle lengths.",
"     </li>",
"     <li>",
"      If there is sinus node dysfunction present, the PAC may depress the sinus node and there may be a long delay before sinus node automaticity recovers. In this situation the pause is much longer than a full compensatory pause.",
"     </li>",
"     <li>",
"      The PAC is said to be interpolated when it does not affect the sinus node and sinus rhythm is not altered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonconducted or blocked PACs occur when there is premature activation of the atrial myocardium from an ectopic atrial focus at a time when the AV node is still refractory due to the previous sinus beat (",
"    <a class=\"graphic graphic_waveform graphicRef70469 \" href=\"mobipreview.htm?21/43/22200\">",
"     waveform 8",
"    </a>",
"    ). Since the block is in the AV node, there is an isolated P wave with no QRS. The P wave may be difficult to see if it is located within the ST segment or T wave of the prior beat.",
"   </p>",
"   <p>",
"    Aberrant conduction of a PAC generally occurs when there is conduction delay or block within the right or left bundle branches, although abnormal conduction along an accessory pathway can also be a cause (",
"    <a class=\"graphic graphic_waveform graphicRef81828 \" href=\"mobipreview.htm?41/36/42568\">",
"     waveform 9",
"    </a>",
"    ). The PAC is conducted through the AV junction but reaches one of the bundles or its fascicles at a time when it has not yet recovered and is still relatively refractory. Impulse conduction via this pathway is therefore blocked, although conduction will occur normally through the other parts of the His-Purkinje system. This results in a right or left bundle branch block pattern, depending on which bundle or fascicle is involved. The mechanism is similar to Ashman&rsquo;s phenomenon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22038?source=see_link&amp;anchor=H13#H13\">",
"     \"ECG tutorial: Intraventricular block\", section on 'Ashman's phenomenon'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ATRIAL FIBRILLATION AND ATRIAL FLUTTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;These topics are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/42/26278?source=see_link\">",
"     \"The electrocardiogram in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/53/15192?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type I atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12165?source=see_link\">",
"     \"Electrocardiographic and electrophysiologic features of type II atrial flutter\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;AV nodal reentrant tachycardia (AVNRT, also called junctional reciprocating tachycardia) is a supraventricular tachyarrhythmia that originates within the AV node and adjacent atrial myocardium and is the result of dual pathways within the node (",
"    <a class=\"graphic graphic_waveform graphicRef70522 \" href=\"mobipreview.htm?1/21/1368\">",
"     waveform 10",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate is generally between 140 to 220 beats per minute and there is usually 1:1 atrial-ventricular association; as a result, every QRS complex has an associated P wave. Rarely is there 2:1 AV block (due to lower common pathway, infra-nodal or infra-Hisian block) with two P waves and one QRS, or 2:1 VA block (due to upper common pathway block) with two QRS complexes for every P wave.",
"   </p>",
"   <p>",
"    Atrial and ventricular activation are usually simultaneous; as a result, a P wave is superimposed upon the QRS complex and therefore not obvious on the surface ECG. In some cases, the P wave may fuse with the terminal portion of the QRS complex producing a pseudo-r' in lead V1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a pseudo-S in the inferior leads (",
"    <a class=\"graphic graphic_figure graphicRef54290 \" href=\"mobipreview.htm?32/3/32830\">",
"     figure 1",
"    </a>",
"    ). This is referred to as typical or \"slow-fast\" tachycardia since the antegrade limb to the ventricles is a slow pathway while the retrograde limb back to the atrium is a fast pathway. Less frequently, AVNRT will be associated with a long RP interval, also called atypical AVNRT (",
"    <a class=\"graphic graphic_figure graphicRef66828 \" href=\"mobipreview.htm?31/31/32240\">",
"     figure 2",
"    </a>",
"    ). This occurs when there are two slow pathways and no fast pathway (termed \"slow-slow\") or there is antegrade conduction via the fast pathway, with retrograde conduction to the atrium via the slow pathway (called \"fast-slow\").",
"   </p>",
"   <p>",
"    In contrast to an atrial tachycardia, AVNRT does not usually manifest a warm up or a cool down period. In other words, no progressive acceleration of rate or shortening of the RR cycle length of the first few beats, or progressive deceleration or lengthening of the RR intervals before termination are observed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since this arrhythmia is usually initiated by an atrial premature beat, there is an initial ectopic atrial P wave and prolonged PR interval. Infrequently, a ventricular premature beat initiates AVNRT as a result of retrograde conduction through the AV node.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ATRIOVENTRICULAR REENTRANT TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrioventricular reentrant tachycardia (AVRT) is a supraventricular tachycardia that utilizes an accessory pathway between the atria and ventricles. It is frequently, but not exclusively, associated with a preexcitation syndrome (ie, the Wolff-Parkinson-White syndrome) (",
"    <a class=\"graphic graphic_waveform graphicRef54720 \" href=\"mobipreview.htm?28/50/29478\">",
"     waveform 11",
"    </a>",
"    ), since pathways may conduct antegrade only, retrograde only, or antegrade and retrograde. Retrograde only pathways cannot be seen on the ECG. The circuit involved in this reentrant arrhythmia includes the accessory bypass tract, AV node and His Purkinje system as well as the atria and ventricles. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39256?source=see_link\">",
"     \"Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common type of AVRT uses the AV node and His Purkinje system (which has a relatively short refractory period) for antegrade conduction to the ventricles and the accessory pathway (which in these patients has a relatively long antegrade refractory period when compared to the node) for retrograde conduction. During this type of arrhythmia, called orthodromic AVRT, QRS complexes are narrow (",
"    <a class=\"graphic graphic_figure graphicRef71302 \" href=\"mobipreview.htm?15/35/15926\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef68804 \" href=\"mobipreview.htm?6/4/6217\">",
"     waveform 12",
"    </a>",
"    ). There is always 1:1 conduction of the impulse between the atria and ventricles since both structures, along with the AV node and accessory pathway, are a necessary part of the circuit. Since there is retrograde activation of the atrium during orthodromic AVRT, a negative P wave may be seen in the inferior leads with a short RP interval.",
"   </p>",
"   <p>",
"    Less commonly, particularly when the refractory period of the accessory pathway is shorter than that of the AV node and the His Purkinje system, the antegrade limb of the circuit activating the ventricle is the accessory pathway and the impulse is conducted retrogradely to the atrium via the His-Purkinje and AV node (",
"    <a class=\"graphic graphic_figure graphicRef50433 \" href=\"mobipreview.htm?34/52/35655\">",
"     figure 4",
"    </a>",
"    ). In this tachycardia, called antidromic AVRT, the QRS complexes are maximally pre-excited and very wide, and there is a retrograde (and negative) P wave in lead II (",
"    <a class=\"graphic graphic_waveform graphicRef54484 \" href=\"mobipreview.htm?24/55/25464\">",
"     figure 5",
"    </a>",
"    ). This form of AVRT may be difficult to distinguish from ventricular tachycardia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146591731\">",
"    <span class=\"h1\">",
"     JUNCTIONAL ECTOPIC RHYTHM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Junctional ectopic rhythm is most often the result of an acceleration of impulse generation from the AV junction which, if more rapid than the sinus node rate, assumes control as the dominant pacemaker of the heart (",
"    <a class=\"graphic graphic_figure graphicRef86497 \" href=\"mobipreview.htm?32/0/32770\">",
"     figure 6",
"    </a>",
"    ). In such cases, there are no P waves seen before the QRS complexes; instead, they occur either simultaneously with the QRS complexes or more commonly are retrograde (seen after the QRS complex located in the ST segment or T wave). Sinus node activity is suppressed by the retrograde atrial activation. If there is retrograde VA block of the impulse to the atrium, sinus node activity is not suppressed by the junctional rhythm, and sinus P waves can be seen occurring independently at a slower rate than the QRS complexes. This is known as AV dissociation. When the junctional rhythm is faster than 100",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    it is called junctional tachycardia. In some cases, the junctional ectopic rhythm develops because there is failure of the sinus node and of an atrial focus to assume pacemaker function, which is therefore assumed by the AV junction. This is known as a junctional escape rhythm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     JUNCTIONAL PREMATURE BEATS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Junctional premature beats are early ectopic beats which originate in or near the AV junction and have a QRS morphology which resembles the sinus complex (",
"    <a class=\"graphic graphic_waveform graphicRef70990 \" href=\"mobipreview.htm?23/13/23766\">",
"     waveform 13",
"    </a>",
"    ). Although their timing and morphology are similar to that of a PAC, there is no sinus P wave present before the QRS complex, though a retrograde P wave may be noted if there is retrograde conduction through the AV node.",
"   </p>",
"   <p>",
"    As with atrial premature beats, junctional premature beats may be conducted with a bundle branch block pattern. Junctional premature beats may occur with a bigeminal or trigeminal pattern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     JUNCTIONAL ESCAPE BEATS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Junctional escape beats or rhythm occurs when there is failure of upper pacemaker tissue. In other words, the absence of impulse generation from the sinus node or atrial myocardium and an escape rhythm from the AV node. This rhythm occurs after a variable pause that is longer than the underlying sinus cycle length (",
"    <a class=\"graphic graphic_waveform graphicRef53638 \" href=\"mobipreview.htm?12/21/12631\">",
"     waveform 14",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In this arrhythmia, there are one or more normal QRS complexes that are not preceded by a P wave. In addition, there may be continuous normal supraventricular QRS complexes that occur at regular intervals but are without P wave activity preceding each complex. If there is retrograde conduction through the AV node, retrograde P waves may be seen after each QRS complex, in the ST segment or in the T wave.",
"   </p>",
"   <p>",
"    The rate is slower than that of the underlying sinus rate. An escape junctional rhythm may also occur when there is a complete block of AV nodal conduction, preventing the sinus impulse from reaching the ventricles. In this case, there are P waves observed that are disassociated with the QRS complexes, and the PR intervals are variable. Such P waves occur at a rate that is more rapid than the ventricular rate, resulting in AV dissociation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94003368\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial tachycardia occurs at 140 to 220 beats per minute and usually has 1:1 AV conduction. In some situations, there may be block within the AV node, leading to variable or repetitive block patterns. P wave morphology can be used to determine the atrial tachycardia site of origin.",
"     </li>",
"     <li>",
"      Wandering atrial pacemaker and multifocal atrial tachycardia demonstrate three or more different P wave morphologies with no dominant P wave.",
"     </li>",
"     <li>",
"      Atrioventricular reentrant tachycardia must have 1:1 atrial and ventricular conduction, and, therefore, a P wave follows every QRS, even if not well seen.",
"     </li>",
"     <li>",
"      Junctional beats have a QRS morphology similar to a natively conducted QRS, but have no P wave preceding it.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94002741\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Philip J. Podrid for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2118 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-A0D016103C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_40_34438=[""].join("\n");
var outline_f33_40_34438=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H94003368\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94002758\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      ESCAPE ATRIAL BEATS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ECTOPIC ATRIAL RHYTHM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ATRIAL TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H146591646\">",
"      Atrial tachycardia with atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      WANDERING ATRIAL PACEMAKER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MULTIFOCAL ATRIAL TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREMATURE ATRIAL CONTRACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ATRIAL FIBRILLATION AND ATRIAL FLUTTER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ATRIOVENTRICULAR NODAL REENTRANT TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ATRIOVENTRICULAR REENTRANT TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H146591731\">",
"      JUNCTIONAL ECTOPIC RHYTHM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      JUNCTIONAL PREMATURE BEATS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      JUNCTIONAL ESCAPE BEATS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94003368\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94002741\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2118\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2118|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/3/32830\" title=\"figure 1\">",
"      Typical atrioventricular nodal reentrant tahcycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/31/32240\" title=\"figure 2\">",
"      Atypical atrioventricular nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/35/15926\" title=\"figure 3\">",
"      Orthodromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/52/35655\" title=\"figure 4\">",
"      Antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/0/32770\" title=\"figure 6\">",
"      Junctional ectopic rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2118|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?24/55/25464\" title=\"figure 5\">",
"      12 lead ECG antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?36/61/37847\" title=\"waveform 1\">",
"      Escape atrial beats tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?15/38/15975\" title=\"waveform 2\">",
"      Ectopic atrial rhythm tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?18/12/18629\" title=\"waveform 3\">",
"      Atrial tachycardia tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?10/18/10536\" title=\"waveform 4\">",
"      Atrial tach with block tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?9/37/9815\" title=\"waveform 5\">",
"      Wandering atrial pacer tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?21/61/22486\" title=\"waveform 6\">",
"      Multifocal atrial tach tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?25/58/26534\" title=\"waveform 7\">",
"      Atrial premature beat tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?21/43/22200\" title=\"waveform 8\">",
"      Blocked APB tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?41/36/42568\" title=\"waveform 9\">",
"      APB with aberration tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?1/21/1368\" title=\"waveform 10\">",
"      AVN reentrant tach tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?28/50/29478\" title=\"waveform 11\">",
"      Orthodromic AVRT tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?6/4/6217\" title=\"waveform 12\">",
"      12 lead ECG orthodromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?23/13/23766\" title=\"waveform 13\">",
"      Junctional premature tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?12/21/12631\" title=\"waveform 14\">",
"      Junctional escape tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39256?source=related_link\">",
"      Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/54/9064?source=related_link\">",
"      Diagnosis and evaluation of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22038?source=related_link\">",
"      ECG tutorial: Intraventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/53/15192?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type I atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12165?source=related_link\">",
"      Electrocardiographic and electrophysiologic features of type II atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21864?source=related_link\">",
"      Focal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/20/38216?source=related_link\">",
"      Multifocal atrial tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38756?source=related_link\">",
"      Sinoatrial nodal pause, arrest, and exit block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/441?source=related_link\">",
"      Supraventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/42/26278?source=related_link\">",
"      The electrocardiogram in atrial fibrillation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_40_34439="Mullerian anomalies";
var content_f33_40_34439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mullerian uterine anomalies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 448px; height: 637px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJ9AcADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoori/EnxDstB8QRaPcaRrlxdzhzbm2tQ63GxA7+XlgW2qeeOuQMnigDtKK5W78e6FbXnie1M8klz4dt1ur+ONMlUZC+V/vYUZPpkViWHxf8N31vBJBFqXmT3NtarCbcB91yu6A/exhxz1yO4FAHotFcjdePdMg8Xz+G/s2oS6jB5Bk8uIMirKwVWzuyRk84GQATjApb7x7pdr4+tPCCwXlxqs8YlYxKnlwqQxBclgeinoD2oA62iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKbIgkjZGztYYOCQfzFADqK+a9T8BXCr8UxYeHdR4SCPQDtk6+Xscx5PPzHJJ/wB6qmr+DPFs2na8v9k391cXGg6ZBZvHEsOyVGjMibTIcMFGCcjO0igD6forznQ11XQPhvqSaPot22qiWb7ND9mity7uflfyxIVCruAOWydhOOa8wm8HeOD4VXw2tjqEl/oOsTahour749kqqGdFcs+/DOWHIxyvZaAPpRmCjLEAepNM86Lcq+amWxgbhzmvlnU/AXjK5mu/tWh6hc3Uvii11WS8H2dw0CxOJdqs/wB3e3yoeCuM0eMvhx4s1fV7W60nw1PFbWekQQTLIbaCS7ljvTI5TY5ELuuGyOnK5x1APqkMp3YYfLweelIJEZQyupU8Ag8HtXzxqfgrxRf+IfEOowaFcxaZca9Z6hcafJLCrahaogEkfDkEhsttYgNnrnitf4iaJ4r17TVi8IeGZtBi0ucaraIz24+2XSPFsG1Jhs483IYMpGD97GAD3FWViQrAkcEA9KNw3bcjdjOM84rwPVvBHiHWvEF54m0/SbjTbm+vrWHU9LvnieK6tQkIZ02uQHR0kIJxkH8Dt/Fnwdqvib4meEZbCwZdMgtLyC81DyoZVj82MqgKOwLAHJ6cbsjmgD2EkKMkgD1NBYAgEgFjgZPU181nwP4giufHgbwzfypqFxqB06NUtSgWVAsb+YZN6ngjaOPmzwRVXRvhv4jt/h/4wstU8NzXOs3VnaNp0iPCqLL5AiYBN+EkUltz5+bJI9wD6eBBzgg44pa8C8W+CdQXXNMm0PwnJ9hPhy8gkWPyQUu51OFYFxyDnkcDdwai1Lw9q+seFPhnoVx4R1NBot3YjUmlEQRoxEVnwVkJILYJ9c+ooA+ggQcYI55FFfP+ifCy11HTPiHa6z4Zltne/uJNGkjCowhZQIxFhsDBjBwcdfc10vhLw7qkXwX1BNXtNSi8UanaNHfm38tbpmC+UpTkLwgBAyM89yaAPW6K+d/C/hbxRpd9oreJNLk1Xwpb3FyrQw2oilk3RIkVxNaqxBI2suByPvEZOTN4Y8N+K9N1vSLjxhYahqfhJVuxb6crfaHsmaXMJnjGfMxHlRjdtJ7Y5APoKivmfx14a1u5Txx/Y/hnWbdb200hdKXy97RGN180ZVzhggweecYz66mu+EHvYvBhttA1KSVdeUalL9kkgR7TJLHyt7bI8yAYOCdpOKAPoSuV8QeE31fxr4b8QrqLQHRROFtxFuE3mptbLZGOMdq4DQPAraV8Y7mxt7PUD4NSCHU7cShmhhv4wUVEcnJTY5fBON2PTFX9Ytb6P4ieILjxXpOravo8ttB/Yo0+N5FiIGJEwhHlyFjnzGKjH8QoALz4PPNd3N7b+IDBf3+n3en6jMLTcLtLiRnY7TJhSC3GO4/Cqem/A5NMhtBYa+YJLe6srtVjsVWFntVIRmjD8u2cu2ct7VW8L3eu6b4Q1rRYNC1+PU9S1W7EFzJBII4IJJVVJC/JULG2QApx5fIHGeTj03x1Lp3h+0ms9Sm1bQG+xJb3dnLJZaigmG2YTAqYnCAHc23IHXkigD0yD4XXQ8dHxVd+IIrrUmESs0mmplAjZ/dnd8hIJTOCdp7nmt3xJ4HtvEPizSNXvRZxjS547qF4bbF1I6A4Vps/6vJzsA5x1rxfXNB8Yf8ACP8AjG3sbLVr2O+a3nt53tXt7+Ob7ZveAsCRIqxmT96MjBCg4wAj+C9cu9N+I93Hp2oKjTXLaPZvaSLM4lCiN43LDao+YlNvfJoA+m6K8P8ABemanYXtzN4z0DVNTP2SwOkeVEX8hUiUNFjIETq+SxbG71PAp+had4pm8YatP4k0m8vPD/iK1a4ltXwfsE0MjeTERnnMaoDjgtgnrQB7bRXzbo/gbW7TwF8P1Hh27j8QQa9BNq7lgX+zRyzEFzu+YbZV45JAx2FXtN8KeKodH8PW0ml3i+JdOvrmXWNR3q0d/bMXJUOW/eeYCgCEZUjkKMEgH0JRnnHevF/hJ4K13wv4o01bxZJ/Dw0iSa2+1YafT7qRoPNty2T8pw7L/wACHqTnav4U8V3H/CQWiWFyfEFx4kW/07XFkXZDZ70IG/cGUIispjxznjOc0Ae80V5B8HvCGoWHinxJrGrWTWStqV29nFNboHaOUxlXEisTtwjDYRgbs157rfgHx4E1VrHT7ltEv9bTWF0vfEZEk+0ybkPz48vygrYzyWTHRqAPqGivD/DXhjUrGz1jRdV8P3Fwx8RyaukwjjeB7f7y4Jb72AU24yCR2Oa5aLw34jHwR8OeGG8I6p/atjqMV1dErFtcCd2Yg78sdhAP1AoA+maK8A8Q6RrOtfFv+3m8KarFo8dhDCI3tYJHnkjuA2BmUeXlQMPnIHHtXO+B/BvivS/Ed3f3nhy9isLpdWiihiEayReaFaLzjv8A3iEfKo42sDxjkgH1DRXzUuh+P4vAfhKHSdLv7bUvC3lXjW0hX/T52lKugbdjAjY5J67jWlc+DvEc/iNvEGkadf22n6nrsB1fR74qS0AmicXMYDYDDDqwzypPXk0AfQdFeSfG2HxffTWUnhG1uT/YjR6moXpeyiQL5IA5OELkg4B3deK5nVfCviW71xfEei22o2+n6rrVqNV0e9j5WESxMLiNQxwR8wbpwWyCASQD6Bor550zQ/FMNlottcafqZ8W2etS3Graltcw3lkWcsBJ911ZNirGOQQOF61zuh+HfiFo0PhCC8g1ifQ7DWoL3yUVpJfJdFeYSqOcRvuVV/iLOcEAUAfVFFfNOvr46Fn4yS40rW7iPxPYpe2a28ckjafdB9iwHCjYQirk9PlBzzW9rov9S1n4erHofiKPTtNt7u11AtZzBWY2iCMkDlh5pwGI6qx6c0Ae8UV8saZ4f8SDwJp1hcweIbbWlRLiaQ6TNNA7IZdsFypdjLuyDvRcL8u7GBX0f4NF6vhLRV1W1S0vxZwie3RiwicIMrkkk4PHJP1PWgDYooooAKKKKACiiigAqtJf2kV7HZyXVul3INyQNIA7DnkLnJHB/KrNedeNfh/ceIvFV1q63Ece3ToILNfOkj23EckzB3KANtAl42uOQcgigD0GWeKFoxNLHGZGCIGYDcxzgD1PB49qkrxiP4W+KFtYlXxKsd4Gt83okkeRVjWdeAeD/rUYZxytW0+GGs+Xp2NclgktoohJtvLmRZJVmhZpAGbjckbKR/tnrkkgHrCTwyTSxRyxtLFjzEDAsmeRkds1VbV9OWd4Gv7UTJMtu0fmruWRhlUIzwxHIHeuD074e6jZW/g9YtShiuNHCreTRqT9sCsnLBs5JVWGeGUucMRlWTxN8NrjVNdvtasNUWx1G5nJkwrGOaIW4jjEgBB3o4LKykEBmGecgA9Lorxuy+EWrqtqb/xKt08DD70LhSm64JXbvwAfOQYHGIxx0x0vw38B3vhS+urrU9YfV7iaMRieVpt4G2MbdpkKbQUJB27vm69cgHf0ViX8XiRtQdtPu9ISx42pPayNJ05ywkA6+1IkfiUM2+50cjPAFvKMD3+egDcorEkXxIEJjl0hm7BopAPz3GoB/wAJZnn+wsf9taAOiorAY+KcfKuiA4HJaU89+1Tb/EP/ADw0n/v9J/8AE0AbNFY2/wAQ/wDPDSf+/wBJ/wDE1FJJ4nGfLtdFbkY3XMo/9pmgDeorEjuPEgX95pujs3quoSD/ANoGnfaPEP8A0C9J/wDBlJ/8YoA2aKxvtHiH/oF6T/4MpP8A4xUct14mA/daRozH/a1SVf8A23NAG7RXPC78WZ50XQgPbV5f/kWlF34q5zo2if8Ag2l/+RqAOgorA+1eKf8AoD6J/wCDaX/5Go+1eKf+gPon/g2l/wDkagDform5L7xarEJoOiuB0I1iQZ/8lqeLzxWSM6Jogz1/4m8vH/ktQB0NFc9HeeKmQF9E0VG7qdXlOP8AyWp32rxT/wBAfRP/AAbS/wDyNQBv0Vzwu/FeedF0PH/YXl/+Rqct14pz82jaIB7atKf/AG2oA36KxI7nxIUBk0nR1fuF1OQj8/s4p32jxD/0C9J/8GUn/wAYoA2aKxvtHiH/AKBek/8Agyk/+MUfaPEP/QL0n/wZSf8AxigDSvLy2sohLe3ENvEWCh5XCAk9Bk96fbzxXMCTW0sc0LjKyRsGVh6gjrXO+K9I1DXtEsIvLs4b231C1vWQzM0eIZ1k2h9gOSFxnbxk9cc+f6x8LfEd7c3klprkFjDeNdTSW1vJMkcbTJIuxQDgqC0bk7QWYMSPuhQD2aiuM8H+G9V0W/1O6v7pb2Wbcbcm8l2ohCbYTGQVAUqQHGTgngEtna+0eIf+gXpP/gyk/wDjFAGzRWN9o8Q/9AvSf/BlJ/8AGKjmuvE4x5OkaM/rv1WVcf8AksaAN2iufW78VY+bRtDB9tXlP/ttQLvxV30bRP8AwbS//I1AHQVWgv7O4l8qC7t5Zfm+RJAx4xngHtkZ+orn9b0/XvEPhrWdJu1s9IkvLR4IbqzvZJ2R2BGSDHHgfQ5+lclr/gjxBqN7pl7pUGlaHdWFlLBG1leSx5kZ7ZgWKRjcgELjawIIIyOwAPVqK8btfA/jy6nvY9V1wxWzxXRgNrq90dsskSLGWBAJCsrtjJA38Diu1vPBket6N4ct9bu7+OTSvLlaO1vGKTSKoGJHI3SLweuM5OaAOvorH1K612K7ZNO0qxubfAxJLftExPf5RE386q/b/FH/AEAdM/8ABq3/AMYoA6KiubOoeKcf8i/pp5/6Crf/ABmj+0fFWP8AkXtO/wDBqf8A4zQB0lFc3/aPinn/AIp3Tv8Awan/AOM1ZsbzxBJdxpe6PYQW5PzyR6i0jKMdl8oZ/MUAbdFFFABRRRQAUxpY1lWIuokcFlQnkgYyQPbI/MU+vN/iL4T8Qanqp17RNQKXdjbPBaWiMV8xHikEoz2kZjEVIIA8tc0AekUV4x8OvAniRZdOvvEd2/8AokxP2WSeZVY/umEyKjAKcoy7W3A9f4iD6Zdx+JDdymzutHS13fu1ltpWfHuRIBn8KANuisDyvFP/AD96J/4Cy/8AxykWHxUZF3X+hhMnOLKUnH/f2gDoKoPq+npqX2BruL7YCoMQOSpYEqD6EgEgHrjirdsJlgQXTxvMB87RoUUn2BJI/M1x6+Dr221y4uNO1mW2sLvVk1e5iVT5sjiJY2i37sGJgiHBBxgjpjAB2lFYV5beJXupms9U0mK3J/dpJp0jso92EwBP4ChbfxMFAbU9GLZ6/wBnSjj/AL/0AbtFYog8RY51DSc/9eMn/wAerUs1uFtkF7JFJcc7miQop54wCSRxjvQBTXXdKbWm0gajaHVFGTa+aPMHy7vu9fu8/TmtKuTs/BdpH451PxLdt9ouJ3ie2QlwLdlhMTNjdtZiCecZAOKs+T4u3H/T9BK/9eM2f/RtAHR0VgeV4p/5+9E/8BZf/jlIYvFeRi80PH/XpL/8coA6Cq1rf2d3NcQ2l3bzy27bJkikDNE3PDAHg8Hg+lTQeaII/tBQzbRvKAhS2OcA9s14zrvw/wDET+MSunXskGlalb3iu8E0qxWEzMrJOi78iQksQo+QMrHjeaAPZZriGAgTSxx5BI3sBkAZJ/AUlpcw3lrDc2kqTW8yCSOSNtyupGQQe4Iri/GnhDVNd1mw1Ox1SO2uNM2NZb0JXc25Z/MAxkOhC4BGMZ5qXwN4V1Hwto09ul5BNOYIIoovn8hWjTaZMEkgv1IHHA9zQB2lFc+w8VbTtOhluwIlH9aRG8Vj78WhH6SSj/2WgDoahvLu3sbZ7i9uIre3TG6WVwirk4GSeByQKy7RvERuY/tcWkrb7vnMUshbHsCoGaua7pdvrei32mXqlra8heCTHBwwxkehGcg9jQBFP4g0aC8ltJ9X06O6iGZIXuUDpxnlScjgirVlf2d+rtY3VvcqjbWMMgcKfQ4PBrk7LwbNDb+GlvLmG+ubKZrjUrmZPnvHaCaP06ZmbAPRRin+DfCc/hfRpmt2huNamXa7ySOIdold1UDHAHmN2ySaAOyorA3+Kf8Anhon/f6X/wCJoL+KccQ6ID6+bKcf+O0Ab9RXdzBZ20lxeTxQW8Yy8srhVUepJ4FZli3iD7VGL+PShbZO9oZJC+O2AVx6d6r+P9Cn8S+DtV0e1mSCa8i8tZXzheQc8c9qANqzu7e+t1uLKeK4gbIWSJw6nBwcEccEEfhU1eV6l8OtZ1Gy1C0uNUhaC5VTD50s8rW5V2bZksPMVtw3FufrgYg8UeC/EZvLCa1vpbyP+1C80cc0kfnQSTB8TYb7kSgou3+E9B0oA9XjmikkljjlR3iYLIqsCUJAIBHY4IP0IqSvM9E8A65pt/FJc64dSsflV7W4lmAx5USGRWDZ3qYjtz2du/NdrfjXvtb/ANnnSxbcbfPEhfpznBx1zQBr0VgY8U/3tE/75l/xox4p/vaJ/wB8y/40Ab9QrcwNdvarPEblEEjQhxvCkkBivXBIIz7Go9O+2/Zh/aX2c3GT/wAe+7bjt15rjvF/gq+1zxMNRgv44LYw20UkXzhpBE8zEEqRwfNHBz92gDsor+0lvprKK5he7gVXlhVwXQN0JHUZqaeaKCMyTyJHGMAs7BQMnA5PvXkWh/C/XbK7tbi+1qK6IdTdKs1xEZisUCJLvVwd6+Sx5yMSMPc2bX4aavaaXp8UOsA30dksFzPJPMxklE0TmQEsSNyxbSPf3NAHqNpdW97brPZzxXED52yROHU4ODgjjqCKhttV066dEtr+0md3eNVjmViWT7yjB6juO1cL4K8DavoWvRXV/qi3NnGJDHDFPKixMzSEjy87XB8zPzdCAewxHrvw9v59S8QXeh6hFp41CW1njiRnUblcNcgkfc84LGGK8nZk5yaAPSqK4fwj4Y1vQdR1K4k1P7Vby26R21tPcyTCORQBnew3BTgZHzdyMdK1mk8WBmxa6Ey44JuZRz/37PvQB0VFc7HL4sDfvLPQiuf4buYHH/furcU2vGVBLY6Wse4bit7ISB3wPKGT+NAGszBVLMQFAySeABTI5opCojkRyyhxtYHKnofp71BrFs95pN7axbfMngeJd/AyykDPtzXm1l8OtY0dli0rU1Olqseyx8+SFo18ucPCsyfMIhJIkijttK9AKAPVKKxLaPXbHTNPtl+x6jcRW0cdxc3E7QtLKFAZtqxsOSM9utMjufEzE79L0hfT/iYSHP8A5BoA3qKwBd+J8H/iU6Tnb/0EZOv/AH56Vp6c+ov5n9pW9pDjGz7PO0ueuc5RcdvWgC5RRRQAUUUUAFZereINJ0iUR6nfwWzlPNIdvupuC72/urkgbjgZPWtSuO8TeCjrOparcw6h9mj1bTl0y9jMPmFo1aQhkO4bWxK46Ecg4yKAN6PXtLl1ddMjvYnvmiaYRqcgqrBW+bpkMygjOeRxV/7RDu2+bHu3bMbh970+teWw/BqxgkQQaiUhhleS3Athvi3XUNwfnzy2YAm7AO1qv+D/AIV2Hhy90afz7e7/ALMSZYy9kgkkZxGBI75OZB5Q+YAZyaAOvj8SaXLqMljFPK9wk3kNtt5CgfBJG8Lt42nPPBwDgkCrralYqsRN5bnzv9ViQEycE/KP4uAenpXl3jv4QJrj6xqFjerHqV0JpEhWPyopnaGaNfMwSCwE2N4AOF5zVHQfg3PJp3m6vqCQ6iZUkDpbI7ErO0+6TJI3s7NkKduMAUAekab400LUtVm0+yvGkuIYfPlJhkVIl2q2HYqAp2upwSDz7HGjJrmkxx75NUsUTyvP3NcIB5edu/Ofu54z0zXncPwasks4YX1m9aWIh1lEUancFgCk8cgfZ0+U8Hkd6ua18KoNY1xdTu9ZuVf5N0MVvEsTESQys23b95ngQljk44zjGADuLXXNKvPO+xajaXRhiWeRbeVZSsbAlWwpJwQCR69qy7Pxz4fvZbKO2vnY3ltDeQlraVVMMocxuSVAUHy364xjnGRVXwr4Ht/DcWpJZ39y4vohG/mKnysC+GGB/t4weOK5tfgtokUNrHb3csKwWcFmQkEWJfKimjDuNuGYidsk9cCgDu4/FGgSpK8euaW6RIskjLdxkIrEhWJzwCQQDViTW9KjujbSanYpcBd5ia4QPt27s4znGOc+nNcJpnwls9Mjg+xaxfiW3aOSIyhZVRkEqjhgSVCzMoUngBfSmw/CfTrGwstPsm862TUIbqSW4YCVIo7cQNGuF+cOiBGBIGJHPoKAO6vNd0+zuZbeaZzLFbfa5FjiaTbFkgMdoPUg4HU4OBwavPcwJcpbtNEtxICyRFwGYDqQOpFcv4j8InWJtajFwsNprFglncELmSNoy+1k7HIkYEHGNoIzk1GPA8Y8XyeIzfB9SkhEXmS2kTtGVMgUxsRlMLIVIB+bHPfIB1T3lrHdC2kuYVuCu8RNIAxXOM464zxmkkvrSJS0l1AihQxLSAYBOAfpkgVxfin4cWmv69cas2o3NrcyJEoEKjbuidHRmU8PgpxkZG4jOMAcV4i+Cs0eiww6Lfi4uxcQM000SJJHGgnJ2EDBLNMAQccDg5AoA9rN3bhmUzxBlUMwLjgHoT7GpEkRxlGVu/BzXkWlfBOwhtbYXs1m0gktriWNbNZFV4/LLxq7/MYiYhhT0HrgAdd4Q8LT6Bf3U9t9mtra6u5pJLZfn2QkkxxxnACje0khGODIRz1oA6M6tYrZyXUlwscEYkZjKChAQkMcHBwNp59BnpSaTq9lq2nRX1lKxtpE8xWljaJtv94q4DAHHBI5HNeZz/Ba1ltWiOrtv2qiSfZEyqiS6Yjr3F0R/wAAXr0qzafCK2szK9rqSiczw3KSyWgZg0ZjPlt8w3RExL8nGOOeBgA9GXU7J7wWqXEbzneCqHdtKhSwYjhTh1ODg4Iq0JEJUBlJYZAz1FeZD4R2itN5OoLbRvLPMI7a0WNVaUQZUAH7gMA+XuGIJ71HH8J/sWrT6zpuqRpqpuxfRFrUCNJAtwNgAbIjJuOR/sD1oA9PmmigjaSeVI0VS7M7BQFHJJJ7CnqyuAVYMCAQQc5FcJ4z+HVv4p1W+vLq7QLd6adOMcsHmeScTASxncArfvjnIOcDpzVzwt4Ok8P6ldXUV7azG4l8xmaxCyqpVA0auG4TKKQuOMAc4oA6fTr621G0W5spRJCWZM4IIZWKspB5DBgQQcEEEGrNc94a0W70uw1RjNEl9qN5LenKl44S+AFxkbsKq55GTk1Otp4gCgNq+nE+v9nOP/a1AG1RWN9l1/8A6C2nf+C9/wD49Uctn4jYDy9Z01Prpjn/ANrUAbtFc6bDxR217TP/AAVN/wDH6lWy8RbRu1rTye5GmsP/AGrQBu0Vh/YvEP8A0GrD/wAFx/8AjtH2LxD/ANBqw/8ABcf/AI7QBuUVh/YvEP8A0GrD/wAFx/8AjtH2LxD/ANBqw/8ABcf/AI7QBuUVh/YvEP8A0GrD/wAFx/8AjtH2LxD/ANBqw/8ABcf/AI7QBuUVh/YvEP8A0GrD/wAFx/8AjtNey8RFTs1vTw3YnTWI/wDR1AG9RWF9i8RYH/E70/Pf/iWt/wDHqY9j4lJOzXNNA7Z0xj/7WoA6Ciud+weKP+g9pn/gqb/4/TnsfE5Yldd0xR6f2W5/9r0AdBRWCll4kV8vremsnp/ZjA/n51S/Zdf/AOgtp3/gvf8A+PUAbNFY32XX/wDoLad/4L3/APj1H2XX/wDoLad/4L3/APj1AGzRWN9l1/8A6C2nf+C9/wD49R9l1/8A6C2nf+C9/wD49QBs0VjfZdf/AOgtp3/gvf8A+PU02niHnGr6YPrpr/8Ax6gDborG+y6//wBBbTv/AAXv/wDHqdFba4JUMup2DxhgWVbBlJHcA+acflQBr0UUUAFFFFABRRUF7HNLayJaz/Z5iPll2B9v4HrQBPRXPnS9eIIHiJQT3FinH61CmieIQ6l/FkxXPIFhCCR9cUAdNRWHHpGqDPmeJL9vTbb24/8AaZobRdRLg/8ACTaoo/uiG1/rDQBuUVk/2Vef9B/U/wDv3bf/ABmop9FvZVA/4SPV0wc/IlsCf/INAG3RXN/8I1ff9Db4g/8AJX/4xSv4bvWYkeK9eUeg+zY/WGgDo6KwY9CvkVF/4SfWmCnPzJa5P1/c1KNHvdwP/CRatwMY8u1/+M0AbNFZA0m9x/yMGqH/ALZ23/xml/sq8/6D+p/9+7b/AOM0Aa1FZP8AZV5/0H9T/wC/dt/8Zpr6TekceIdUU+ojtv8A4zQBsUVif2PqG7I8Sapj0MNt/wDGad/ZOof9DFqP/fm3/wDjVAGzRWN/ZOof9DFqP/fm3/8AjVMl0jUzGRF4kv1fsWgt2A/Dyx/OgDcornm0fWisgXxPchs/ITaQHA9/l5/DFKml6+qgHxGGI7mwTJ/I0AdBRWB/Zmvf9DCv/gCn+NH9ma9/0MK/+AKf40Ab9Fc9JpfiEofK8RxK3q2nqw/LcKYmmeJ1Ug+I7Nie50vkflLQB0lFc3/ZvifOf+Eisvp/Zf8A9tobTPE5xjxHZrj00vr/AORaAOkormxpfiXA3eJYN27JxpqgbfT7/X3/AEqX+zNe/wChhX/wBT/GgDforA/szXv+hhX/AMAU/wAaP7M17/oYV/8AAFP8aAN+isD+zNe/6GFf/AFP8aP7M17/AKGFf/AFP8aAN+isD+zNe/6GFf8AwBT/ABo/szXv+hhX/wAAU/xoA36KwP7M17/oYV/8AU/xpG0zX9p2+IkDY4JsEIH/AI9QB0FFc7HpfiIbvM8RxNzxt05Rgf8AfRpX0vxCQ2zxHGD2J09Tj/x6gDoaK5oaZ4oCYPiSzJ/vHS+f/RtA0rxN5ZB8TW/mZ4P9mLjH03/1oA6WiuZTS/FCnnxNaN7HSx/SSpP7P8Tf9DBYf+Cw/wDx2gDoqK53+z/E3/QwWH/gsP8A8do/s/xN/wBDBYf+Cw//AB2gDoqK53+zvE2f+RgsMf8AYLP/AMdo/s/xN/0MFh/4LD/8doA6KiudOneJsceILDP/AGCz/wDHaP7P8Tf9DBYf+Cw//HaAOiornf7P8Tf9DBYf+Cw//HafFYeI1lQy67YvGCCyjTSCR3GfN4oA36KKKACiiigArA13xfomhXc9tql20M0FqL2QeS7ARGQRhsgEE7iBjr3xit+uJ8ZfDjSfFmrTajqMswnexWxTCRsIgs3m703KcOT8ufQ/jQBetfHegXbiOzupriV7hrWNI7aQmWRd24J8vIXa2T0GOSMjPR2dwl3aQ3EayKkqB1WWMxsARnlWAIPsRkVwsPwv0uDWX1i3vryHV3cs1zGkI8wFXVg6bNrFg/zMRuOxOeOdWx8Iy6Xoel6VoviHVtPtLC3W3Xy0t5Glx/G5kib5j7YHtQB1VFc1H4d1Vfv+Mteb/thYj/23pJfDepyFceM/ECY/uxWIz/5LUAdNRXPL4fvx18Va43AHKWn/AMYpT4fvSMf8JRrf4Laj/wBo0AdBXL6L470DVbWOdL2K2WWQxxC4lRWk+6M4DHHLquGwQxCkA8V0+OMEn61wS/CnQBez3Zlv2ubsoL2UyruvEQoypL8vODGp3DDnnLHJyAdBH4w8OSW7Tx65prwqwUulwpAyCex6YBOemAT2NNm8aeGIHlWbxBpUbREK4a6QYJJHrzyCOO4I7Gufj+FOhwyxzW91qUVzHbraJMsqFlhCupTlCMMJGycZ6EEHmsTwn8HItG16a9m1Sf7It79ttrWEJtjZZpHjUMyl1QLIQU3EElmyCaAO+/4TDw1uRTr+khnbYoN3Hy3y8Dn/AG1/76HqKqaX498OX9qZjqdtaOrOskFzMiSRlDJnIyR0ikPXop9DXJp8H7SLX/PTVb99KuIJUv4ZpA8t07mEfM5XgbYVBxhj6jnOpcfDDS/MtPIkkeNJoWnFwdxZIpppgFwAAWeeRGzkFHYY6UAd+CGAKkEHkEd6Wse+0e7ubqSaLX9VtUbGIYVt9i8dt0RP5k1XbQL4ggeKdbBPcJa8f+QKAOgormB4Z1MOGHjTxDgfwmOxI/8ASapf+Ee1LcD/AMJhr308qy/+R6AOiqK7uI7S0muJyRFCjSOQCSFAyeByelY9pomoQXMUsvijWbhEYFoZYrQK49DtgDY+hBrV1G1W+0+5tHkeNZ4miLx43KGBGRkEZ57g0ActofxJ8L61qa2FnqSpctFHKq3CmHeJAjIF34yWWRCAP73rkVuv4i0VJUjbV9PDu5iVftCZLhSxXr1AVj+Brkh8KNAWxsrSGS7ggtrS3tCsIiTzRDNHKHchMl2aFAxBGR2B5pkvwn0ia0FtLqOqtCtv9jUB4wRb+VLGIs7OQBO/zH5unPFAHYrr+jskTrq2nlJSRGRcphyDggc88+lNTxJockfmR6zpjRhd+4XUZG3dtznPTcQPrxXmWu/CfULnxvHq1hqaNbTNHNeNc7SZJFZQSYhHtbEaKEGRtbLHOa0Nc+FKMNPn0XUbjz7NbOBILpoxB5cM0MjNtWI5kIhHPc8HjigDsoPGXh6bU7iwXVrNZ4Io5iXlVVdHDFWRicMMKckZxW7FLHKpaJ1dQSpKnIyDgj8DXmdz8H9JFjexW9xczG4ZpTDOyLEzlLlTnamQpN3I2B0woGAMV2ltodxaaXYWVlq11ALaPbJIEjdp27u29TyTknHc0AbdFY39lal/0MF5/wB+IP8A4imvpOpspA8RXqn1EEGf1joA26K5xtB1cqoHi3VAR1ItrTJ+v7mnQaJq0cgZ/FWpzD+69vagH8ogf1oA6Gsmx8R6Re2NndxX0McN5u8jzz5LSbSQcK+Dxj0rWrzLUvhSk+lWdtH4g1aQadHJ9kgkaFImdsnMpWLcwJPPPHUDPUA7yPXNJlWNotUsHWQsqFbhDuK/eA55xkZoi13SJo43i1SwdJFZ0ZbhCGVc7iDnkDa2T2wfSvOIfg1Z3Fnp732r38F/FHEbhbIxiCSRIY4h8rRnIAjOM8/MSewGxJ8K9FfTI9PM939lWK3jZCIm3tDE0SucpjJVuRjaSOgy2QDsBrelE4Gp2JOwyf8AHwn3f73Xp703+3tH8xY/7VsPMZDIF+0pkqMktjPTg8+1cnpXww07TNNudPt9T1N7Ka6hvljmdJDFPE0bIysylsfuUXaSRtGBisqz+FcUXiLXL268q8srmVbyGKWTDT3B+0F/NIj+RC1wQAuTgDOeQQD0+3uIbhS1vLHKoOCUYMAfTj61JXM6N4Ym0vw3pml2WrXlm1rEFllhWKRpnwMljIjZ5zjpUo0LVhKGHizVSoOSjW9pg+3EINAHQ0Vzp0LVyuP+Et1QH1Fta57/APTL3/SpYNG1SNcP4m1CU+r29uD+kYoA3aKxv7K1L/oYLz/vxB/8RWtAjRwxpJK0rqoDSMACx9SBgflQBnW/iDS5xeFbyNFtLk2czTAxKJgAdoLYBPI6ZqVtZ0tfN3alZDynEcmZ1Gxj0U88Hg8e1cd4g+GcGtW1/aya7q1taXt5LeyxW4hGXdAhG4xlguBjAPOTnINYB+DUOr6XMut6hLZ3cr3KN/ZwjAMMlxNIFZmTLHEoyeOhUcFtwB6iNX00vsGoWZfzPJ2+eud/93r19utJBrOmTpG8GpWUiSbtjJOrBtud2MHnGDn0wa4sfCvS1t/KS7uF80TpcOI4laZZpxO33VABDKAGHIHHOAaqt8H9Leymsn1TUHtJhEsgIj34illlj2tt4+aZsnGWA7ZOQDvINc0m4JFvqdjKc4wlwjc5x2PrxV+KRJYw8Tq6HoynIP415TffByxWxuEsbuWSd12xmUrGY28q3jEgZUJyv2ZXAxgtnoDXoT6RLFFbwaZqM9hawRLEkMUcbjA6HLqTnGO/agDWorn30jWifk8Szgc9bOE/0p8Ok6wM+d4juH9NlrCuP/HTQBu0Vjf2VqX/AEMF5/34g/8AiKWPTNRWRWbXrt1BBKmCEZ9uEoA2KKKKACiiigAorz/xHoGl+IviZb2utWxuoYtIaSONnZVDecATwRzitaT4d+D5SDL4a0qQgYy9upP60AdVQTgZPSuVX4d+DFXaPCmhkf7VjGf5ikj+HHgiJtyeD/DoPr/ZsP8A8TQB0pu7dRkzxAepcU03tqDg3MAPoZBWH/wgXg//AKFTw/8A+C6H/wCJrzs3HhD/AIU/d+NB4G8OefBbSzGzFlCRlXZAC2zIBK5zigD2D7daf8/UH/fwU19SsYxmS8tlHTLSqP614vp3ivwS+ozWl74CtrQPqEem2SNpUSvJIyxEKykDaf3hPptQmqlt8Q/h1caaLpfA9srlVmERs7TJgMMkpk3Z2ghYn+QkNkAY5oA9s/tzSf8AoKWH/gQn+NKut6UzBV1OxZj0AnT/ABrxLUvHfgOG9kt7bwdpKiG/Fs8s9nbhWiWYxSuAOVIIyA4GQapy/ErwC+lLNb+BLSO4mtL2eIT2EARXgieQKx6/OE445z9cAHv66jZPnbeWzY64lU4/WnfbrT/n6g/7+CvINF8ReBtb1S802x8I6THeWl6ttILiygUGIB2kmXAPyqI359cD1FczofxN8AXmh39/deDNJLw38kMMMFlCpa28p5kmYyBVBKRSfLnJZcDrQB9C/brT/n6g/wC/go+3Wn/P1B/38FeKP418Au16LPwFHcNb3aWYP9mQIsshDZCu2BxsI5PTBqCb4g/DdLLVLyDwMsttZQwzGUaTCFkMnlfIDjAYCZDgnkBiMgcgHuX260/5+oP+/go+3Wn/AD9Qf9/BXinhzxH8O9Z8Safo3/CF6P51/PcRW866db+UFjZwuTjqwQ9K9P8A+EC8H/8AQqeH/wDwXQ//ABNAG59utP8An6g/7+Cj7daf8/UH/fwVh/8ACBeD/wDoVPD/AP4Lof8A4mj/AIQLwf8A9Cp4f/8ABdD/APE0Abq3dsxwtxCTjPDjpU24biuRkdq5z/hAvB//AEKnh/8A8F0P/wATXMfD3wT4UuNDuXn8MaFI41G9UF9PiJCi4kAH3egAAA7AUAel0Vzf/CBeD/8AoVPD/wD4Lof/AImkbwD4OYEHwn4fweP+QdD/APE0AdLWH46sL7VPBmuWOjyNFqVzZyxW0iymIpKVIVtw5GDg5qjL8OfBMrZk8IeHmPvpsP8A8TTV+G3gdTlfB/h4H1GnQ/8AxNAHEnwn4wi1Dw5f28bOdPBS+tp9VfbextIXAwPlVoyAQed27DcZFEnhz4lTNPjVYYZm1KPVraXz2McGVPmWboDl4ugGCM5zgVd+INn4E8FWkE914K0e4WaO5kAjsoRjyYHmPVe+zH41qa14d8EaXb6TNJ4P0R11C7htF/0KIbDJ0J+X9KAOQsfAHjieOX7fr+pwyQWMggdNScvPcedclQ5BwAySwhiB1jAGNoq3qPh3xxfX9gwGoW9rDo6WLrDrGHNyDjzt2fvY53EMTgZHJxnXHib4W21lcSXPg/To54UnYp/ZaNHmJrgBTIEwCwtZSB7Vp3WpfC2C0muh4RtZoEuHto3i0RSJ2Tf5hjO3DBfKfJ9vcZAO/wDh7p2q6T4VtrLXrj7TfRPIDMSdzpvOwt8zANtxkA4B6V0leKy618KkuIUTwhayxSyyRCePRYzGAhiDOeM7AZo+cd/aqmqeJPhBaWsVxP4U02WNihX/AIlUGQGaVc4bB48l849vWgD3WivE9C1H4Y6h4rTQIvAmnRai9zcW5P8AZMDopilkjDMVBwGMUmOOMc4yCfRj8P8AwaWyfCXh8nGOdNh/+JoA6aiuWk+HfguRFV/CPh5lXoDpsPH/AI7TT8OPBB6+D/DvTb/yDYen/fNAHV0VybfDbwOxy3g7w6T/ANg2H/4mk/4Vp4G/6E7w7/4LYf8A4mgDraK5MfDXwODkeD/DwPqNOh/+JrmfBnw/8HT33ikT+FdCkEOrPFEGsIm2J5EJ2jK8DLE4HqaAPUqK5Rfhv4IUEL4Q8PgHsNOh/wDiaavw18DqwK+D/DwI5BGnQ8f+O0AdbRXnHjTw74P8N6XZ3Ufg3QJ/Ov7Wy2myiXAmmSMt93tuzWB8N4fBvjW5uo5vAvh22WG0trhD9kicuZWuFI+4Oggz+J9KAPZqK+dNQ1zw1pGoanHd/DvwsbCC6vbS1aGKPzC1tjJkTy/lVgeCCefrVyfxf8Lba9vVufBVktnE0UdvKulxM9yWa4V2VMZ2L9mbk8npjpkA9/or5/fxX8Nbe3vvtngbT0ubeS5QCPTYmjIjlljj3NtBUuYT24zWjpWvfCy7s4JLrwfY2Vy4/eW8ukxloz/o/GQOR/pURB9CemMUAe30V5r4I074ceMrK8udF8L6QY7S5a1lWbTY0ZXABPBHow68+wro/wDhX3g3/oVNC/8AACL/AOJoA6eiuY/4V94N/wChU0L/AMAIv/iaP+FfeDf+hU0L/wAAIv8A4mgDp6K5Y/DzwWSCfCegkjkE6fFx/wCO1X+Dyqnw00FEGFWEqoHYB2AFAHY0UUUAFFFFAHJN/wAlZj/7Aj/+j1rra5SX/kqtqeMHRZfr/r4/8a6ugAooooAKzY9D0e3tbiCPS7CK2nTZNGtuipIoycMMYI5PX1Nec6BYp8Ub3WNS1+e6/sS2vPslnpUVxJEF8o8yTBdpLsxyPQDgnNO8TfBDw3qGiahaaL5+l3FzEyo3mtPGGPcpJu4+mCOxFAFvWvFvwvXxBY3GoeINCGo2M7Tx+XdKVExTy9zhTtLBSQC3I7Yrf8J6L4Kl8N29p4YtNEu9FhdXjFv5dxH5ijActzlwP4iS3vXxT4O07wu1p4jXxdoxW+0ZWaUw3DxhyG2lQM4DbsAcgEnp2r0j9m7wDY+Lb298UTsdG08TPbWenWU7AykKC5ZnJJUBgOOpz0xyAfT9h4a0DTHuVttNs43vrp7uXegZppmZnZiWyScsxHpnjAq1DoWkQIiQ6XYRokbRKqW6AKjY3KMDocDI74rg9R+Emh2Y/tLw7eXeh6xaq0kF8sxdY2xyXDH5kI4Kk4I9+a6j4d+IZPE3ha2v7r7MLwExzrbtuQMOQRnsylGHswwSMEgGvDo+mQXM1xDp1nHcTkmWRIFDSZGDuOMnIA61m+J/BugeJ7EWmtack0GFBEbvCSqhgqFoypKje3yk45PFW/FOsxeH/D19qs0bSJbR7ggONzZwoz2ySBntXD6H4FvPEFjbav4x1/V7jULqIS/ZbO7MFtbbuQEVMZIGBkk5569aAO8XStJtFkmFjZQj5Wkk8pRnau0FjjsvGT0FYK3vgG/lks1ufC1zJOiQPAJLdzIqH5EK9wpxgdu1eQfH/wCH17pXhNtbi1fWfEGlWMqy3ulapqEzo8ZONylWXBXPoeOe3PFav4b+EVj8JrPx1HpGpSNfN5EGmG/cf6QN25C3XaNpJb0A7kUAfWiaNpkd3FdR6bZLdRFzHMIFDoW+9hsZGe/rV+vCvgr4C12bwZY32q+JNY02zvohNb6VZXUgW2iblAHdmYZUg4GMZ9c11viS21TwHbtr+m6rqOqabDsS806/uDMzqWChonbkMCw46HnuACAekUVHbTx3NvFPA4eKVA6MDkMpGQakoAK5P4ZsH8O3LKcg6nff+lMldZXH/Cv/AJFef/sJ3/8A6VSUAdhRRXmWrC5+IXjDUNEg1C/sPDmjjyr5rSYwy3Vyw4TI52Kp57E9iMEAHptFeY33wN8C3SYTTrm3bHLRXchzznJDFh19q8h8I+B7LUvHfibwnDqupaD4x0WU3Fnq1lI0Yurc4wZIgQuQHQHbtBB+uQD6c1nRNM1qNI9Wsbe8RA4VZkDAB0KMOfVWIP1qve+GNDvtJfS7vSrSXT3k84wNGNu/Odw9DnuOa8++CXj/AFTXNQ1zwj4w8r/hKdBkKSzRDat3EG2+aBxjnGeACGU9yB6zQBzy+CfDCWy266DpogVBGI/s67doWRQMY/uzSj/gbetMm8C+FZ1vFm8O6VIt3MLi4DWyESSDJDHjk/M3/fR9TXSUUAZTeHNFc5bSNPY/PybdP4yrN27lEJ9dq+gqi/gXwlIZfM8MaI3my+dJusYjvk5+Y/Lyfmbn3Nc54mu9Q8W+M5PCmjahcWGm6fEJNYu7WTZMHcBooUbquVySR2PXggwSfA7wLJbNG2lymVgd9wblzIxP8XJwD9AKAO6h8P6NBfpfQaRp0d6jySLcJbIJFaT77BgM5bue/etOvlm18CaVD8XNU8Ey32o6Pq7Qi/0XW9PnaGWSPGTHIikKxXD4YBSQhyc4r0f4R+M9fTxhrHw/8dyxXOuaZGJ7a/jAUXkBxgkD+LDKfzzyMkA9fooooAKKKKACuV8Df8hDxd/2Gn/9J4K6quU8DADUPF2P+g0//pPBQB1dFFFAFbUILOe2zqMVvJbxMJv36qVQodwfngEEZz2xmvNZPiD8PrPUkTRrFdTvoAGB0rTd5jVQwDB8AbQJHGVJxvb1NTfGO+muLzQfDC6iNOstXdxeXC8OIlaNQoJ4AZpAD65AIKlq77Q9L0/R9Nt7TSbeKC1jjVEEY6qBgEnucdzQB5RZ/Eb4UXGp3ZksbK3vrxXF476YrSOM5bziiscZGSW44yTxXe2PhrwZrFg97Y6NoF9Z6hIt000VtFIlw4LYkJAwxBZ+f9pvU1mfGnwyPEPgPUXs4gNa09Pt2nzoo8yOeL512n3xt/GvNNJ1dfCen+HPiF4XOzwh4hlij1zSUH7q0nc7DPCP4MSZVgODx7EAHrGq+EPBdje3XiLVtL0iEpCyy3N1GgijVmcu3zfKpYyNubqc8151q3xC+FEmp20EPh2HVriOUT27w6bEoLYVfMjMpTcMRoNy5GFXnAFRandweNfEvijxD4qZj4G8GTSRQaeR8l3cxLmSSQfxAHhV5ByPfPW/AHR5bbwQmu6nAia14glfUrltuCFc5jQHqFCBcL0GTQBU8NfEDwR4e/0QaNc+Ere9nLI9zYrDDPIVBLb4yy9Mckgce1erIyuiujBkYZBByCKpa3pljrOl3Fhq1vFcWUyFZI5Bxj19j79q8v8Ag3rsNprmq+Gk1pL7Rg5OgO7qxmhTPmrGwxvVCyqMcYVscdAD16iiigArj/hF/wAk40PjH7pv/Q2rsK5D4RDHw50QHHETDg5/jagDr6KKKACiiigDj7g/8XesB2/sK5/9KIK7CuPuP+Svaf8A9gK5/wDSiCuwoAKDyKKKAKOl6Rp+kx7NOtIbcFFQlFwWC5wCepxuPX1NXqKKAPgr43aZND8WPiGlhbzyRlUmkMMW4LveF2LHPAyTzzzgY5yPp34AeEdLtfhn4M1GayhfVILSSWK4OdyCZ2dh+TYrzz4pvoth4i8a+fHeHXZoprqLy7iWOJ44oISI3VWAKlRKSeDjjPPHvngK3S08IaXbQqyRQxeWqsSSACQASevSgDeZQylWAKkYIPIIpsMMUIIhjSMHBIVQM4AA/QAfQCn0UAUtW0u01a3jgv4zLCk0c4TcQCyMGXODyMgHB4OOal06xttNsorOwhSC1iG2OJBhUHoB2FWKKAMPxzYxan4L12yuADFPYzRtkZ6oa/Pm1l/tjwn4U0BJGaU61dAxqpJAlW0VT75KvgD0NfovrAB0i+B6eQ//AKCa4E2cEXwe8OkW8SOselt9wAhjLBk/WgD0eJFijSOMBUUBVA7AVFd2dteGH7XbxT+TIJY/MQNscAgMM9CMnmp6KAIbK1gsbWO2tIUht4htSNBhVHoBU1FFABXH/CsH/hF5899Tv/8A0qlrsK5j4boE8LDaMZvr1j+N1LQB09YGheFbDRNSuL6ylvPPud5uPMmLiZmfdvYH+JeQMYwGIrfooAK+ev2iRJ4D8d+EfiXp0ZPlT/2fqEa8edGVJA+pTzBn1C+lfQteffGvSLHX/Dmk6RqsLS2l9rFpA4VypAL8kEe2R+NAHimt69d2H7Rw13wTc22pXXiXS4vs1rHB5rvE0KMC4aSJV/1Qbl84HI5FbWueIvFp1Ax+Jr74h20pX5bLQfD8MSk5/hlEsob/AL6rtr74Z+HPDfj3wRrmjW81veRTrpgXzSyNEtpPgkHkthFGc9q9coA8U0bV/HPg3SYtd8Vmabw88wSe3v545r2ziZgqyu0car3yVG7GVHHzMvtSsGUMpBUjII5BFed/G27kl8H3miQ6deXE2p+VbxTIo8kO8qqFZs5BP07j3I77T4WtrG2gdgzxRqhI6EgAZoAwtL8IWmmeJrzXLa8v/td6zvdI0gMcxIQLuG3ogTC4PG5uuTXSUUUAeB/tSaZcaMfDXxG0cY1HQLtI5h0EkLNkBj1xu+XHpKa4X4meObqb4y+AfFfgG3iv73UtIRIbWQY80vJKhjc5GCCSDzwVr3v436bDrHw21DT7niC5ubOOTDbTsN3CGwexxnFcf4k+E3h3w7P4J1PRFu4LvRr60s7cNLuR0e53OXBHLZkc5GOvTAFAHK65408ZPOV8Uah4u0B1O42mkeGUZW9knMsgb68Dit7wzqnxDsdIu/EiQ6rPocH7wWPiGaEXlxCBlpAscS+Vgdix6E4PGfd65b4k6yNH8Kaiz2d3cLNbSx74FBWMlcAuSeASewJ9icAgG3oep22taRZ6lYsWtrqISoSMHBHQ+46VermfhnpV1ofgLQ9Nv0Ed1bWypIgOdp64/WumoAK4/wCHspmvPGDMu0jXZVxnPSGEZ/Suwrjfhxj7V4xw27/ifT8/9soqAOyooooA57XvBmg+INSS91qwW9lSIQhJpGaLYHD4Medp+ZVPI7D0roFUKoVQAoGABwAKWigAr5X+I0tr4Pt/iP8AD1sJYanaDxBpCZ+428NLEAewaJmA9Fb1r6orzPXvCmjeIfjIJdc06G8Efh8xx+YTwGlkRxgHByshHPrxQB41oN3D4o0zw34AgcuNa1+91LVlU8/Zorh22k9t2zH4V9YIqoioihUUYAAwAK8ssfAPhrwt8UfDE/h7S1sZDYXkZ2M7KVXy8dSfmzIxz1Oa9UoAKrQWFpbzNLBa28UrZy6RhWOevIHfAqzRQAUUUUAFcp8LM/8ACBaTnrtk/wDRjV1dcr8Lf+RC0r/dk/8ARjUAdVRRRQAUUUUAcndqB8VtKbHzPot4CfYT23/xVdZXIaiT/wALb0HHfRb/AP8AR1pXX0AFFFFABRRUVzk28qrN5DlDiTglOPvYPHHvxQB8w/G/Q9P1/wCIWoSLqlpBcRSQwSJKSEIYQLl3HC45yD2U+lfRPgx/M8M2MokjkSRWkR4+VZWYlSD34I5qpoMeheGdIi06LUbdxvbzJJpUMk8rv8zPtABYs3PHfsKi8N3OhaDAmkWWtR3MTuZbWDzEfyIndVWJNg+4GkULnJAIGSBwAdVRRRQAUUUUAZnieRYvDWrSSHCJaTM30CGuZ12N7f4ZaRFIpLI2mI4BHa4gB/rW1rkcXibRb/TtO1OCKN3a0vHVfMZF5WRByNrnkZOcehqTxLb6bq+g32l3N5FBHNARvR13RY+66g8ZVsEcYyBQBt0Vn2F2I4rS1vr61n1B1wTEuwSkDJKpuYgd8ZOPWtCgAooooAK5v4d/8iuv/X5ef+lUtdJXM/Dnd/wi43Y/4/b3HHb7VLQB01FFFABXHfEpWePwyFUtjXrMnAzxuPNb0uuafFr8ejSThdQe1a8WMj/lmrBSc/U9PY+lc5qXxN8M2C2xmuZ5DcYMQit2YsuwPu6dNpzmgC/4y/5C/g7/ALDB/wDSS5rp689i+K/gy7Ec0t1IsUcTXcc01q4UKuVZlJHUZZeOeorVsPiJ4ZvmdYNQO5EMpDQuDsz97GM4759CKAOmvLO1vViW8t4Z1ikWZBKgYK6nKsM9CD0Pap65G1+I3hi5+z7dS2C4iM8ReJwCgcoSeOBuGOcdRXUWdzFe2cF1bNvgnjWWNsEZVhkHB5HB70ATUVFdTrbWs08mdkSF2x1wBmufm8b6HB4fi1m4unjsZJfJ3NG25XGcggDjAVjnpgZzQBH8SYWuPDUESRtITqmmkqqk8C+gJPHYAE0/x6rNZaQFVmP9r2R4GeBMvNRxfEHwvLJMiatHiG2N5I5RwqxYBzkj0IOOtN1X4heHNMuvs1zeSGfDMyJA52BTgk8ccjH1oA6yoL20tr+1ktr63hubaQYeKZA6MOvIPBrkh8TfC/mXCSXssRhZEO+3cbi+Nu3jnIZT9DU1v8Q/Ds0F5L9raP7I22ZZIyrJwMkj0ywX68UAdcBgYHSiuEl+KvhaAr9pu54VMqw7mhYgOyqyg4zjIb9DXcQSrNDHKmdjqGXIwcEZ6UAPrivhoQbjxjgY/wCKguP/AEXFXa15b4M8M2mr6l4wuJ7zWIJBr9yuLTU7i3T/AFcX8KOFz74zQB6lRXJf8IHYf9BbxP8A+D27/wDjlSweCrKBiyar4jJIx8+s3Lj8i5oA6iiuWvPDFrbW09xJqviARxxs5C6nMeAM8fN14rgvD2u+H9e1TTtOstW8areX0cM8Mct8QfJlgaYSnDH5AFKE9nwOc5oA9mrl1trhvidLdfZ8WsejpH5+37ztOx2574C5x/te9cD4013w94P8WaZ4f1bWfGRutQWN45YtQzGoeQxjdlw33hzhTgc1a0zxJ4PvLQXieMfEEW21juZEkupD5auE2qcKVMn7xPlBLfMPWgDttbtZ5fHfhm5SGR4IIbwSSKuVQsI9uT2zg/lXTV5PN4r8GQxeY/jfWimxJMpJK2AxIUHEZwcqwx14PHFWX1/wklp9pPjfVfIOSHFy5ziJJTjCc/JLG3H971oA9Porx+Pxt4KaaRZPGmtxRAwiOeSdhHN5qb12nbngdcgY7133/CL/APUc13/wL/8ArUAdFRXO/wDCL/8AUc13/wAC/wD61RS+D0lbLa94iB/2dQZf5CgDp65X4W/8iFpX+7J/6Maj/hC4v+g/4k/8GT1H8Jo/K+HmjR7nfZG67nOWOJG5J7mgDrqKKKACiiigDj9R/wCSt6B/2Bb/AP8AR1pXYVyGo4/4WzoPBz/Y1/z2/wBdaV19ABRXl82p6l498VX2j6Xq8mjaFYrHN9otcpdXwLOpMbngRBkKlgDkjrzirknh7xX4WWW78O6/c67Aqs8mn61JvZ8dPLmABU8Y5GOcmgD0Ssq68P6ddaw+p3ELyXT2v2Jw0rbGhyxKlM7Tksc8c4HoMfO0v7WNqJTHF4RuS+NoU3q53+nCcivWtH8Hap4ht/7R+Il7NJezopTTLGd4LaxHUqCjBnfnBYk9MDigBlz8F/Bc+sQX5sLlREmw2wu5DE/AAyCxIxgfdI6c55z0eg+CPDugavLqek6atvfSo0byiV2yrNvIALED5iTwO59ayNK8P67oPiwLo13c3Ph1oY1mi1S9ebYdzZ8knc2VAHDYB3deOO7oAralewabp11fXb7La1ieeVsZwigkn8ga8CuP2gfEGqRfavBnw21nVNMLsqXhDsH29RtjRgD/AMCNfQkiLIjJIoZGBDKwyCD2NfI9vrTfBb44+LtJ0oP/AGDcWE97BZFiY1kFuZ0wPZlZPofagD2H4c/F+bxJ4oh8NeJPC1/4c1ue3NzDFO25ZFGcnlVZehIyO3WvWa+Z/wBkbTZvEF/4l8ea9NJe6zcT/ZUnlOSoIDOR6dVUY6AYHFfTFAGFL4T0aT7R/oro1xMtxIUmcbpFlMqt17OzH05x04rMg+GvhK3hkih0eNEkjMTbZHB2ESDbnPTEzjH+7/dXHV3dxFaWs1xcNshhQyO2CcKBknA5rzfTP7T+I8VzdHW7vRNNtbp4EtdOdoblZEOCJ2PIOCPkwOv0NAHUaP4H0HSNUg1CxtZUu4IVt4ne5lcLGqlQAGYjgEjpXS15j4l1zxJ8NdHn1LUVPiXw/bKDLKCsd3AvAyc/K49/vcntXF6Z+01pOt6hb6ZoXhnV7nVbuVYLaJ2iRXdjgbm3HA9/T0oA+gqK4N/CniPVit7q3iu+sL3gpa6ZhLaLH8LAjMnuSR+WKv8AhbUdfTVrzStatnvYYJfLj1WKIQq3yK/7xCRz84AKAqSCDjHIB1tc18O8/wDCLpnr9svP/SqWulrmfhwwfwpG69Gu7wjnP/LzLQB01MmljgheWeRI4kBZ3c4VQOpJPQU+vMPiXdQ654z8OeC7yeGLTrxvtV2pb5pgu4pF7Bih9DkAryKANy6+J3hCCbYNWFxhgN9rby3CDPQ70Urjrzn1qGT4reBLe4jt7jxHY20jfdE4aID6lgAPxroB4V8PCBoP7C0owsxZkNpGQzHqTxyT614h8V7DRfh54+8PX76NYHwZrzfYdV082ym2SUY2TiPG1XAJOQMkKaAPfYvsGqWMcsX2W8splDxuu2SN16gg8gjvmnSWFnKcy2tu55+9GD1BB7ehI+hNfPxgk+C3xm0HTNInn/4QrxS7RCwllLJa3G4DMeegy0fuQxB6A19ESyJFG0krqkajLMxwAPrQBSvdG02+tJLW6sbeS3kTy3QoMMuc7T7Z7Vas7aCytIbW0hjgtoUEccUahVRQMAADoAKg07VdP1MOdOvrS7Cfe8iZZNv1wauUABGRg9K53WvFfhfRZja6rq2m286jcYGkUuo9Sg5A98VW+J2szaN4Una0nit7y6b7NDPI+1YSwJaQntsQM2e23J4pPD3gDwzo9jHHFpFhcztGFmu5rdHknOBlmYg5yefSgCE/EbwOAZJfEWkxL9zfNKIwc9stj06V0umXmnanZx3Wl3FpeWjDakts6yIQOwZeK8h+Pfhez8O+C5fFPhLSbGz1LS5o5riO3tlWK9tywV4p0XAkT5g3IJG0kEda5HxZYWvhrwVp3xZ+FBfSUkEM+oaXC3+izxsdrK0Y4BVjtOOByRg80AfSxijJUlFJU5Bx0OMfyNBijLBjGhYZwSOeev8AIflVTQdSi1nQ9O1O3/1N7bx3Cf7rqGH86vUAVr6wtNQtjb31rBcwF1cxyoGUspDA4PcEA/hU0MUcMKRQoscUahURBgKBwAB2FPooAK4r4Zf6/wAY/wDYwXP/AKBFXa1xXwzH77xhyDnxBc/h8kdAHa0UVw0vi7WNY1K8tfBWj219bWkpgl1K9ujDbGQfeRNqsz46EgYBBHvQB208STwyRSrujkUqw9QRg1zVv4C8OWzWz29g0M1tpZ0aGWO4kWSO1/uBw2QR2bO4c81y8vxG1zQL9oPGvhZrOAIZvtGnXP2oCFSA8u3aGKqSCwHzAHO0gEjr/EPi/SND0C31aWc3UF4USyjtB5sl67jKJCB98t1HbHPTmgCDxF4D8P8AiPVrfUdYtJri4hjSID7VKkbqj70DorBXw/zfMDzWfD8K/CEEEkEGnTxwyRJEY0vZwqlNm2RRv+WQeVH84+b5BzWTpvjfxnrsS3mgeC7WTS3JCT3OrIhkwxB27VbIyDyOD2JGDXU+D/FcevyXlld2cul65YsFu9OndWdAfuurDh427OOOCOCMUAVbX4b+FLS3WG30oIivFL/r5SWePftYndkn945JPJLEnJrOn+D3gedVWTR5dqxpGqrfXChdiIisAJMBtscY3Dk7Rk1oeMPEupW2sWfh/wAKWtrd69cxtO5uy629rAOPMkKgnlvlVRyTnsKwdcvfiR4b0u+1W6u/C+oWVtF58yrazxPEgGXKgOdwAyfXC8AnggGk3wj8EkWw/sYgW7RNEBdzDaY1Kr/HzwcHPXjOcV3leMQ/H/QdMj1G18Z2V3omt2Chms1HnrcggFTA4wGDZBBOBgg5q7oHi3xv4zu7mPSLbSdCSBIZpI75HnniWUMUVwCBvKAOV42hk5JJAAPWqK8/XXvE3hW7s18anTb/AEm6cQf2lp0Dwm3lYgKJY2dvkOcblPBHI5zXoFABXK/C3/kQtK/3ZP8A0Y1dVXJ/Clg3w/0hgcgo5z/20agDrKKKKACiiigDktRT/i6ugv8A9Qe/H/ka0rra5bUR/wAXO0E9/wCyr/v/ANNbSupoAMc571Fd/wDHrNnpsb+VS1W1JgunXTE4Aic56Y4NAHmV5bRH9nYlIIxI2iK2QozuMY5+terV55qqlfgPgjbt0ONmzxjESk/1r0OgAooooAK8E+JXwvm8f/Ga6uotQitLez0BYJQylnZpxdxoQOmBjJ/+vXvdc1o7B/HviQqB8lrZRsQP4h5zY/J1/MUAcf8As4+HJPCXgrU9EnnS4ms9WuI3lQEKxAQZGe3Feq1yXw4UrZa4xOd+t35+n79h/SutoAKKKKAOV+J08cHhGZpsmE3FssgAByvnJuHPHTNfO3wheO98d6f5GmQQBZ7V13QxiWNTHJmPjnaPs6vx0JJOC3P0F8V3aPwoGC70FzEHTswLYwfbJFeDfCrQE074xaPqDx+VLcE2/lrtZSVtWZnypPJKnjjoD3oA+qqKKKACuT+FoI8FWoYgkXF1kg5/5eZe9dZXKfC0lvBVqzDBNxdEjp/y8y0AdXVC60bS7u5FzdadZzXAZHEskCs4ZDlDkjOVPI9Kv0UAFef/AB68Mx+KvhVr1m0PmXFvA15bY+8JYwWGPcjK/RjXoFUdeAOh6iD0+zSf+gmgD4Z+IXje78V/CHwLcz+ZHqWjXk9g1ypwWKRwsjg9Q23bk+qk16H4q/Z78f8AiGKC4n8bxayZFVyuoyzLsJ7KPnHGfavXrvRdMP7PBS50yykEXh03Wx4FIEwtP9Z0+/8A7XWvTLBSljbqwwyxqCPfFAHzz8P/ANmweHbSTUb3XZ/+EnjBa0lsXaOG3ccjJwGcHoc4GCeO9evfCfxHeeK/AmnarqcSxXr745guMMUcru445AB49a1PGV7qmnaBc3uixwSz26tLIksbyFkVWJCKnLPnGB39qy/hPob6B4HsLeZ2eefN3IGVl2GQ7tuGAIwCByByCcDOKAOkvtMsb90e+sra5dEeNGliVyquMOoJHAYcEdx1qWytYLG0gtbOGOC2gQRxRRqFVFAwFAHQAdqmooAr6hZ2+o2FzZXsSzWtzE0MsbdHRgQwP1BNfFujeIrnw34M+KHwz1HzLiGxSeSzfGdm2ZVcewOQ/sd3rX21XB+C/Dui3Nx4pu7jSbCW7u9Sure4mkt0Z5Y9wGxmIyV9ulAGf+zZeyX/AMEvC8szbnSKWDrnAjmdFH/fKivTK474UafZ6Z4UnttNhSC0TVdRWOKMYRFW8mUBR2GFFdjQAUUUUAFcd8OITG/ityciXXblx7fKi/8AstdjXK+AFCr4iOD82tXR5+oHH5UAdRJuKN5ZUPg7SwyM+9YHgPw0PCXhq20ZL2W7it87HkUKVzyQMdtxY85POO1dDRQBxHxasbgaBB4g07J1Hw9KdSjjHSeJVImhPs8ZYfULXgVlmHVLl9GuGn0/UW+weCUZMJB9u+e4lUdQIASpP8J+U19PeLgT4T1oDqbKfvj/AJZtXDp4Y0DTm+GUun6VBbNbXTR2uzP7pZLSeRx15yygknnNAHf+H9JttC0PT9JsFK2tlAlvED12qoAz78Vly+GN/jyDxML+QSxWjWX2fy12mJjuI3deXCNzn7uBgE56OigDCXw1bDxfJ4i+0XP2xoRb+WrBY/LAPysAMtySRk8E1r3trDfWc9pdxiW3njaKVD0ZWGCPxBqaigD5gfSfBqT6hD47NzLqXw4ASEg4+3WOQ9qr8ckblTAI6+hr2T4M2NxH4MTWdSIOqeIZTrF1joplAKIPZYwi/gas2FlBcah49H2eGSaa5RGygJcfYoMA+ozWp4AJbwH4bJ6nTbY/+QloAt6/oWn6/arbarC00CsWCCRkGSCMkKRngnGeh5GDzWjFGIokjUsVQBQWYsePUnkn3NOooAK5D4R5Hw60TJyfKbJzn+Nq6+uP+EP/ACTfQ/8Ark3/AKG1AHYUUUUAFFFFAHJaiD/wtbQDk7f7HvxjtnzrSutrk9RX/i6egNk/8gi/GM8f660rrKACs3xFp8+q6Nc2Fvci1+0r5Ukuzcwjbh9vIwxXIBOcHBwcYrSrPkv511Z7QWUhhWASifna7EsNgwCMjaM5I+8MA0ALeaTZ3ehTaPNFmwltzatGD/yzK7SM/SrNnE8FrFFLPJcOihTLIAGfHc4AGfoBXD/8Jr4gjQiTwZqMsscYkkETEA5YDahK4Zvmz1HCt06Vq+HfEGq6nrLWl5ok9lapFI5uXVwrMHUIq7gDypJP9MEUAdTRRRQAVyvg2RLzW/Fl/Cwkt5dRSGGVeVdY7eJW2noQJPMX6qR2rqScAkAkjsO9cnDrurQ+G47uLw1Kbks/+gI3lmNRG7AZI5JdQnAxlgelAEXwzkKQeIrOdsXdvrd60kRPzKkkzSRkj0KMpFdlXnl14o1+F7+5t/Bc0k8keLWZc73AXIWQbQR82cDPfHB6+h0AFFFUNVu7y1azFlY/axLMEmbzNghjwSX6EseMAdyRkgc0AZ/izw//AMJIljZ3bwnSknE93A6FjcbeUTrgLuwTnOdoHc1map4B0pLqw1Pwzp2laRrVhKJIJ47RVV12sjRuE2kqVZh14ODzjBvarretWrXwsvDct4IWKw4ulQz/ACqQRkYAJZh16oc4yM5f/CSeLftiIfCOyAyiMuLsPtG3PmdBkZ+XHXvz0oA7iiuJTxT4il0syt4TuLS8OVEUkvmgE52n5V5B24PTBI6jmu2oAK5P4WZ/4Qm0ycnz7rn1/wBJkrrK5r4dAL4WQKAALu8AA7f6VLQB0tFFFABVTVonuNKvIYl3SSQuijOMkqQKt1S1LUUsJLNXhnkFzN5IaJNwjO0tlvQYUjPqQO9AHN3ej303wfm0VIP+Jk+gtZiEsB+9Nvs25zj73Gc4rq7NGjs4EkGHWNQ3OecViT+KBDrF1YNpGrMIJIoxcJADHIZNvKnOcLvGSR/C3pTJvFsC6jFYwaZqtxcSeZ/q7cbV2PsJYkjAJ6e3PTmgDpKKwPCniVfEMCv/AGbf2L+SszLcx7QAzugAPUn92x6Dgqe9b9ABRUN7cfZLO4uPKlm8mNpPLiXc74GcKO5PYVz8niqSPSlvRo2pzsbuW2MMERLqqyMquQ2OGAUj/e696AOmrn/Bthd2Ftqv26MxyXGp3VwgyDmNpDsPHqoB9ain8S3Ud5p6J4f1WS2uZZIpJBGN0BVioZl/uHGQc5wRx2o0TxLd6neQxS+HtVsYpckS3KBQmAfvDPBypHfqvrwAWfBem3OlaI9rehRN9tvJhtORskuZZEP/AHyy1uUUUAFFFFABXL+AiDFrxBBH9sXQ4/3q6iuR+HAxa+IOMf8AE8vT1z/y1NAHXUUUUAVtUtje6Zd2oKgzwvFlhkDcpHI7jmsu50SVovDkcM6f8Sq4WR2ZT+8UQSREAdid+fwq5d6dPPJfOmo3UJuIBDGE24gIz86jHLZPf0FYeseELq+hmFr4m1y0kbBj2T/KhEjOOgBI+YKcnJVRznJIB1tFchF4OuYIrpYPEmsI07mUOZAxjfBHGeoxjhs/dFdco2qBnOBigBaKKp6zZyaho99Zw3D2stxBJCk6feiLKQHHI5Gc9R0oAS00y2tLzUbqIN5t/Isk2WyCVjVBgdvlUVJptlBpunWtjZqUtrWJIIlLFiEUAAZPJ4A61iarpGuzx2cWn6+1r5QlMszW6SNISw2Arjoq7hnI7Hnms/UvC/iS7tZ4IfGU8AnEgZhZJuUMwI2EMCu0ZUY7HPXBoA7SiiigArkPhECPhxoeQR+5Y8/77V19cr8K12/DzQhk/wDHsDz7k0AdVRRRQAUUUUAcF4vt9XufiL4eTQtQtNPnGmXxeS5tTchl8y1+UIHTBzg5yemMc1eGleOAefFWiH2OhP8A/JNJqP8AyVvQP+wLf/8Ao60rsKAOUXT/ABsIwp8SaAW/vnQpcnn/AK+8e3SmNpnjcrgeJ9CBznI0KTP/AKVV11FAHH/2V44/6GvRP/BE/wD8k0f2V44/6GvRP/BE/wD8k12FFAHH/wBleOP+hr0T/wAET/8AyTR/ZXjj/oa9E/8ABE//AMk12FFAHDQQeLZ5Vig8a+HZJGQyBE0ZiSoO0tgXXQHjPrTIG8Ty6pPpkXjjwzJqMSB5LYaOxljU9GKi6yPx9aPC/gKXw34m13V7HUIpP7SuldIpoCRbW5dpJIkwwwWd2YHoOODXOeJvhDe6x4p8QapaeIv7Mj1SIrtt4G37j5P38ybcYhAJVVLBsMTjkA7C6t/GdrayzSeJPDCRxJvaSbRZlVQOWZj9rwBjnNQTr43txGZ/EnhGISOI036RONznoozd8k9hXn//AApXWL26v4NS8SO1kdPWyin2M8shNs0TAjfgRhmDbCCTsX5hU8fwMum1C6urnxSzmW+tb2MR2WwxNCzEbfnPzBXKq2MjA69KAO/+x+P/APoO+Fv/AAS3H/yXR9j8f/8AQd8Lf+CW4/8Akuj4W+DX8DeGDpMuotqLGdpfOZGTgqq/dLNgnbk4wCzE4yTnsKAOP+x+P/8AoO+Fv/BLcf8AyXT47Px5v/e694YC/wCzok5P/pXXW0UAcnJZeOtq+Xr3hkt33aJOB+H+l1ILLxrgbtf8OZ740Of/AOS66iigDmPsXjT/AKD/AId/8Ec3/wAl1y/w1tPF7+D7VoNc0KNDPc/LJo0rNn7RJnkXSjrk4xx05616fXN/Dv8A5Fdf+vy8/wDSqWgBn2Lxp/0H/Dv/AII5v/kuj7F40/6D/h3/AMEc3/yXXT0UAcs1j41PTxD4eHBHGhzfn/x90g0/xqFYHxH4fJPQnQpePp/pddVRQBy4sfGgHPiDw8froc3/AMl0gsPGvH/FReH/APwRzf8AyXVD4reHtc1/SrGPwxemzvFnMM8nmFf9FlRo5SO29QwdT2KcVY8JWOuaNb6zbXEAuFe6urmzkkut+VZyYoznkDGOe1AE39n+NNxP/CQ+HskAZ/sKbt/2902TTfG7kFfE2gpgYwuhS8+/N0a4Xw14V+J2naRLZXOu2wnkuZb77Uk3mHfJbviEiRDhBPsbjsxxU40z4pQnTha3iGL5PtAur2KR02ylm+YQAEMnyjjIHrQB2sdh41RAG8ReH3I/ibQ5sn8rsU1tN8bMCB4m0FSTnI0KXj25uq8w07wl8XUiN1d67EdRNq0A/wBJ3Bf9Ihc4G3buKLKobqM44BBHtmgRXsGh6fFq04uNRS3jW4lAA3yBRuPAA5OegH0FAGGmn+Nl6+JNAb5s86HL09OLvpTxY+NAAD4g8PEjudDm5/8AJuuoooA5j7F40/6D/h3/AMEc3/yXR9i8af8AQf8ADv8A4I5v/kuunooA5j7F40/6D/h3/wAEc3/yXR9i8af9B/w7/wCCOb/5Lrp6KAOY+xeNP+g/4d/8Ec3/AMl1y/gDT/Fy2WsNBrmgoH1i9LB9Hmf5hMykjF0MAkZA5xnGT1r0+uV+HjhtO1cDOU1m/U/X7Q5/rQA42XjXB26/4cz2zoc//wAl1FLZ+Ogq+Xr/AIYz/Fu0Scc+3+l11tc78QNCn8Q+FrqzsJIodSRo7qyllztjuInWSMnHONygHHYmgCh9l8e5x/b3hXP/AGBrj/5LoNt47XCtr3hUO33c6PPz+H2quNg+GOt6Zc6VLplzYSmynsblvtEzjzZIYboSEkIcbpJ1bjtu79bHxQ+Hus+Ltds76CDRWJ0p7B5LmaTfYTPIrfaLfCcuoBwcoT7DNAHXxQeNMEPrfhlmXrt0qYY/8mTT2g8ZBc/2x4bwemdMmA/9KK8wPwr143Hj1WhsZP7beVre5N0iOyNKr7WIty4JUEHLunqhFaN38O9em8EeDdPubHQ9TutIuriW4s7qUpbusiTLGMrGRlPMQ8IoyvyhRjAB332bxrn/AJCvhzH/AGDJ/wD5Ioa28bfw6r4cP10ycf8AtxXC/wDCFfEDTNGaHTPEQuruJILaATXkkcflLZeUz/dbDeeS/fIVckGjwPYePf8AhPfElv4invZdM+wyRW9zJLi3eVjH5flpjK7QHBYZJ6nBPIB3PkeNWP7vVvDbL6/2bP8A/JFH2fxx/wBBTw3/AOC2f/4/Xk+hfCvx54a0aC00HXba3eQWjXLQyeV8yxusgGI8NhijbmBLgYbOMG7qvgT4kzy3dlaazaxaTPb6krKt3IpZ53umjJG3jDSQHI5AUj2IB6X9n8cf9BTw3/4LZ/8A4/R9n8cf9BTw3/4LZ/8A4/XnereEvifdwa3ENcVre5uf3MKXpjbyCJcKH8slCA0QOPvbD3JJ9d8N2c2n+HdLsrtg1xbWsUMrKcgsqAEgnryKAMb7P44/6Cnhv/wWz/8Ax+l+Fm7/AIV34f8AMKl/sibiowM+1dTXMfDD/kn2g/8AXqtAHT0UUUAFFFFAHH6j/wAlb0D/ALAt/wD+jrSuwrj9Rx/wtvQf+wLf/wDo60rsKACvP/EPjLWbjXr3Q/A2lW+o3tiqm8ubmXbDAzYwmMjc2Dn7w6EckHHd3cwtrWacxyyiJGfZEu52wM4Udyewrzj4C6Xrej+FprbXtMa1eV1uxPK486eSRAZPMTqGVgRknJ/UgDbrUfivYwSTvpPhrUFRS3k2rSpIcDoCz4J/AV5l4u1z4r+LvBZ8TeC9f0qTRgjGW10eJormMr94HzAX3juFI9geM/TdeEeDVn+Hn7QeteHJZGGg+LFfU7AMflW5GWdR2H8Y+gjoA8Y+Cup/GDxjqlyvhjxVemG22m4uNUuDPCm7OBiQPknB4A7fSvf9C8Z+PBqOqaC+l6L4j1XTEjFxd6dO9vFG7c7H8wbS+OSFPHcDpXIfDS/g+G3wk+IuuxrGkkGsXkdsrjhnUiOJSPTcRx6Zr0z4EeG7rw78O7RtVeR9Y1WR9V1B5PvGebBOR2IUKD7g0AU5PFXj3RIZ9R8S+GdPk0mIbpP7Puf30KZGXYMSGAGTxj3IAzXoGiatY65pVtqWlXCXFncIHjkXv7EdiOhB5B4NWrgyrbyG3VXmCkorHALY4BPYZrzn4U6V4j0Ia5FquiWtlHezNqEaQ3StGkrAL5KgDIQKqANjscDGKANDxT4zvl18eHPB1jBqWuKnm3LTORBaJkY3kdWOfu5B6eoqjeX3xUs5SU0nwzqMQA4t5ZImJxz99sewH6jrT/hPouvaJPq66zpNjZxX0pvXmiuBJI07sS68DlB1BODliMd69FoA+eNY0T4jfE7QJNV0Tx5BYRgvGdLsoJLMxTJkNFI+4uHBGCCSO/TFeTfA7wZ418beIdZVfF+r6C+kSKl1L50jyGUsw2bd4/uNkk+nBzXvrXB8A/HkW/MegeM4/MHynbHqCcHB7b1259SfatK8sbf4T+H/AIi+KzPE/wBuuX1GGMqVAkZAqRn1JlJ6f3hQBi6NJ401LxFqHhrRPG894NICJf6tcafbhElbkQooUl2A5Y7ht4BJNdJc+FviBaxLJpnj5Lq5HLJf6XEI3x2+TBAPtzz14pv7Pfhm58N/DSyOqbjq2qO+p3rPneZJcEbs87goXPvmvSaAOZ8BeJz4k0uQXkItNasn8jULPoYZRnkcn5Wxkcn0ycZrpq4nw94Y1LSfH+sa3PPbXUWsQKLl1UxGJ4mIiVU5yPLbBJbOVz0OB21ABXN/Dv8A5Fdf+vy8/wDSqWukrm/h3/yK6/8AX5ef+lUtAHSUUUUAFFFFABRXjLQa18XNc1Qwa7qeg+C9PkFrB/ZsoiuL+YAM0hfBxHhlwO/fByBe1D4QTW1jKnhjxp4q0+Ty/khl1GSSJnA4LYIcA99rD2oA9Yor5qg+H+t+PvAUes+HPG/iiw1td8U+mXurSzQRXUbFJIw2dyDIOCS3BHrVP4c/CP4j+TcXvjDx1rvh+CIlvJt9SaVmC5yzHeUC/n+FAH1DRXiHgLQfFnijQE1CDx1rNvokzv8A2e9yiyXcsIO0Ssw2gBsbgrBiARzzitXUrnxp8OpbfUNT1WTxV4VUBL5mtFS8tBk/vRswHUDGeM4GfU0AetUVDZXUF9ZW93ZyrNbXEayxSIch0YZBHsQRU1ABRRRQAUUUUAFcl8OFxY64efm1u/PIP/Pdq62uR+G7lrLXQc/Lrl+Bz/02Y/1oA66iiigAooooAyPE3iTSPDFgt5rt7HaQs2xMgs0jYztRVBZjweADXNP8WPCqny2n1JLknCW8ul3MUkhPQKHjAOe3NX30XUbj4mx61cRW76Xa2H2a23yEukjMS8iLjAJGFJODgfUHf1zS7TW9HvdL1KFZrO7iaGVGHBVhj8/egDgD8UNTXVjbyfDrxgLMNj7SLVW49doP9a1G+KvhVFYSXGorcodstp/Zdy08TejoIyV69+PevjpF1yLQLfwfbajeo/8AwlMmngJMwy21IwMA+uePevu/QNHsdA0e00vSbdLeytUEccaDGB6n1JPJPckmgBuga3pviHS4tR0W8ivLOTIWSM9xwVIPIIPUHBFaNczp3hyaw8calrNq9tDZX8KpPbxqQZJF6TN2L8spPdQvpXTUAFFFFAATgZPSuX+F5DfD3QCpBBtEII710s5CwyFgCoUkgjIrlfhIwb4Z+GmUAKbGMgAcAYoA62iiigAooooA5HUFz8WNCbKjGjX/AATyf31p0rrq5S+IHxU0UYbJ0a+6Dj/X2ldXQAUUUUAFeIftR6Tqt3pvg/UPDEMk3iKz1gCzWPG7mJ5Gxk/9MV474r2+uT8bRebrvgdc4xrTNnHpY3Z/pQB4Fqnh3xS/i/who3iTSJLfw3e+IZdSugWR4pZnkZkjbax42oeD2Y59K+qa47x+7LrXgVQcB9eww9R9juj/ADArsaACiiigAooooA8n/aa0SfWvhpjTo92q21/ayWbhgjJI0ojBDEjb9/rmuP8Ain4U8b+IfC/w8i8SvbTWdpcwHX4o5QPMdpY41Yjo3ys2ccZJ7Yr1v4qbh4IvHRQzxz20gBGcFbiM5/Sm/FuV7f4e6tcxsVe28q4BAyf3cqP/AOy0AdeBgYHSiiigAooooAK5j4bhx4X/AHhBP269xj0+1S4rp65X4Zlj4Xbc+/8A0++A4HA+1S8UAdVRRRQAUyZWeJ1jcxuykK4Gdp9cGn0UAcx4G8HWnhC1eKzurqYyxQpKJGxG0kaBDKEHCs+AWI64HpXT0UUAeP6FeQeBPjhq/h24lWHS/FijVrHdwq3n3Zkz6vtDf98jqaufHDXTdQad4C0mfGt+JZRbOE5NvaH/AF0p9PlBA9efSoPix4LsvG/xJ8F2V/c3dr9ktby+jltWCvvjltMDJB4+Y9MEHBz6pp/giKx/aMufEUuoT3k13pckywzKMW2GjjAVs9MbuMDGe9AHqWlWFvpWmWen2MYitLSFIIUH8KIoVR+AArM8baNd+IfDtxpdjqAsDckJNKYfN3RE/OmMjG4ZGc8ZrdooAw/BGhN4Z8LWGjtcLcfZVZQ6x+WoUsSFVcnCqCFHJ4ArcoooAKKKKACiiigArj/hp/x5+IP+w7ff+jjXYVx/w0/48/EH/Ydvv/RxoAreP9YuW13QfC2n6idJn1cyPJfArvSOMAmOLdkea5PHHCq56gUy8+HbyWRjs/GHi62udhUTnUjJlufmZWGO/QbfwrtzbQG5FyYYjcKuwSlBuC+meuKloA+E/FAsZbjxsfFGiofEnh5IUSeO9uCLl/PWNpH3OTyGDDBFfQXwx0XxD4t8MWGtXWt6r4b0q5gT7JpdjdGZxEBgSNLMHILDBAUAAY7k1538Uvhf4i1nxd8T9S0ezjmtZ4bdYx56oXkBt5XGCR0QE84HpzX0t4Oto7LwjodrCMRQWMESfRY1A/lQByFveah4I8YaXpGoa1Lq+i6wxige+kU3VnKBxlgBvjc7VGeQzAdDXo9NdEfbvRW2nIyM4PrTqAPGYfhp4eFpba6sM39pjxOup+YZOPNN6EIx/d29vXmvYL25hsrOe6un8u3gjaWR8E7VUZJwPYVm2+hQ2+iwabHNJ5UNwk4dgCSVmEuPzGKv6lZQ6lp11Y3QY29zE8MgVipKsCDgjkHB6igDgdGufGvi+yTWrDVNP0LSLpPO0+3ax+0TSRN/q3lJcBdy4bavIzgnINcX48vfF9rruj+Htf8AFd9YXer3EcGnXWgWKJDLlgJPODsXVlBB+ViCDxk5A9y06wtdNtFtbCCO3t0JKxxjCrk5OB25PSvNP2gbi+07SvCuraNYPqGqWOuwSQ20aFmlBjlDoMc8qTz2xntQByXhW/8AFdl4x1fwnoXirU9d1qwkJuf7btUFpBEVUq+9WMhJ3AAD3yABmvRbyfx7o1u2pXTaPrNvF89xp9jayQzeXxuMTNIQzgZIVgN3TIOK5z4JpdX/AI5+JmuapZPaX0+qrZrG67cQwqVQj1yOSRwT0r1m8toby1mtrqJZbeZCkkbjKupGCCPQ0AVLPUrXWPD0OpafJ5tneWouIXxjcjLuBx24NYHwe/5Jd4X/AOvCL/0GukWzgstNlt7OJIYQrsEXgAsSx+nJNc38H+Phd4X/AOvCL/0GgDsKKKKACiiigDj9R/5K3oH/AGBb/wD9HWldhXH6j/yVvQP+wLf/APo60rsKACiiigArH1rSJNR1fQLxbgRx6ZdyXTRlc+aWt5YQM54x5pPfpUniPUL3TNOFxpuly6pOZUTyInVCFLYLZPGAOax/EPiDxBZLff2R4Vl1JoSogH2tYvPBVTnkfLgl155ymehFAGpr+iDV73QrgzmI6Xf/AG4KE3eZ+5li29eP9bnPPT3rYrzOfxd49aS4t7fwRGLqBYpCDfApIpcAhWIAzt3c5JGM4PQ72h6r4q1G9kgv9Dg0qAKsqXTzecD+8G6LYCDnZn5sgAnoccgHXUVHbLMttEtzIks4UCR40KKzY5IUk4Htk/WpKACiiqOtjUDpsg0d4kvSybGlXcoG8bsjIz8ueMj6igCDxTpB13QbvTRcG2M4UeaE3bcMG6ZHp607xNpEWv8Ah7UtIuJHiivYHgaSPG5NwxkZ7jrXNarqnjiNNMXTtH0+S5NmZb2NySgmGBtjfeABnJAOSR3GKigv/iElrNLc6TpMkz48mCJtvlHfIMOxkO4bREcrj7xGDigDvaKo6D9u/sPTv7X2/wBpfZo/tW3GPN2jfjHH3s9OKvUAFFFFABXH/Cv/AJFef/sJ3/8A6VSV2Fcf8K/+RXn/AOwnf/8ApVJQB2FFFFABRRRQAUUUUAclqAZvitof91dGvz07me0/z+FLlj8VsbDsXRfvY7mfp+ldXgbs4GRxmloAKKKKACiiigAooooAKKKKACuP+Gv/AB6eIP8AsO33/o012Fcn8O4/Kt9fX11u8b85M/1oA6yiiigDlGSVbbxrIbeYh5GMamMgy4tIl+X15BHFbnh9Gj0HTUkVldbaIMrDBBCjgir9FABRRRQAUUUUAFc74pUNrPhJSjMP7UY5UH5cWdyQT6DIFdFRQBhaPG6+J/EDsrBGaDaxHBxHzit2iigCK8/49J/9xv5Vynwe/wCSXeF/+vCL/wBBrrpVDxOhzhgRx1rlfhOgi+G3hyMAgLZRrgnJ4FAHWUUUUAFFFFAHJ+JtH1iXxRpetaDPpwmtrS4tHhvQ+GEjwtuBXnI8rp71BFceNpH2rL4TZssAFecn5ThvyPB9K6ae0sLq+s7uaKCW7tTILeVgC0ZI2vtPbjg15zfeBLi6vYRZ+ILW3EWqXV5bmLcHkMtyk0sbgMM7NjD34yBigDqEPjkZ3jw0eOMGcc/lQT448sAL4a39zunx37Y+neuRb4fa1a6RK1/4uuklgsLtPtj31wqidwm24YGTaAoR8r90FsjmtHRfBXiW3k1iS/8AFM0n26yureJUaRlgklmaSORMtkGMPt4PIC424JYA2/8Aiu/+pY/8j0TzeM43Tc3hiMOQih5Jss+Og456E49Pzrjrz4ZeKEgeHSvGNxbqZA4eWW5kIALkKAZSB94A/TOMgEazeBdQv/CtvZXeo3RuYdTe8jF3cyMyQr5iRReYj7gQhQlgxJbPJzQBt/8AFd/9Sx/5Ho/4rv8A6lj/AMj1m2/hTVbDR/Eaaj4nlZ7mzeGDUZJpVa1HlBTIV8zYCpXduGD1561lw+AtckiZLHxlP9lDyiIxyzMYcSXHyZMh3f61UYscjyRjB+6AdN/xXf8A1LH/AJHpgl8bmYwiTwr5yqHKZn3BTkA49OD+Vcrb/DTUXuLa+svFdw6K8csbG4uZVYKYCeTNyCYpf+/vtWl4Y+H+s6Vp2pRXfiZrm+u9NksUvBE4khdpJXWQFpCTt83AGR90c0Abg/4TrcNx8Mgd8efUufFsaFrm68OxDcFU+VNgkkADlxyScY+lUfDXhHUdP1x9R1LWZ7lDFKsVok03lQs7k8BnIYAHA3DI7YGBXG3fws8Qz2I06PxmsSxWtrFCiwyExvDNDIJ/mkb5iYnx0AL/AFyAei+X4s/5+dC/8B5v/i6PL8Wf8/Ohf+A83/xdYui+EddsvD2s2d1rnnaheRmOC5MlwywA5IG1pP4SxAYEMQF3EkU2/wDBOsXXhrRrEeJbuPULG0e2nuEeVVu8qCrNhwwYSJG24NnbvXIDmgDaceKk27rvQF3HaMwSjJ9Pv07y/Fn/AD86F/4Dzf8AxdcVD8NPEJtUW58Z3r3sKxLBdB5jt2iUMTGZNpJ3x89Rs96sXXgTXI2guLTXL1LnyLSAmG6lbZIly0kk37xyGVo5GBQg9BjtgA6xx4rRGd7vQVRRkkwSgAf991AJvFTQRzJeeG2jkK7HCS7WyeMHfznPHrWR418E6xr0F1Z2WuyW+nTxJH5UjyEhVjdChw3zBi4YsfmyvfjFfxv4B1bxB4itru21vyNJgS3X+zy8oEhjuI5clg3ytiPAYDI3GgDc/wCK7/6lj/yPWb4U0Xxpodi1mbjw68T3E9wz7JiwMkjSEAZHQtjrWfb+A/FFtdR3K+Lbq4lQoCs0022RFEB8sgPhcmKUbx82JOSxzlNR+H3iK702SL/hK71bw5Czrd3ChV+yyRgbVcDKyskm7qdnOc0Aday+K1GWutBA9Tby/wDxdJ/xVRkKC70DeBkr5EuceuN9clP4B8SzXRVvEYfTULeXbTPNLn/SxOhYsxyVUKg7479K1NU8H6xJ4h1bU9K1cWh1AhSoZwY8RxqsnH3ipRiE4U7+elAG35fiz/n50L/wHm/+Lo8vxZ/z86F/4Dzf/F1x0vw516SzRf8AhKb9Ln7IsTyC+uSDNsuQ0gzJxlpLdsdB5OO9dd4N0jWtIN+msasdTimmMsLSEl4gcfKD/dzkgds4yaAH+X4s/wCfnQv/AAHm/wDi6PL8Wf8APzoX/gPN/wDF10VFAHO+X4s/5+dC/wDAeb/4uo54vGRXEF54eRvV7SZh+QkFdNRQByYt/HXfUvDP/gun/wDj9S/ZvGn/AEFvDv8A4K5v/kiunooA5j7N40/6C3h3/wAFc3/yRUclr44JHl6z4aUd92kzn/25FdXRQByi2fjjcu7XPDQHfGjTnH/k1Un2Lxp/0H/Dv/gjm/8AkuunooA5j7F40/6D/h3/AMEc3/yXTJLDxsykJ4i8PIfUaFMf/buuqooA4/8Aszx3/wBDT4f/APBBL/8AJdUdI8MeM9L+1CDxVobi5uXunD6DJ95zkgYuuld9RQByL6b45Ynb4n8PrznA0GXp/wCBdPl0/wAbtjZ4k8PJjOcaFMc/+TddXRQByZ0/xwY8DxJ4eDf3v7Bm/wDkunrY+NQoB8QeHSfX+w5v/kuupooA5j7F40/6D/h3/wAEc3/yXSGy8a5GNf8ADnv/AMSOf/5LrqKKAOUaz8cfw654aPXros4+n/L1TTaeO+2t+GP/AATz/wDyVXW0UAcslr42A+fWPDhPtpU4/wDbmnfZvGn/AEFvDv8A4K5v/kiunooA5c23jXHGreHSffS5/wD5IqI2/jvPGpeGcf8AYPn/APj9dbRQByiweONjB9Q8NliOCtjOMf8AkY1qeENIfQPDGmaVLOtxJaQLE0qpsDkDkhcnH0zWvRQAUUUUAFFFFAGfDomlwXEM8Gm2cc0LyyxyJCoZHl5kYEDgt3PfvXmGofCK8k1q81Ox17yJbm5vLkRmJtkDTghmTDA5IEe7JwSnTBIPp2t63pWg2yXOt6lZ6fbu/lrLdTLErNgnaCxAzgH8qtWF5bahZxXdhcRXNrKu6OWJwyOPUEcEUAedaL4A1OHwz4j0i/1e5uGvbA6fBLcO0iAtAEeXZuPDEA7T0KtjAaq3/CsdZGoSvF4tvLeyHmmCKLzC0RM5mj5ZyCFO1duMEZB6jHqtUdU1aw0kWx1K7htvtMy28PmNgySHoq+p4J/A0Acfp/w/nttE8VabPrNxdHWYJbaO7meR5IkdGUblLlCV3YBUKSBzWZN8L9QN5fz2vi3U7SO6hZRbxM3lwylAAyksWChy7bQehABAUV6VFd20t1PbRTxPcQBTLErgtHuyV3DqM4OM1PQB57rvgTU9T8Ito6a6YmmkujNvV5I/LnjkTy1BfOE8wFckjK9OmMy4+FmoXWq291deJHlihnWfyJIS6OVvTchTuYkAA7OCMgDIO0V6rVOw1Oz1CW9isrhJpLKY29wq9Y5NqttP4Mp/GgDzhvhnrCPYz2/iy6W5tTCCWEpWZIwuY3HmZ2uUy2Dk56+u7a+DLrT9H1a203Uktrm8vre+R0jYKnlLApiPz7mRhAQeQdrkc9+2ooA85uPh5e3F4Wl1y6NsbqCYxi6uQREgQPBxLt2nZwcbuTknkmr/AMKz1SDUI7i18V38kKNza3LyFJIw7bUYq4PyoVGepZATkHaPUKKAPOofAWrwa7DfReJrsRx6gbkq0kz+ZAWLeQyPIY8DO0MFBwAc8c+i0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc78QvDI8Y+DtS0Frs2a3iqhnEfmFAGDcDI9Mde9eZ+O/hNeavqGuX9jBZyTXV1ZvbxO+Ixgxm6mKcAFwgXbk5Ck5+YivbqKAPMPAHwjtfB/iL+1V1e7v5BaC2QXAYGIdwhDYVPRdpx2NYegfC7RPDfinSLi58V202oafcJcfZ50jV5iVaNXYF8+YxlGX6sypxkCva68x1jw/awSarpZ8S6TaG/1SPVR9qVTcxyeZGwQfOpIJjwD1wQvYGgCrrfwdXU9S1u8XxDdQtrYC38ZgDpNsmEkRwWwCgAQY6gt61lj4K6daNa2lx4mZHlSSC2QxIkn3bk7IvmyExcEsg6+WvTFWZPhDrLW0kTeMZ23wPCcQui4eTeePNOBn069GDCu81zTYFv8Awreajq9vbnSp5JMzqqm6Y20qEAlgFwrM5wDwp6AZoA8xH7PNmkF3Fb6+9ul3F5M3lWEa7k3xP69cwjB7bmPetGz+CcFtqujzT3638VtdrPcyyp5cjxJbJCsG0AhkYxRs2SPucA7uPYYZY5oUlhdZIpFDI6HIYHkEHuKpXkWqtOTZXtjFDgYWW0eRs/USr/KgDQorINvrxBxqemA+v9nyf/H6R7bXyPk1TS1Pr/Z0h/8Aa9AGxRWT9n17/oJaZ/4L5P8A4/TJLbxA0bCPVNLVyOGOnSHB+nn0AbNFc8lj4pAXdruksQ2T/wASpxken+vrX0+O9jiYajcW9xKWyrQQGJQMDjBdsnrzmgAvtRsrDZ9uu7e23higlkCbgoy2MnnA5PoKdYX1rqFstxYXEVzAzMokicMpKsVYAj0YEfhWF4ntbcaxpepf2rFp99bQ3MMIlQSCRHVGf5cgkr5StkHjBz1rgrT4YWWpwS3Fn4pea3kS4gDRwquGN75ztuVgSVkTb6ce+KAPX55o7eCSaeRY4Y1Lu7nAVQMkk9hiorO9tb5N9ncwzptV8xuGG1gGU8diCCPWue8KeHLfwvZ6wZtRe7guriS6mM4AWPI+cd+DyT254AHFM8EQeHvD9ha6No2oRTfaC9zArShmeMgMoX/ZWMxqP9kLQB1lFVtRiuprVksLlLWckYleLzAP+A5H86xDpvibnHiOzx76Z/8AbKAOkorCWw8QhCDrlozb8gnTui+n+s/WmPp/iMsxXX7NQTwP7Nzj/wAi0AdBRWH9i8Q/9Bqw/wDBcf8A47R9i8Q/9Bqw/wDBcf8A47QBuUVlWNrrEd0jXup2k8AzujjszGTxx83mHHPtWrQAHp614Xr3hX4pXem67ZwX9pJbavM1w8ZutrwCSJkaBGKtiNW8tgRgkBhwTXuUjrGjO5wqjJPoKyh4k0k5AuwSOD+7fj9KAPEV+HXxLnvnmvdSsGkhtYbKCQXBKrHHcwSrtXy+oWNxubkn2Na8Phj4pW/2SaPUrUz/AGC3tbtvtAM00kYn+cOUxjc8bHjJAIz6+sf8JHpX/P1/5Df/AAo/4SPSv+fr/wAhv/hQB5nc6D8WCb5o9cs5ZZo3hjJmEKIc2+11URHH3bjjrhhznmlg8CeLLvwp40s9UuLAaxrltZqlws7bDPHbpHJI2EG3LITwtel/8JHpX/P1/wCQ3/wpD4j0oDP2r/yG/wDhQB5fc/DzxtYrcw+GtbsbKGWKFfMEpik3JFcZB2Q4A86WNhjHyqeBwKz9R+GvxA1bU2v9W1bRbq7FqbdJWmchQzWzlRH5O0ANDJ83Vt4OBivXG8UaYpxm9PuthOR+YSk/4SnS/wDp/wD/AAX3H/xFAHkXjDRPixpum3M2maq1/LdOAYra5ZmiPmTsGGY1KrsaBfl/iTkbSTXYfDjR/HtlfLd+KdVimsbhFdrOSbzZoDsPyMwjCkglc7cDIPLcV1v/AAlOl/8AT/8A+C+4/wDiKP8AhKdL/wCn/wD8F9x/8RQBE134rDHbouhlc8E6vKCf/Jam/avFzOv/ABKNBjTPzH+1JnJ+n+jip/8AhKdL/wCn/wD8F9x/8RSN4q0wDO3Ujxn5dMuTxnHaP3oAgM/i84xp2gD1zfzH/wBo1D9o8b5/5Bnhv/wZT/8AxirS+LtNZSwg1oKOSW0W8HYnvF7UL4v0osVKaqhHPz6Tdrn6Zj5oAghuPGeW87S/D2Np27dSm+9jjP7jpmm/aPG27/kGeHMev9oz/wDxirE3jDSoXKNHqzMBuOzSLt8D3xEaYPGmkFSSmrqAM/No94CR7Axc/hQA1J/GZX59O8PBvQX8xH/omia68YkDydI8Pqe5fVZjn/yXGKF8caMxwE1f8dGvB/7SqwnivS3RWH9oYYZGdOuQfyMfFAFP7R44/wCgX4b/APBlP/8AGKPtHjj/AKBfhv8A8GU//wAYq6PFWlkAj7fg+unXA/8AZKX/AISnS/8Ap/8A/Bfcf/EUAU1uPGn8Wm+HR06ahOfr/wAsKVbjxpj5tN8Og89NQmP/ALQq3/wlOl/9P/8A4L7j/wCIo/4SnS/+n/8A8F9x/wDEUAUluPGv8WmeHB9NRnP/ALQoW48bc7tM8NjjjGoznn/vxVk+MdGVtrTXSt0wbGcY/wDHKsjxJpRAIujg+sTj+lAGatx42J+fTPDgHtqM5/8AaFdHZm4a1iN6kSXJUeYsTl0Dd8EgEj8BWf8A8JHpX/P1/wCQ3/wrVBDAEdDQAtFFFABRRRQAUUUUAFea67oFmlzq+np4n02yTVNQjv5oLqMPOswEeFVvMXCny0wCuRzyRwPSq8z1zR7BL7WdOTxTY2iarqMN5NbTxiWZLj9yqoreYMBtkWFIyM8HBGADGHwd1DyGSTxfIWMcyFktWQHe2TwJuADnpjPfIyK63xjoMM2h+H7K+1+2sTYswSe6jXNxJ9kmi6blA+V3cgf3ew5rmk+Dk3lBZvEsrPiVXMds0YdZDkqVWTAweQVwe2SMg9D410iwHh/QLTWPEFvYjTizi5ulUeeVtJYmJG5QMLIznH93sKAOm8MS2f8AY1ra2N/b34s4Y4HlhYEEiNSCQCcZBBxnoRSana63NcltN1SxtbcrgJLYtMwPc7hKv5YrL+H+gQ+H7bUIINSjvy80QkZEC+WyW8Ue04Y8kIrf8Cq/rFhr1zeb9L1y2sbfaB5T2HnHPc7t4/lQBX/s/wAU4P8AxUOm/wDgqb/49R/Z3ir/AKGLTv8AwVH/AOPVD/ZHi3/oarP/AMFI/wDjtH9keLf+hqs//BSP/jtAEx07xTgf8VDpox/1Cm5/8jUf2d4q/wChi07/AMFR/wDj1Q/2R4t/6Gqz/wDBSP8A47SrpPisMN3im0K55A0kAn/yJQBKNO8U4OfEOn+3/EqP/wAerX0mC/ggddTvYryUtlXit/JAXHTG5s9+c1m/2Zr3/Qwr/wCAKf41paXb3tvG66hfC8YnKsIRHtHpgHmgDL8SWFk2q6Zqs2ppp19aJPBBJIybWWQKXBVup/dqRjpt7jIrjh8MtI1qO6urTxFeXEc/nReZA0RUObszudyKDuEgx14212ev6DNqOsaVqtleJbXunpPGgmh86N1lChsqGU5BRcEH1HeuFk+E+pGW5MPiswxXBldljsSrK0l01yWVhKCCGIAByMLyDkigDtvCXhe28LWuoRxXlzcRXU7XL/aWBCkj5j6DJyTjAyTwK57RtG8JaJcaPe2GuwJBZJdXUIe7RlkimXOck/cRISFxwFjOehNb3gbw1c+GbW+hutXm1M3Ny1wGlj2GMkDIHJ4yM44AzgADisW/+GVjNp72dpfT20TS3kgG0PsFxBJF5a88InmlgPX0zQB3F0klzbYtrpoGbBEsaq3HtkEVR/s3Uf8AoOXX/fiH/wCIqxdWt22nxQWV6LedAoMxhD5AHPyk45rN/szX/wDoYY8Z/wCfBen/AH1QBa/s3Uf+g5df9+If/iKZJpmqEDytenU991tEf/ZRUDab4hUZi8QW5b/prpwYfkrqf1pjaf4pKkDxBpin1GlN/wDHqAJ103WguDr+45BybNM/TrT20/WCrKutgZ6N9kQkfrj9KrfYPFH/AEHtM/8ABU3/AMfo+weKP+g9pn/gqb/4/QBfsLLUYLjfd6s91FyPLNuifqOc1p1i2Fpr8d3G99q9hcWwzvjj09o2bjsxlbHPsa2qACio7hHkt5Y45WhdlKrIoBKEjggEEZHXkEVgz6HrMmzZ4rv4sDB2Wtt83ucxn9KAOiorBXRNRBbPinWCCeP3VpwMf9cPrTv7Ev8A/oZ9Y/79Wn/xigDcorD/ALEv/wDoZ9Y/79Wn/wAYo/sS/wD+hn1j/v1af/GKANyiuf8A7B1Hyyv/AAlmt5Jzu8qyyOen/Hvimx+H9SUHd4v11/8Aehsv6W9AHRUVgf2FqP8A0Net/wDfqz/+R6P7C1H/AKGvW/8Av1Z//I9AG/RWB/YWo/8AQ163/wB+rP8A+R6ZJ4dvXkLnxVroJ6BRagD8BDigDoqK5pvDN6zZ/wCEs8QD1A+zc/8AkHj8KU+Gbs4x4p18YBHDW/P/AJBoA6SiuaPhi8IUf8JX4gGDnhrbn2P7mh/DN6wQDxZ4gUKD0Ntz7k+TmgDpaK5lvC94VAHizxCOc5DW2f8A0TU39gahtA/4SzXOOn7uz/8AjFAHQUVgf2FqP/Q163/36s//AJHo/sLUf+hr1v8A79Wf/wAj0Ab9FYH9haj/ANDXrf8A36s//kej+wtR/wChr1v/AL9Wf/yPQBv0Vgf2FqP/AENet/8Afqz/APkeoz4e1P5v+Kx17np+5sePp/o1AHR0VgroeoLnPirWm+sVn/SCt1QQoBYsQOp6mgBaKKKACiiigAorlPijqWraN4H1PU9AlVb+0iaVIzbmYzHBCoAOmWK888AjjORxupfEbxJoz3EC6AmsQ20tvC195j227z4/MR2Ty2CqB8hIJ+bHAzgAHrtcTeeBXltdUsrbVDDYahqK6o6Nbh5FlEiSFQ+4fIWjyAQSM9cACuSPxd1iTVri2i8J3Edva3JhkmlE+2RRFOxCnyuDvhRckEfOPrVSD4y+IDDO0/gW6DpbCcLHLKcEi3PzExDAAnbJGceS3GOaALz/AAUiaARf8JBc48poyfKIBLSeZnAcBQG5AUD3JGRXoOr+GYNVOkJdztLb2PmCSKRFIuVeB4SGwABw5PAHPoOK871r4q+JLRb6O28HO80NszxsrzSqZBbed0EQyufkzkEnHTts+LfFGvxXurQaOI4pYNJtbuzjeMkXDSzskrElCy+WqqBlcKZMuCMYAO08K6HB4c0K20y2llnWFcGaYgySH+8x7mnX9rq0tyz2WpwW8OBiN7TzCPX5t4/lXlSfFbxTBatBL4F1KXUI7YSAMkuXbbCcsEiIGfMk4HdMcZ4z5vjF4gvPE1zoFjoG7UNPvoYrlbGRpjIizrHNtBj5TGctxt3KDzQB679g1/8A6Ddr/wCAH/2ypFstZwd2sQn6WYH/ALNXmmpfEzxPNbWcdh4Uv0kvLKWR5IbeeV7KXy32qwaIDcsi7SOQf52tV1jx7Ld+C00WOQPdaWt1qX2mzKQrKDCWWQ+WWVirTDYCpyB6YIB6ELLWOc6vF/4Bj/4qhrLVyCBrEYJ7izHH/j1ecW/xH8Z/ZNPlm8DXEk11Ek/2eJZg2GcqY8sgCOgG5t+AQRipX+Ini5ZLXyvBM9xHJp73zELcRkvtYi3AaLiQEAHdw2QRjpQB6H9i1f8A6C8X/gIP/iqvWMVxFEVu7kXEhOQwjCAD0xk14no/xH8eW5b7f4U1DUFub5/Kb7BND5MO+ABQPLzgLJKdzc5jIrXtfH/jsm1a78FrGk9pNebf9JBUrkLASIiRJld3zABlYY5oA9dory7RfGviGfXvDiXekXKDVraRr3T3jIfTWSZY1lOFJ2OGY/Nx8mQRzXpN9eRWUIkmWdlLbcQwPMc/RATjjr0oAsUVk/8ACQWf/PHU/wDwWXP/AMbpreI7FWVTDqmWzj/iWXP/AMboA2KKxf8AhJbAttEWqE52/wDILuev/fv2pB4m08yCMRapvORj+y7r/wCN0AbdFYcnijT43CvFqob/ALBV0f8A2nTT4r00KG8rVcHj/kFXX/xugDeorCbxXpqkgx6r+GlXR/8AadKPFOm+WX8vVMf9gu6z+Xl5oA3KKzbDWbS+nEVut4HI3fvbOaIY+rqBWlQAjZ2naQGxwSMgGvLY/iVqWl29gfEukKlxcXTae0cAZCZo22yyJuJBjJK7ckcZ5NekavejTdJvb5opJhawPOY4xln2qTtHucVxMvj2y8rTLLVreC+l1qDzktrIiVEgZV3eYXIBGH7D5gDxxQBzenfGptSsnv7HRo57cxxGONbruwnZiz7TjAhA2lQcsOSCK7LwJ48g8W3eowxWb2otZCqs8mS6jHOCARySOMjjrXP6H8QdMtLfT7bT/Dd3pxvvslxtYRbPJuHWOKVmV+c8KOp+Xpha6rwN41sPF+mveWccsCoSJFmZMoVA3A4J7ng9CMEcEUATx+N/DMhIj1ywYjrtlBp//CZeHf8AoMWf/fyr39uaT/0FLD/wIT/GoLjxRoFs6Jca5pUTP90PdxqT9MmgCD/hMvDv/QYs/wDv5Ucvjfw3GcNq9ueM/Jlv5Cp/+Ev8Nf8AQw6P/wCBsX/xVH/CX+Gv+hh0f/wNi/8AiqAIR418PsMjUAR6iGT/AOJo/wCE00D/AJ//APyDJ/8AE1N/wl/hr/oYdH/8DYv/AIqoZvHHhOA4n8UaFGcZ+fUIhx+LUAH/AAmmgf8AP/8A+QZP/iaP+E00D/n/AP8AyDJ/8TUR+IPgxTg+LvDwPodSh/8AiqlHjnwlz/xVGhf+DCH/AOKoAdF4x0OZisN3JIw6hbaUn/0GmP410JNu65uBuGR/oc3I/wC+KX/hOfCf/Q0aF/4MIf8A4qj/AITnwn/0NGhf+DCH/wCKoAIfGmhTuUhuZ3YckCzm4/8AHKH8aaHHJse5uFf0NnN6Z/uUf8Jz4T/6GjQv/BhD/wDFUjeO/CK43eKtBH11GH/4qgB6+MNFYoBPc5fO3/Qp+cdf4KB4x0UybBcXBfkY+xz+/wDsexqFviB4NU4bxb4eB99Sh/8Aiqkj8ceE5V3R+KNCceq6hEfT/a9x+YoAcnjDRXKhZ7klhkf6FPyP++KQeMdE88w/aLjzQM7fsc2cf98VJ/wmXhjOP+Ej0XOcY+3RdcZx970pf+Ev8Nf9DDo//gbF/wDFUAH/AAlWk/8APW6/8Apv/iKP+Eq0n/nrdf8AgFN/8RR/wl/hr/oYdH/8DYv/AIqj/hL/AA1/0MOj/wDgbF/8VQAf8JVpP/PW6/8AAKb/AOIo/wCEq0n/AJ63X/gFN/8AEUf8Jf4a/wChh0f/AMDYv/iqaPGXhgnA8R6MT1wL6L/4qgBH8X6MhO+e5XAzzZzdP++K27aeO5t45oSxjkAZSylTj6HkfjVIa7pBGRqlhj/r4T/GtBGV0V0YMjDIIOQRQAtFFFABRRRQAUVT1ae8trJpNOs1vbgEYhMwi3Dv8xBFYjav4nUDHhaJsrnjU04Pp93r+lAHT0VzI1fxMWUf8IvCAWwSdTTAHqfk6VH/AG14o/6FJf8AwZx//E0AdVTWjRpEdkUumdrEcrnrg1zSax4nZ8HwtEo/vHU0x/6DVmO/8RPGrNoVkhIyVbUTkexxERQBvVTtNL0+zu7i6tLG1gubk7p5ooVV5T6swGW/Gs/7b4h/6Ath/wCDE/8Axqo5L7xKCPL0LTm/3tTYf+0TQB0FFc29/wCKwo8vw/pTN3Das4/9oGm/2h4u/wChd0jp/wBBh+v/AID0AdNRXMf2h4v7+HdH/wDBy/8A8j09b/xYQC2gaQCTgj+13OB6/wDHvQB0lFc2l/4sLkPoGkKvZhq7n/23qX7Z4n/6Auk/+DR//jFAG8FUMzBQGbqQOTS1gfbPE/8A0BdJ/wDBo/8A8Yo+2eJ/+gLpP/g0f/4xQBv0VgfbPE//AEBdJ/8ABo//AMYo+2eJ/wDoC6T/AODR/wD4xQBv0VgfbPE//QF0n/waP/8AGKPtnif/AKAuk/8Ag0f/AOMUAb9Fc8174pBXboekEE8k6rIMf+S9IL7xT5ig6FpOwnBP9rPkD1x9noA6KisAX3iUqP8AiR6aH99TbH5+Tn9Kat94nz8+haWP93VXPf3gFAHQ0Vl2NzrElyq32mWsEBzmSO8MhHHHy+WP51qUAFQLaWy/dt4R82/hB971+tSyoskbxuMqwKkeoNeWyeC/E+l6bLB4Vl0yxkuL27aYhyuYHmLQf8szkomV28D5utAHqBhiMaoYk2LjC7RgY6YHtSpDEmdkaLxjhQOPSvKtK8J+PdM0TS9PtddjjgtrfyXjS4BZWWKAIyyPAxK745soR0kHJxgbV/4c8Tar8ObvRtT1C1fWJjGBcqx2YEisSQVPOAcj5gSew4AB3P2aD/nhF/3wKPs0H/PCL/vgV4fPoPj/AMP3mg2FnI1zZZjjmks5XyyxPGMsxj+UspfCOSgBfkFUrsPh/wCE/EmgTaTHqmqLPYWVqLfyEupGXP2e2TIUqAQJIpiATwJMjuKAPRAAowAAPQUtZ2qS6vHJGNKtLCdMfObm6eEg+wWNs/mKo/aPFP8A0C9E/wDBlL/8YoA36KwPtHin/oF6J/4Mpf8A4xR9o8U/9AvRP/BlL/8AGKAN+iue+0+LPmzpehf7P/Eyl/X9xUcc/jA58zT/AA+vptvpj/7RFAHS0Vzom8W45sdCz/1+Tf8AxqjzvFn/AD5aF/4GTf8AxqgDoqM8471zom8W45sdCz/1+Tf/ABqsPxP4Z8SX+rXmoaNf2dhPeWFpayOJHDxmGaWVgjBej+Zs3dQMnBOBQB3oZSxUMCw5IzyKWvN/B/gTV9F8XnWrzVpLiOVXWaF7uaUsDFCi5LYDFWjbkqOHzwRXTGbxZniy0LH/AF+S/wDxqgDoqK5wS+Lu9loPX/n7m6f9+qWJ/FrMBNBoUa46rNK+T9Nox+dAHRUVzbv4vDnZDoBXHUyzA5+m01OP+Elxz/Y+f+2tAG7TFijViyooY8EgYNY3/FS/9Qf/AMi0f8VL/wBQf/yLQBr/AGaD/nhF/wB8CpQMDA6Vh/8AFS/9Qf8A8i1tR7vLXzNu/A3bemfagB1FFFABRRRQAUVT1aC7ubJ4tOvRZXJI2zGIS7Rnn5Twc1j/ANkeI/8AoZ1/8Fyf/FUAdJRXN/2R4j/6Gdf/AAXJ/wDFUf2R4j/6Gdf/AAXJ/wDFUAdJRXNf2R4j7+J1x3xp0f8AjUq6Tre0b/EsxbHJWzhAz7DBoA6Ciuf/ALI1rIx4lnx3/wBDh/wpj6LrjHI8VXa+ws4P6pQB0dFc3/Yeu/8AQ2Xn/gHb/wDxFKdF1zaB/wAJVd59fscGf/QKAOjorm20TXCxI8V3aj0Fnb//ABFH9h67/wBDZef+Adv/APEUAdJRXPQaLrCvmbxRfSLjoLW3X9fLNWP7J1D/AKGLUf8Avzb/APxqgDZorA/sbVvN3f8ACT3/AJf937Nb/wA/Lp50fVPNyPEt+E242m3t+vrny6ANyisUaTqGOfEWo5/642//AMapf7J1D/oYtR/782//AMaoA2aKxTpOo5GPEWoe/wC5t/8A41UbaNqxnVl8TX4i7p9mtyT+Pl/0oA3qKwpdH1Q7fL8S364OTm3tzken+rqOTRdZIOzxTeqc8Ztbc8f98UAdDRXOrouthWDeKrwk9D9ktxj/AMcpq6JrgPPiu8I/687f/wCIoA6SisnT9P1K3vBLda1Ndw8/uWt40HtyoB4rWoAq6rcmy0u8ulG5oIXlAxnJVSen4V5V4a+Lc15ZaZLqtksN1cqPtFqqFTag+QBK7En90RKZNwBAXgnKmvX6KAPKNN+Kd5FpNjJquiNJcSRRiV4JNg34ti77WHyxgXOSxY48ts4AzWvJ8Q57e6aC70C4Qx3Udo7xXCyKGdFdSuB842uuducZ54BI9AqG3toLYymCJIzK5lkKjG9j1Y+p4H5UAcH448Xa1o2u6RHptkkum3EHm3UrRF/JywAyytwDnAIBGSM4GSOeX4u3V9OLfS9MR7q1kP2mCSQiSRVhkcgIFJXlVwfmHzBSQensdUrLSdPsbq4ubOzgguLhi0skaAFyTkk/U8n1NAGZ4R1+XW9Bl1K/tDYbJ508lixZUjdlVmBAwSoDcZGCMGp/+Eo0b/n+X/vhv8K2aKAMb/hKNG/5/l/74b/Cj/hKNG/5/l/74b/CtmigDG/4SjRv+f5f++G/wpj+K9HU4FzLJxn91bSuP/HVPPt1rcooAwP+Et0r/qI/+Cy5/wDjdH/CW6V/1Ef/AAWXP/xut+igDn/+Ev0nOM6hnrj+zbn/AON1z/iTxhq+ja5qcEGk3F9APsSWm22l2KZDJ5ru6Ix2oFQnAOMj1r0CigDz3wb4i8TX3iy/tdc08Q6cRK0EiQShVMZQbVZkXcDvJBPXHAGDXR/8JbpX/UR/8Flz/wDG636KAMD/AIS3Sv8AqI/+Cy5/+N0f8JbpX/UR/wDBZc//ABut+igDnU8Y6QwUganznrpV0On1j4qKPxzor/dTWByB82i3g6/WKunooA5b/hPNFwCI9bx/2A73/wCM0f8ACd6LnBj1sZGedDvRx/35rqaKAOaTxrpL42Qa4cjIxod7/wDGa6RGDorDOGGRkEH8j0paKACiiigAooooAwPH+oahpPgnW9Q0Zd+pW1rJLbJ5Rl3yAZVdo5OTxx6155b/ABD8Z6WWt9Z8N2l5sgjvDcwzSREQyzeWm9BG4DoMNIAxwOa9iooA8Lu/jtf2+qNp7eEJPtv2R7iOBrpg87KHIEY8r5gwQFeAxBzjFa8/xW12GRom8E3bTxyvEyrJLibbNJGWiPlfMoVFkOcfK4xnv6idMsDqI1A2Nr9vAwLnyl83GMY3Yz0OKuUAeGRfGHxIbgTP4L1Hyp4oClvtY7DvmWVlfbhydsWFB6HIz0Ot4o8b+KtE+IGtQ22k3OoaLbQQxwItuyxeY0MkrMZFjZmYmNYwF+UGQZGa9dooA8wbxn4xvfCniXUrLwutrdWLLFaW8hllnkPymRjHsUNtViQFY7ipFQX3j/XNL1G3sdO0TVdft2KEX0tlJbmXczBwMR7R5YAJJA3ZwBxk+rUUAeQaJ8S/Fd8bZLrwZdWzSlSZGguNi7oUkER/d5DFmZNx+UFeetVZPiv4nhtdG83wkv8AaWomZk09TcCb921uGj2tEuGHnt83Kfuzz6e01BJZ2sl5FdyW0L3UQKxzNGC6A9QG6gGgDxWy+InjiO8hku/Dt7LFNZwmZV0+dYrWYtNu+Xy/Mb7sa8Mw+YN0rqfB/jTxRq3iS2s9a8K3Gl2UwlUu0Mp8lkihcFpCoQhjJIg6cxHBOcV6RRQB5D8NvFfjjVPE3iOHxHpF7baYyST6W89i8Zi2uwER+QBjtK9X5x8pOTin4a8ZfECws7O313w/fahLPOE+2payYI8y3Vm2CJTEoWWdx5i9YiASMV7UDkZHSigDw7wt46+JEVjpFtqPhK5v2xHHcXb20kEsjFAWBQqqrtJwZCQp/hBIIFqX4meLtP0jTb7W/DMVnHcTpHMxhuAsRaaCMROWVdjASyN5nMbeXgHLcez0yaGKeMxzxpJGeSrqCPyNAHjq/ETx/M8cUXgeS3PnRRSzXMFx5cZIk38IjMy5RQHUEDeCeDTl8feO5tfWz/4RSWCxF2ivdf2fcOFg+1GJyOm4mPa4I6Ak4OOPY6KAPK/GV148sNR8UHTZLqfTYLVbzTmtreN5GdlKG32+USxDAyZGTjaD1rAvfH/jy5u0urTw1qdvDZXUy/Z206bZep9nl8tW+QsD5qIAwwAXGRivc6KAPH/Cfi/xyfFb6XrHh6dLK51K4K3d3HKFihDoFiQxxEHCliHfCtjG7inar4x8a6Rq3iCO10O/1WBL24+x77GQKIY7VZFVWRBu3y7kDEnnHWvXqKAPFtM8c+MbLxVdRahomrXtjeapNDDu06VEtbVCQjhljzyChLEtnn7uDm94f8ZeMfFFxDpsukS+Hjd27/6c1lLIbeRrdXTh1C5VmYHdwSuOCa9booAis45YrSCO5m8+dEVZJdoXzGA5bA4GTzipaKKAKWt6jHpGi3+pTo8kVnbyXDpGAWZUUsQM9+K56DxRrc8Ec0fgrVikih1Ju7McEZH/AC2rS8eAHwP4iB6f2dcf+imrR0f/AJBNl/1wT/0EUAYUfiHXHkVW8GaogJwWa7tMD3OJSatR6vq7IGbw1doSM7WuoMj8nxW9RQBh/wBrat/0Lt1/4Ew//FUh1bV+3hy5/wDAqH/4qt2igDl5NZ8TBjs8KKy5OM6lGDj3GP6mnLq3iZhk+GIVPodTX/4iumooA5v+1fEv/QtQf+DJf/iKjm1bxSIyYfC9q79g+qhR+YjP8q6iigDkBrHjLBz4S0/OOP8Aic98/wDXH0o/tfxnkD/hE9Nwep/trp/5Arq7lzHbyurKhVCQzjIHHU8jj8a8Ik+LPi5fClrqEGmafd3dxBZSnybSTbDLNKUe3KmUbpAo3g7hgDDAAhqAPT11XxkRk+F9KHTg603/AMYpp1fxmFBHhTTCfQa0cj/yBXGad8T9c1U6XaWGn2P2y+0tityySG3TUwgkFswJVgpUNknkMQMnvn6B8UPF+qaTcahcaTaaekeo20KxXFjMpkguJIlTBMgy6BpS5xj5Bjg5oA9Ij1LxgyAt4a0hCf4W1l8j8renf2j4v/6FzR//AAcv/wDI9cAvxP8AE0EE4vtEtsgI8V5Ejm2aGWdI1nPzbgIwWLp6gYYA5r0fwRrba/oIvHdZWWeaAzJB5KSmORl3Iu9/l44O45xkcEUAV/7R8X/9C5o//g5f/wCR6ji1Txi5YN4Y0qPHQtrLc/lbmurooA5WPU/GLDLeGdJT2bWW/pb0iar4veR1HhvR/kOCf7aY84zj/j39COtdXRj9aAOUfVPGKnjwxpL/AO7rLf1t6i/tnxp/0KOnf+Dr/wC012FFAHH/ANs+NP8AoUdO/wDB1/8AaaUax4zzz4R08D21r/7TXX0UAcudY8Thsf8ACKxH3Gppj/0GtLwprI8QaBa6mtu1t524GJmDFCrFSMjryprWrkfhOmzwBpYJz/rW/OVz/WgDrqKKKACiiigCtqMl3FZyPp1vFc3QxsilmMStzzlgrY4z2NZUd74jKAyaJp6t3C6kxH5+SK3qKAMP7b4h/wCgLYf+DE//ABqj7b4h/wCgLYf+DE//ABqtyigDkvHWlax4g8Ix2lkIbTUWuraWQCfKqiTo7gMUIJKKRgrg5wciubt9A8e2pEUGpRf2aPIC2ougJERYykiLJ5PG5tjg442lejcekahfWunWpuL6eOCAMq73OAWYgKB6kkgADkkgUW99bTxLJHMu1gzYf5DhTg5BwRgjvQB5hrPg7xnqUNwLjV0nnFzO8LPMFRY2DeWFVYwQRlQQS3K5Hvet9A8eLDaGbXy86Su9xmVNkp8yAqUAiBVCiz/IScFx8x4x38uo2cV3aWslwguLvd5CZyZMLuOPwGat0AZPhOzvtO8M6ZZ6tcG51CC3SOecyNIZXAwW3Nycnnn1qr4ds7y20jUrfUYVuLpru6fMhG24R5GaPnnjYyJgjjaRyAM9BWbd65ptpp13f3N2iWdo5jllwSAwIUqMD5juO3Az83y9eKAKfhvR7vTJbh57w/ZpAPKsEdpI4O5w75Y+gA2qBwF71meJfBNnrOqX188PlSTWLW/mW8myWZyR94kEABUVRwQQ7AjgVu2viDS7q+jsobxDdyIJFhYFXwVDYIIGDtIO08gHkVS1TxnoOlX91ZahfNBc20XnSK0EmNny8ghcNy6jCkklgOvFAGBoXg/WdKvtGuf7RtpTbW8cN1Gd6o7AIhZEXCLhFIACgZO7HOB0unWl0nivWLxlaKxlht4o0LZEkqeYXkAB4yrxrnqfL9AKdp3ijRtQu47S1vo2vHVWFuylZBlA4ypAIO0gkHpnmtG3vbe4ubm3hlVp7ZlWWPoV3DIOPQjv04PoaALFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYfjv/AJEfxD/2Drj/ANFNWjo//IJsv+uCf+gis7x3/wAiP4h/7B1x/wCimq54dYv4f0xyclrWI59fkFAE+p3tvpmnXV/eyeVa2sTzzPgnaigsxwOeADVhGDorKcqwyDVTWtOg1jR7/TLzf9mvYJLaXYcNsdSpwexwTUlhbfZLVIPOmn25+eUgsefYAcdOnagCxRRRQAUUUUAFFFFABRRRQAUUUUABGRg9KAMDA6UUUAFFFFABRRRQAUUUUAV9RvbfTbGe8vZBFbQIXkcgnao6nA5pNNv7bUrQXNlKJYS7x7gCPmRijAg8ghlIP0qHX9Kg1zRb3S7xnW3u4mhkKY3bSMHGQR+lR+G9FtPD2kx6bp28WkTu0SNj92GcttGAPlBYge1AGnXI/CVy/wAO9FdvvNG5P/fbV1xOBk9K5b4WlT8PNAMe0q1qpBXoc96AOpooooAKKKKAK2pW811Yyw2t5LZTOBtuIlRmTnsHBU+nIPWsT+wta2gf8JbqGfX7JbZP/kOukooA53+xNZ/6Gq//APAW2/8AjdH9iaz/ANDVf/8AgLbf/G66KigDB1bw4NW0a2s7+/uZLm2uI7uG8CRq6yxvuRtoXbjtjHIz35rlbz4TadfSSSX2ranNLLKbh3Z1Leb+8C4JBPlqJWXy8lcBcjrnrvGfiCLwv4cutXngluI4GjXyovvMXkVBj8WFc7D8U/DjKvnzTQyqm+aJreXeh2F8BdmTkAkcDIwcYIoAXw38NrLQdeh1S31K9ldHeZopBHsaR1dWIwuVXD8KCACPc13dMglE0Ecqq6h1DBXUqwyM4IPIPsafQAVgWPhuGDQNQ0eYQXFncT3EqLNCJABNI0pDq3DYd2xnqAM85Nb9cpqHjBYtCvdUsNPlvo7a/ewESPiSV0kMTbFxyfMDKB3xnIFAFPR/hvpOlXdvJbXN/wCTBFsSLztmG8gQbwyAMp8sADaRg8jHFdDqGg2l/LcvdAT+daC0Ec6LKiLkkkKwOSx2ZzkHy19K5i7+I8NjJqgv9Ku7dNPulhlMnyHy2fakvzhQVbDEbS33eSDxVzVvHMFjd6KkNutza3lwtrd3cMvmR2Uj7BGjmNW+ZjIoGcL6sMjIBNYeBNK0+bS5LKa+gbT4Ut4xHNtDxqVO1wByCUXPtx0wK1rHSjB4h1PVpZQ8t3FBbIijASKIyMufUlppDn0wO1cZY/FS2u4oJl0i6WCf7OY5GmjAInjDxA5Iw2DyOgweTXZ2OtQXmt3WnRgForWG8jlRgySxSlwCCPeM/gQe/ABq0UUUAFFFFABRRRQAUUUUAFFFFABRRRQBh+O/+RH8Q/8AYOuP/RTVZ8Lf8ixpH/XnD/6AKreO/wDkR/EP/YOuP/RTVZ8Lf8ixpH/XnD/6AKANOiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAivP8Aj0n/ANxv5Vy/wkjaL4ZeGUfG5bCIHH+7XTX7bbG4briNj+lc/wDC9/M+HPhlwMBtOgOPqgoA6eiiigAooooArajY2up2UtnqFvFc2soxJFKoZWGc8g+9YY8CeFVYFfD2mKf9m3Udsdvat2/u4rCzmurnzBDEu5/LjaRseyqCT+ArnR4+0AnAl1D8dLuh/wC06AJx4H8MDpoVgPpEKX/hCPDOc/2HYZ/65CoB490AnHm6h0z/AMgu6/8AjdTjxnoh/wCW91/4Az//ABFAF4+H9JOjtpR062OmswY2xQbCQwYHH+8AfqKpTeCfC811cXMugaY1xcMzzSG3XdIzbtxY45J3NyfWqni7xFcR+BNQ1bwyss93EFEKm2cszb1BGwgE8E9veuYh8d+KNNk/s/WPDv2i8hlEVxc2/meVGhaHE7fJymJmyFJOYX6DOwA9TorkfAHiXVvEq3suqaGdHihMaIksjtK7NGrtkFFGBuxkE8g5xXXUAFYd94T0LUIZYNR0y2vLeS6N75NygkRJiuC6qeFJ5Jx3Zj1JrcrE8OalcagNYM/l+bbX0tukA4MaqAEDH/aGJM+kg9KAL0mlafK1w0tlbSNcHdMXjDeYduznPX5cj6EinPp1lJ9mD2sLLbNugUoNsbdio6Ajse3PrWN4a1DVL29lGtQy2FwEyLFYC0SjI+b7Rysh9MbCAeV71zfijVvEr634gs/D95JbLa2SyRte6fIIvM3xk+VKImD/ACFhj5yWYYX5TkA7SDw7osEMsMOkaekUzmSRBbph2OMkjHJ+VfyHpVi1021tb24u4Y9s86Rxu2eiIDsQDso3McDuxPeuO8Paz4pbXbKDWNOuVsZ7dHZltwTDKw3GN3yB8oZQWAwWBA7gdDoWo3N3rev2srJLa2c8aQyquMFo1Zoz6lSQc+jgdQSQDcooooAKKKKACiiigAooooAKKKKACiiigDD8d/8AIj+If+wdcf8Aopqs+Fv+RY0j/rzh/wDQBVXx2D/whPiAg8f2bc5GP+mbVa8Lf8ixpH/XnD/6AKANOiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAr6l/yDrr/AK5P/I1jfDuFbfwD4bij+6um24H/AH7WtnUv+Qddf9cn/kayvAQx4G8OjJONOtuT/wBcloA3aKKKACiiigCtqK3jwINPlgimEsZZpoy6mPeN4ABHJXcAexxwa8c0z4r69aajexavo6XdqLwwwyQRTRlE+0Tx/N8jAkJHG+CRw2cnIA9sooA8l034u3l0JGuPCtxaRxpEztLOcLvl8vdny/mjXqzrnA7HvcuPiTe6V4S8PalqGk/arnUoHaXyWeNElV0XaAVJ5DOwJxwnocj06myIssbxyKGRwVZSMgg9RQB5Po/xdu9RtbSceF5BHcRpKkkV2ZElDGEeXEfLG+UeccoQoGw/MeSLtv8AE67fwt/al1oCWlw19Z2aQzXjLHtuY4nVzIYgRt83DDacFTya9HsrWCxs4bSzhjgtoEEccUa7VRQMAAdhimX1ja36wre28U6wypPGJFzskU5Vh7g8g0AeVaT8U9ckaSS88KzG3dw0arIyzRIWgTaylMMd04wQ3IDHAxzOvxUvhq7W114fa1iWaS2Z3lZo1YOgWR5VQ7UIbspwSAcENt9SuLeG5VFuIo5QjrIodQdrKchh6EHoaloA8lk+K+oW+pT2Evh1prhJp4gyySInyTFEyfKIwQCcjnj7oyK2tD8Y6nc63osF3oyrDq5n3TRM3+ieUuArErl9zpIQ2FADKCMnn0CigDyj/hbFxDPFbzaDJJI82wyxyN5aRkkecfkP7tcEEjJ4zjnFVPDnxZ1K9eewm0WCXUbaxe6ZhcPGsrAIVVV8snB8w9MkBMkAMufXreGK2hSG3iSKFBhURQqqPQAdKrx6XYRajLqEdlbJfS/6y4WJRI/AHLYyeFUfRQOwoA86s/iXq8mowWNz4aWGWSbyzP8AaJfJA3MudxhyCxQkDGMEc1N4e+IGqXuvWFne+HP7OsLhZZJLhWlkCnaGQf6pcMTuyD6dc8V6XRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBh+OgT4I8Qgdf7OuP/RTVZ8Lf8ixpH/XnD/6AKh8att8G682AcWFwcH/rm1TeFv8AkWNI/wCvOH/0AUAadFFFABRRRQAUUUUAFFFFABRRRQAjEgrhScnBxjj3paKKACiiigAooooAKKKKACiiigAooooAr6l/yDrr/rk/8jWX4E/5Efw9/wBg63/9FLWnqh26ZdnBOIXOAMn7prM8Cf8AIj+Hv+wdb/8AopaANyiiigAooooAyfF1nd6h4U1qz0yRo7+4spord1kKFZGQhTuHI5I57V5H4N8N/FbQbDS7B9UjkhjmkkuZJp1uWk3JEUUmTLLGGEoO07iTkdcD3KigDyW1s/ir5ulmbUkA2x/bA62xXzPNXzcYQExGPdsxhwxw2RzWZY2HxnSGQ3GqxyzSWrLhxaBY5jGmGXbGOknmfeyNpGQTXttFAHiv9nfGdI5YxrNqyNPGfNZLYzJEHl3BAIgmShhzuHVWwRmrN5pXxcGo6o0GtWs1hJIwhjYQJIIhLERsIiwrmPzhltwyV47j2GigDw3w74a+LOj+HRpqarabbeCJLdVkjY4Dr5gMjxlvMK7sMQVGenFaY8CeJ5vBHgrRXv5bS5sbmQ6lcW9824wsJAADgbzlkbnGCvB716/RQB4V4g8E/ErXUhTUtQ066hgd28t5fLy7RTxlkZUyExJFhWyflPPrbsvC/wAVrfS3tIfENpbGC12W+0o8bMq2/lpzHuH3ZwzE871IA7e1UUAeOR6F8WbMWDv4is711kAuvuopSOZMMq+USS8SvkA8M/HSk8G6F4z8SfDDXbfxncyzXWpWYFlbXoEUkFwqt8z7EUqpcRkL82Nuec4r2SigDxWHwL4+0vRLe08O63Hp32bSbWIQLOHjlu8/6SxLRFhuH3WycNk454kuvDHxTl1mJxr9u2lQtasI2vSssux4WkDMkCgZCzDIHO7nIwB7NRQB4rbeEvi7HI7nxZp/mEPtZrhpFUsJudnkAHloMcgDY2OuKsr4W+KBm0uQeI4AkEcZuI5b4tvkE+6T7tuMqYsqM9CfbNew0UAcZ4D0/wAV6N4W+y65Nb6jqUMUSRGW9ZlkYIA5aTydwy25uQ5GcZxV83vi4Oq/2DohB/i/tiXA/wDJbNdJRQBzv2vxZ/0BNC/8HE3/AMi1C+o+MFJx4b0dvprL/wBbeuoooA5mPUPFrbg/h7SVIGVP9ruQT6H/AEfj8qY2p+MM/L4Z0oj31lh/7QrqaKAOX/tPxfuP/FNaXt7H+2Gz/wCiKmGo+Ju/h+w/8Gh/+NV0VFAGHaX3iCS6iS60WzhgLAPImoFyo9QvljP0yK3KKKAMPx3/AMiP4h/7B1x/6KarPhb/AJFjSP8Arzh/9AFM8XoJPCeto33WsZweM8eW1P8AC3/IsaR/15w/+gCgDTooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAKWtxmXRb+NThnt5FB9CVNUPAn/Ij+Hv+wdb/APopa1NS/wCQddf9cn/kay/An/Ij+Hv+wdb/APopaANyiiigAooooAiu0mktpUtpVhnZSEkZN4U+u3Iz+dYbab4jLEjxDageg03p/wCRK6GigDGS119SSdW05wccHT34/KbvQbXXyW/4mumjIwB/Z78e/wDrq2aKAMgW+vY/5CWmH/uHyf8Ax6oWsPEDIB/blorD+JdP6/XMh/THWt2igDCXTte53a9CeeMWCjj/AL6pf7P1z/oOxf8AgCv/AMVW5RQBz8ml68+dviJUyMfLYpx78k0sOma8kYVvEKyEfxNYpk/kQK36KAOfm0vXn27fESx4PO2xTn8yaE0bWdo3+J7st3ItIAP/AECugooAwP7H1f8A6Ga8/wDAW3/+Io/sfV/+hmvP/AW3/wDiK36KAOfbRtYIwPFF6vuLW3/+IoOjawenie9H0tbf/wCIroKKAOffRNWZR/xVOpIe5S3tv6xHmg6DqXH/ABVmtdf+eNn/APGK6CigDA/sLUf+hr1v/v1Z/wDyPR/YWo/9DXrf/fqz/wDket+igDn20HU+NvizWRzzmGzPH/fihdB1Lnd4s1o88Yhsx/7QroKKAMD+wtR/6GvW/wDv1Z//ACPTToWqbht8Waxt7gwWZP4HyP8AGuhooAxrDSL62ukln8RapdopOYZo7ZUbrjOyFW/Ijp+FbNFFAGX4qz/wjGsY6/Y5v/QDS+Fv+RY0j/rzh/8AQBR4p/5FjV/+vOb/ANANHhb/AJFjSP8Arzh/9AFAGnRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAV9S/5B11/wBcn/kay/An/Ij+Hv8AsHW//opa1NS/5B11/wBcn/kayvAWD4F8Obfu/wBm22P+/S0AbtFFFABRRRQAyeJJ4JIZQTHIpRgCRkEYPIrBHg7RQxIhugSAMi+nGMenz8H3roab5ieYU3rv/u55/KgDCj8I6TE4aMagrAAAjUrnoOg/1lPXwtpqlyr6kpdtzY1O5GT6/wCs61uUZ5x3oAxD4X04lCX1P5Mbf+Jnc8Y6f8tKik8IaTI7PINQZ24LNqVySeMf89PQkV0FFAGCnhLRkGBbzfjdTH+bU7/hFNH/AOfaX/wJl/8Aiq3KKAMP/hFNH/59pf8AwJl/+Ko/4RTR/wDn2l/8CZf/AIqtyigDn5fBugy/62x3gEkBppCBnr/FQvgzw8owNLh/Esf5mugooAwP+EO8P/8AQLg/X/Gj/hDvD/8A0C4P1/xrfpjmQMvlqjL/ABFmII5HTg54z/noAYf/AAh3h/8A6BcH6/40w+CfDZUK2j2pUYIBUkDHSuiooA59fBXhkBgdB01txyxa3Vi31JGT+NIfBPhYgA+HNIIHQfY4+P0roaKAOd/4Qfwr/wBC3o//AIBx/wCFH/CD+Ff+hb0f/wAA4/8ACuiooA53/hB/Cv8A0Lej/wDgHH/hR/wg/hX/AKFvR/8AwDj/AMK6KigDnf8AhB/Cv/Qt6P8A+Acf+FH/AAg/hX/oW9H/APAOP/CuiooAxbDwr4f067jurDRNMtrmPOyWG2RGXIxwQM1tUUUAZnin/kWNX/685v8A0A0eFv8AkWNI/wCvOH/0AUeKf+RY1f8A685v/QDR4W/5FjSP+vOH/wBAFAGnRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAV9S/5B11/1yf8Akawfhj5n/CufDHmgh/7Nt8gkn/lmvrW9qX/IOuv+uT/yNc98K2L/AA08LMxyTplv/wCi1oA6miiigAooooAK8y1zwJqkniPXdf0u+2313dQmKBZEgzbiGFGHnCJpY2LRv0Yrjtkkj02vLvFHgrxDd+K7/W7LX4rOG98u0liE8sLQ2itG2UkX+MsknGF4mYbqAH33hfxwvgCexs9eWbxHPdCR7mW7kRRGBjajKgKdAcAY61y1z4A+Id5JfTXWrW80t5CbaZhqsihuZdpAEGFRN8YKD7xQnjODevvAnjsW0UFp4wlOInTzG1KdXSZoVBOSrbwXDEKcbQcrgnh2oeB/Gtsb2DRtciMRYiF59VuEZEaViUcKvzOysp80ncCMcg0AUrb4eePdPZzZ6tAobzN4hv3Rm3RqF2sYvkVZF3FQMEDHfFX7vwp8Sjc2raf4nt57czia4aS7cZImclVUIQEMRRdvQN+dbPg/wp4ws7W8/wCEi1sXkt1YS27xm9lljWXCLG65VdvSQsVwfmHXGRzdj4A8eWWmvb6VqNnpRO94PIuyBA+wKTIkcMcc27aACVXZjd8zE0Abus+H/HkZ8PxeH9Qto4bHTkt7tWu2VZJVXnA2Hk4UbjnjsO/Oz6X8T5NSuHuJrzyPtaRultqYjV4zFE2EJh+VVbzQZOpzjHAItXHgLx9PeqY9aitrGYMJYV1OZ5FyoADS+WrSgAFfmyRnIIOCNTSfCniXVfBWtaVrV/cB5Z4re1E87HEEcokclvvNks8YJ+8kaEgZNAEvgfRfGmn67LbaxqZlgW1knllVSYpLt2YAqSBlcHcVAwDj6Vk23hj4lzwgHXTCxj27/wC1PNCSeW6yNgQDIZihUE/Jg8/w10Pgzw14qtNWF14h1157UQSIkCXryrJMyoDKQUX5TiRgmSEyMZ7cfp/wt8Z6D9hTw/r8UMXkWgvQkghYzIJN5UxxgMo3qf3gZn/iJ2gUAWpPCXxQs9Qd9O1yCSNrrzPMmu3b92NqqpUqAcIvP94n15HR+BvDviuw8RG+166uZbd4oY9jaqZtpRZ95K+UoYM0iEDqPX5QK5rRfCXxIm0mC71DWblJPIiJ046rIsjsQnm7pRH8hOGIAztzgHvUq+D/AIlwzi4OtW91fLAbZ531B40mDQugZUEJ8vY7RucElyhPy5xQB7VRXh7+APH17f29zca9JHLHvUznUpHG4up8xIjEAowCApJxgYPJJ6fwhoHjyy8XR33iHXYLvTHtmaW3jc7VlbLFFUrjarE7W4O1VB75APSaK+frP4Z/EfStMs/7P8Q2xv7W3FkrC6kG6HcJCMleMO7jP92NBzyDfbwP8Rxqt1qL6tFNK8ccUu3UCklwFnLt5b+T/o4ZDjAzj1PWgD3KivF5vBfxHgsboad4jVLl5pNqNcfu/KZ95PyxpiQkn5gB1+ter+HYL620Kwh1ecXGoxwItxKDkO+OT0Hf2FAGjRRRQAUUUUAFFFFABRRRQBmeKf8AkWNX/wCvOb/0A0eFv+RY0j/rzh/9AFHin/kWNX/685v/AEA0eFv+RY0j/rzh/wDQBQBp0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFfUv8AkHXX/XJ/5Gud+FH/ACTLwr/2DLf/ANFiui1HJ0+6A6+U38jXO/CoY+GnhYc/8g236/8AXMUAdVRRRQAUUUUAFeW+P/A7a9qmtnT7jSmk1GKxjngvZWYoYmnBYKQygkTRhcqQDlsbsGvUq8U8S+CZdb+IGsXGleJ9KsdUufmjWG4JulVVhVlKAgqAYslhnrjigCpc/BvUiFdb/T7RY3BLqxYkBpj57l0JMqrKqhshsR5DrnA3PHfwy1fXfEeoalputQ2cF3PaXLxOrH57bZ5R9BgmUnrn5PQ1n3/wy1VNGuZbXxte24aORVnm1S6kiQMFXJ3SEHHz/i3sMUvFnhHxFHFaW2n+Ibm5ilwl5KdXkRbeR5FYSsGlGR5eVEYBU88dMgF+5+HHi++0e7ifxLLE0sDxQQrqVzIiB4pFcljy+WZGGQccgYwKraV4U+IV9f3TPqd5YwQSCNDdapO3mSCUlp1Vc5Xy/kEZIU7s9VqS7+Hfiazk0+007xYLaC2tpFVW1K5RlDRCMkAscgP8wORtPTtjr/B2g6v4e1C8jtdT/tOwuI3ZBd6hPcNAwlmaPHmMxAMbwocY/wBWTyTkgHKXPw88ZJBHHpfi65IBAkV9UuSz7VUcMS23D7mOBzwp46dL4Y0bxDp3jUi/1e8utKW2a4uGmnLq900kgREyeEEbcoFUApGR1NY3hDwbrvhrWLa5sNa0jU7djLJIJ3MbGWXyzOV2qc8xg8nq3NZPiT4XaprOuaxe2X/CP+XeTi5gRmLB8+btndSjByvm/dbcDj5SgwtAEV38OPFOhWen3unaxLqbWNpDbS2kBWOTaHbzIoHVFZFKvjOS4BJGSADNpHw/8bHTHvV8VT6TfXzF7om7eUrlIIhuGNu9VWf5hzuMeSccWLT4dvpBku9Vv9I0m6k1RLmK4iuCiMFWQfdIX94d+dxLMTnnAAptv8Ktft/A0+ifbtMmR5kcWTRIIDhI1MrMIstISjNhlZRuHBKg0ASX/hv4iWkzzx68008ghiQwXMjIszFN7NE/ARcyng5xs4JFex2qLDbxwpI8giUR73fcxwMfMe59TXgEHwZ1W1e8VrzRlWZpJMSzSO8eS5W4DFdxkjDgKWJORncBgD0r4T+E7nwlpuoW95eW1w9zOsyLb42hRGqhjhVJZtuSxyT1LMcmgDuqKj8+LcF82PJ5A3Dmhp4ViWVpYxG2CHLDBz05oAkopFZXB2sGAJBwe9AIYZBBHqKAFooooAKKKKACiiigAooooAKKKKAMzxT/AMixq/8A15zf+gGjwt/yLGkf9ecP/oAq5fWsV9ZXFpcAmGeNonAOCVYYP6GuXXwMiW8EEfiPxJHDAgjjWO+C4UDAHC89O9AHX0VyMfghEcM3iTxO4H8Lak2D+QBq1/wiFv8A9BfxB/4M5v8AGgDpKK5abwVaykFtY8RjH9zV51/k1IvgixHXVPEh6ddbuv8A45QB1VFcq/gbTnJzqXiT8NevB/KWhPAulqMNfeJH928Q3/8ASagDqqK5WTwHo0gAkuPEDAf3vEF+f/a1EfgPREGFfWv+Ba3en+c1AHVUVzH/AAg2i/39Y/8AB1ef/HaP+EG0X+/rH/g6vP8A47QB09FcofAGgnGRqxwSw/4nF51Pf/W1J/wg2i/39Y/8HV5/8doA6eiuY/4QbRf7+sf+Dq8/+O0f8INov9/WP/B1ef8Ax2gDp6K5VvAeiMMF9a/DW70f+1qZ/wAK+0L/AJ6a7/4Pr/8A+PUAdbRXJf8ACvtC/wCemu/+D6//APj1H/CvtC/56a7/AOD6/wD/AI9QB1tFcl/wr7Qv+emu/wDg+v8A/wCPUq/D/RFYMs2vBh0I1+//APj1AHWUVzH/AAg+lf8AP34i/wDCh1D/AOPU1/AulsOL7xInuPEN/wD1moA6HUv+Qddf9cn/AJGud+FH/JMvCv8A2DLf/wBFik/4QTTdjIdR8RsrDBDa7eHI/GWug0jTrbSNLtNOsIzHaWsSwwoWLbUUYAyeTwKALdFFFABRRRQAV5v44+Hl7rOsXOo6Fq39lTXP2YS+SPLZ/L8/cWYA5J81D0/5Z9ehHpFFAHnl14J1M+B7rQ4LjT5Z5Jo5EmuVaRQFcMTtfcocY4wuAcHGa5CT4KXQtYobeXSohBjyQBLuBO7Bd+r+Xu2oGyCowcV6/wCI9e0vw1pM2p67fQ2NjF96WU9+wAHLE9gASa80ufi/qV87N4V8Earf2SMyteXz/Y4Rjrk7WK/8C2n2oAdrHwt1S/8AEo1SfWLXUmW0ZA+o2kLGSbyZo03osYHlqZQ2AQMrypOGC6T8JptF8VXt9ompR6bYPZi1hEMatIy+XApVwy4wTCzFlIYmTsRksg+Mlzp9wieLvB2q6XbO/lC8tibqEt6A7VLdD9wMeOlenaBrWm+INLh1LRb2C9sZhlJoWyPcH0I6EHkHg0AeLH4J6nJo5sBdaPaKwISSGN3ktsKw2xuRuIkLYfJzt4+bArpfAvw2vvD3imPVLiTTBGJLif8A0VGV4xKWxarkY8hN24Dj5gDgV6pRQBxWq+A4tSfSEvdRvbuGyup7pnuZA0p8zOEBxjaucAY6AVyuh+AfG1nfLLf+JRc26zyytCL+7USiRFXZkEFQGXeOSQSRnkk+v0UAeTeOfhtqPiPxTDqcSaQIoYIlBmZzJKyH5klO0l42GUI3AYYkhjiqnhf4UatpGp3VxHq1tpwuYGillsUDyOreXiEeYh8uNArKNhBI28AivZKKAPE7D4Ly/wBgyW+oyaU9/suDDMlsg8qRolji2lY0woAdzgDLtnkjJnu/hVrM3g/TtJ/tKzmNpdSXUNvOq+RbOxmIdSIgZCPN5VlCnGAF5z7LRQB49p3wmvYLSMPc6fBdxSsVkt1fEmbeSJpnHGZZGZGY/wCwMEmuz+Fvha48H+E49KuXt2ZZnkVYPuIGOcA7Vzzk/dHXv1PXUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVT1nU7TRtJvNS1KZYLK0iaaaRuiqoyauV5L+0A8+qw+GfCFoxV9b1BTOQekEWCc+xdo/yNAHlHiTxFeeIryXxNrtuJphE02l6LLcLGbe2OU81UfCyyZ5K8kgHPygLJsCx1i6sftWryfYra3e5F1cLIkULGY7GhmMsixqAgKhI95U7QcFOdLT/C8k3xDuoWg1G3WOSGC0jvYIohDJtO2SPY7rJthjkZXwpLIoOeap/tfa3ZaX4U0HwfZ2xBuJRc4jzmKKP5VA68szYzz0PrQBc1efUn8NeGrHw4tymjWkjEGSVJjeBi3yqQ3lSYDY2SspOD8rgnGJoeuXfgq9tfEWlJGltJbwT65pMc6uJI3Uf6QgXhWB6KcHovOcJ33wUvIPEPhrXPC2qW/wAlgYNhHBMMkSlHU9QwdHII6EAiuM8R+HX0vXzLHBNPcPdGK6htoJpCxJCSsI0TykEkTpKXZsqZMAEAUAfSFheW+oWNveWUyT2txGssUqHIdSMgj8Knryf9nu5ubTRtb8MXrMz6FfNDEW4PkvllGPQHeB7CvWKACqWparp2liI6nf2lmJW2xm4mWPefQbiMmrtcn478Lad4kk006xeyW1rC0kJjSbyvP80BPL3Z79MDk5oA6ykJCgliABySe1eNap8JdShgB0rVVlcvEXSVpl8xfMBkQnzMCMgliAMkjANRaf8ACCYa3Imq+LJLxJIQTZMX/wBWFCqmN+fLRhxknrg85LAHtSsGUMpBUjII5BFRpcQvPLAksbTxBWeMMCyA5wSOozg4+hrzDwx8PdUsPDuu6XJfGGOWKO0sULMY0RQDIcByQkkhbjO4KQPatn4a6Fp/hq71awGq2F3rU7rPcwQyfvIIwMIhVnZtihgqk44xQB3dFRvNFHLHE8qLLJnYhYAvgZOB3wKerKxYKwO04OD0NAC0VHBPFcKzQSxyqrtGSjBgGU4ZTjuCCCOxFVF1nTG1VtLXUbJtTUbmtBOvnAYzkpnPTnpQBfoopksscQUyyIgZgi7jjLHoB7mgB9FNlkSJC8rqiDqzHAFEUiTRJJE6vG4DK6nIYHoQe4oAdRUH2u28yRPtEO+NlR13jKs2NoI7E5GB3zTrm5gtY/MuZooUzjdIwUZxnqfoaAJaKb5iGUxB18wDcUzyB649ODTqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvF/iRfC0+O/hCe5illtbDSby7VIwCXb+ILkgZwq9T3HSvaK8X+O8ENl4x8B61cx4tXnuNKuJSCwVZ0G3I+iSfmaAFHjwT6RFf6Paau0uni7uI4tbiIkll2qQo2EnAWRlHoMde/gH7Qura1ruveHtT1azWyurnRI/NtVB/eAXkwAUZJ5AjbGe45r1v4SXFlofiS8soIreJbS7jDtBatbK6kPFI5DuzE75kJPQLGfu42hf2zPDdtd+FdH8RDcLyxuha4ReZY5ATjPsVyPqaAOa+GniDXdD17xZqelaVNqrw6TpyQW0CbiVYjJIXk4/en/Acj0208cLZ2rX3iODU9KuNQltrqWKxgJZJVVgY3DAnDLAinA6EcgZIn/Z60B9P0zW9YlPzarPFsHpHHEoH/AI8z1y/xTltvEOutaNPa/NcST26PHK8k3lbIURdmQCZEuD86sCNpANAHQ/DSeKb40+NJrVnEN9YWd2Y2wCjNuOCB3w3PNexV458EETUfGvjrWo/MMImg0+JmXAby1YnGOOjJ0A+lex0AFch8RfBsvjO1sbYavPpsVpI1yjQRhmNwBiJiTxtXLErjJO0hl289fRQB4vd/BW8a0l+y+KJIryQgySC3OyXlSVZC5G0lScc9e9ST/B3UGNqU8SiTyhiVZ4ZmFx+7VFLlZg3yld688N3NeyUUAeQeHvhFqWn3zXV/4pkuZFuBcxeXA0QjffGzHHmEZKxsv/AznPe14k+GWqan4k1DU7PWrW2huJBL9ma3kZZvmiJSX97wpEWD5YQsCN2cEH1WigDxU/BvWPsjQf8ACWMZAoH2oxSmabkHEpaUqQMbR8uQvUmtXwb8NtQ8OeK7Wc6pNcaeM3VyysUFxOIlijDLuOcZmcnvlM5Ir1WigDyaD4SzQ6wJE1ny9LFws32eJJUZk8xGaAkSY8s7WPTOXPbg2PGPwql1/VtS1S11+6sry6uPNUKCURPshg2AZ4JPJYc7cr716jRQB4rpfwh1hbidb3xHIsKSJsmRpmkmQLCSp/e7QoZHAXHcnodtMvPg1rN3bmF/E0KBxwRDO3kMBjfEDPwz/eYknkcYr22igDxi9+EetakbiXVfEFpc3U1wLsSmCcGBhceb5UY87HlfUE579MPk+EWtiCyjj8aXxW3kQqMMAqhSSQSxJbezsOnG0ZG0GvZKKAPKvF/wnm8QeJtR1WHXGsheXNtdFI4iSskCIkTZ3dVHnngDl1/u840Xwe182Vtb3Xip7gxb2WWVpmeElXGE+cKQd4Jyufl4PevbqKAPGR8IdYl8w3HimUOImVDC1wC0vlMqzsTMfm3sHIGFz27nt/h54U1DwvHqY1PW7jV5LufzRJNnK9ecdATkZ+nWuvooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5X4n+FV8Z+CdR0cMsd06iW1lYZ8udDuQ/TIwfYmuqooA+Rft99dmPVWATVrKZLTV7GcZYSAGNzIFQ5jaMFD3y52/f2ts6rpfhzx5fWM3iiXxI1zBHEYoBMomaMKGUzW0md+VYZkj+9/EFJ59W+JHw2fWdQPiDwtcx6b4kVNsm9cwXy4wEmHrgkbsHglWDLxXlPia6mguYE+JXhLWlMZijaW2h+2QGGKKVEjjcZ2/NLvLFixYDgAAAA6exisfCyX17pN7q+n2NrbGG5lu/Li8lZGG0rCq7g5K7Vkk2opJJ3YxXnlxrdxJJBq0Ns08sp8nTLNZVmj3lAkMcSYDRvH77iGCMGw7M2/wCD9Zv47qU/D7wxr2oi8s47S4TUrXybWWQfK87lsLubuAwJ75xivT/hr8NZdI1FfEHiueG+18RiO3jjH7ixQDGEz1fGcvgdSABklgDo/hb4V/4Q7wTp+lSsr3gBmu5FOQ87nLke2eB7AV1lFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The American Fertility Society classifications of adnexal adhesions, distal tubal occlusion, tubal occlusion secondary to tubal ligation, tubal pregnancies, mullerian anomalies and intrauterine adhesions. Fertil Steril 1988; 49:944. Copyright &copy;1988 American Society for Reproductive Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_40_34439=[""].join("\n");
var outline_f33_40_34439=null;
var title_f33_40_34440="Sonographic differentiation of benign versus malignant adnexal masses";
var content_f33_40_34440=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sonographic differentiation of benign versus malignant adnexal masses",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/40/34440/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/40/34440/contributors\">",
"     Douglas L Brown, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/40/34440/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/40/34440/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/40/34440/contributors\">",
"     Deborah Levine, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/40/34440/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/40/34440/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/40/34440/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sonography is a clinically important imaging modality for assessing whether an adnexal mass is likely benign or possibly malignant. This is important for assessing the need for surgery and for planning preoperative",
"    <span class=\"nowrap\">",
"     evaluation/preparation,",
"    </span>",
"    the type of surgical procedure, and the surgical expertise required.",
"   </p>",
"   <p>",
"    Optimal gray-scale sonographic criteria, the usefulness of Doppler sonography, and the value of combined gray-scale and Doppler sonography for assessing the probability of benign versus malignant ovarian disease will be reviewed here. A general overview of evaluation of the adnexal mass and the general principles of gynecologic ultrasonography are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19352?source=see_link\">",
"     \"Differential diagnosis of the adnexal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36824?source=see_link\">",
"     \"Ultrasound examination in obstetrics and gynecology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     APPROACH TO CHARACTERIZATION OF AN ADNEXAL MASS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H445316\">",
"    <span class=\"h2\">",
"     Ultrasound versus other diagnostic methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morphologic assessment by pelvic ultrasound is the first line study for evaluation of malignancy in an adnexal mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/1\">",
"     1",
"    </a>",
"    ]. Ultrasound is relatively less expensive than other imaging modalities, its diagnostic performance is comparable or better, and it does not involve exposure to ionizing radiation. Use of other imaging studies is reasonable in the minority of patients in whom adequate characterization of the mass is not possible with ultrasound. Magnetic resonance imaging (MRI) is generally the next best imaging modality after ultrasound to characterize an adnexal mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnostic performance of pelvic ultrasound compared with other methods of evaluation of an adnexal mass was best illustrated in a meta-analysis of 204 studies by the United States Agency for Healthcare Research and Quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/3\">",
"     3",
"    </a>",
"    ]. The sensitivity and specificity for the diagnosis of ovarian cancer for the diagnostic tools evaluated were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bimanual pelvic examination: 45 and 90 percent",
"     </li>",
"     <li>",
"      Sonographic findings:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ultrasound morphology: 86 to 91 and 68 to 83 percent",
"     </li>",
"     <li>",
"      Resistive index: 72 and 90 percent",
"     </li>",
"     <li>",
"      Pulsatility index: 80 and 73 percent",
"     </li>",
"     <li>",
"      Maximum systolic velocity: 74 and 81 percent",
"     </li>",
"     <li>",
"      Presence of vessels: 88 and 78 percent",
"     </li>",
"     <li>",
"      Combined morphology and Doppler: 86 and 91 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Magnetic resonance imaging: 91 and 88 percent",
"     </li>",
"     <li>",
"      Computed tomography: 90 and 75 percent",
"     </li>",
"     <li>",
"      PET scan: 67 and 79 percent",
"     </li>",
"     <li>",
"      CA-125: 78 and 78 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A limitation of this analysis was that the classification of ovarian tumors of low malignant potential as benign or malignant was variable. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H445325\">",
"    <span class=\"h2\">",
"     Diagnostic performance of ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many ovarian neoplasms have a typical, highly predictive sonographic appearance. A minority of adnexal masses have nonspecific sonographic findings so that a reasonably confident diagnosis by ultrasound is difficult. The expertise of the ultrasonographer influences the likelihood of arriving at a correct diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/4\">",
"     4",
"    </a>",
"    ]. A multicenter study reported that 90 percent of extrauterine masses could be correctly classified by the ultrasonographer as benign or malignant, but 10 percent were unclassifiable by their ultrasound findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/5\">",
"     5",
"    </a>",
"    ]. These unclassifiable masses were usually borderline tumors, struma ovarii, papillary cystadenofibromas, and myomas. &nbsp;",
"   </p>",
"   <p>",
"    When the sonographic features are indeterminate or ultrasound images are suboptimal, other imaging modalities or combinations of tests may be useful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=see_link&amp;anchor=H3883756#H3883756\">",
"     \"Approach to the patient with an adnexal mass\", section on 'Imaging studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H445575\">",
"    <span class=\"h1\">",
"     PERTINENT CLINICAL INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical findings can help in formulating a differential diagnosis but are not diagnostic. Tuboovarian abscess, for example, may have a gray-scale sonographic appearance that would be worrisome for malignancy (",
"    <a class=\"graphic graphic_picture graphicRef60914 \" href=\"mobipreview.htm?9/18/9509\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77543 \" href=\"mobipreview.htm?3/21/3411\">",
"     image 1",
"    </a>",
"    ), but the presence of fever, leukocytosis, and pelvic tenderness helps to suggest the correct diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36823?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bilateral multiseptated cystic adnexal masses in a woman with gestational trophoblastic disease, multiple pregnancies, ovarian hyperstimulation, or a pregnancy complicated by hydrops are likely to represent theca lutein cysts rather than malignancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/17/16660?source=see_link\">",
"     \"Pathogenesis of ovarian hyperstimulation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the woman's age, family history, and menopausal status should be considered for predicting risk since malignancy is more common in older and menopausal women and those with certain heritable conditions (",
"    <a class=\"graphic graphic_table graphicRef59585 \" href=\"mobipreview.htm?11/59/12221\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25978?source=see_link&amp;anchor=H6092142#H6092142\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with ovarian cancer often have one or more nonspecific symptoms such as lower abdominal discomfort or pressure, bloating, constipation, irregular menstrual cycles, urinary frequency, or dyspareunia. More advanced disease may be associated with abdominal distention, nausea, anorexia, or early satiety due to the presence of ascites and omental or bowel metastases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23927?source=see_link&amp;anchor=H5#H5\">",
"     \"Early detection of epithelial ovarian cancer: Role of symptom recognition\", section on 'Clinical approach to symptom recognition'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=see_link&amp;anchor=H27#H27\">",
"     \"Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GRAY-SCALE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gray-scale ultrasound features of ovarian masses are often reliable and, in our opinion, should be considered before any Doppler studies. The ultrasound must be technically adequate, using transvaginal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transabdominal scanning as necessary, and the ultrasonographer should be able to image all of the mass clearly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ovarian versus extraovarian",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first task in the initial sonographic evaluation of a pelvic mass is to determine whether it is ovarian or extraovarian; this information significantly influences differential diagnosis (",
"    <a class=\"graphic graphic_table graphicRef69013 \" href=\"mobipreview.htm?20/40/21131\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1216199\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Pedunculated fibroids",
"      </strong>",
"      - Pedunculated fibroids usually appear as heterogeneous, hypoechoic, solid masses (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63661 \" href=\"mobipreview.htm?8/34/8737\">",
"       image 2",
"      </a>",
"      ). They are more likely to be confused with an ovarian mass if the ipsilateral ovary is not seen",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      if there is cystic change within the fibroid. Visualization of the ipsilateral ovary or additional studies with magnetic resonance imaging can help with the diagnosis. The pedicle can be difficult to identify; Doppler may be useful to detect a bridging vascular pedicle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=see_link&amp;anchor=H5287506#H5287506\">",
"       \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Imaging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hydrosalpinx",
"      </strong>",
"      - A hydrosalpinx is usually tubular in shape and may have septations or nodules in its wall (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52212 graphicRef65022 \" href=\"mobipreview.htm?14/53/15190\">",
"       image 3A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. The nodules are due to thickened endosalpingeal folds and may raise concern for ovarian malignancy if one does not recognize the extraovarian location of the mass. The septation typically appears to be incomplete and is really not a true septation but is just due to the wall of the tube folded in on itself. These incomplete or partial septations are suggestive of a hydrosalpinx [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/8\">",
"       8",
"      </a>",
"      ] but can be seen with other lesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/9\">",
"       9",
"      </a>",
"      ]. The waist sign, indentations along opposite walls, was found to be a useful feature for identifying a hydrosalpinx [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/9\">",
"       9",
"      </a>",
"      ] (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Characteristics suggestive of a malignant mass'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      <strong>",
"       Peritoneal inclusion cyst",
"      </strong>",
"      - Peritoneal inclusion cysts (also called multicystic inclusion cysts) are uncommon mesothelial lesions that appear as septated, cystic masses that surround the ovary, usually in women with pelvic adhesions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. One should look carefully for a normal ovary (either within or at the edge of the mass) when presented with a septated cystic adnexal mass; otherwise an ovarian neoplasm may be considered the most likely diagnosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Paraovarian cyst",
"      </strong>",
"      - Paraovarian cysts are common and generally appear as simple cysts adjacent to the ovary (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef67393 \" href=\"mobipreview.htm?26/35/27186\">",
"       image 4",
"      </a>",
"      ). Paraovarian cystadenomas are uncommon but typically have a small nodule within a cystic extraovarian mass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Characteristics of the mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining the characteristics of the mass can help determine its etiology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Characteristics suggestive of a benign mass",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Anechoic fluid filled cyst",
"      </strong>",
"      &mdash; Simple cysts are characterized by anechoic fluid filling the cyst cavity, thin walls, and distal acoustic enhancement. They are unlikely to be malignant. Simple cysts (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66655 \" href=\"mobipreview.htm?29/40/30336\">",
"       image 5",
"      </a>",
"      ) less than 30 mm in diameter in premenopausal women typically represent normal follicles and may be considered a normal finding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/13\">",
"       13",
"      </a>",
"      ]. Simple cysts less than 10 mm in postmenopausal women can also be considered normal. Larger simple cysts may be follicular or luteal cysts, or serous cystadenomas.",
"      <br/>",
"      <br/>",
"      There have been occasional case reports of women with a sonographic diagnosis of simple cyst that turned out to be malignant upon examination by the pathologist. In these cases, small areas of nodularity noted grossly or histologically were not seen on sonography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/14\">",
"       14",
"      </a>",
"      ]. This is probably more likely with larger masses where the greater inner wall surface area increases the likelihood of a small nodule being overlooked. In the report cited, all of the cases of ovarian cancer in simple cysts occurred in large cysts greater than 7.5 cm in diameter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/14\">",
"       14",
"      </a>",
"      ]. The management of simple cysts is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19352?source=see_link&amp;anchor=H4#H4\">",
"       \"Differential diagnosis of the adnexal mass\", section on 'Differential diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30905?source=see_link&amp;anchor=H25409875#H25409875\">",
"       \"Management of an adnexal mass\", section on 'Overview'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=see_link\">",
"       \"Approach to the patient with an adnexal mass\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Homogeneous low to medium echoes in a cystic mass",
"      </strong>",
"      &mdash; Homogeneous low to medium level echoes in a cystic mass (whether unilocular or multilocular), in the absence of a solid component, are suggestive of an endometrioma (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef77161 \" href=\"mobipreview.htm?43/22/44386\">",
"       image 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/15-18\">",
"       15-18",
"      </a>",
"      ]. There may be varying degrees of echogenicity in the different locules. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5863?source=see_link&amp;anchor=H3#H3\">",
"       \"Diagnosis and management of ovarian endometriomas\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Fishnet or reticular pattern of internal echoes",
"      </strong>",
"      &mdash; A fine network of thin linear to curvilinear echoes, sometimes called a fishnet or reticular pattern, is strongly suggestive of a hemorrhagic cyst (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83933 \" href=\"mobipreview.htm?37/18/38177\">",
"       image 7",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/19-23\">",
"       19-23",
"      </a>",
"      ]. These linear echoes are usually very thin and do not extend completely uninterrupted across the cyst, unlike true septa.",
"      <br/>",
"      <br/>",
"      The appearance of hemorrhagic cysts and endometriomas may overlap, however, and not all of them have the typical appearance described here. Sometimes they may seem completely solid or may have a solid nodular component due to clot (or to focal endometrial tissue in endometriomas) that may be difficult to distinguish from the true solid tissue of a neoplasm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. Color Doppler can be useful in these cases because the clot generally does not exhibit detectable blood flow (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef83933 \" href=\"mobipreview.htm?37/18/38177\">",
"       image 7",
"      </a>",
"      ), while a solid mass is more likely to have identifiable blood flow (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Spectral Doppler'",
"      </a>",
"      below). However focal endometrial tissue in endometriomas may have detectable flow by color Doppler imaging, and thus these lesions are problematic.",
"      <br/>",
"      <br/>",
"      Most hemorrhagic and physiologic cysts will have resolved or become smaller if a repeat sonographic assessment is performed six to eight weeks after diagnosis. However, many typical simple and hemorrhagic cysts however do not need routine follow-up imaging in asymptomatic patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/13\">",
"       13",
"      </a>",
"      ]. Nonphysiologic benign cysts usually remain unchanged [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/26\">",
"       26",
"      </a>",
"      ]. Performing the follow-up sonogram in approximately the second week of the menstrual cycle in the follicular phase (approximately cycle days 7 to 12) should help minimize the detection of a hemorrhagic corpus luteal cyst in another cycle. Practically, however, it is not always easy to schedule the follow-up sonogram at such a specific time, particularly if a patient's menstrual cycle is irregular.",
"     </li>",
"     <li>",
"      <strong>",
"       Markedly hyperechoic nodule with shadowing",
"      </strong>",
"      &mdash; Teratomas (ie, dermoids) typically have a markedly hyperechoic nodule within the mass [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/18,27-34\">",
"       18,27-34",
"      </a>",
"      ]. This appearance, particularly if the hyperechoic nodule has distal acoustic shadowing, is generally a strong indicator of a teratoma. Teratomas may also be uniformly hyperechoic or have bright linear to punctate echoes (the latter sometimes referred to as the dermoid mesh [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/27\">",
"       27",
"      </a>",
"      ]); these latter two appearances may occasionally be difficult to distinguish from bowel in the absence of peristalsis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51762 graphicRef62484 \" href=\"mobipreview.htm?23/4/23621\">",
"       image 8A-B",
"      </a>",
"      ). Teratomas occasionally contain a fluid-fluid level. If the echogenic fluid is non-dependent, this is predictive of a teratoma, although this occurs in the minority of teratomas that have a fluid-fluid level [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/35\">",
"       35",
"      </a>",
"      ]. Calcification also can be present and may vary in size. Calcification alone is not a sufficient criterion to diagnose a dermoid and should be evaluated in the context of the overall appearance of the ovary [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/36\">",
"       36",
"      </a>",
"      ]. Floating globules is an uncommon appearance of teratomas but seems to be predictive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5721?source=see_link\">",
"       \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Characteristics suggestive of a malignant mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a mass does not have any of the typical benign appearances discussed above, malignancy is more of a concern. Sonographic characteristics that have been typically associated with malignancy are (",
"    <a class=\"graphic graphic_table graphicRef79259 \" href=\"mobipreview.htm?1/0/1035\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Solid component that is not hyperechoic and is often nodular or papillary",
"     </li>",
"     <li>",
"      Septations, if present, that are thick (&gt;2 to 3 mm)",
"     </li>",
"     <li>",
"      Color or power Doppler demonstration of flow in the solid component",
"     </li>",
"     <li>",
"      Presence of ascites (usually any intraperitoneal fluid in postmenopausal women and more than a small amount of intraperitoneal fluid in premenopausal women is usually abnormal)",
"     </li>",
"     <li>",
"      Peritoneal masses, enlarged nodes, or matted bowel (may be difficult to detect by ultrasound)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A solid component is the most significant gray-scale feature of malignancy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64039 graphicRef52787 \" href=\"mobipreview.htm?11/38/11879\">",
"     image 9A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. A thick wall can be seen with malignancy, but many benign masses, such as hemorrhagic cysts or endometriomas, can also have a thick wall. Wall thickness alone does not seem to be a reliable feature for distinguishing benign from malignant ovarian masses.",
"   </p>",
"   <p>",
"    Historically, size of the mass was considered useful, with larger masses more likely to be malignant. While many ovarian malignancies are larger masses, this relationship has not been confirmed, as several studies have found no significant difference in size between malignant and benign masses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/38,41\">",
"     38,41",
"    </a>",
"    ]. This may be due to the widespread use of sonography such that smaller masses are more readily detected and to improved characterization of masses based upon morphologic features. Ovarian volume is typically used to describe ovarian size. It is calculated by multiplying the longest dimension of the ovary (in cm) by the two orthogonal dimensions by a factor of 0.523. Variable numbers have been reported as upper limits of normal. Most studies suggest an upper limit between 10 to 20 cc in premenopausal women and 8 to 10 cc in postmenopausal women.",
"   </p>",
"   <p>",
"    Septations can be present with benign or malignant disease. Thin septations are more suggestive of benign disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51648 \" href=\"mobipreview.htm?15/4/15427\">",
"     image 10",
"    </a>",
"    ), while thick septa suggest malignancy. Septations are generally considered thick when greater than 2 to 3 mm in thickness. Ovarian cancer may be unilocular, however, and the absence of septations does not guarantee that a mass is benign.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ADDITIONAL TECHNIQUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Spectral Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler evaluation of adnexal masses was initially proposed as a means of decreasing the false positive rate of sonography for ovarian carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/42\">",
"     42",
"    </a>",
"    ]. The neovascularization that accompanies malignant tumors is associated with poor muscular support in the arterial walls, leading to less vascular resistance that potentially can be detected by pulsed Doppler [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/43\">",
"     43",
"    </a>",
"    ]. However, spectral Doppler does not appear to be useful in diagnosing ovarian malignancy as many studies have found too broad an overlap in resistive index and pulsatility index between benign and malignant masses.",
"   </p>",
"   <p>",
"    Doppler features, such as velocity criteria or the presence or absence of a diastolic notch in the pulsed Doppler waveform, have been investigated and are generally not found to be reliable for differentiating benign and malignant masses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/38,44-48\">",
"     38,44-48",
"    </a>",
"    ], although some believe them to be useful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/49-52\">",
"     49-52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Combined gray-scale and Doppler evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When masses do not have a typical benign appearance, using color or power Doppler to look for the presence or absence of flow in solid areas or septations can be useful (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52113 \" href=\"mobipreview.htm?33/54/34658\">",
"     image 11",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75776 \" href=\"mobipreview.htm?12/16/12545\">",
"     image 12",
"    </a>",
"    ). Meta-analyses concluded that combined evaluation of ovarian masses with gray-scale morphology and color Doppler assessment performed better than morphologic assessment, pulsed Doppler assessment, or color Doppler assessment alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/3,53,54\">",
"     3,53,54",
"    </a>",
"    ]. Combined evaluation can be performed with the use of a scoring system, where numerical values are assigned to different features and a total score calculated for the mass or a probability of malignancy can be calculated. In daily practice, however, many experienced sonologists will use the features that individual studies have identified as most valuable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/38,41,55-57\">",
"     38,41,55-57",
"    </a>",
"    ] to arrive at a subjective impression of the likelihood of malignancy. A subjective approach, using gray scale and color or power Doppler features, has been shown to be highly reliable and usually superior to other methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/58-60\">",
"     58-60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26064447\">",
"    <span class=\"h2\">",
"     Other techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three-dimensional ultrasound does not appear to improve the sonographic evaluation of adnexal masses, in our experience. Some investigators feel it is helpful for masses such as hydrosalpinx.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H445727\">",
"    <span class=\"h1\">",
"     ULTRASOUND COMBINED WITH OTHER APPROACHES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     CA-125",
"    </span>",
"    &nbsp;&mdash;&nbsp;CA-125 combined with sonographic features of the adnexal mass appears have a higher specificity for ovarian malignancy than CA-125 alone. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=see_link\">",
"     \"Approach to the patient with an adnexal mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Prediction models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple risk scoring systems have been proposed to differentiate between benign and malignant adnexal masses. In a systematic review, 83 prediction models were evaluated. The most accurate models were the Risk of Malignancy Index I (RMI-I) and a modification that uses the same factors with different score values assigned to each factor, the Risk of Malignancy Index II (RMI-II) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/61\">",
"     61",
"    </a>",
"    ]. These scores calculate the product of an ultrasound score (based on the presence of one or more of the following: multi-locularity, solid areas, bilateral lesions, ascites, evidence of metastases), menopausal status, and serum CA-125. Using a score of 200 as indicative of ovarian malignancy, sensitivity and specificity are: RMI-I (78 and 87 percent) and RMI-II (79 and 81 percent). Other prediction models and use of some simple rules regarding sonographic features have also been found useful in some practices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34440/abstract/62\">",
"     62",
"    </a>",
"    ]. Such models can be cumbersome to use, however, and as stated above, the sonographic component is often best utilized by the subjective approach rather than a scoring system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gray-scale ultrasonography is commonly the first line imaging study for evaluation of an adnexal mass. Ultrasound is a commonly used modality, with lower costs and absence of ionizing radiation compared to most other imaging modalities. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Approach to characterization of an adnexal mass'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most adnexal masses can be characterized using gray-scale sonography alone or with addition of color Doppler evaluation. Surgery for histologic evaluation or therapy may be indicated; in occasional cases, magnetic resonance imaging may provide additional useful information. (See",
"      <a class=\"local\" href=\"#H445325\">",
"       'Diagnostic performance of ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first step in assessing an adnexal mass with gray-scale sonography is to determine if the mass is ovarian or extraovarian. Examples of extraovarian masses are paraovarian cysts, hydrosalpinges, and pedunculated fibroids. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Ovarian versus extraovarian'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The next step in sonographic assessment is to determine the characteristics of the mass. Characteristics that are suggestive of a benign mass include: anechoic fluid filled cyst, fishnet or reticular pattern of internal echoes, homogeneous low to medium echoes in a cystic mass without a solid component, or markedly hyperechoic nodule with shadowing. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Characteristics suggestive of a benign mass'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Masses that are suspicious for malignancy are those with the following characteristics (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Characteristics suggestive of a malignant mass'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Solid component that is not hyperechoic and is often nodular or papillary",
"     </li>",
"     <li>",
"      Septations, if present, that are thick (&gt;2 to 3 mm)",
"     </li>",
"     <li>",
"      Color or power Doppler demonstration of flow in the solid component",
"     </li>",
"     <li>",
"      Presence of ascites (virtually any intraperitoneal fluid in postmenopausal women and more than a small amount of intraperitoneal fluid in premenopausal women is usually abnormal)",
"     </li>",
"     <li>",
"      Peritoneal masses, enlarged nodes, or matted bowel (may be difficult to detect by ultrasound)",
"      <br/>",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/1\">",
"      Liu J, Xu Y, Wang J. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis of ovarian carcinoma. Eur J Radiol 2007; 62:328.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.acr.org/~/media/ACR/Documents/AppCriteria/Diagnostic/ClinicallySuspectedAdnexalMass.pdf (Accessed on June 12, 2012).",
"    </li>",
"    <li>",
"     Myers ER, Bastian LA, Havrilesky LJ, et al. Management of Adnexal Mass. Evidence Report/Technology Assessment No.130 (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025). AHRQ Publication No. 06-E004, Agency for Healthcare Research and Quality, Rockville, MD February 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/4\">",
"      Yazbek J, Raju SK, Ben-Nagi J, et al. Effect of quality of gynaecological ultrasonography on management of patients with suspected ovarian cancer: a randomised controlled trial. Lancet Oncol 2008; 9:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/5\">",
"      Valentin L, Ameye L, Jurkovic D, et al. Which extrauterine pelvic masses are difficult to correctly classify as benign or malignant on the basis of ultrasound findings and is there a way of making a correct diagnosis? Ultrasound Obstet Gynecol 2006; 27:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/6\">",
"      Kim SH, Sim JS, Seong CK. Interface vessels on color/power Doppler US and MRI: a clue to differentiate subserosal uterine myomas from extrauterine tumors. J Comput Assist Tomogr 2001; 25:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/7\">",
"      Tessler FN, Perrella RR, Fleischer AC, Grant EG. Endovaginal sonographic diagnosis of dilated fallopian tubes. AJR Am J Roentgenol 1989; 153:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/8\">",
"      Timor-Tritsch IE, Lerner JP, Monteagudo A, et al. Transvaginal sonographic markers of tubal inflammatory disease. Ultrasound Obstet Gynecol 1998; 12:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/9\">",
"      Patel MD, Acord DL, Young SW. Likelihood ratio of sonographic findings in discriminating hydrosalpinx from other adnexal masses. AJR Am J Roentgenol 2006; 186:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/10\">",
"      Kim JS, Lee HJ, Woo SK, Lee TS. Peritoneal inclusion cysts and their relationship to the ovaries: evaluation with sonography. Radiology 1997; 204:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/11\">",
"      Hoffer FA, Kozakewich H, Colodny A, Goldstein DP. Peritoneal inclusion cysts: ovarian fluid in peritoneal adhesions. Radiology 1988; 169:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/12\">",
"      Korbin CD, Brown DL, Welch WR. Paraovarian cystadenomas and cystadenofibromas: sonographic characteristics in 14 cases. Radiology 1998; 208:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/13\">",
"      Levine D, Brown DL, Andreotti RF, et al. Management of asymptomatic ovarian and other adnexal cysts imaged at US: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology 2010; 256:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/14\">",
"      Ekerhovd E, Wienerroith H, Staudach A, Granberg S. Preoperative assessment of unilocular adnexal cysts by transvaginal ultrasonography: a comparison between ultrasonographic morphologic imaging and histopathologic diagnosis. Am J Obstet Gynecol 2001; 184:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/15\">",
"      Patel MD, Feldstein VA, Chen DC, et al. Endometriomas: diagnostic performance of US. Radiology 1999; 210:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/16\">",
"      Mais V, Guerriero S, Ajossa S, et al. The efficiency of transvaginal ultrasonography in the diagnosis of endometrioma. Fertil Steril 1993; 60:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/17\">",
"      Kupfer MC, Schwimer SR, Lebovic J. Transvaginal sonographic appearance of endometriomata: spectrum of findings. J Ultrasound Med 1992; 11:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/18\">",
"      Jermy K, Luise C, Bourne T. The characterization of common ovarian cysts in premenopausal women. Ultrasound Obstet Gynecol 2001; 17:140.",
"     </a>",
"    </li>",
"    <li>",
"     Filly RA. Ovarian masses: what to look for, what to do. In: Ultrasonography in obstetrics and gynecology, Callen PW (Ed), W.B. Saunders Company, Philadelphia 1994. p.625.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/20\">",
"      Stein SM, Laifer-Narin S, Johnson MB, et al. Differentiation of benign and malignant adnexal masses: relative value of gray-scale, color Doppler, and spectral Doppler sonography. AJR Am J Roentgenol 1995; 164:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/21\">",
"      Okai T, Kobayashi K, Ryo E, et al. Transvaginal sonographic appearance of hemorrhagic functional ovarian cysts and their spontaneous regression. Int J Gynaecol Obstet 1994; 44:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/22\">",
"      Jain KA. Prospective evaluation of adnexal masses with endovaginal gray-scale and duplex and color Doppler US: correlation with pathologic findings. Radiology 1994; 191:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/23\">",
"      Baltarowich OH, Kurtz AB, Pasto ME, et al. The spectrum of sonographic findings in hemorrhagic ovarian cysts. AJR Am J Roentgenol 1987; 148:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/24\">",
"      Jain KA. Sonographic spectrum of hemorrhagic ovarian cysts. J Ultrasound Med 2002; 21:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/25\">",
"      Swire MN, Castro-Aragon I, Levine D. Various sonographic appearances of the hemorrhagic corpus luteum cyst. Ultrasound Q 2004; 20:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/26\">",
"      Alc&aacute;zar JL, Castillo G, Jurado M, Garc&iacute;a GL. Is expectant management of sonographically benign adnexal cysts an option in selected asymptomatic premenopausal women? Hum Reprod 2005; 20:3231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/27\">",
"      Malde HM, Kedar RP, Chadha D, Nayak S. Dermoid mesh: a sonographic sign of ovarian teratoma. AJR Am J Roentgenol 1992; 159:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/28\">",
"      Patel MD, Feldstein VA, Lipson SD, et al. Cystic teratomas of the ovary: diagnostic value of sonography. AJR Am J Roentgenol 1998; 171:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/29\">",
"      Cohen L, Sabbagha R. Echo patterns of benign cystic teratomas by transvaginal ultrasound. Ultrasound Obstet Gynecol 1993; 3:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/30\">",
"      Caspi B, Appelman Z, Rabinerson D, et al. Pathognomonic echo patterns of benign cystic teratomas of the ovary: classification, incidence and accuracy rate of sonographic diagnosis. Ultrasound Obstet Gynecol 1996; 7:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/31\">",
"      Laing FC, Van Dalsem VF, Marks WM, et al. Dermoid cysts of the ovary: their ultrasonographic appearances. Obstet Gynecol 1981; 57:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/32\">",
"      Mais V, Guerriero S, Ajossa S, et al. Transvaginal ultrasonography in the diagnosis of cystic teratoma. Obstet Gynecol 1995; 85:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/33\">",
"      Quinn SF, Erickson S, Black WC. Cystic ovarian teratomas: the sonographic appearance of the dermoid plug. Radiology 1985; 155:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/34\">",
"      Sheth S, Fishman EK, Buck JL, et al. The variable sonographic appearances of ovarian teratomas: correlation with CT. AJR Am J Roentgenol 1988; 151:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/35\">",
"      Kim HC, Kim SH, Lee HJ, et al. Fluid-fluid levels in ovarian teratomas. Abdom Imaging 2002; 27:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/36\">",
"      Brown DL, Laing FC, Welch WR. Large calcifications in ovaries otherwise normal on ultrasound. Ultrasound Obstet Gynecol 2007; 29:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/37\">",
"      Tongsong T, Wanapirak C, Khunamornpong S, Sukpan K. Numerous intracystic floating balls as a sonographic feature of benign cystic teratoma: report of 5 cases. J Ultrasound Med 2006; 25:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/38\">",
"      Brown DL, Doubilet PM, Miller FH, et al. Benign and malignant ovarian masses: selection of the most discriminating gray-scale and Doppler sonographic features. Radiology 1998; 208:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/39\">",
"      Granberg S, Wikland M, Jansson I. Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: criteria to be used for ultrasound evaluation. Gynecol Oncol 1989; 35:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/40\">",
"      Granberg S, Norstr&ouml;m A, Wikland M. Tumors in the lower pelvis as imaged by vaginal sonography. Gynecol Oncol 1990; 37:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/41\">",
"      Tailor A, Jurkovic D, Bourne TH, et al. Sonographic prediction of malignancy in adnexal masses using multivariate logistic regression analysis. Ultrasound Obstet Gynecol 1997; 10:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/42\">",
"      Bourne T, Campbell S, Steer C, et al. Transvaginal colour flow imaging: a possible new screening technique for ovarian cancer. BMJ 1989; 299:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/43\">",
"      Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/44\">",
"      Buy JN, Ghossain MA, Hugol D, et al. Characterization of adnexal masses: combination of color Doppler and conventional sonography compared with spectral Doppler analysis alone and conventional sonography alone. AJR Am J Roentgenol 1996; 166:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/45\">",
"      Fleischer AC, Rodgers WH, Kepple DM, et al. Color Doppler sonography of ovarian masses: a multiparameter analysis. J Ultrasound Med 1993; 12:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/46\">",
"      Hata K, Hata T. Intratumoral blood flow analysis in ovarian cancer: what does it mean? J Ultrasound Med 1996; 15:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/47\">",
"      Kurjak A, Kupesic S. Transvaginal color Doppler and pelvic tumor vascularity: lessons learned and future challenges. Ultrasound Obstet Gynecol 1995; 6:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/48\">",
"      Sladkevicius P, Valentin L, Mars&aacute;l K. Transvaginal Doppler examination for the differential diagnosis of solid pelvic tumors. J Ultrasound Med 1995; 14:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/49\">",
"      Pr&ouml;mpeler HJ, Madjar H, Sauerbrei W, et al. Quantitative flow measurements for classification of ovarian tumors by transvaginal color Doppler sonography in postmenopausal patients. Ultrasound Obstet Gynecol 1994; 4:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/50\">",
"      Tailor A, Jurkovic D, Bourne TH, et al. A comparison of intratumoural indices of blood flow velocity and impedance for the diagnosis of ovarian cancer. Ultrasound Med Biol 1996; 22:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/51\">",
"      Hata K, Hata T, Kitao M. Intratumoral peak systolic velocity as a new possible predictor for detection of adnexal malignancy. Am J Obstet Gynecol 1995; 172:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/52\">",
"      Alc&aacute;zar JL, Ruiz-Perez ML, Errasti T. Transvaginal color Doppler sonography in adnexal masses: which parameter performs best? Ultrasound Obstet Gynecol 1996; 8:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/53\">",
"      Kinkel K, Lu Y, Mehdizade A, et al. Indeterminate ovarian mass at US: incremental value of second imaging test for characterization--meta-analysis and Bayesian analysis. Radiology 2005; 236:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/54\">",
"      Kinkel K, Hricak H, Lu Y, et al. US characterization of ovarian masses: a meta-analysis. Radiology 2000; 217:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/55\">",
"      Timor-Tritsch LE, Lerner JP, Monteagudo A, Santos R. Transvaginal ultrasonographic characterization of ovarian masses by means of color flow-directed Doppler measurements and a morphologic scoring system. Am J Obstet Gynecol 1993; 168:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/56\">",
"      Timmerman D, Schw&auml;rzler P, Collins WP, et al. Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience. Ultrasound Obstet Gynecol 1999; 13:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/57\">",
"      Kurjak A, Predani�� M. New scoring system for prediction of ovarian malignancy based on transvaginal color Doppler sonography. J Ultrasound Med 1992; 11:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/58\">",
"      Valentin L. Pattern recognition of pelvic masses by gray-scale ultrasound imaging: the contribution of Doppler ultrasound. Ultrasound Obstet Gynecol 1999; 14:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/59\">",
"      Van Calster B, Timmerman D, Bourne T, et al. Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125. J Natl Cancer Inst 2007; 99:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/60\">",
"      Valentin L. Use of morphology to characterize and manage common adnexal masses. Best Pract Res Clin Obstet Gynaecol 2004; 18:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/61\">",
"      Geomini P, Kruitwagen R, Bremer GL, et al. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 2009; 113:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34440/abstract/62\">",
"      Kaijser J, Bourne T, Valentin L, et al. Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies. Ultrasound Obstet Gynecol 2013; 41:9.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3208 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_40_34440=[""].join("\n");
var outline_f33_40_34440=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      APPROACH TO CHARACTERIZATION OF AN ADNEXAL MASS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H445316\">",
"      Ultrasound versus other diagnostic methods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H445325\">",
"      Diagnostic performance of ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H445575\">",
"      PERTINENT CLINICAL INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GRAY-SCALE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ovarian versus extraovarian",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1216199\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Characteristics of the mass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Characteristics suggestive of a benign mass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Characteristics suggestive of a malignant mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ADDITIONAL TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Spectral Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Combined gray-scale and Doppler evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26064447\">",
"      Other techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H445727\">",
"      ULTRASOUND COMBINED WITH OTHER APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CA-125",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Prediction models",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3208\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3208|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?3/21/3411\" title=\"diagnostic image 1\">",
"      Tuboovarian abscess ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/34/8737\" title=\"diagnostic image 2\">",
"      Pedunculated fibroid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/13/39121\" title=\"diagnostic image 3A\">",
"      Hydrosalpinx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/44/16064\" title=\"diagnostic image 3B\">",
"      Hydrosalpinx 3D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?26/35/27186\" title=\"diagnostic image 4\">",
"      Paraovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/40/30336\" title=\"diagnostic image 5\">",
"      Normal follicle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?43/22/44386\" title=\"diagnostic image 6\">",
"      Endometrioma sonogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/18/38177\" title=\"diagnostic image 7\">",
"      Hemorrhagic ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/9/23696\" title=\"diagnostic image 8A\">",
"      Dermoid cyst ovary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/16/23808\" title=\"diagnostic image 8B\">",
"      Dermoid cyst ovary2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/11/8370\" title=\"diagnostic image 9A\">",
"      Ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/51/32561\" title=\"diagnostic image 9B\">",
"      Ovarian cancer solid cystic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?15/4/15427\" title=\"diagnostic image 10\">",
"      Septated serous cystadenoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/54/34658\" title=\"diagnostic image 11\">",
"      Endometrioma sonogram Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?12/16/12545\" title=\"diagnostic image 12\">",
"      Ovarian cancer color doppler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3208|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/18/9509\" title=\"picture 1\">",
"      Tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3208|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/59/12221\" title=\"table 1\">",
"      Risk factors ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/40/21131\" title=\"table 2\">",
"      Differential dx adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/0/1035\" title=\"table 3\">",
"      Sonographic findings ovarian CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/1/24601?source=related_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/46/5863?source=related_link\">",
"      Diagnosis and management of ovarian endometriomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/57/19352?source=related_link\">",
"      Differential diagnosis of the adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/23/23927?source=related_link\">",
"      Early detection of epithelial ovarian cancer: Role of symptom recognition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36823?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuboovarian abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31849?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/23/25978?source=related_link\">",
"      Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/11/30905?source=related_link\">",
"      Management of an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5721?source=related_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/17/16660?source=related_link\">",
"      Pathogenesis of ovarian hyperstimulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36824?source=related_link\">",
"      Ultrasound examination in obstetrics and gynecology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_40_34441="Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer";
var content_f33_40_34441=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/40/34441/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/40/34441/contributors\">",
"     Carey K Anders, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/40/34441/contributors\">",
"     Lisa A Carey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/40/34441/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/40/34441/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/40/34441/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/40/34441/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/40/34441/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H98882311\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triple-negative breast cancer is defined by absent expression of the estrogen receptor [ER], progesterone receptor [PR], and human epidermal growth factor receptor 2 (HER2).",
"    <strong>",
"    </strong>",
"    These cancers tend to behave more aggressively than other types of breast cancer. Unlike other breast cancer subtypes (ie, ER-positive, HER2-positive subtypes), there are no targeted treatments available, other than the administration of chemotherapy. Although the basic principles of the diagnosis and management of triple-negative breast cancer are similar to those of breast cancer in general, many aspects, including risk factors, molecular and pathologic characteristics, natural history, and chemotherapy sensitivity, are unique to triple-negative breast cancer and will be reviewed here.",
"   </p>",
"   <p>",
"    A more extensive discussion on surgical management, neoadjuvant chemotherapy, adjuvant chemotherapy, and the treatment of metastatic breast cancer is covered separately. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=see_link\">",
"       \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7354?source=see_link\">",
"       \"Systemic treatment for metastatic breast cancer: General principles\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H267308777\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triple-negative breast cancer accounts for approximately 20 percent of breast cancers diagnosed worldwide, which amounts to almost 200,000 cases each year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/1\">",
"     1",
"    </a>",
"    ]. Triple-negative breast cancer is more commonly diagnosed in women less than 40 years compared to hormone-positive breast cancer. In one study, there was a twofold higher attributable risk of triple-negative breast cancer in women under 40 years compared to women over 50 years (odds ratio [OR] 2.13, 95% CI 1.34-3.39) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, triple-negative breast cancer appears to be more common among black women, compared to white women (OR 2.41, 95% CI 1.81-3.21) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors associated with the diagnosis of triple-negative breast cancer include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Maternal related factors",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Parity: Some studies suggest that nulliparity is associated with a lower risk for triple-negative breast cancer (hazard ratio [HR] 0.61, 95% CI 0.37-0.97) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/3\">",
"       3",
"      </a>",
"      ]. However, for women who gave birth, three or more births were associated with a trend towards an increased risk of triple-negative breast cancer compared to having only one child (HR 1.46, 95% CI 0.82-2.63).",
"     </li>",
"     <li>",
"      Age at first pregnancy: Some studies have found an association between young age at first pregnancy and an increased risk of triple-negative breast cancers, although it has not been consistently shown [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/2-4\">",
"       2-4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Breast-feeding:",
"      <strong>",
"      </strong>",
"      One study suggested there was a lower risk for triple",
"      <span class=\"nowrap\">",
"       negative/basal-like",
"      </span>",
"      breast cancer associated with breast-feeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/4\">",
"       4",
"      </a>",
"      ]. However, this has not been replicated in other studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Obesity",
"      </strong>",
"      &mdash; In the Carolina Breast Cancer Study, a population-based, case-control study of African American and white women, elevated waist-hip ratio (used to define obesity) was associated with increased risk of luminal A in postmenopausal women and an increased risk of basal-like breast cancer in both pre- and postmenopausal women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/4\">",
"       4",
"      </a>",
"      ]. A separate 2012 meta-analysis of 11 studies that included 24,479 women (3845 diagnosed with TNBC) reported that obesity (defined as a body mass index &ge;30) was associated with an increased risk of TNBC (pooled odds ratio [OR] 1.2, 95% CI 1.03-1.40) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/5\">",
"       5",
"      </a>",
"      ]. This risk was significantly higher for premenopausal women (OR 1.43, 95% CI 1.23-1.65) but was not increased for postmenopausal women (OR 0.99, 95% CI 0.79-1.24).",
"     </li>",
"     <li>",
"      <strong>",
"       Positive BRCA mutation status",
"      </strong>",
"      &mdash; Up to 20 percent of patients with triple-negative breast cancer harbor a BRCA mutation, particularly in BRCA1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/6\">",
"       6",
"      </a>",
"      ]. In contrast, less than six percent of all breast cancers are associated with a BRCA mutation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274813343\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study suggests that triple-negative breast cancer is more likely to be detected through clinical examination than through imaging compared with other subtypes of breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, a separate report indicated that triple-negative breast cancers may occur more frequently as interval cancers between mammograms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/8\">",
"     8",
"    </a>",
"    ]. These observations may reflect the aggressive and rapid growth rate of triple-negative breast tumors, or perhaps intrinsic differences in the density of breast tissue among women diagnosed with triple-negative breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98882326\">",
"    <span class=\"h1\">",
"     PATHOLOGIC CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Triple negative breast cancer is usually a high-grade, infiltrating ductal carcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/9\">",
"     9",
"    </a>",
"    ]. These cancers exhibit geographic necrosis, a pushing border of invasion, and a stromal lymphocytic response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By definition, triple-negative breast cancer lacks immunohistochemical (IHC) expression of the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2). Cut-offs used for ER, PR, and HER2 to make this diagnosis are discussed below. (See",
"    <a class=\"local\" href=\"#H1340632742\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Since these three biomarkers represent the only known targets for breast cancer treatment, considerable effort has been made to better understand other biologic forces driving triple-negative breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H493962740\">",
"    <span class=\"h2\">",
"     Molecular classification of triple-negative breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The triple-negative clinical phenotype is mostly comprised of the basal-like molecular subtype, which is characterized by expression of the &ldquo;basal cluster&rdquo;, a unique cluster of genes that includes the epidermal growth factor receptor (EGFR, also called HER1), basal cytokeratins",
"    <span class=\"nowrap\">",
"     5/6,",
"    </span>",
"    and c-Kit; the proliferation cluster; and low expression of the hormone-receptor and HER2-related genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Separate subtypes of triple-negative breast cancer have been characterized by gene expression, including 2 basal-like subtypes (BL1 and BL2), an immunomodulatory, mesenchymal, mesenchymal stem-like, and luminal androgen subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/13\">",
"     13",
"    </a>",
"    ]. Additional subtypes that have been characterized include claudin-low and interferon-rich subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The different subtypes of triple-negative breast cancers are covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/28/43465?source=see_link\">",
"     \"Measurement of prognostic factors in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, triple-negative and basal breast cancer are not synonymous. As an example, 172 triple-negative tumors based on immunohistochemical (IHC) staining were correlated with gene expression profiles that defined the basal subtype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/16\">",
"     16",
"    </a>",
"    ]. Only 71 percent of triple-negative breast cancers were assigned the basal subtype. In a converse analysis (where subtype was identified and correlated with immunohistochemical staining) of 160 tumors, 77 percent of basal tumors were triple-negative by IHC. &nbsp;",
"   </p>",
"   <p>",
"    Gene expression analysis has also revealed that the tumor suppressor gene p53 and several DNA repair genes, particularly the BRCA genes, are either mutated or aberrantly expressed in triple-negative breast cancer. These molecular features may have implications for chemotherapy sensitivity to platinum agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1136598543\">",
"     'Metastatic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340632742\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of triple-negative breast cancer mirrors that of other breast cancer subtypes and requires testing for ER, PR, and HER2. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/28/43465?source=see_link&amp;anchor=H29980905#H29980905\">",
"     \"Measurement of prognostic factors in breast cancer\", section on 'tests done on breast tissue'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the American Society of Clinical",
"    <span class=\"nowrap\">",
"     Oncology/College",
"    </span>",
"    of American Pathology",
"    <span class=\"nowrap\">",
"     (ASCO/CAP)",
"    </span>",
"    panel and define hormone-receptor negativity as less than one percent staining of tumor cells by IHC. We define triple-negative breast cancer as hormone receptor negative and HER2-negative (IHC 0 to 1+ or fluorescence in-situ hybridization negative). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19194?source=see_link&amp;anchor=H4#H4\">",
"     \"Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy\", section on 'Assays for ER and PR'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=see_link&amp;anchor=H6#H6\">",
"     \"HER2 and predicting response to therapy in breast cancer\", section on 'Assays for HER2 expression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In support of this definition of ER and PR receptor negative status, a recent analysis of cooperative group studies with centrally determined ER, PR, and molecular subtype suggests that fewer than 20 percent of tumors that are &ldquo;borderline&rdquo; positive for ER or PR (1 to 10 percent staining) had basal-like molecular characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/19\">",
"     19",
"    </a>",
"    ]. Therefore, inclusion of these patients is not likely to select for triple-negative breast cancers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1340632749\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical staging of breast cancer is identical across breast cancer subtypes using the American Joint Committee on Cancer and the International Union for Cancer Control (AJCC-UICC) TNM breast cancer staging system (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"mobipreview.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    ).",
"    <strong>",
"    </strong>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10009?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98882362\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACH TO TRIPLE-NEGATIVE BREAST CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles for the surgical management and radiation therapy options of breast cancer are applied in a similar way across breast cancer subtypes. In addition, the neoadjuvant or adjuvant chemotherapy options for patients with triple-negative breast cancer are similar to the approach used in other breast cancer phenotypes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31402?source=see_link\">",
"     \"Breast conserving therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35831?source=see_link\">",
"     \"Metastatic breast cancer: Local treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link\">",
"     \"Role of radiation therapy in breast conservation therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/55/42873?source=see_link\">",
"     \"Radiation techniques for locally advanced breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=see_link\">",
"     \"Postmastectomy chest wall irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97090639\">",
"    <span class=\"h2\">",
"     Neoadjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with triple-negative breast cancer, neoadjuvant chemotherapy is a reasonable alternative to adjuvant (postoperative) chemotherapy, particularly in patients with locally advanced breast cancer who are not considered operable at presentation or who are not candidates for breast conservation at diagnosis. For these patients, pathologic complete response (pCR) is associated with improvement in disease-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=see_link&amp;anchor=H1192795#H1192795\">",
"     \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\", section on 'Chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the response of triple-negative breast cancer to neoadjuvant chemotherapy has commonly been referred to as &ldquo;paradoxical&rdquo; due to the relatively high likelihood of excellent response but a poorer overall outcome compared to patients with hormone receptor-positive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HER2-positive breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/22-26\">",
"     22-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of the largest studies involving 1118 patients identified in a prospectively collected clinical database, women with triple-negative breast cancer had a higher pathologic complete response (pCR) rate compared to those with other types of breast cancer (22 versus 11 percent, p=.034). However, there was a higher risk of recurrence or death among women with residual disease after neoadjuvant chemotherapy (HR 1.5, 95% CI 1.3-1.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This paradox can be explained by the overall better prognosis associated with hormone receptor-positive breast cancer following surgical treatment, which is improved with the addition of adjuvant endocrine therapy over the next five to ten years post-diagnosis. Therefore, the breast cancer subtype must be taken into consideration during attempts to determine prognosis on the basis of pCR. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=see_link\">",
"     \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97090207\">",
"    <span class=\"h2\">",
"     Adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant chemotherapy is recommended for women with triple-negative breast cancer &ge;0.5 cm or with node-positive triple-negative breast cancer (regardless of tumor size). These patients have a higher risk of relapse compared to other breast cancer phenotypes and are not candidates for other forms of adjuvant therapy (ie, HER2-directed treatment or endocrine therapy). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=see_link\">",
"     \"Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a larger benefit to adjuvant chemotherapy among patients with triple-negative breast cancer compared to those with hormone-positive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/27\">",
"     27",
"    </a>",
"    ]. In an analysis of three randomized trials that involved a total of 6644 women with node-positive breast cancer, compared to those with ER-positive breast cancer, patients with ER-negative breast cancer had the following significant outcomes at five years following adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A larger reduction in the risk of recurrence (55 versus 26 percent). This translated into a higher absolute improvement in disease-free survival (23 versus 7 percent).",
"     </li>",
"     <li>",
"      A larger reduction in the risk of death (55 versus 23 percent). This translated into a higher absolute improvement in overall survival (17 versus 4 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data emphasize the importance of adjuvant chemotherapy for women with triple-negative breast cancer, who (unlike those with ER-positive or HER2-positive breast cancer) are not eligible for targeted therapies. Although there is no standard chemotherapy regimen that specifically applies to women with triple-negative breast cancer, anthracycline and taxane-based chemotherapy remains the most commonly used regimen, especially since taxanes have significant activity in the treatment of triple-negative breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. As an example, in the GEICAM 9906 trial of 5-fluorouracil,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (FEC) versus FEC followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , the addition of paclitaxel was associated with a significant improvement in disease-free survival at seven years (74 versus 56 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97090260\">",
"    <span class=\"h3\">",
"     Treatment of tumors &lt;0.5 cm",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are inadequate data to make recommendations regarding adjuvant chemotherapy in patients with very small triple negative tumors (&lt;0.5 cm). The natural history of small triple-negative tumors was demonstrated in a study of 965 patients with tumors up to 1.0 cm in size, diagnosed between 1990 and 2002, who were not treated with adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients with triple-negative tumors had a lower rate of recurrence free survival at five years compared to those with ER-positive cancers (85.2 versus 95.2 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/31\">",
"     31",
"    </a>",
"    ]. Given the lack of prospective data on women who present with small tumors, the decision to administer adjuvant chemotherapy must be individualized based on patient and provider preferences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97089718\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with triple-negative breast cancer have a poorer prognosis compared to patients with other breast cancer subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/7,17,32,33\">",
"     7,17,32,33",
"    </a>",
"    ]. In a 2012 study of 12,902 women who presented to National Comprehensive Cancer Network centers, compared to women with hormone receptor-positive, HER2-negative breast cancer, women with triple-negative breast cancer experienced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Worse breast cancer specific survival (HR 2.99, 95% CI 2.59-3.45).",
"     </li>",
"     <li>",
"      Worse overall survival (HR 2.72, 95% CI 2.39-3.10).",
"     </li>",
"     <li>",
"      A dramatic increase in death within two years of diagnosis (HR 6.10, 95% CI 4.81-7.74). However, the magnitude of this risk declined substantially over time (HR of death two to six years from diagnosis 2.30, 95% CI 1.39-3.82; HR of death &gt;6 years from diagnosis 0.86, 95% CI 0.30-2.46).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The poorer prognosis may be attributed to biologic characteristics of triple-negative breast cancers, which we are only beginning to understand. Two features that illustrate this are BRCAness and the proliferative rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624350409\">",
"    <span class=\"h2\">",
"     BRCAness",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of characteristics that BRCA1-associated and sporadic triple-negative breast cancers share, which has given rise to the term &ldquo;BRCAness&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/34\">",
"     34",
"    </a>",
"    ]. Although this relationship remains far from clear, data lend support to the notion that BRCA1 pathway dysfunction is present in some sporadic triple negative tumors. &nbsp;Whether there are therapeutic implications of this dysfunction is not known. (See",
"    <a class=\"local\" href=\"#H158129670\">",
"     'PARP inhibitors'",
"    </a>",
"    below.)",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97089916\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific posttreatment surveillance guidelines for patients with triple-negative breast cancer. Patients with breast cancer should undergo a similar surveillance routine according to ASCO guidelines following breast cancer treatment, regardless of breast cancer subtype. This should include history and complete physical exam every three months for the first three years then every 6 to 12 months for surveillance. A further discussion on posttreatment surveillance is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link&amp;anchor=H346411030#H346411030\">",
"     \"Approach to the long-term survivor of breast cancer\", section on 'Guidelines for posttreatment follow-up'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1136598543\">",
"    <span class=\"h1\">",
"     METASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of distant recurrence and death peaks approximately three years after diagnosis and declines rapidly thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/20\">",
"     20",
"    </a>",
"    ]. Triple-negative breast cancer is characterized by higher relapse rates compared to ER-positive breast cancers, including an increased risk of locoregional recurrence, lung, and brain involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/33,35-37\">",
"     33,35-37",
"    </a>",
"    ], but less likely to recur in bone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/33\">",
"     33",
"    </a>",
"    ]. In one study involving 116 patients with triple-negative metastatic breast cancer, brain metastases were the initial site of metastatic disease or occurred during their metastatic course occurred in 14 and 46 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/36\">",
"     36",
"    </a>",
"    ]. The median survival following a diagnosis of CNS metastases is less than six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of the general principles applicable to advanced breast cancer of other phenotypes apply to that of triple-negative breast cancer. Chemotherapy has been the mainstay of systemic treatment for triple-negative breast cancer, as endocrine therapy and HER2-directed therapies are ineffective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with metastatic breast cancer, a confirmatory biopsy of a suspected lesion should be obtained when possible with reassessment of ER, PR, and HER2, because there is a possible discordance of these markers between primary and metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. As an example, in a pooled analysis of two prospective studies, the rates of discordance in ER, PR, and HER2 between the primary and recurrent disease were 13, 28, and 5 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624350438\">",
"    <span class=\"h2\">",
"     BRCA mutation positive breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most breast cancers that arise in the setting of a germline mutation in BRCA1 are triple negative. In light of the association of particularly BRCA1 mutations with triple-negative breast cancer, we recommend that women diagnosed before 60 years with a triple-negative breast cancer undergo BRCA mutation testing regardless of family history. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=see_link&amp;anchor=H1971989#H1971989\">",
"     \"Genetic testing for hereditary breast and ovarian cancer syndrome\", section on 'Patients with triple-negative breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the role of BRCA1 in DNA damage response and cell cycle checkpoint control, some have theorized that BRCA1-associated breast cancer will be sensitive to certain DNA-damaging agents such as platinum agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ). In one clinical trial of BRCA1 mutation carriers presented at the 2011 Annual Conference of Hereditary Cancers, 67 women with stage I to III breast cancer were treated with cisplatin for four cycles prior as neoadjuvant treatment; the pathologic complete response was 67 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/45\">",
"     45",
"    </a>",
"    ]. However, survival results were not presented. While these results support the sensitivity of BRCA1-associated cancer to platinum salts, they must be considered hypothesis-generating. More compelling evidence supports a role for PARP inhibition in germline BRCA1 or 2 carriers, described further below. (See",
"    <a class=\"local\" href=\"#H158129670\">",
"     'PARP inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624350455\">",
"    <span class=\"h2\">",
"     Sporadic (nonfamilial) triple-negative breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In spite of the concept of &ldquo;BRCAness&rdquo; described above, current clinical data do not support that sporadic triple-negative breast cancers have a higher degree of sensitivity to platinum agents than other breast cancer subtypes. Several trials of platinum-based combinations in triple-negative breast cancer have been performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/10,46-49\">",
"     10,46-49",
"    </a>",
"    ]. However, there are no data that demonstrate improved survival outcomes when platinum agents are used (as a single agent or in combination) over other standard",
"    <span class=\"nowrap\">",
"     treatments.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H274813743\">",
"    <span class=\"h2\">",
"     Experimental options",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98882405\">",
"    <span class=\"h3\">",
"     Epithelial growth factor receptor inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;EGFR/HER1",
"    is perhaps the most well-known protein overexpressed among triple-negative breast cancer for which several monoclonal antibodies and small-molecule inhibitors exist. To date, three phase II clinical trials have evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , an anti-EGFR monoclonal antibody, in combination with chemotherapy and show it has only modest activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/46,47,50\">",
"     46,47,50",
"    </a>",
"    ]. A better strategy for identifying the subset of patients within triple-negative breast cancer who would be most likely to respond is required to optimize the use of these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98882412\">",
"    <span class=\"h3\">",
"     Angiogenesis inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although clinical trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    with chemotherapy have demonstrated significantly improved progression-free survival (including the",
"    <span class=\"nowrap\">",
"     ER/PR-negative",
"    </span>",
"    subsets [which were virtually all triple-negative], and those with triple negative breast cancer) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/51-53\">",
"     51-53",
"    </a>",
"    ], no overall survival benefit was seen in any of the phase III trials nor in any subgroup. A pooled analysis of the triple negative subset of randomized phase III trials demonstrated progression-free survival impact but no evidence of overall survival impact even in this subset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/54\">",
"     54",
"    </a>",
"    ]. However, without an overall survival advantage, it is unclear whether any magnitude of improvement in progression-free survival is clinically meaningful, given the excess toxicity and expense of adding bevacizumab. Approval by the United States Food and Drug Administration for bevacizumab in metastatic breast cancer was withdrawn in December 2010. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22202?source=see_link&amp;anchor=H111524024#H111524024\">",
"     \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'Vascular Endothelial Growth Factor Receptor Inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Efficacy of anti-angiogenic agents in the neoadjuvant and adjuvant settings, including triple-negative disease, remains under investigation. Supporting this continued investigation, subset analysis of the neoadjuvant GeparQuinto study, in which patients were randomly assigned to treatment with anthracycline and taxane-based chemotherapy plus or minus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , found an increase in the pathologic complete response rate particularly in women with triple-negative breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/55\">",
"     55",
"    </a>",
"    ]; however, this was not seen in NSABP B-41, in which a modest effect appears to be primarily in the hormone receptor-positive subset. Results from the ongoing",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00861705\">",
"     CALGB 40603",
"    </a>",
"    evaluating the addition of bevacizumab",
"    <span class=\"nowrap\">",
"     (and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ) to standard",
"    <span class=\"nowrap\">",
"     anthracycline/taxane-based",
"    </span>",
"    neoadjuvant chemotherapy in the setting of locally-advanced triple negative breast cancer are eagerly awaited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H158129670\">",
"    <span class=\"h3\">",
"     PARP inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors of poly (adenosine diphosphate-ribose) polymerase (PARP) are another class of agents they may be particularly useful in BRCA-mutated breast cancer, of which the majority are triple negative. The role of PARP inhibitors in the treatment of triple-negative breast cancer continues to be an active area of investigation. However, it is not commercially available for use.",
"   </p>",
"   <p>",
"    PARP is involved in the molecular events leading to cell recovery from DNA damage. When PARP1, the most abundant member of the PARP family, is inhibited, double-strand DNA breaks accumulate and under normal conditions are repaired via the BRCA pathway-dependent homologous recombination mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/56\">",
"     56",
"    </a>",
"    ]. Investigators hypothesized that inhibition of PARP, in combination with DNA-damaging chemotherapeutics, would render tumors lacking BRCA function exquisitely sensitive, a hypothesis that has borne out in both the preclinical and clinical arenas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. Given the shared clinicopathologic characteristics between BRCA-mutated and triple-negative breast cancers, the efficacy and safety of PARP inhibition is being tested in both settings. There are several PARP inhibitors in clinical development (",
"    <a class=\"graphic graphic_table graphicRef72354 \" href=\"mobipreview.htm?37/18/38187\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/60-66\">",
"     60-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Olaparib (400 mg orally twice daily) was administered to women with BRCA1-",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      BRCA2-deficient, advanced breast cancer (of which &gt;50 percent were triple-negative) in a single arm study and resulted in an overall response rate of 41 percent and progression free survival of 5.7 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/60,62\">",
"       60,62",
"      </a>",
"      ]. The drug was generally well tolerated with the most commonly reported grade 3 adverse events being fatigue, nausea, and vomiting. A separate study found olaparib had no activity outside of patients with known germline BRCA mutations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Veliparib (ABT-888) was tested in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      , an alkylating agent, among 41 women with advanced triple-negative breast cancer (of which eight had a BRCA germline mutation) in as single arm phase II study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/66\">",
"       66",
"      </a>",
"      ]. While the overall response and clinical benefit rates were 7 and 17 percent across the entire study population, any activity appeared to be concentrated among the patients with BRCA mutations, in whom the overall response and clinical benefit rates were 37.5 and 62.5 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Iniparib (BSI-201) was originally thought to inhibit PARP inhibitory activity, although more extensive mechanism of action studies illustrate that the DNA damaging effect of iniparib is not medicated through PARP1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/67\">",
"     67",
"    </a>",
"    ]. It was evaluated in a phase III trial in which 519 women with pretreated metastatic triple negative breast cancer were randomly assigned",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    with or without iniparib (5.6",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    intravenously, days 1, 4, 8, and 11) every 21 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/49\">",
"     49",
"    </a>",
"    ]. The median progression-free survival was modestly but not statistically significantly longer in the iniparib group (median 5.1 versus 4.1 months), and overall survival was similar (11.8 versus 11.1 months). Additional studies are ongoing to better understand the mechanism of this novel compound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98882442\">",
"    <span class=\"h3\">",
"     Src inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene expression profiling has suggested that triple-negative breast cancer might be preferentially sensitive to inhibition of the proto-oncogene Src.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/39/22136?source=see_link\">",
"     Dasatinib",
"    </a>",
"    , a potent orally-available inhibitor of Src-family kinase, is being studied in the setting of advanced triple-negative breast cancer. One phase II study reported a clinical benefit rate of 9.2 percent among 43 response-evaluable patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/68\">",
"     68",
"    </a>",
"    ]. This drug is being investigated further in combination with chemotherapy; it should not be administered outside of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98882450\">",
"    <span class=\"h3\">",
"     Histone deacetylase (HDAC) inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epigenetic mechanisms (ie, DNA methyltransferase and histone deacetylase inhibitors [HDAC] inhibitors) might play a role in the loss of ER-alpha in ER-negative breast tumors. Preclinical studies have shown that pharmacologic inhibition of these mechanisms result in re-expression of functional ER mRNA and protein. The addition of an HDAC inhibitor,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/29/27093?source=see_link\">",
"     vorinostat",
"    </a>",
"    , to endocrine therapy in the setting of endocrine-resistant disease appears to restore sensitivity in select patients; a hypothesis that is being carried forward in the setting of ER-negative breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/40/34441/abstract/69\">",
"     69",
"    </a>",
"    ]. Currently, clinical trials evaluating vorinostat in combination with chemotherapy are underway to test efficacy among patients with ER-negative breast cancer in the both metastatic and neoadjuvant settings, but should not be used for the treatment of breast cancer outside of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98882467\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Triple-negative breast cancer lacks expression of the three most commonly evaluated biomarkers (the estrogen receptor [ER], progesterone receptor [PR], and the human epidermal growth factor receptor 2 [HER2] protein). (See",
"      <a class=\"local\" href=\"#H98882311\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Triple-negative breast cancer is more commonly diagnosed in younger and premenopausal African American women. (See",
"      <a class=\"local\" href=\"#H267308777\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The triple-negative clinical phenotype is mostly comprised of the basal-like molecular subtype, which is overrepresented in BRCA1-associated breast cancer. Triple-negative breast cancer shares a number of characteristics with breast cancer gene (BRCA)-associated breast cancer, although the therapeutic ramifications of this association are unclear. (See",
"      <a class=\"local\" href=\"#H98882326\">",
"       'Pathologic characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principles that apply to the surgical treatment and use of radiation therapy in breast cancer, and the systemic treatment approach in both the neoadjuvant and adjuvant settings, are similar in triple-negative breast cancer and other HER2-negative subtypes. (See",
"      <a class=\"local\" href=\"#H98882362\">",
"       'Treatment approach to triple-negative breast cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite a higher risk of relapse compared to other breast cancer subtypes, there are no specific posttreatment surveillance guidelines for patients with triple-negative breast cancer; ASCO surveillance guidelines apply similarly across subtypes. (See",
"      <a class=\"local\" href=\"#H97089916\">",
"       'Posttreatment surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chemotherapy remains the backbone for systemic therapy to treat triple-negative breast cancer. There is no evidence to support a preference for any one chemotherapy agent or combination for initial therapy of metastatic triple-negative breast cancer. Although clinical data are limited, platinum activity appears robust in BRCA1 mutation carriers. However, there is no compelling evidence that there is a greater inherent sensitivity to these as compared to other active agents. (See",
"      <a class=\"local\" href=\"#H1136598543\">",
"       'Metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Swain S. Triple-Negative Breast Cancer: Metastatic Risk and Role of Platinum Agents 2008 ASCO Clinical Science Symposium, 2008. June 3, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/2\">",
"      Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009; 20:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/3\">",
"      Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 2011; 103:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/4\">",
"      Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008; 109:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/5\">",
"      Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 2013; 137:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/6\">",
"      Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res 2011; 17:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/7\">",
"      Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/8\">",
"      Collett K, Stefansson IM, Eide J, et al. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005; 14:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/9\">",
"      Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19:264.",
"     </a>",
"    </li>",
"    <li>",
"     Carey LA, Rugo HS, Marcom IW, et al. TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer (abstract 1009). J Clin Oncol 2008; 26:1009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/11\">",
"      Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002; 82:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/12\">",
"      Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10:5367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/13\">",
"      Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121:2750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/14\">",
"      Teschendorff AE, Miremadi A, Pinder SE, et al. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007; 8:R157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/15\">",
"      Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12:R68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/16\">",
"      Bertucci F, Finetti P, Cervera N, et al. How basal are triple-negative breast cancers? Int J Cancer 2008; 123:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/17\">",
"      S&oslash;rlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98:10869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/18\">",
"      Troester MA, Herschkowitz JI, Oh DS, et al. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006; 6:276.",
"     </a>",
"    </li>",
"    <li>",
"     Cheang MC, Martin M, Nielsen TO, et al. Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG. J Clin Oncol 30, 2012 (suppl; abstr 1008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/20\">",
"      Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/21\">",
"      von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/22\">",
"      Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11:5678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/23\">",
"      Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13:2329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/24\">",
"      Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/25\">",
"      De Laurentiis M, Cianniello D, Caputo R, et al. Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev 2010; 36 Suppl 3:S80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/26\">",
"      Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 2010; 3:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/27\">",
"      Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/28\">",
"      Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/29\">",
"      Hugh J, Hanson J, Cheang MC, et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009; 27:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/30\">",
"      Mart&iacute;n M, Rodr&iacute;guez-Lescure A, Ruiz A, et al. Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat 2010; 123:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/31\">",
"      Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009; 27:5700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/32\">",
"      Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100:8418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/33\">",
"      Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 2012; 118:5463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/34\">",
"      Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/35\">",
"      Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008; 68:3108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/36\">",
"      Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008; 113:2638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/37\">",
"      Hicks DG, Short SM, Prescott NL, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol 2006; 30:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/38\">",
"      Niwi��ska A, Murawska M, Pogoda K. Breast cancer subtypes and response to systemic treatment after whole-brain radiotherapy in patients with brain metastases. Cancer 2010; 116:4238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/39\">",
"      Anders CK, Deal AM, Miller CR, et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/40\">",
"      Hull DF 3rd, Clark GM, Osborne CK, et al. Multiple estrogen receptor assays in human breast cancer. Cancer Res 1983; 43:413.",
"     </a>",
"    </li>",
"    <li>",
"     Amir E, Clemons M, Freedman OC, et al. Tissue confirmation of disease recurrence in patients with breast cancer: Pooled analysis of two large prospective studies (abstract #1007). J Clin Oncol 2010; 28:15s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/42\">",
"      Simmons C, Miller N, Geddie W, et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? Ann Oncol 2009; 20:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/43\">",
"      Amir E, Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer? Lancet Oncol 2009; 10:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/44\">",
"      Khasraw M, Brogi E, Seidman AD. The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury? Curr Oncol Rep 2011; 13:17.",
"     </a>",
"    </li>",
"    <li>",
"     Byrski T, Gronwald J, Huzarski T, et al. Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers &ndash; results of treatment. Hereditary Cancer in Clinical Practice 2012, 10(Suppl 3):A3.",
"    </li>",
"    <li>",
"     Baselga J, Gomez P, Awada A, et al. The addition of cetuximab to cisplatin increases overall response rate and progression-free survival ini metastatic triple negative breast cancer: results of a randomized phase II study (abstract 2740). Data presented at the 2010 meeting of the European Society of Medical Oncology, Milan, Italy, October 8-12, 2010. file://annonc.oxfordjournals.org/content/21/suppl_8 (Accessed on September 07, 2011).",
"    </li>",
"    <li>",
"     O'Shaughnessy J, Weckstein D, Vukelja S, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. San Antonio Breast Cancer Symposium, 2007. Abstract 308.",
"    </li>",
"    <li>",
"     Isakoff SJ, Goss PE, Mayer EL, et al. TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response (abstract). J Clin Oncol 2011; 29:86s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=76639 (Accessed on July 08, 2011).",
"    </li>",
"    <li>",
"     O'Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) (abstract 1007). J Clin Oncol 2011; 29:81s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=78038 (Accessed on July 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/50\">",
"      Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012; 30:2615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/51\">",
"      Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357:2666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/52\">",
"      Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010; 28:3239.",
"     </a>",
"    </li>",
"    <li>",
"     Brufsky A, Valero V, Tiangco, B, et al. Impact of bevacizumab (BEV) on efficacy of second-line chemotherapy (CT) for triple-negative breast cancer (TNBC): Analysis of RIBBON-2 (abstract 1010). J Clin Oncol 2011; 29:82s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=78329 (Accessed on July 08, 2011).",
"    </li>",
"    <li>",
"     O'Shaughnessy J, Miles D, Gray RJ, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 28:15s, 2010 (suppl; abstr 1005).",
"    </li>",
"    <li>",
"     Gerber B, Eidtmann H, Reza M, et al.   Neoadjuvant bevacizumab and anthracycline&ndash;taxane-based chemotherapry in 686 triple-negative primary breast cancers: Seconday endpoint analysis of the GeparQuinto study (GBG 44) (abstract 1006). J Clin Oncol 2011; 29:81s. Abstract available onlione at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=78777 (Accessed on July 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/56\">",
"      Tentori L, Graziani G. Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 2005; 52:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/57\">",
"      Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/58\">",
"      Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917.",
"     </a>",
"    </li>",
"    <li>",
"     O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol 2009. 27: p. Abstract 3.",
"    </li>",
"    <li>",
"     Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009; 27(18s): p. Abstract CRA501.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/61\">",
"      Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/62\">",
"      Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376:235.",
"     </a>",
"    </li>",
"    <li>",
"     Gelmon KA, Hirte HW, Robidoux A, et al. Macpherson, and A.M. Oza, Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J Clin Oncol 2010; 28(15s): p. abstr 3002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/40/34441/abstract/64\">",
"      O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011; 364:205.",
"     </a>",
"    </li>",
"    <li>",
"     Dent RA, Lindeman GJ, Clemons M, et al. Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial. J Clin Oncol 2010; 28(15s).",
"    </li>",
"    <li>",
"     Isakoff SJ, Overmoyer B, Tung NM, et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 2010; 28(15s): p. abstr 1019.",
"    </li>",
"    <li>",
"     Ji J, Lee MP, Kadota M, et al. Pharmacodynamics of four reported inhibitors of poly(ADP-ribose) polymerase: ABT-888, AZD2281, MK-4827, and BSI-201 (abstract #4527). Presented at AACR Annual Meeting 2011.",
"    </li>",
"    <li>",
"     Finn R, Bengala C, Ibrahim N, et al. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059. San Antonio Breast Cancer Symposium, December 12, 2008 2008: p. Abstract 3118.",
"    </li>",
"    <li>",
"     Lacevic M, Minton S, Schmitt M, et al. Phase II trial of the HDAC inhibitor, vorinostat, in combination with tamoxifen for patients with advanced breast cancer who have failed prior antihormonal therapy. Breast Cancer Res Treat 2007; 106(Supplement 1): p. Abstract 2097.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14227 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-2332FC6495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_40_34441=[""].join("\n");
var outline_f33_40_34441=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H98882467\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98882311\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H267308777\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H274813343\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98882326\">",
"      PATHOLOGIC CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H493962740\">",
"      Molecular classification of triple-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1340632742\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1340632749\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98882362\">",
"      TREATMENT APPROACH TO TRIPLE-NEGATIVE BREAST CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97090639\">",
"      Neoadjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97090207\">",
"      Adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97090260\">",
"      - Treatment of tumors &lt;0.5 cm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97089718\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H624350409\">",
"      BRCAness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97089916\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1136598543\">",
"      METASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H624350438\">",
"      BRCA mutation positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H624350455\">",
"      Sporadic (nonfamilial) triple-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H274813743\">",
"      Experimental options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H98882405\">",
"      - Epithelial growth factor receptor inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H98882412\">",
"      - Angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H158129670\">",
"      - PARP inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H98882442\">",
"      - Src inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H98882450\">",
"      - Histone deacetylase (HDAC) inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98882467\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/14227\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14227|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/14/29920\" title=\"table 1\">",
"      TNM stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/18/38187\" title=\"table 2\">",
"      PARP inhibitors clinical development",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/4/37961?source=related_link\">",
"      Adjuvant chemotherapy for hormone receptor-positive or negative, HER2-negative breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=related_link\">",
"      Approach to the long-term survivor of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10009?source=related_link\">",
"      Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19194?source=related_link\">",
"      Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/28/43465?source=related_link\">",
"      Measurement of prognostic factors in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35831?source=related_link\">",
"      Metastatic breast cancer: Local treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/31/1529?source=related_link\">",
"      Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=related_link\">",
"      Postmastectomy chest wall irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/55/42873?source=related_link\">",
"      Radiation techniques for locally advanced breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22202?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_40_34442="Chronic rejection Light I";
var content_f33_40_34442=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F72574%7ENEPH%2F52555%7ENEPH%2F65391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F72574%7ENEPH%2F52555%7ENEPH%2F65391&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing chronic renal transplant rejection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of an intermediate stage of chronic vascular rejection in an interlobular artery. The arterial lumen is narrowed by marked subintimal thickening with loose connective tissue (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing chronic vascular renal transplant rejection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph shows end-stage chronic vascular rejection in an arcuate artery. The vascular lumen is virtually obliterated by the marked subintimal accumulation of connective tissue (arrow), a response that represents the healed phase of previous inflammatory injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing late stage chronic renal transplant rejection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADzAXoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD0x9QnjdRdwTI7kKJ4QB97+8TwBz1I4p8NpG14lzFJd3U0haOR5yHKcclumMdMMDjI4qBLY2ml298iSSCIlmTnyyCD/Cck8lepNSX9xaSWcWoQRIs4KyyK6lyTk/IwzyMZ4HevT/wn070enX+rGlZ290l9b3AkECB2R4imUdTnI657Yzj8qdLpbxwtLpM001nvCiAL80JA5BDA5HocdCOowai0u6S+0dYzMykhkTDYZsE4Jz0PFEF9c6TAkKRzlsYjZMsrYOcAnueTzisnzX03MpRmpe7uhfMuPNitruORtxO/LFzFIACRkYyMBucd+o71zZ2xmmtrSaNobyQNIByH2AgAYPUEqeOhFS6jJfah5D3UBjkCh98aD51wOc5GCOfy/Cp4Q6aa3myvJtYywlQoZH54756DHX37Ci9kJN21I7kR2NrC9jDZSWxjCRytJsKkE7sk8kZwOQfpVGGZJtc2wbt1xD5h8xCcjOFIHXqGz/8AXq7BYzT3EYuy0ojtl5eMbFPO7kH6dRj07gSXFql9I0VqbZIYxh8kNtB7Efhnn0ppx2bKVlo2NtbT7PLDFJMSsQ/eIyBvkPQBhzwc9+KZZG7uHLfOqKxIMb4Vl9Bzz+Axz+cElzpxt5Ypr5JWCmMIzqiMM8AkDP8A9eryaxZCOK1tFa4mK7RBbKWzjtxwB17j8qHzLpcpxqb2v8gkmlM8c6IkEh4AJDsQRyGB5U8+uOvHao0heG9MkzTKzOF3yTAgnqOgHA/LkVN9p1ZEZLfSrlX6OMYwT6Ho31/yYYZ9TiKi8g3xZUOwkIZO4DD1yOC3GehpLbp94lF26fei1Dp0N28rXUbxfNj5WOG4GcAHP6/SsjUraxeaC3vJLzfE4WJIdwVipOM9wBjOehzmrp1VrcPHJ5sU6MFCSDcdp756fj+farEyPqVuGt0gA2jKOp+ZTxkbTnIx74oTlF3lsS1KGstirawvd7JbgFdsjALFLuRVB6cnHTrkeuB6W5fJWUfaJhFK7AgOSQ3AIyOAcYPbj681Wty0C7YJzOEBjMZUgBtuQAT06jJrMttDnn1L7ReSi7mtuUR1bCqAAOePm5yeTyM07J7sLK++hs3DSTxyQrKrySRnyn3/AHjknBHbPH6VhpDcQzuJZ4lupApBGQVdQSWwcAkg859PTGN2a7WCVg6GWbAIi27juHTnrnoQff8AGqMZEqy78RywqM4jMe4kcHDE5BGB+HPpTg2kNe78zVijSe2ga3bKjbtUv2wQVI79Wp8H35IXkYiO4L/Puy2fmGOBnBbtnHH0qlpasttcTuMB1OTjjAHGD0xznpirmlQw20O61kkmwWG/O9h833Tnr6c1lJWuZyVrmJqFqr+JZ/njt18kuu4YWQ45Vv0J649DW5aS/b4+WhPl8rJE5YZIBBwe3+eKfPLHc2pEtrIyHs2DtOf0+tMWJLeeUxQxQxumA6Kc9Mk8D9M/yocuZJPdFzqOaSe6G3s8qm5Mkcohi2t5sLfM/HIC8nPTg4zmm6Rawm7vNQLRRIEMjJy2T3YZ5z2yOOeneotTucRIqlIdzbp5mAXbjgZJGByRyf61mww3d5ZR2umxRJauB50uXKAjAyGH3m7AgkZXPSnGPu72JUXy2va5rWlwdThimmkKzM2RFbgFQgI+Y7iR+IOTntzijrTvdXVpYwNA2pmT55xEJVhXPOVJ64985FbcEJsWmkismkg2Dou5l5JIz949Saz11OPTtYu/NjTyJ4ftEeYys5bcF2jjJztPHrgUoy1vFChLVuKvbYj1Zv7A0W1iaSC6hQNGFu2ZnLjccg5yDyuOuAOMdTc0eO7hsgt6rxyuxwhcP5Q5AGeewBz6sfSud1TxRPqms2kdho1232ZpC4cL5jRsoCygDJAzn8VH4b9jfidUaVoYpNucO2Hx/ukA4+uc05RkoK61e5ThJU1davcrzeILManPZTIFljPluH44IyCeMBTkdT3rPS5RbiLy7fW1siFjCIjeQM8csM8e/X3raLWSySSTSxPJLhSBgbsdgOpPTjk9PWsqayuPtUbw2U8MTAhDCViU5I+8CoPr1z9KqHL2sVHltpp+QkUi2FzE13ZSWDuzFJLYs7qM/wAec5yDzwCPQdav3um2yLJcTed9m2lsALlGZhubLDPP881XtVnt4i86wGKMMXX7QzkLjlSR8p9cHj9MR2niayupwsgZ/MYYCRNg5GBkg4AxjPUfWh8zd4g1O91qXbOI6ezY+3LASqBJjlMAdBu4wOP1+tWrmQW81uyqVGQ5TyyQy4weOAMYHP6d6xo0K6uWtdMcKAN0oZVwhJOAGDE9DgcexqSx1JWu5IZFWSRHwHwu0Jz6Y57cZ/GpcW9ROEpe8zcnc43R30qpNLgPuIIP93n7p9BVSynhmuIojdSC+gjLSSqvyvsHPnHABwWz/DzTYZLYwxFY7hFLEI0ZAwN2eNuGK89MHOPWmSC4+xSyRPHNZbnYrAQqvxkF8gEtwARwOvoKjl6HPyW0KtreQpZrqMTQq1ztH2eJ93mEllYh93rjBHZR1yANzSzFIYrqMNGJj5hGGBPBAG0jJ6njA9azbW2099Ohu7ySOGIxoIdjeXhio43DnqOB7A1PbXMDQySNMQmGBIJZztBwRt5PGetOet7FVEpXsSSacL9OJUXeoAdQQykj+HPGMYPIIzmo/shtbuNYjJI0jEFXzwTnLtt4HTGT3I6ZrFt9buQt6loqxyYUQRhOEOGOW54HAzwCOa27ON7m3FxO29CMbt5AkHUZBJyCDn9MGnKMoaN6FzjODs3oU7iyVJiLNlIBMiKRvMe7GRuPQHrjBz/O3p0bQQSyXMyqSxJUfKqjH6dvTr0oVbmMyKkaJErbUVDgbRnGB2J/r2rIlurNHlW/0me4P3Wn8wkd8nOeMex79qavJWGrzXf01ZsWsouNkFu6eXGd0hODuHPAGT37/lVDxHqV3ZTp5UgVCFOWyBnnGT6VHF5MTC8itptPtokDuXbIcnsBnjOTn8PrUKfbdauD58ctpbmPBKEZcYJxg84IPt+NOMUnzPYqmop881oaOm3clxuhvAROgDDb8u/oQOnHTsfxPWoNcZhphtkkMe+VYR1MnJ77vXB5NVJxGuoWNuskMrJDsZ45C7DpyzEfMOQOTnp70muRQodPiM8h5WNmKGQ8HI/Hrn601FcyYQWqnbz+4ZdWM0GiW86ebHIw3StI+7JwcNhOD9OAec81lwazdxwxoum3UgVQA4yA3HXkVu6rObeJkSzmY3M6BQrs6sBj+HomRkYHoarPbDccQ26jP3SAMe2M8U4yVveVx0bW95X/AK9SG0nbTS0ccbXGndZUfO8En5sL1wAw7Y980XMenyIfs8MJkAJyUwAO3JG3pgjAP0prLdXMkcUZniuoxzPCHQDGTtDHr9M5OKuW8AhhYI4lQH5y42s4JPQ9jg5//XmtLpa9TVO2t9f63KWgRSySFOVtnjw5UrmI9jn1+bngevat66cJEVk3pEVVlmTGUcuAMj0yRnPBAOazbO0jKoZnPmgnG1MZGMHn8+f/ANZ1bUKYPMjT94U5ZeR146H1z9Oazqu7uZ13zO6MxtQMrzwpD5sdu3UqxVTnjBGT6duCRnHe/fKlxDbTwSyrNkjC/MBuU+vByex68HpWWHtdIErTaYsr3BA85doMYXPIYA+gIz349Kd4clRp723tY7r7PGUVfMABVScY4HbH+eaHHTmXQXJJpytov+GNaXMkriTekGwBicAs2fTGScEdcAcYzzSW1lYXq3V7csYdKtiVEaOVEg2gl2Ycnr64pLqeOa3iguC0Pmv8odyVdUGWG4DHQH69s9Kvajex6b4ct5ItMaeCUKHiByEVhkliQc84H41ldqyW7MZOSso7t/18zPOtaPdQTLZafbMlou8T3MSiJIxk788n6DAOTUdp4tnFnCY9PQGSPzd0SYU/McgDJ7D72T644rF1KC50+CKFbRhbPCzPG6hclsgFj1yNy5HbHHBqAaxJc6Vp+mRQ+ZcBGLSAY8tMMBgjGcY6nPX8K3VGLV0rr1OlYenJXtdX6s3ZfGV7bXKxCCyukfEgMTsGKtyBznDYxnj0ro7OSx16JneLy7mA7HAGHiPpnuP89a84jt11SxP9o3tyPKmZt0cReTZtGPmHXH4VpW98iwz/ANm24tmtAJS8s5VpU4GFAOcZByD3PqaVShG3uaMirhY6ezVn3/r9Do7/AMPXscIfStSlMiNvEMpAVhnoOP51ztndz2FtLbyK1tGJfLWVQCUckn5gcjPJx9ME966Lw/ftfaXGvnTQ304ZjMYzhieeM8ZwBwMdDWf4j01k1q31FYA8E0iyGOQHB+XBUqejYyQfUGs4Sd3TqE0ZvmdGr/Vh9lHfR3JWaKNH2gtsOQG54HQH8eefrS6QojsY7V9hSPcFCSBtqqcDDDnPXjORj89ONI3VEj3GNRkMDk5xxnPsR19ay7q5NkcQ2UzBnKxlI8nGfmLcAAfNnqe/tS5nLQjmvpYuWl3ai3G/9zdyRbXEbs6Mw5IGcE59cAnnpWTJBKlrCSQ07BmmIIBdupxx24444+lXlmnghnlYK4EatIgDM2Dk4yvX8s0+O9jaXN3JtYyFUTYQRwcqfXoTnimrxd0Uvcd1qZdjIPIeBlCb/mQEdwPXPv6d614VhEUZmtHWZ+HYfLvOByRu5PAHTP1qnPaGxSKZUdpGbO123LjPPOASe/5/WrczGWMC6t2idQGjJfCucHgn2OePpTk+bUqb5tRrMitvkijSIuMhc7iRyASMDg9jnrVxFWZGwqZDkEFR1+v0/nzVOVTDbCWYJIiAMSxyNp45Jxgf1q1Bdwu3DqF4wwIIJxyMjj0rOXkRJaXRm6la2WowWtwZZhHHuCiM43gjBU/lj/8AVVy+srW8Ek0jOvmRmHPmbSUzjg9R2PB64+tT2sflSzqUYIXBUBsjGB8w4GDyeOenuaVljUy4K+TGMuWchgeMA+oxj8h1pc+yE5tpLsVVl8tY4VlnkaJRlIrjBwpzgncPUdfxNRahaW2rSq15B5rxDiRXAZM9iM5H1/nWBr9nDd+IW8u6uoFB/etGCRG20c9c9Op7V1ZUeUTblNjpncY92SCOBj1H4cH8dJLlSkt2aygqajKL1f4GTqmkpZpb3LXbky5jmuUbycY6BwvBXAI55yc96j1TQJdSt4UNxbC9tkT5IByEAxgEtlsjkE/n1p9zeNYyXlvdxMVEW6OKM5QkADc3AIGCOnTrUFsZY0iu5ZY2u2GxztKyOjBtqBsZHAJBPJ+UnFUnOK5rhH2kGpp6/wBf8MNCQw3DMH/01lwJyjIuMbvvYIBwo6DoR6k1CmntcyLDChZkWNmk8zczK3RlyAeh657VjJOFmWS6WZUZFAh80sI8cFQQT8wByAegPStW83LbyRZuN6gO8ZX7ox1LKBkcYOT36em/K1bXc3hfm0epFJo8mpiFlmjCNDu+fO3KkggkA8YxwfXv1OhbxQ6fp8gV7i1nYhlaONJPK4HyjCjAI744yTmq2jSvZ217ZRxBbtUFxHuXgp3+bOc47DGPzxZ8PXkt/eTXUkNvDG6/Z22qTuKA4685xx16A9etTNys+yFV5ne+y/r+vQuWGrC7WQRMs2ZQNzNhx02v78jvjsPaobKy/s55bmNQtw0hEqjBZcg/dyDngFsD6Z45xtZLyT/ZYbGGG2kxiR03ONvG5W7ZORjgfTrT5rDUFsHmuL+UxRqhWOQ/cPzDAC5I6daXs0lo7XFKmopNO1zQlupJblrmVXt4o4jG+whg7HGcKeeuAT345FWJr6Vphc28clrczoWEIcbpSuWKna2M5BUdye+MiqumX1nHpUiTWhSKJRHCGBkUSEZZQT16DAPA9alm+zTBnZWjuAn2dI0jASMcASEleAMseCPTFJrWzRMo30aNuSeG9W3JDIHCzJBKDuyORgHAyp788nsae8hghkIt1Max48nZn5gecdzwB69KzrAWkltbraSSs1tMGZixBbI28g/wlvLOOnB4FOvhKY5WAVZVkLwlUxtHG0jrkg8896w5dbI5nCz5SHUrfS2g0+4tSLeTlTGCIhKGIXByQCRgHHJ+XgdAZdWjkby3jaJN7CKMPllKnncgXo3J+96elIZpLOzllnWNUxgtHgPMeQST2JPoP0qrrV45LCCX5T8pTapwd3DFiMgYGMZ7+uauKk2kjSMJN6D9IuZjNCF8zZtYyrnOW7HOe+eB9KkS/wBTvdQkjgRbe3i4LEB2bB6r04PT8eOlVMW8No1sqSyR3bBUjhjKjy8DLNyOvvj71Tac0On2EkmyGNid3lzNtJA+8cc45PbPanJLe2o5au1tTX1aH7RZrGFZ28xG4UZ4YE98D8qzX0qRL6S7urrbGgZw0aDcAM8njrt7gfyrUiuIhcYSMBGUAzbgFLdlHqeR/KuZ8Qz3a3LLozO0hz5rr75wACMHqTnr0FTSUvhRNJy+FFqGCwnsXl0qWKUI+1ioI2ZOWG09CeO1QT3MTay0e9sohaGJIwRvCkZPqOQe1OsII7FC4ie4v7ggysVCqCem4547jt07dag81l1G6M9nB5soIaPn90hwuc7SeeuPbtWqWr6l3aUm36fNj7w3GqtC01q0mzL5cEkSFvujaOOBnPp0pUW+CLts4EGOFDMce33asaAfsmmPNPIzJ5pZX24yoAAycYAwM/lTndXYtHeQBCcr8obj67+frUXs7dEQ19na3zE0TU4YbuFr5yYrpWUrhsAhvlLDB5wBz7cdhVmTTjp8yW07KYHO+J0Xbnn7p69Bj161zfnSzeaZ4MzRbX2Plcrn5tx6kcfStiHUpru0tzdiJgCoW6j+Rgzbvlx1xjA5AzVzptO8f67GlSnKE7rZ/wBIpwWht0EBuZbZJA2HSVgrsw+UEDuD+BxVnTxd6fN9nnvGuIpHRY3YGMvkD5ueACeOvYijUolJhiilXy5D50Ue0N0/hJzjByKypGjltI1aQNJK5dED/MvP8XHTLEH/AMdIyate+vU1k3Oz3TOhlka48hrZVhAdlYooBTg89c9e49TUBluBqMiQW73UiKC0h5ZmwQQEGOmR09e3FLHcG1s5RcPDFOu0gLkmPJHBJHUlT7ZzVe402Nbp7+R5hcMFWSUrvYcnAwPZsAjBx+NZJWMbW0NW6uRfadcRwHbOVZXQjDLlDjPPfIHHTNQ+MNZhW18gACK4tVuI+pJJOFVQPx61Ctt5l+ron2lVHMsYwGQDnJJ5Ycep/Crdlp9tqIuNJulPmxZlgmC8Kuc8DsQzc+oIHaptGLUn0FaMbTfTX+vQzbuK41y4eO6jZZEMJWIhzuX5sqQDheoGfUZ71Ha2z2AvjZSwfbYpgIYnO51iLONoB6MeMexo/t+206zuY9NuJppI5t8s+Fj8w4OAgOcoCM9/1qnfzx6tqFle3rQxuMq4ZQpVlHQjIJGQR349zitkpbP4f66eZvGM2rPSP+Xl5lizIs3na6ZIrqV1UtaMGZOrbSBkKQVT8M0kl5ugZZNMW8hbLS3MW+XnOfm4/wDHuOmc00WsEupmOOGSzlMwzOvcqDuZR24BOOvAqW3M9lptvZah5r300YdYoyyl12kBWYdWJ6dem0nB4btv1KbW/X+v63L3h9pNUntbmO4gtkjeMbRGwIVQWES5PTAyR15Oe2dzX5Bd3KIRIbS2VpZGXnc/KhQOSxHzdATkcc1wmk/aJlW1MTiKykMrzqcGKMfMzgHvx6egrqdFikubNZ7kETSnef8AeJznngAZ/U9eKxrQ5Zc1zCvBRnz32/r+uxal2WzI0UcbSEiDjrgZwOOuMmq7LMss8Mn2ZreVcCRnO8t2yPx9R2q7IfNygXJBKsw5GRjqM+4wM9KzWni+2OZIJ5IHIhOwnaqqCVPPvjkdcj0rKJlG72IG+YJDaXIiUkjeiFgQPocLz1B6+3UTRRvMjSXE5DCRniDD/VKSMcDGOCRnjt+NKKCO11O7mBEnlwKDFy8hXdnk5IIJ5/PnrV2NHWdmClQQvm4+YAH6ev8AnpWrNHvuOt7x5b9wUkiiiIiAK5y3Y8dQcj6Z7VdYE3bLIRvVQQqjgHPGfTqPTvVTVXZo2eGQwuoHyqp+YFvYd+B+NRwW4d2MAJcsBKzjJYr0A9B36d+gqLJ67GdvkPn8y4sFtp4CLac7R/eUZzk57Dj/ACKrxW0l5p8G25uZlRG8ppYAGHQdCm4DrwTz3IqzPcRQ2Zmvg6MigyB4t/J4CgAnuTgDPT6VXuBcBBLaXSWmPmeOdfMAGANuMgDA7c/QEctPsWm9kWLOc28KxAs0Yby0aR9oTnBBOBnb6YPUDNTIUNs1zdxAKCTgMX4DZBBPfhfxA9KxItY09GWGS6aJlJVllj3gMON2QfX2HuKs2t5piv5dxfpNM/3nLDB5x1JPbHp06CqcHvYudGV7tP7g8LCCPUJNLnaIAcQTAHc2eVIPfgnnoar2b3Ol6m1qtxiRZZA1s6lWkXAIdTx3ycA/xH0qfULfbpzyW0jLPaMJF28/KDzjHbGT+NXZHh8S+F3u7u1Ikt8iOYr6feYcjI9focZNNyt7z2ej/wAwnKz53qno/Xv8zHmdUvtRhuyGVLU5VHLHYwID8kZGBj2LD61CZJmuLb7Hp0qxKofK4k/hx0wWHp7j6VT0TxNp9ykcF+FmEy+Vu647cnqM8fXArTu7ZjPc200UZbKvHcT4dljyochsjJHzY98Z9tWnF2kjeScHaS2/Igto4Lm9hs0U2V4OjxjLocnnBPGOOvoa2NP/ALNvLAxx3FzJdyK0TSTs27hslMntuzwPT04rG01JVa3nuVRpYI8Fyd2+PaQQyg5Bwc/l266eoWUF67GbzjNKSzL5m0dOu04HT1Oeaidr2uZ1V7yu7f1/XUiuraS608S2k8TvKQJJIsE7huGOfQHGOPfNRaRfGEPHqiAyMVQGNAXGBkdeCOvQZPvUenosU6Qpta1UM3O7aH52l1yflz1PQc8kcl+oWkdxI64uVBPmYEX7tWVvlAlAITsO/HOBT0+F7BdL3XsWdVktYUMjQSTEFmEkiLtxyAV5yTwPmwfXjOah0n7RrO6OUI+EDeay42yfNt25JPUt1yME8c1lXb/2mWgv0eSaLOzEi4cjnBOMYwOoHbJz21Le9byJDaLJLdZWNYnU7mByQTn03Y6c47ZOW4uMbdRunaNuv4Gdpsdjuns3iaV1JK7kKt8rYJGcDgEdAeCfw19chin02G8TyQ4A8vchUbP4ecgEcjkL9Khg1GxlSMG6Mb27LEJs7lOAOSQCDkZIAPpzjBGtIsKWFxHfgRiWMTEmTJ7YBLAnPBxkfyzUzk1JNkOUuZNmTY3dq80JjaBWljEcsargKMHJDnuODyeoHWt55IxdgCfyXWRgE8lmBwTuGegHGMnA5FZmn21lBCtvp6CeaY+YokYyRjDADdtAyPmPqOCB6Vq2xDyCdWYiaRnCdGGGIzjPOcd6yqNN6GdVpsoX6yywRx7sgo0hLRswBDA43A5HpgDJ5weOZ5NNkeVLu8n3syB1SJWUR8HoCc55PbPsKbOsk7GWVf3IPylV+dTkgYP0z/8AWqCfUntrFUBaS/l3GNVIJwBk9T2Hr+AoXM9Ijjz7RZIbi1XUIVlCIxi+dmkwzHPHy9Tnk/gapXCyarfs4tpAqKUhMo6gkljx0yMD2x61ZnuIrJwbuG6nlznADbVB9TkgnI7YHNWdXvsWHl20Mm9gqiMg+Y+f7h9R+XFNNp6LclSa0itzOtVe1u4ofLSQPjID5EUgUgben6duaVrh4yt6toVvJWbzIhFtJAAwDuzk9/kxnmppJpbO1hM7TS3JOxQ2VVF45LEjk8DPJJ/Spq8rxCzvLlWRyCjyEfLC3GCTyPUZFUveaHBObUX/AMP/AF/wxp2dvEyw3KItxdg7vMLkFWxjJHGTjH06Vmahcl5hZ2khlmcMMy5zDj+JdwAHJ+8Pw5FT2zvHBIYw9wzsFUKWChT3LY9Oec1VW2eC+lhgnjtpQQskskYTO7qFJzjjHT880oqzbYQjvKRtzSDy44D5j7Rjfs+VgBjqBt/X+lc5JpTtIxFzJgkkf6IT+u/mrN5o9nZShWubrcgVvMTO4DGMEgDjgcemKp/2bL31hgfQzycfkcflUrT4H+Aotx1g39xZQLfKH3DcmQ+M5HqoJ4I6dOnHfgOtoJ3SQSfvDFys00uWyGzk++MYGOMcY6U+2crczJBDJPAQCCvygH/Y65UBenPbHvZeaGX5IJT5uV3BJCFAB/ixz257H860ba0LatFRauPlS0ge0DTGGYgFJGwC2MEnnnHTPFZc0ccuoyXENrGGxlhIZO3OSOOw9PpmrEkihyskoECkxmPJKbT05AGD/j+TpLyyW1dRM4jCMInkfa8DqMNsPGQOD+PGSacboSk46p6leG8g+x3KrblplB3CNR+9BY8KcAEjgZzxjnmtC0uZ5oR9tLJLLkxwvLvKccnng8nk8daq2/mm3kuI4Jp3LEhpOVK8AfmAe/6iizikWHetuxnL7laSSRSY2bPAfJHHbjp2GMEraiktCyfMSJorZYpVJDGNF24zywUEEHke9WNJvobTUI57kCGGRDEGkfayAtkBvcE4J7hgelNuzaW3l/a5gJWf5EDZZmB6Kvc578/hTbGSDULVGkhgDzuRGwXcSB8yk/KNpxxg1m7OOq0E3FqzHazo0th9pvYJPKuCW2NFGNhLHhTk/wCzyDnlq5Sa3EBum1NUmupDuKxvu8vJU5KjGCPmyOnPtXTvef2TZESSweTLlfst+w5AJ7qSOik8dhyOOJJ7Ow1KItJpssbvg+dazbwM8/xYyMH078VdOo4fFqu5pQrSp/Fqu/X8znxZC1ulvdlveWOcPvZlMkbZ+YAZ6Ac++Rirmi6fNc3jalqLBLezeNg4jLCfnIKhuSxyvPXkd60Y7+w8NaZIrytcJK4ZVlw7kZwRhevIPfrSy+InN3BFercQiXaYNwVFLYHRcnpkHljg9cUSnOV7L5lSnUkmkvK/l5Iv3lws8UkItxbWZYuVI2hjgsWfHGPXPH1JGM6/mZYkjJMNq0btuZypOOcY7f8A16fbWsiaossl3NK8qtgSpvGAQD82cdxx3/CsV4Q9o067plNw5mKHPl7sFeMA4PODnHGMVMIK5nCEb2T0/U17Bni0eKSQCSYnBdvmPoMnq3f6Cp5YSjxBZ0JPJUJtOCOg/liluDBBbRSQx+ZuPyEEYHUcf5/WkkJZ0Zi4UP8AKOMkY+bIx3qd3cXmiutmom8yI5eMjzGyo3kAjDEjnGfbn8qQwpDdwJcs+CxVUxgIWGCd3XuPUHHvRHckOyg87gy84J/L1x+h+tNRYmSTyN5DP50ayfvNh54BPRepx79qrXqVZ7GiTI7II2UADLIo3t6ZByOQcde1QNcRWq+dMiQRhmld2IBH/wBc8E56/jTPtxdZi6eUkI3eYVyMZOcd+Ppzmpm+zXUMUkSyhJP3ivgqACQd3Y8cHtjFTa26ItbRle81FLKxiWKNG85j5ccR35QHO49ACcg59+/UmkW8niCG3W8vkhhkQy/Z4S4kK4A2ktjHbOBU3hpGutXknuI3Kx5ijZjvAUYzyTkkkrzj1FM8Uazaujw26W7vGw/eMMDryORg9xjPr1oSfNyRWvcrXn9lT379jRNt4btHe3Fjau0MRLfud5WMcnLHqM+/eqUUHhjWEW+t42tmUKQ0W6M88bcLwehBA5/nWSk8Kx3QM0oV2LGCJWWEAKC3G1iR8p4+vQU3ckFnYJpEwMxwBaGLJYM2TkYz/wDW6HFNUn3Y1QcfttN9b/fc1f8AhG9GmdptLmSOaJtuycsQH7EgkMeo6nGMY9axr3U7/RrU6ffXPl3DgloygC455TaBhSMjGeD6Uov31LVZoJYrWxtYCBI8kh3KVbonAJOcn05+ldzqulW2s6fGbyELPtDK2AGQ+mSOPShydNpVdUZufsWlW95P718zwLwlo+qTTPekbooZ/LJKnCsWJzkDpgV6VNbSXDfY4fLWQKZ/3oBDNgAAqc4VtpBPqOela2mPLa239jalbCIopmgMZBJVWAOcfUc9++DVKWMW0lhG4WUjequrkOqnkHBJzjIOSOo4FbTrOb/I6KuIdRqy2263RiXNjeS3sc6sEL7i3mZbBA+dSRxncMc9iKiNoy2Vh5QunliKjzIyy7GOWwp55+YjFbsHmX0SNPbm3vGAZS8vD5HBYYHUHH3QR+GKjkW8e9lJ3La8CS0iX5kb1ZQPZSGzz2HWn7R7PoV7Rz3KUu8NbrqEqwSOrq7EBXxnlwpH3voe+RTRcWscM4W4knjZwVkEO1Y8dDs45Gc5OeD+eujlbiNdnklVMskkLmNEyRtBJXqcgbQc+lU7k6dpSGU2tvP5sm5/3xxuBboGye2PqDUqV9LBTld2t8io+n3iwRnTLmR2aTMkloC4bH3eRg5Hpxg1ZtdFubm3Mk63q3IwJXkAZs99gLDjtknPeo5rVbHTkFwNPS3kPmPIZQrQ5GcKRktn0HrVCSdZrOPzkm8mQDazrs3nPBwCfQYB6e3SqvKWzNOaU9Iv52NS6017WYXth5DzDiIpmRH6KQxPCnGPYH8Kr2Vr9o1mVru68wwxszxRt8pbpsBB7dAB6fnesL7SLGNbW5uBLbygOzuSgRiuCoyPm4wee4B69IdTtEs4pLnS7gEwDczDbllbgEgcbcdunsMVKlK/K/vMlN3cXfyF0WHT5L62a0hvMlzH5cpVMY5JbBJb1xgfWtq7maO2jO/z7l0GSGKgDvgDvzxn1qlYW08glDCCOZ9iu4wkhGclSvIDMCo55w3bOKram3m6qIZI1dY2WRQ6jkrjAGCT97HGME/lWb96e5lOSctCaG7u0iuVDzMwUFU2AncTgHrg42gj2P5OuYY7y1jkvI1Cj5fNcLGMnGT14/Cm2cq6bEnmkS3PlKkqxgkMwOWPy5PAxjgdhluAL91p9xqsKRyHyYdwYrCvDAj+IcHufT3FJySlfbzJc1CXNt5mPb6bZsUu7+8iurUghA0hfc3YgZOc9cc+1R6rvZhFYu0FqCuVSzKkDHOGPXnHbPWtu+063hiMgURKcj5mH70noCxyR6dDWW0E9wnlRK0tuiAyO9wxwccKepx3wCPwqozUveuV7X2j1d/wJLexRg80Nw0kbLwZHIMDcFeOrdeQ3tV99Ts42S0upg0rxkuVjwhB4yc8DJPfiorSzji0y5VLhIp5CXZ2T5UPsCenHUntmok0hjZ3HlTTXF25EqzyYA3A5G3tg1Oj+Jku0pXb/rT+v61IdQKSFIIy0akozs3RcfKQFGBxk9qpXM3nvNJasXZ/nZXUZVsbfmycYO3OQec/nYtL5rQra35J3E5DrhlPTg5GRweQD9aqQmxjuBJGNpeTCxMW2kA8nqRgYJ7Yq4qzvYcbpu8SBry5uWjisGaG0j5eKRWG498Y3ZP86svHIWJC3GCf70i/pt4+lXVtN8oaYwG54bzYhjn+ZHQelJJBqokcbbluTyAAD+Hm8VLlG47rm0sjRGjxEw5uIsbd5hdMqCe2e3/1qrXtvDBMSpEskUZ/dbQzIQDgZPqM4x/Wt1WYsplVUyg+VTkn3z6dMVT1QnfA6x5bdhnIOQBnBxjnkf1rCFRt6nLTnK9mZ8EsqRwCARNZsQylwUbPoVGT1z+dCC1EYFx5dwR+7bYB8i4yeDzgEf8A1qpveJFNPAlvJ5LY3XG0EJydwI9RjoOeR61LpdrDfTG2t2USgFhOUdlkAxnKnGMggZznpitmrK7N3azk9ipM8xgeCJY/szvkq0auoOQd2DheCPTHpnmp9FvzIZITPI8iruQSHdIoLAdAchemBwOKe1tb/YLq40uaa6ggLNL5x3K45+6ccHjn9cVQ0fU7RrqaKOKKMiRhtRQu3OCOTyevX/8AXV2Uouy2Liozi3FbGmunxTTLczzSOxwEYykjIzyvuN2CSfQVNCsOZ2tpgvlYDIpJGeTg4+vPr78VWu4pbW4EVupgWYiJSsQcpnOSCDkE54PQFTmmtBfBGie+VpPLAhJTLqR1Lgnr05H4YqN+pktSWSS9Tzore3AUjAlLkDkc9MkNk4A46ZrPS4EVuxuNRiaQkhmMhAdTkAKqMezdT6A4HBF6/wDOhZbqaMNG6lAiIFO/djv1ySuMADAzzxXHiZLG/tJp41urSHDOjLyNw5x2zyetaUocyN6VNTV+vka9kbW2ZrG2v2YyyBl+QCVxkZVWADHAA4HOPUcVavIpTJFCiLHZ3aj5gEQuDuI3j5W4AyfTdjnpWdctYXcySaFpt1E0LqyebGSGPqzFjxyOuPr6dHc2cskWZbmVD5bKHhwpJO0b8EHptJH1NOTs0/zKqXg1LbydrkOmuI7SSFJUuXgQxsVcEHpj5QeDx09Kg8nUHeR4B++nkJePfgbc85xjB5xxkHr7UStbtNBLbpPGEG5V3jLNjYSxx0G5R7ZqzbyvbK48sCV0EsskePm+6vP05xuzxx7VDbWqMm3q0L5DwW3kpsaIMWU5yUHf6jpg/pVgCaOGWZ5EinLBPnG7KAdPbPryM0wszxojM7yHAJDAkj0z09RgcenrVSWa3DogdY0Q8fNgydcAjuT/AEqVeQ0nLcLqO4UxBVj8tWGUBBduDwueAeo5x1PTOai037fdTSyphFjYhd+0kj37VTnn3ElADGCWZWOScnr9etaTQGDTR5Evlgj5gCAW7lQTnvn61q1yq3c1ceRa7sluIBFGhulDTAMFbnb+g7/hVaJY5S8gNyz267CecN8o4JPGMsDj1X2qS3O93LuW2ABwGz344z/9aq80FzNaX0YmVo51Kbl42qMHkD7uMnnvkelSl0uSlsix8M521CylWeQDYWBUcl9/f271iLo94r3FrcXOZbcf6gsSwXGTgDqpOT+vrVjTb8eDL5IZ4BJZybS08Yxxg8ehOWHfmn32uGWSbUrK7+R5xCESNsIcHBIwewPPc/pdpqo5Q2ZtKFSNWVSC92WqH6RKi38Ty3SNLEkixpGgQEcjhm7Y9cnnmppLrT7XU3e5jdrhSjD5QM4GAwJOdpBxgEYA6VHbWQM4Voppb5ot/mhtwGD8zKAe5GOeOmDnohlgs7eKTU4POu2feY8MoRQCCnPcnk/UdaHZshuLk2jpZ77Tba3JgtYprsx7thXhdrd/Tkk8dccdqq2/ie9u5dOe2toUt55NmxidzjOCUxzgDvjFZli8kME1y7bYpo1dgpy0YXnOQABkk8cn8c42fCzXIe61C6gsbTTNpaFY4dsnXq30+Ye9c8oRim2rnJOnCmm2r+v5CarOJfF0iRtHIIbLLENloyJAWAx3IKgj0we2KoXsP2ny3GY5d77JYgDt5xweRnlcj29qy70T6j4hsHsZpRqCymcQTcIiYIYbgM4I+oxn6VuGytJNNuW82GWcoY5VQrsXk7skDB+YH+VUkoJF8qhCN+w3TyL4syMmFzhSCOQcHjg4yMc/rUb6evmwPbpIlxuKeZHlWIPJOQBjJx14+vSobFo7W0YQjzAjMzOUA2qxAILMRk5yPbvnmpHeAXkO2PFs4KtGw2lT1LL1HU+nvkdx3voCk7+6Rhb2UH7W0VwiZETMShcnpnGArDnk4z6dax/stjaXyrqLLI+z5xcSAbTn5cEkcYJxWsu+Odw8f2qdcZMMuFCMQAXweSOvXtx1qS7eOeIOy280JyNr7WXbn5myvOR6fpVxk4+hpGXT8jDuYdJtATczoyyEHzFbfJjjdtUZPLBucenrVu8mXUGtjO0LwKnyvLIQSM9QoUEcAZz39as/2Ta3Ec/mwQQtGBK7YjBVegI4yAcZGSe/pirls9vAHR/PZiMlpmJBOBwpPygdPl4HWhzXTVobmmlZtspyQW01skdttuIIgrKsRU5XI3MSzYAOccEnn2qzayIlnFxbwTgsrwi4YkAk52nncckZJ9foKQmCze3mnl+zWgX5olEYjcn1I4+mD0GaJ/s2pW9zcafCYxHINzwFQX2kbo9zD7uQM+2cCobvo9jOUna0iWRNnlRBosRRsDswF3kAblI6dST1qhZpJcXUdzEzOszkZY8ghOuD68/mKSa4to7+GOzKG4bIKgbirKQeMdskgd/51fs0kdt7Ry2+MKgG0LLwQTgnPX88DFV8KuW1ypSKuqMraxClvMlvc42nECyCVeflJwQDjIHB/WrENhqNrGrw3a5ztbeGfAB4AG7HoMAewNXYkZGZplBZevG3dnqeuB9M8U2bfcyi2jEaTMcBXYc92CjnJx9ff0rPm2SIc7pLsQJYCZ/+JjLLNJgqwwVGM9MDJ9eN3PpWhFLCiMqKqwjj+EBvwH9fxqlbaHLJbyb5GhbzCEDMxYgYA+YAH+8cDPXrRZpIl+9hJ5GxI8lBuLqD0HJIpNqXXYycoyvqZxljm1FvJMZK/K3mymVSTk7MlwPoBkdsCn2N4NMnFo0MfmgfwLs8wnnIUDaOvcj2zUt1p0d1OJNPuEguUyCMBt47c/w9Tg+/eq0elXlxcf6WbiSID5EWTYuc5Bzk7sA8HCt1/Ha8WtTWTjbT7ut/68zad0uLPzJNssLDcQ6rtUcYByfXPb61Svb+2is5UECwgq2Ni4yOnAA49j274zViWzk8pENwWvJCCRk/MoIJGP69frWbFdQWUzJd6e9tGzBjO0ZO5ie2M8/h/jWUUumpEfLUoppcNxOg+0AwREeYpykqjsGGBjjHOOfatsWlvgYLgdh5ROPzNczdXMVxd/b9PW6W6C/NGWKncGxtZdpJ4HqO/FXP7N1B/mW9dQeQDH0/StZpu13Y1qyk/iZ3cRiCHkYG1cLxj8M8d+PasK4uFlvWnboxKxhQTlgBgZHAJ7fzpzavG1qJVmzGMqwj2qRyB36mudbWLy5STytOuDaM/wDrwcj5eeOORnpz1rGlRlqzGjh5ybdvvL6S3F4xJL4yQFTjeccgnPB5AwR/DTjp95IbWZVijYRgOBnCMBjKZ68ZHI6fhT0t5IbxpHG9Bl1AcgoMDI24JJPOOec9qq3V0jzN5M0yk5HlbiMjHTHHqff8K2V2/dNYxcnZEmqa/PPEyMiERup2QS7DvDc/vPu4IGefyrR0hbCWE3dtAu4giVckqcE5AYgcZ6nGOvvVKxtkumlaYL5PRLUIF+QDaTjj3GfetADZD5ZAtolVkleUHevZdnXPvnPXHbFROyXLHQiSjD3YaGHe6xFcPOLeWaK5XeSuSIV4xuPc4xgYrXtdHu7nT7dl1gRmRA37uFTJzjjdwe/oO+farItpfSyyQ2ExDMAs0ahSx6lsAjPXuTVNLG6nvWms7C5gld97SshVmYDJBORnJJ5AxzjpVvay0+4qTVrRdvuZYv7WXTNQa1nuftNncgIDK5J49D2wWB/zisLWEgspp4AWaNXDscbj3ABA44Jbj3HvVjT4tS1Wd0ur9Zo4WCeXgIzHGSFLjK4ZfTI6Z71rPa20MwW7CfayWBnOAzBsldyKOcZIGc529Sc1alyOzd35Gy9xqNTV+Qnh+VZLUvI7qyndGhHKoT8uM9BgHnpikmnLgvNaXEAgQSAkAk53AEjoDz0II+tXYpYLr7OYpERE53QvwSvGCQQcfNjn27ioYofPtp8FkuG3fOSCjBR8uMEgj5d3Pqc9aybTbbMm022JcM7WCmRWRJ5fMCqACDnrzzjjrxnHrUkEbyTokzMgTBVQAAhUk/LznGDg5zkD61DY6ZEqLLOJd55I3Z2t05PPp/Lg1d01Hd1eWRJZFBQZYnJ64H0xySMn3pSaSdiZPRjpBIWPlsFRsdFwQePyH5VSubaG4lJDmKSDqQSAw5xnGfXv/SnNNc2QWe7xJaFtu5eGhJ4AbsBgZ3ZGO461al8p1ZIzOXXHy7TycZ4OMN9Qfpzikm4ijKxRZJrfz57fc7yZCoVOQO/ByPwH0qGC3M2nR/aWcNeTNLtlUFFGcKew6En1rT0uV7qOVLi7EgGx/KCbdoZcjIIHb9c1JqTIg0yaaMtuYJIEJAUAg4x3IxjFPmadhynZ2/rYxIiI3DWkbl0Roj5ibfM5YAjPG07etaw22gkjnVipJbGScjBOT3HA/wA8Vf8AEsjSy29qhzuYl0wWIXnBIGDjg9+wqlFL5k2bkFoiArjcQU5PIPqMdOw7nkUuZzjdijNzjdnP6jFbBJLa6i2W7u2CzAhlJ4IwO+VPtWVoNreaa98NOuolimwrLLGHG3BwGHfjPauq11fsUUks0LSSBHMLM58tix6kDP06Hb24rPijVH3SwbUlJCliNrjHcen+NbwneB20q3NBxfUXfPr0AgSS1sb6yUQPGhx5iAhgyDj+6Rtz+Iqz/wAIffl1u764a6kK5lUPhmxxjPIHH19qZJbWVxE0LW6W11EwKyIwG4dsHt/kj2sW9xPK5W6uZRCnOwNlicY7ZyOPUCobkvgdjGTkl+7dkulhmqyWUEUNnczRWdo1sXnVpv3iFn3KuN2SRn8MdDUmpaydaFvFpRvYrNiqtKiFUjQcllYck9B6VW0rwzaXNzdXlxaiMq27exzkH/ez2x0q8I4V/eWZjkt0BGUKndwOBxgj6A49al8qfdol+yjLe8l91/x/Mo2eoPpsUkGm2bxMzAC5lh8xsk4+YlgS2OcE9D3PFbkBWeJTGYZFYZ3/AHeD7DtxnHHXvWZb3EPnKXuIJZLzcixq25FQD73HOeeep49qzNO1FbaGKGx8ob2bywH8uNY8gZ54GWycnn9ckoOW24nTdS8l/X9WNVZWigT7ZGiqWUA7DIA5GDwFyOnHrnpVLUXRZpY2EAnfgxmNv3mccnjntnryPpVoTx3kEb3tvc2qSgeXKdjoccghuu7jpj0I71XuHRxDG8jfZkwogtXyBnlSVUAjgcHpx3wMNKz1JSad2K13aTXVtHcTQSSXQAUS5WXaAcEAjjgc/UmrYnjhs2ELRwyldotsooJ43Y4UkDjnaOPrVCWz/tBQkkdpdfKpG9pCDgDkgrwT1xkY/SrumWMVtLMViRyeI/n3GNepUH3zjrk470pKKCUUle5c33KRQyQKJDk4wq/d9ycYBIIyAT+WaYkqz2pjkE+4ERKwhK7iOm0H+Hk9Mjr9anl3W5eRiGMkoVLdSo2KQAQDjJ7nn1wMcVnvaS3olE1xFLaO2R5TBGC54yQegyV4OMep5OSs9zNW3KskFw2oRxTXbwPHEA8YDEhR824KSVGRwcDI7VYFncw6iq4cWsXzqsUgxICMYdSM55J49u/NP8tIVTMoSI/u1C7mwB0UDrj2HFWLaW4uI0fK7UOxWkALOAfvHbyD9euO1aN6Gktr9DmLiCS01KFYJpfNmXLjy3AYcfdOAvAzkZ7V08kryLFGCI5ePMCjaVHHJ/Tqe496rI0l2v2c3SqWUuoQhJFBHJUOc/kuBV+CSCISrJDBFHnMbNIHab+83tjHqfw4FE5N2vuh1q3NZPdFEX0D3ws/tRf92zFJVYE4PXPAx+fXrxVuW4msyZLSUCDqygKfoVOP85qnF5aXE2yeKYySblKEj5dvACkn8cHmnXNvetcxiHBiIAZAgwSScgt1xilZdfxJ5U9Ht5j31vUvOlWK6ick5UPFjYN2cEZ54GM5FKpMDT3UrZjyWk2nIAzwMcnGT6f40sW2MqIYVMwYK2TgBcckOfvYGOOOvaporlJSyy2kpiAJQlRiYe3zEEfWk7LZEe7H4UU5GTUZbd7WRE8kh1KkEHIOc7G5GMfeFaNtaxxAKQ2890dkyfwpii2tEl+7HsG+QDoufXB6nPTvWbrt+SLaBAsP2osCJMAsB2I6jOT6dhQk56LYUU5Oy/rqP1m6sbeSEXf7+6Q7kUlXaI47Mcbf6+9R2et6dJ5pkf7LKzBZDKmSfqVJA/H0qvAllYW07iKSO1TIaVm+VScA5BGeTWV/ZOpXzRG2vhBaT8RRsFAmGMjIUDPt9M4rVQhaz0NlGD0bsu/9XOsuXYRxrbpHNG7ZUqcg/T9fyrPaeIMQ1woYHn7vX86eEXTdPgtRcQQw2zKJSIuW3HoRyQSSDn+lSt5oY4gyM8FmOfxrDl7GXKm7f8AzvLtoibe1yHlbam47iAQxyRu7gHqMflWjcyizsikSplYxtl8zq5+9x2AAzn3rl7me8thC9tGpRR0JDgbjndkdSff1xVh76bU0aZrWeG22jai4Z3Ixj5e2OT3rrlTbs+h0yoykk29DYtLtIIrTcpuPO5Z/J3KoX5iHPQHnv3qLVIpBKk1tvLzALJhCT9Qf89algvbWW2E8IaW13DZO6hVPXPGT04BJGfqDUTxFpkM0rpLJkxIzb5DkKWYlQcYJwMk/XGMQtJXIhLllzGnpRdJ2zJcSfu8gH/VbgSDg4zk+nsOKZezfZLpcxvczOsiwW0SqFUAsS7EkHDEcY/kadZpOYjbtsLF3BaM/wg9vc5we3XFOuwtr4YhOrB2kmwoS3Qb0Ug7eDxn17DnGax+0YuyfqYUeoSXN3Lb3VzdR2jgIwAKggc5jCg7fukepLde1aC65HdakLa1S4t5LcK8UkxZfMJwNnXnnr+NZFi8uoWsV3bebC/myeYHj5VGycgfeJHP6eua1bAzWatbo0Mk0a5MbLjD5A3MyjAAGM888+tbzjFep0zpxWy1Fu9SQ3edUsLa5m8wr/owCS7gRgq+QcdfTp17GbW7OOwsrbVNBSYQsSJQhZicnq2ck85HPTjGMVnQSzRWE+yaOWQRuYxZou0OCMDIPzcFu3HzHOK09N1iXT7FY75HukliVtkh/eDgb+COn6cH6Vm04/D93czalFpw1t06MitlW6tpbiHzYp5suyq3O4qBySfYd+1Og3HzLe3jyi/e8sfIuzA+TGOc9h06Ed6sJo/21UvNEmGnyO26aCX5kZWA24wenHH1I4xinSefp9zGl3ZpGjHEdzA29d+OQejAkevp1qW09vuIcoydovXt1/wCD8io0g+zRXcKgiOQsUlUpuAY5HzAc4xgdaligOqSvdWgFuUGwwFF2E/7R2gjIOO/060tzdiGORIZBNOR5qIwZiTnHX0J/L2xVFobmK4L2jzfaFw8/lqY03Y/hBDZ78DIHTIprVaDT08zQke0ks1kQ4nmYSMuQrKAPm47jJyevWptMuPItYwZopVChk8mMY24z05zkenHpVKL7TsiVldQBs8yEgklmJctkbcZXHQ+2Mmrxu7eNpIRaSZUnLGFlU+pBxj/IqWum5DjrbcfEYdQiFzHAkT5ZBIh+YqD3PHIJbj/GqGqTRvPbBGlG8O3GBjOPyb/PpVtpkgnZ5mz821TL1ySo4A7e/X8jVW/bEiInl5RyQrcHaOMnPblR1/wKhuEVZ+Rd1OW0u44J/MSSWL/WOgPBHb3OR+GDVOIEh/tIjiZENxI5bYoyVByeONuR7D61kMt3fXv+ilFjCF3zGCrnvkKM4yD0IJHet1Unlt7hiuIigUiQAgqPu9u4PTnvVOKgrXK5PZpK/wDwCFpzOgtXjeCSPJZCdxC52iQcYXJBOMnjBOM1Cj3BWayVYYYopTGFdGQhcYypHA6rx0I9KuW0cixwysBK2CSQB93gd/p0/wAiHUJHmmkikWWQSfvQAdqqQ6gDIOdoJyfZfwIrXsK1tDmbmzleN0a7d0gw26eGRMoQAcYGWAJAJx6nnpW3pNxbae0Ud7PaNKqnYyZYq/ygqMgDjcDnrgn0NV7a687SbmEXDDzBPELiGICFflUKuAWwSMEbcAnJxnq+NN1tPFfiGbBjeOM4CvHvHQsSu0ZHfOQcbcCtJSclyyE6spLlbLpcT3FvJcySSKwyrKxfL8A5wD03L1/vZHes3w3ZxJNEou3Ezq/lRNtMYXd82wJhQflHcgbjkc0+S6aaSOGyjtY7eSVRIr5Qsw42M+PvfOMbSSTnBOCKJ4jLpV3a23kwhGOJoiY43QZBG9kYKQw575GRjOKWyt3Fd7D7Kx021vgVYLcwzERLJKBv+XJHJ5PzZz+nHNHStMn0/XQFe2cMpV4ncn92eOUHbnB7Umq6zaw3spaJor23kAYwnLMxBGMhuegx2xkHqa6CeVPsVrBKVgVl83zLiVAuOcZz1OcdCMdjVOUorXqdKqTjG3SSJbXVftM76VeafDCEGQu8AjJ4YAjBH457YNUp7CW2j/0aUSxxSlmijYEbeu5QfunrkDg806a1jvdsDiKckAxzjqpA+8pBI9OOOnfBqvd2OpypNE2ox7NuG2Iu9s/3uR2x35rONk9HYzpxino7LqnexPZ3S3NgEso4g0WUKoCqk+2Bx19Ovr3ur51vpxK2r7ydoMYBPJI3ENgEAcnvz0zUen2EOmx3kskn71t0rHadinGNwXJ5OOeeaztLu54IoIrj5p23kAlm3DsSAO5Iz1A9hxSa5r8op2bfJsX/AJNqyzlpLlCXi3l0yxGMnGSV7cjsDjIBp0qN9tkllSF7MqqrC6HBIJY8cg8gYIGR+VQRTSm9Mbq0ccg2K+AATjJQKcDAHOepAPoaR5G+1QRtKm9mwIPNJcHnqe468HIOBxxSaJaXUngnhlt3u8RecSBtjR2Uc8DaThTyQR1OPwEMt8EdZhJuVd2/90QUHHGM4BwOvPSpbO7IM9u94VuxmNJLqARhu4wvyhiPVfx61M8P7+NYfLSRujFMHGeSo+pqbpPUlNLRmUsEF6ytPYx3aFfMlujb4LMOm9gMHOAM+3bmm67eb4VSMiIqycbQodSoYY4yME9D3q1e62lteyKxWdR8u2IH92fUknjn0H+Bxr6WO5vvMToxzuA+YE854+lb04ttNrQ6aELyTa0RcYWUmsWxs7tvJYbnLFt4dc+v/Aeme9a13dzmOSK1+xvtAiZXldFVht6YQ54J5/CsOAMRby3TTeYZkjUwDzA2ePmLLnAP8QwRn8ti5cP5kcMoiWIiNipUlfqGBxz359e9TO115GdS0mkuhfkzMgRAfOAx5jKPk9f/ANVVC32GUyEgBfldpf3ZJB5bAP8ATkUefHHIdPt4vMvvvJCjZJB5Lt/dXPUn3/Gt5Wm2k8h1C6F/fRgqbQNiFGAyflPLYHJPPToDxWcV0Iiun4f1sB1aAPmyntAMkvu+XknqSP8ADn2qK5l0a681rgp5u7LyRxeZtBBH3sEDNQT6nI7ywRhJrbdhyybdi45CIpx7ZOSO+KxYZL+XUSksVvFaow3OUG2PcNm4nGDweOv1rojT67f16HRCl12+f/ANq90iykgS6jur+5t94CQRuWBbOOmM4x1xz1rZhnZLOJrcskWChVTt2EHAAJ78fh1rkbK4H9o+XawxSRBd/wB7ZG5C9GB4HIPYDPU1ux3+nbILpp/JcP5YTGzY3Hy7R78fNU1IS0T1IrQmn72th0hsdOgtEUCOONtsXmOxXd6Z6ljnOfrVxb6QKA8wDAchVUgH2PesvVLh71fJsWlSdMF5skK4JxtyOh56fSs4212hKoUVRwFALAD0yE5qVBPcz9jzbP7/APhmaum6c2oQXdysSukKlo43ICu3OFJI4AwCTngk9MYFS3jNr9pnnchi3lKiSHavyAEA9gTnGPUfStXwhOU/tCymlFzEiLLk7yuOoAPTGOoz2INZsAkuU8mOImESCT53LAKd21lJHJBP6888VSb5pLoOMpc8l0/Qmt4WsvOUJMwCgqAM7eBnbz26k4A/XEum3du5uBGJCRIUZmdQC2BgkjGD83Ycc/jl6tci4uvs1sjvsHlxs0YXMjd1bGeRjvj+uraJBpUVrFcTLEspjILMwIc8beTxk5H4nvyXJaa7sck931HuiNbJHDKrzXTeSuG/jY5POe3OePQUniqW1stXgZvMnumjETOGKlSdv3WyAvY4z3/2q0vDqm81X7SzKUghyd3JEr4B5/2QhX8a5fxJdXkpa7uptunTNkYhIzywXDkc/Ke35+kQV52/rUKS5qtm9l+f/ALOr3D6dKjR3V88r3UYfNzl8BgOgDYU8Z55x9ao6rc6xa30z2Vu50+2YPO1u553AZB2hQcdSeSCTggGqqz/ANk2iPEpukUbGUguyAEFtwAGMngEj19KrLe3+p3Xl2SBtqbyzLjAGVAJ/vYOOhJyRkjArojT6myp9UdJHcteabbySSNHGyENHgFEYbAvo2DnBPrislI4k12OCKUW9vco04miy7Lhiz4znPG4fgPpVDxFrlrprxWF1bC8lAR8SyvF5LEZYfKRkEYB7djnpVTw1rlrexXAkjazu1ZhGyP5hl3fLtYYwAQASRweeKI02otpaGipS5W4rRnXeGbFjcxx2V6ZUjnjAPGNijcAD2IVjxjHNdP4rlif7FarKXujOGEQPO3BBJA7DJOfUVT8M2tpPG+prLvMcjsLmFtqTDkcrgYIAAOBj0J7YGo3dxI15cJMVk1ArIDEuGhQAbApzndjk545wK5be0qX7HJyurW/w/n/AMMS6vLciQQRI0YeNZCd4XK8ggn6AnHHX3qhAZoreK5DuItwwqqSFbPbg896j0231C5kS4lkM9uQQVmU7sjkEcjJPPfH6V0EEMLRBLWO7jmVRulZ3RgcZxnr74HBraTUFy7m75afuvUo2urQmFbaGNI7o4VxC+Coyec4OW6HGfYnPS/Bd6haskJS0msxkNIAUmbk9QTgn6Ec9iDWXCAWIgtlMSBQpjwG55wFHzHp6eue9XIGDS+RdSyrJnMcb42HBzjAz83PTrUTiuhnKnDoWkZLy8i3u567hGu5h7Hj6df0rN1W5uLdnREEivKuGFuzOi56Ehu4yMYH1rWit7YS7/s8KFIygOxRkN3x6Hk1HHYiNZkYSyLMCkkchVuOMEA9OmOPaoUkmTzK5mWFooKypcyIUGxEzsGXzyV55HXn0q7Y3gMBicxSIWMbGNTu3L0JPGOp9e1VZjcNfW6LGkHnEb5bnOwYU8qfU5Pp268VpiFIVkZ5IcL8uY/lwDjnJ4PX9cetXNp7lzae/UrwLKZpfs53Ky7inC+Xxy3vk54+noaQ6pDBezWQi86W1YBiduMDvk9DyjAZ7de1SRLsk85Yj5Eisd6sR93cMDI5we1M1UPbQrexLv8AtEUYGzDFyVxwpZQXyExjJPIHrUaN2ZlO17GDd3CQS24ZZUkt1l8yTbIoIDFcHLljuMaYXOTkE8ZB25RaGCxaW9hkNsVQSsysw+TJLAdWwD93Gcng4xWdfRNLbCJIZnkSJjFMwZXjVs78AKGTI46ck4x3q7BEVt5w6zu8flK7QFTKAVbPAy5xuI55G0bR1NXK1l/X9bmDHyl4Lt7a4muf36Yj5Z1jOW5ww2jGcdeSAAOwozwQOfMnN3HbzKLcyFlLszsduAAQSSUODgYPTgirEsgktZGuJvOTG1GldVkR9+PlCqQF4xuJyCvrmpVtFnurrY00fmkOXIKq5woPIUYPzD1zlvQihaFxWporptlPM8Lb42ZwdsKt8hbj5lUDqxJLED1BFYPiqNDHbxQrJPb2yA/aJHZRIv8AdU9GJHOc84Na8iSfZ4Q11DNcRh9rkbHSTaBnYG+Yj5j+H0NVtXs7qXTZbSJYrgrl0I3KrY5IPODnnPPFKm+WSbZ0YeXJUTb0Kfh3WIPKGnlZFSFS0DY2s/Pcc4IzW2YdkM0sdw4k3ATSeaRlgB0A4HHOMDr9c8TpMDT3aH54DEN4cqflx1PvzgAd67y6M8lvmCNWnIKeYyfKqnk5GQe2OD6VVeKjPTqaY2EYVLx67kBike1cXFy8jIS8jRKSWQYOAOMjqOnQfjVK0Rn1l51Lm3jQbSWIVMDgn15Ax16CtDZHb/JcMN87FYs4GWHIwOPwA/oaoCVLW/8ALu/L+xybWBUEbsKflfB6A5OeOgrKL3SOePVIsRQ3ZaWZrrq/IiGwuvIUMT+B4x/SkmkNs6RwspmcBt7KM9OMnHPA9RwPpV64y77bcFGDFvkY4PB6joeT78/SsXWPMhm3OhdWjCuqgsAQSAVGO2R6/hxSj7zsEXcfHqkjRM37o722pEXwzY6/TB+tJaxvFLBIkrOyMVK4L7AWBPT8xjOPwpps2KRTl0fap/csgOWA5GD1z2ye3WtCwvBcAxyxmKREGcptLYyGbbgY6Dpxzx7W7JXiLRozRpM9vK8tvcvIFyxTkMeQCCBncOnbvzjpSwaRGYc3UifZsgBVbgtnsQxyO/8AnJ1ZJYrmVrWddsjRhwrHcGBJXI4znp19RzUiRIXd3hyUypUqUA9z7fnip9rJLUFUetzKlKXumsmnXU1ipO5pgCATzjg8MM5J5ycVDLdCe4gstIiJuLz5i5XZhMcybSORjH6eoqXVmIsluoIIJpYiGiMbY8odmz645wCDg9TXQ6BELDQDqN1iW7mi8+W4YcsCMqDnkADHH/16JS5VzDlL2cee177epl6vNL4V00Wmkwve387CSSaVgXYkgZAGMnAwAOAAK5TULm1svE0chi8xFUovlYL25HDZBA46jPcHrxVzUbifU2VdeuHiuLVzKkexFOCVwQcYK84GPz6VHqsdsst5LO8TxGJVkilB3M33hk4GB04Bya3pRUd9W9zahTUdJO7d7/ev6/q5NqtppklzaTpbhg0ZRI4ZAm1Tn5mVhlWPHoD61FPGZljjF/IuV2pHNBtdF6/wMT2GDtqlHFrU9rMEmZImjBfJZpHOOwPIGABxx0pRHexfZTfaZqDBgdsjI7+WAOufywD/ACrRK2lzWCcbczT/AB/MZbpHo9ssFveO8O4sXR9u08n5uOVwemSKiNwxv4rk4if5N54USjqM+/TH4Vo/ZIpLSS8lmvkkx5kIQRIpbJxkZz25O0Dg4JqG0urq0AMEj2xxiSZRgk+4A5HHf361Ss721ZV1JO2u6L9vcxzy/ZLm3+0Msm4rKCv4r3/Pg9+1VDdSA4S1vNg6f6eo4+m7iiUXdxJLPBI5u2ZYvMKBy+OpJHGB69MVch0+6aGMy3+nvIVBZvJJye57fyrCVk/+HOLEVIUviV/LVm/Zomh6R9ull85RE0jeWpKlmKhcjHbJGR6nPSsW3umTSGuPOhMsswjkt14bdk5O38Rx/hWha67pEWmrHNJHGXU2UcSI2zcyhuQCeO2eOjVm2tvDdWa3USyW8ygk7W468kcHAGcZyen41ME1dyXUVJXu5dx/2SeNLMXz7p2mDKjtnYg6lsEjoQBWmY0fR4rhAZsqHUyR7iTjKHGByDjrjv0rJHmWodp/tThVEvnGN2cduGz8wHp75x3rXW4EMcX2p8xLHudViJckn5dowSRkj8uaJ3di5ttXILhbmyu11JJJQ0SBZoVPEiA5PXv3/HFdhpV3Bqmmw3EKnyZlzsZcfgRXJBJCUacpJcvvU7lK5H3gBwcdQCffp2qroOoHQvEq6fM7fY7vGxQSQkpPbPQZyMY61nOnzx03RnWo+1g2t1+KOkfwhpG9mWF41fO5EchWJ4yfw4rGvPC9/Z6c/wBhkjuGjY+XCP3RdC3O5h/FgDnvjHFdzycY6fSua1DxVAt/JYaXFJf3sTbJfLQ+XCeCQz9OnYZNY06tVuy1OajXrylZO/qcTceAb3WNVu7me0a0eRdwkmnD5b+7kc4z/k8V0mjeC/DvhSwlubxldgreZc3LYHPHA/HA7/pTbxdfun8y81cWcYODBZoFK/7zt+HT9Kw1ttM0+TzkIu9XkXCSSs07565Zmzt9AF9s11OVSouVy08v8zuk6tVJOf8A4Df8zpZLorZR2enyW1lpxXiRIijbT/djYcdfvHOTXNTPHcXsUIE0Nq5CqxGCI1A+bvn7oGPf2qaO4vLmFpLjzEijbkynjdjIxuJJ4/DOaIopdwnkjle4mxHsO0jAPTPAAxtPA7/WnCCga06ap3V9TofJu7qWO6tLiARYIjLooLKcDg4yBn37fjSWDHBkkEjbRhflP3Qeuevtyc1jSafOkgVzcRQkqq28Y43F85J5643dv0rVm2RWw+1JOidDkgAkepUE/iTWTitkzCUVok7/ANfiU7qxa2CLZXBgaUYbj7wyfvHkHO49gP0qW0kvEkP25YSAyAPEh5K4J3D13KOg74xkZLzcwhhHBA5Xco/dqHA6dfl/Hn/9VhmxIGj8hsAk5jYNnPT6/Wm27WYO/wBpDlie7Ko82JDn9zgqdp6nrnHPXj0qLVHhtGEt6hCq23cz4OOpwCeR04GTz+TxZz6hbvJHK3nZCcMCowecjOOM/pWRIEvL5p1maa2CbBJKFO0YPK45JO3ofX8Aoq732Jja+r2ImvZr+1ub60LG4VQypKMgDrjHv/PFbaLEdPxKoGAFIBJIPtn6n/PFZ+hXDK0oZCRGhzGFG4dGAwOnB6GtiWaSC2iklRl+UGRVGdpxzyf/AK/406mj5UhzlrZFbShdHTboNGxAi8uJFbdtUZHTpuPU/XvWJfyrBYpHcCOWJ0DRsWYAEsI9uMEbR5p5Ixk9O9X4roSO8jsFXaVaNiAQWOT0PJGVHTAwOOM0s2nC50kMZGUksYgjHGQY+q+uVBwD601o7y6sJJrV9WZWmNEtplpIZgsmf3bbVmKZCl0O1jgmNQOedm3HFT38VqpjlmYM8Uu5pHTzfLZQWQY4CqN/JA4Hy54JEEshgsYFa2lmt5JPtDCY+WVbGShDKf4W65HQ8jkVUsjbCwRoVhmV9sJMaxoqs3lr8xA27t6oeAT0wMDI0s27mNjXVH82Y5mtIUR97JzsAHAIVWA5JYEEHgDnFXrIOkV1FeRhXZxIioroBgn5myOpIJ49eapQTrBEhjhuPsUjM5jKMwC8YQH5sDgfJ3JOOAcuaNodNhhaNSZCDKnltcY+YFQpJOcHn6DjGOM2rjSLFzCs2os8aKXlBVj/ABopHDYHU8AdOntUaSGJp7YSGXyggiZSxLZOMtgkhdwxnbgAdeCRia0+r3C2MOnj7MGnJkbBRlVR0Jye44PHHbrV/RYhfql/cym53uGG4DAK/L8gHQ8c4AP1zV8lo3bOpwfIpXNHT4LZdsxSYM6Dezbjkg8AZ5HX29anur42lkzWtqs4XG1d+ARyTnuMAE/pzTbpreaLexkmUPkhQ6gYzn5TgkYPUZycYqrLbGZvNilBjIIIlXOAQDuyecY4xjnPas/id5GStLcmiuh9mieKKZYwwLrO5QKCH6dRkEDgkYBHtU0sjiUBstahR/DvDOSAdyAZ49c+uarWzpPO9q8alYSAxPTPOARnqeTg9qVUjsJfKR7hlUK3RsbeQMEfQcD8RzSaVxcqvpuRR/a01LzDdRx2piH7rAYA7u59ce/TsKt3kZvFMHklYto53svJ684xjj3znp3pqwpDGUEMQJBdi7AyA46c8dfTjirNtBFA7lAuWYFmUdXH3W/LA4z296Ta3HJrcw2tNSjiWAQRzRs5BaUMwVcYzg/h6/yq1pcUqNbQ6g5WcMdm7JVkB6BRwD29cfjU8jTwW4WJp7iS2ZG2ykx+YOQckAbhtZsdtyjJ4ps08zxh/LklcTNjC7SoxwTnsMdeufzq+ZyVh8zaskizFKLK7SK43JI3/LyXUhieibiPTpkdutOv2zeFxa73jQ7XMihXzyVAzkDO3kjuOtUpJ0DXDQJHLIjMkpEKSjAb5kyCDn2PAxyKkvpGaFldJRCUVkaCP5gSeQRjPHBxjPWo5dUzOy5hmoxPNYXBilaG4lXCgk7QD3AHf3HXHtWpqV6LbwVDcWls00YgiBgBwxUgLgHsRn9DWfEksQkDyJPbsMmRUZpXYDnIUDJ6Hv0OBVnQZ5rS2l0uEl90LPZSTDOWA+63TPUEeoz6UpbegTV0n2d/8zk55NTvLlFubaGx89DHFbSufM2bT8x6Dqe45P6TPZ6wzwWr3y5T5mmlHlgLnADOvXJBABGcg02ONtIkuSbW4u7qVk812cJL5pw20d9v555qODWJbiW/ji0yOBrOM4dyxKDB4A6FuM52j7tdau9YpW/r5nZZ6cq07+v4/wBXLE9vEzTw2eoKk8DATMxb5c42kKVPTB6+vJHQY8nkxSTxG8kkkdwjeaAqsc9dwAzn6VJbIz2SQ3FhPJLFDvAlchmXcSTnaQF57enB5ok0pFvFWyniWzZDLPEZSSmMDrj34yOma0jaO7NIy5JWk/y/rt27ItWGk28X25oQ0qvEzQ5XG8jq3TPXkA9aNSs7VNY061WdpYrpfNGIySB7/wAWDySQc4q7BcX+maab37Kl3ZyNsVbcGPagJ5Py855Hbt+F7R72xu3i8+FbcWY85LiZcGFF/hLdhz1OeD+WUpyV5boz5pQ5mttdv63uYF3bx/2vdWbl3gVg06I2Ax6ZLc+uex7VJHZakI1Ed8dmBtwzgY7dqvaRZi2ivp7d3uSXZlaNQhddx2gH07/1qwJbphu+yMM84DcfhWdSqouxnUqxjLv6h4e/sy2Dy3l3H9oZizQDAHQrkAYGDuyQRx3ApLKecaf5MG3a8mcxR5UgZOwZ/h6Dtgk9McV54Le5KIZfMmiiIJkix8pJUMDzkg4GT+XSrEM7xw5aRnlVwvmGFTgkDgAkY4HHP4c1bXUnkfxb3I9MjmjtZpm2blLHdKwYoSMfw4BAJ7Ht1zU15ZyW8UMDPJDKxKSIyFlyTnIySRwBzk5z1p7QR3oKyXAMJJkaNicgA/Ln8QOnpV5ZILjSFaOaIXFsWbyyu3aCT1GPUZzzz68iplLW4nJpoqpBnK7lQNuLPk8ucE9TjHt7DA4rC1+X7bLFFd2aTyGUbWgcjC5HI9McnHsMH16hEmGnRyzXlwGChd6hSzYPG7AI5PBwB1pIriCyiniIgB2AS9cdfoQTnP6Uozad0rsuE2ndLVFGza7ttsVtqGoyM8auyMDJtUk8AkHnIPTpirdsqxrGpaK1jRm/1p272Gcn3wePcnNVILppEZpZFdUGFWMkAqeo6ZJ74FUlM108jSs5UJtYsuNvPbB+UcZH8vRuN73LcG276GnPdSyXE3mW58qPdhh82eeuMD+ZPuazLbTYrtvPuosugGxAMFfdsd+R1zVjS7hG1FlDsrEKArKdrDoQT0z656jFal3aRiOTcUCoyy5forDpgn8ee1DfJ7q0Jb9n7q0KUtul7Yxs8Zs7dSwitiuJTtyN5IPBOCQBjircUDxxYkdLiLtljhcDP8xz+FZlvaakLaCb7TE6SSK7gAsQpGMDnk8j07/StSJJY5YAJdkGNr7l25U8AcdDwTn/AOvUyXRMiTsrXuVUv4Su4WzROZBuD58w7RhW56ggHjjqevWnxapLMpzJLCN5Uq6M6EenRsc9vrirGLWRCJg7BRwHXaGHGOuQRnHakFo4kL2siRHozQjIA9T1x9an3baoXuW2EZpngBiA2fwtvyGPHHy7egBOOTjHvToBK8/zO728g3AmNwGP49eAf8akEBy0s8oDIwBckjIx3PqAfp+dLJsuLiJFuYIpFJkQtzuHIyMkAnvwDj8qm6JckhJbl7aC5MUQgupx5alPn2oONxHT/wDXUFvb2NqNySRXKzwOWm43IcnBGCM53duRin3dvML1bqHEbMwIImx2xkjt06c8Dtniqulv+5jlkj8mFpDEWXeELDHAAHfcev8AFmnG1tyIpWE8PGR7K4lgt8FsB5DEUZmY5LkkZI6c9eByQK1LkLNZStiRPk5+UpnHT6c4+lS2akQBIXjRANxkZARkDGfrwD69Kiv5beWCWeExyuhIZlw3lnBz06HBPPXn3qZS5pXSC/vaHJX8JjjV7d2jT5g20YDdOM+4z9cVvw28TWdvKZZXitpi4UvxyRgkDknhuDVUTJJZviDzVD7uhLhDwcYOAQwQ5+tJp8/+gPGRJJ5rB0yu1ldWzg8+vv8AzrebclbsddS842tsxIovInUWrb4HhG6Jl/1oGAzFgfvBAvBUHtnqBSAS2lBiaeedleO3cSkBQAQu0sMsxIGdw2ng55FXNfkSBZXkt4J4SrhWmOUdsFiOvLAJkkgYz1PNQ3NiLJz9tMfkyxiNtkhjCgqD9xjtC/Ie+OnymlF6XfU42PiaWe0061NvEXWNctjMSorc/MMHJHQAYGDkkDmO2eQQJbSW0tuAoj5bmQgk/IEPTHPOM5AxVy7t0tZpPs8anADBERm3YCYRcDjAAAGec5PCnEmmq0iQlHV7dZmLb33HAT24bDA9gOpo5la6LTSVyte2P2t9Nt5ZlRGmEjKnzlyMZx2Axx3HPQVHqFvHpWrTLb2UtvFK5O9VDDcCMjCnAyGzk+nOCeWarr/2e3gn0+e1Ul1I8w7du4Z6dyB1z/8Aqjubs31wi3ks8rRJvaFdrb2QbVIbJ4Jzk8Ak9KuKlo3sdMKc3Zyfum7azweXGux0CpykYxGp5/8ArVFGZf7RWONldVB8xI87icDHX7oxWVpkF5eW2y6+0xRL+7hliH2eRwUU7iqk4PXnPfoK0EgmfUgt5OoQjAKLhsLyoY5OTnI5OOcHOec3FJvUxcUrlz7SsxuYLaOATx5LIsoA3cfeI5H5Zp8soW4S3kG5Dnl9zNn349D19eMVFHaRrMXUorsfM2RjYXO0ruJGNxxxznt7UhaLTreNQjrhRt2plm5PAYjBPHOfYnrWbSb0M9OhY2BIcBZ0WNsn91sBHPbrxTJgkUFzLcJ5lvsJORkEfTP8h+VVbaIC5UwpOgERUyGdZBID1BZjvyOOAMc96W3ECTPb28LJMTlmFsobYc8ngccenOenelYV+44XKr5PzkByQhA8xZGJHyk7icc/hx0Apbu2WdTJtjEsUgYCN9uO3ByDjBP54PHSnA8MHnSG3a2UFfm+VSrsAeikgEcc9OantBNFqWxntvsyM0pVYyHCHOBwcD5sjOMnPfnNNW1RVraokuVlTbPCUWMj50kA4JPGMfxcj1BJ696ktLmzuJDDHIZXQ+W+OcMMkjA44wfSo2MMbMTMgiLbtkpwysxJGPUkk4H1HtWdrFp5uoxPYTyxXO8uWRC4cKDuU8jnHJ6E+XxkjAEk9GJu61NSW78qVfPjVUwW3SrhlHHTAxjrnn8DUbwG9mMy3JazcZUq214z2aNgB6nqT7dwZ5mtp3E8SI8gjDRq67JFDAnHPzKOcEH09hWdePOmoZucR2yx5Ro32qvu+CCfu4A6cGiKvtoxwSeq0Ld3psWpXyXEkL/bo1SSaCM7C/BAIJO32xz04Nc5pF5bJqFyLk+UkxyEV97MgHyx8cEYJ4+mBWqftQuma3t2uLYBSZYnClGGN20jqDgHqB/R7wte7mt3tJEQEiG4tljaNyMZJ2nOeM5HPbkVpHRWexrBrlalqvy/plG5s00y2lPmXayZ2wwKq/McfKxYfeUfTvxjmqEk66WZbXULlJY50zMyK5kRm25wv8QwOv5d66aKxvTBYGRbaN7YBVKgnb9c/wBD060s9lNBK11YQ2MdzgkSG2+cY/ulicH9KaqrZlKt0f8AT6dGZmj2zQWUUF1eXen2ts7XEbFBH1yF2qw3Hr2+nXmmTPb3Vl9ka3lit5ZBK0twxzMem4jsOvc1puMLFJq88sk6HjzWGQ2Oo25Ge+BiqWpWVrqlkltBLcBiAVJHyv8AUHnHX2z60J3ldihPmlzT69ei/wA/mUV1vSw0dpaXE1wwIjwd2Dz1AJHFK+lag7syuQpOQDI2f51lX3hWUTA2oJwvzMZApTjuB0GfqKlDSRjY2pSFl4JGoBQT9NvH0q5RW8Ga1adPR0pGxPdzWyJPLAvlGQo7BMj7wABBJOCepOOntSQRtvuiotgIkjMmw/MDzwQTzxtABA71Wjt5ZY3m1FiN6AIpQbEAIy2GXIPUH2rTit7a5VJLP5o9m+Uo7JuxjBA9Pbj6HJpu0dDOS5XbsQacJ2mbbeK6sACqKQBuPUc88YyAM8CtCSezkW6W3HkR2Z8u4kcABsDOT6dfXvRDfwPNIsRQfZ2AQGIttzkE9Rjp0PPoKlt/s8ju63Lyhjwu8vsPcD8Mj296yk9btGb7irdXFvKhit4vL+8rsuVOQTgYOMAE85FNt7BxbQyiEQxFfOZGmO3cRyp5IznPfPTripYiz7/3qyrG+QB8jKMEbWJPUH6delKkc1rF5iyoiysSUBDlR0B645/p9ai/Ym/bRlZIPPjIsb6K0uEIyrtgfK2SRxhsrgVma+U019tussU4b5w6ZMuAOmMZHzfT8eq3wjF2Jc4lkG4eYq8E9/1z7VoWc7f2XCS8GoIQWXzI0jVNmAY2OOuAcZ/OtNY2lubK9Nqe67FOxvBDpKXk1lJvYYVYxjPGDgZC546dTj1q5qaNdSSxPJ5cEiKuw4OVzuOe2cZHHTnBPeYafH9nus4e2clxGncA5IGCPQd+Mmn2fl3VrPsXGAwj3Ke3UgsBnp+FS5K/MiHJOTmg04vHBCkMQjijRQDs3ceg5H09qt30bSxArI0ZyOcZI7f1qnHta2YsyxiMcmIEkYGcgA859sk1cACpB5j+a65+Ydsqev8A9espb3MpfFcyofPiZ4TLiRwAXgLxhSemQXOPy6cmrEUvlq4twZWdRvlRwx2nPz5J6Zx785qbMcMasFJZU3bRjDHI7H1PHb2ploLKeMPAotzvZpIwNpDnlgc9OvTirb01Kcroiixc20akqysFYbG8xckAkAj73Xr/APrqxFJ5iKIEHlk7JDImCAB7deoGPrViZUTEiuVxksRjOPQevP8AnvU7xh8MQDwM8Yziock0Q5XKbMynFvGiorE7icBRwOnB5xTgZ7uZ0ucMidSpON2ff+lAjKxoI8RPn5RuzwCOMkZ5yOMGmXOI5SZjE0pA2W8rKMA9SPXn1oQb6ItckusQLFgfmLZUdT0z7+n+FUdUjaWH55VDbShI6ZJxk/r6c+tT3V1EYpIoplMwG1lT5ipx6DkVlvDJHax/aWVnZg0hweg6Y9e/SnBdWVTjqmTaVmAsGMrJDF80iAKEGTkc89QMDrz6dGwutpcMk21vmySepI9+uD/SrWltBFazRbQGIX5pEGxlJYgKOmRtJ9vyqtcwLO+UiY3AlCJHkEEbTxnn+7+VVe8ncqLvOSew2R4jZSKgciLlU88jHfDNnJ7dc/zzQu0EEdkE8yKOOQqkRmKb12g5ZCQWx83ynnv6mtN4jKd9qoM+0FBw205BZS3oDnj1qt5BiKRvFAjIoJEUrFd4O7GM7iNxb7wPfORTi0JJPYqDVHL7AvnyBVSSNNu4liBvx264x6kdTg1qWaoL1UGFhQ8Mp4dieODznj6flTJLcPJ5l1cK8MZUAIu4K/UHr0HbAHOcc1JbxXLEqsMqMOdrAtHgMDk8Z3DGMD1Poabaa0H0M3XbO01WC2gmsXTYH/evbjAK4KnnqDkjjv2q9aeE49P06NNOH2llBdJQoQliQDuU8dOeMdO9bMV5HbCS2aI74QHRp5P3bszHhWJLA9eCOmMcVF4mS+kaACf7NEV/e7ZdqgEY5JHPJ47nArNVZ3UVojJV6iagnZFeeyumtQk0tx5shKSyK4UjKsPlAB6dOvQ9eBUTNbxNDLbSyrE0Xyr9/I4IwW57jvUclpZ2aWTlJ8J8kbyTMFzjqFBxj6CltJkmnYzzbnUlNkS7Sh+uffpzxVLXUpa6skv18zTvOhd7ZkYMuVB5zjJAIyCPfjr2qperiJ99k7Iu4tghiFPLMNrlyMkgDrwMDFWmkaC7Nl56tO6GUJwGCjuB15PTHoary2drfThyocxy+W0yQruidTkD5lyB145xnOec0LT0BaaplNngsbdJLWNJZZ2XYjZcsMDCqBjB6dTxnv0pbW71tYDc3enieG42sjBsJswedueBjHQD9amu0t0NuF3BrSQTMVLOQjZBfg5OAeTknjoe2vDYw31hub7KAgJgKjAzz6nsWIpuaSu0VKaitUZLM0jSzS6dN9rgXzk2bmRj0XapyAx6Zx261ftRayPI6M0lxGqpuLltzZ6FhwTkdO3oKxdNa2gtLd5AyNHJ5aKEGJJOfukclsfxHgeorTF6LiCdSsdunKZcCVD9OxzkDgnqepBFKcWtEE1q1Eq+IZ1ims4blLIqzBmEsbfI6nIbIPrjgcepFNhsNQhiMcL2j2k5bc4dnA3A7sgnpnt71VvpVurdLVIHSOMYVRGFZsA5KqR0A9R9OlWNNmhnt8SyzAiU8LGSVxyGyB+768k9+hHFXZxiPl5Yq2/XqWbiKa/s5IbbzQxYhXllUIvOW6c8YwBgcgZJ61XKY1CRbK6R2kAWZtqnMm1ADgEdMZzk/eIyei2ra8toY/Kh5V3D73RpM78HkYBXgkYbBB60uo2sF1cPdKUmAQqRGw39Pu4yM9z1B461KbWj0RKdn5FG2s1MZAkSOTHmEKDGWDDhsMcryD0INTwsYWiuLiUHapRf3eDg45ZmIz075PNQtHFbQtPsYxTIJZZI28vC5yAVyT1PIz3PbAqlHEJZRe3glKIxwfMwNpPAxgkEA4xWlubc13XMy42u2/2sw2sSTOwJBMxCnHUL16c+lW7fUrd7xVnhW1yMmV5RjP8AdGeD0PXt70lxdaZ56TadaJdsg8sQwxnnPfPrx1FZ0txDHfSSNaSrMflMDbIhj/aGNx+n+IpcqktmQlzbR/r8jSu7NL11/s6VNychklDAgkE5wcgcYGB2/ItLJ42uZHdG5KhYgCQ3ck8E9O/TH4VLZOsMDXUcsSxMMFYRlE59+h9TxnFU5tdtpbF4RcyrcgFQ0UDr0AJKjBIH16flULnfuoEpN2jqVi139qa2k8+QgDy54VDYVs43AAnqDnt9KzGGuoxURJgHHMjg/lu4q7qK29/alYb5DeCIFx5Zfdjucc55Pb321WW31FlB+03fPP8Ax8r/APEVordUac2t2l6eZoSNeMdr2gdW6qmMnd2yQc+mOB/OrFsl/DbRhrK7ij+ZX3gMzcnknbgdfUU2dtVsme5mePy1UZjU4CgEDOcZJx24+vWrq61K+ZIYmmKsdw37Fx6+v4Djj0obdtErCblZWSZTCi8kiZPlTJEkbJghhxgj+HAPPXPr1qaz03yZplt4rVEkbdLLG+WRuBjAPBI5Ocf4KAUlZZPM/fAs5jA4xnC9fb26fnbeFEs0SCPypE5KlwjZzwTgYJxk/wBe9TKXRCnLZJkbRrHGJriXCoceYoz6csemP8faoYrrdmdljaGUB4/L2hSTjJGOc4Hr79asxxwMVjKSNGy8ptDFx6kE4x/jVeS4is5YIHtXtbKVxErlM+WAAAAgJxwBzxjp71O4lq7WuZ0sUkqoxSQbjvjOPnx/u5Jzx0/Srun3VtJpiWayWDy7w1z95CqOzAuO+d2MkHGfTitC+IChJHlcffy4+97duff3/LGskistRaYE/apF/dYj3ZYfwE9s9jx359avzx1HJ+0hd9C9o5aTT3tw0qhflAdhnCk9cdSf6e1aaTxiAxHIUYAPmbWxjA6HGTnpkVl2S2QvniAikVZhKq4JAIBGfXOQfXmnXdiLnVVbzZk3yKYSh2g4BGJOcMo4wDzxWcknJ39TKWrt03LMdpmJjFI8cJQKBkk4HfOevXr61YSNY4/KjgLQqAvIwcen/wBaqtlNM0stt5jQTQMYXDoVDhcfOoPBGe/Tn8qd2bm3neS2nZHBALSAt+H1+ho5W3a40nPS5ZIiv0tXtld1kG/IAUKDyMg9+nHWpry1Z2A5k5GWPOGHHYenHSq1t5kMLySAlnAPmqM9CM5Gev1qGWbUpG/0RTtycOQeR+A6n8arld9GWoyb0eho+fNHPFH9lZogxG9QACDyMD/J4pby7SPPnKsaA/Jl9vt0HP5A1nzRXTI51C4aOLnaqlSxPcg8DH1p1pZJawmXEUYWPIdjlunUk9/09PWpcY7sXJHd/gXoImhgFxNLHFEoDeZKPvH1Cjg/ic04XMUVtPlFWOQtulm6ElsAA5xnnt68VnRXkF1Gt2iGZGbGMk7BxgnPHb15/Oqt7fTuvm20KRxKAiveHYMnvjJb04wDxQoNvUnkvqza8/zIZnh2q6k5YDO4cHg46e9Y1kx1K+SeYxpbw7onJPQDnA+uPbr+FWIJ7ea2+V/MEiliy9tvBUeh6/SoFeGEz+VJAm5llLSKMqMYB9zx+g/C4q17GkFyp23NS6vEm8tlTyY7b5liAyrBuOQPXnGO+e2c1GmiijuBdi5uZHBZduECnB5BHMYA4B468bs5rHuEimhbyXjuSNsjNMSUJKkHnnJwSOeP1NSWRkZEVLhzDKfLcuoPlk85XOR/e6jn0pqmkhrDWWhuOyNGGmtJI1aTBjQoNmSCcA4BGdzHqSMnnpWf9ssjcXMV1F5qyQMhkjLBt33cYUYH8XOR29iJ5o5kkkMkyL8xBbztmT8wyc8Y5OOM/pUumWdvAvnRv8204Xd94YGQ3HtnFQrJXIUYqOu3kR6XaxCzikg2izGGUFjtdepPtnHPr1p1xrAZwEs7y53NuH2aHdtORuGMjP1HrSajdW0UyR4jERHRfXqQB098d6raZcDUYWignu7SYgtE5LxsoOcAoCA23HQZ+vWqtf3miZX3sS6it3exyLqsUdhZDLCRZ8OV/wBxgDnG4YqewfT4gnnXs+oxFQI4dhAXsActjj0OPeqOnaFexJNI160l1IGImdiTuI65POD+H9antZv7PuFggiF7ezKP9UdsaKOOTzjof/rc0O1uWL/r5h7PmVk/69TT1JXnvhNbSHacErAoG8j+Fn5wMAdMVTRGjQm3jaSVX3NGGJbPOeXboPQHFQzm9nvgjRRSlCDEjQMQjdB+8IBB6YOPypyXF0EmMkUUflKTIu9sngklhtBxgHsfxzUqNlYFDlSsy9IxKZVxHK+EeYISzAZ+VePX64ye/NMW7aJli+VsKMmViz5wMdRx3HXsD3qg+qNLZpLho1cFvNWM5bnbkKHBPT68dOmY5prsOskMMcqbdzlDiRR8wJ28g4x/ezyOaOTuV7PuaIjkSVZsubcDaY1zhMkZyOmPUn3pv2GIO87RCNQgwqvw4Hqew9Mdu9RxXDTywSWCx3G18vIxIMYxycEE8e/rVtYrrzGUtD5hHyeWmV+mAee3X8Mdaltom7W7IrSwAPlTpGFiUYSLKgAcjHOT0PXPpWFfzI89yij7PbRhl/1eOcbcngc8jn0/Em+rztcDbLJDM6MFkWMPEcNzhQeMdOD3PJ61DfQ2MUx+3xyT3CrvlkgTy1Uc4J5GD7960hpLUqF5aGPCkTmEW6SuzxbGyTsIwSCW4zwf6DGBW/ocUdtbys1xbTTTyIWKhgAqnBGARg4J5OO3XpUN1Jpkn2eSO5nSNEOEz8sgwcgg/e65z071DY6nYwoLNxCimQCNiuUIIO0HHI4wOcj045FybmmkmNrSyuacrG5vn8yB0WzZJInMhUAsCuOPQnnn8qfqLQW15FNcvapGTtjZ0AdWwRwx6dev9KxLWKy8lrVrxY7bzD5a2sUoOd3ILtnPPp61c1G4lvYIlsZIJLjDFQ2S6+uwsBnI/wDrZxmo5NV2CNP3knt9xHeahFIZBFOWCqFf5CxfkjBcgKvbJz24Bqi0MTALeMioRiSGNskehzyAPpgClKakz+U1tLHGNpEscmS7Y6k8gk+mP5U5dOh1Jsy+TFBGRIZURWkZj1+bu3HatopRXkaSbp/Dt33/AC/4f7jStLq3lttsVjNa2zNtDRYG7IBBPABPv/kNb7N9raeV1YAKirL+8YcD5Scnn2HbnPNWL6KJ7mKK0ScLasrSMm0E/LwCCeAMgmo7Xw9d3brci6t4rdwCsezfvGPlLEjOevrWN4rVuxjKUFq3a/8AX+RDPbyzWd/lEit8q0bQ8DCjqARgEcflWxpltoUWlJJcpbkug3iVFL5xyD7nvis+6sdWMUnnkiJY2jMSyHaRj03YzyeTmsSyW0vZxFPD85VkEMICqSo3EsdwYfiMfXmnZTjv9wpRVSKfNa3Yj1GK0ubhTpFtIzCU+SyBwqN6kk80jyaZvb7RLaNNn5z5HVu/r3q7eWUjzbdMwIozsdRweTkhdpGRyeCcZHJNZssFhHK6C51IBWIwLkj9N3FXpLubw1+G7+Z0tpojyxqLm/iWRv3qoHxk5PQA8AZA4pZNLEVyFQqnJJkYEFhnJDFevfp+B61Cmk2wtDEb+Z3OSJOuwEDIPOR1x/QUlrfvp8MVlHPGWI3IzsWVgGweuCD97HUdO2ai8nszNc71i7kl54cihY3SzCSInzDjOMqMenTjP4nrVeLUfspZLVBv3IWBZiMfNk8Drx0wBVe/vp5XiJurwSxoC0UbrIrbjjbx1IGTVaUXN2q27RmAOozLOQiuQOSOAPXAx7+1XGMpK02XCM5K0zptKure6Uy253kELICgXg5KnA4xx9afdIl1IibtoUqd/GcjJ4z1OQPxqn4adnQecpilLbcqvyuoPJyfXPX2rYiKFI5Lcbc/OMDBxz/U9/WuefuydjGfuTdjNmS4ZTFbz+bLHkY5GTjgEfXPfoKqmae1kbzIY4wykSTo2027lQA4yeRnAPt3q/e3Jtpg0Mqxlkw+V2KPc7hz3H+PFZjT2pScu/2pIkxOnks28NwMAD5gR0IyP63G7Ww1qtTXOoXMWLLU7FrpiozLbouCfUjOBznkVHeW9raQzxLA22RGIAlDyOOSfcY6An2yan8PPb/YTY20wmuI0Pls6eWQvAIAwAOnYUlkkMRmbyJFuS26WSRVBY4wFz0AHHGfSs/hehl8Lata39XK8KGOO3EsIikYF3RmDBM4+UHvg9+p7Vnajaw3F/BKZJJraaUR+UgUbBj72cZAyB3/ADNbE1zbypIjtJGc53kABwoB+Xv+eD+HNV51jMtm7yLEsLB+RltpX0B55PfjIq4Sa1NISa16lNJGF4YbE/u1XMvl42KT0H1+99frzV6S/CYVtznHRXwScc8AdefWormW1njQxS48w7nZBgn3OCB1C9SeM1FIpeFo0JuJosssBj5zjI64G7PTJ79RT0e6Kdnuh63vno04hWQBijCVdoj5OScjP6fiKllME9mQBvhK8SQvuTrjI59f61Un0+V0lMjPMUVfkbGWGTj6Ef1qRhLPZxtbsI9pyzhgWUDrgYIJ6Dk8fhyWXRg7LZj/ALCAsYR3EKgBXeUuRj/69OkiFzviMRlkiYZG4YJ4IJOeCR2zVRb0SQiOFlEzxnKMjcKODuODtx6dc++cVYEtfLa1ufNkLAszgqhfGc8kg4+pp8r3Y0nYu272xkYRRpwSpRWI2sD8y/XPp/8AXqrq6kiQ+dFDudwC0mBjgbQcZ6MeQOOau6dBHd2kQ3yRRwKYwGycrnvnvx3zVLVrJ7wWiwsFk8pmCN8qn94wJ4+oP0pxa5tWXTklP3tDMkikhgEquk0Mknlfu5d4DDJHPf8A+vU1nAHiL2twZZSiXMcSMBgD5SQPQscfT0qpZ2VzdRTWqQzKrN94R5jDjgMSfqeR3x+HTRmMCS3geMQKYthQcmNWKucAbckhz179ODWlSXLobYio6furUe0Ucs+JbeV45FBMq4yowOPx5ycdziq2mGJEtreS6mJkllEYcgRPsDEADHPyj2xnvxnodOeGDfPLJ5caAuVY4CdsVzN9qKjXEuL428dwkTiF5JAEG4qAgOR2+vPXiueLcrxOH2kmml0I9MS4vTbK8VnNk+c96yAbEYfdj4yOuMk8+lbN/dLptvJdeRGI8nzDEoyigHB6Zbt6f0MMduILN8D5pNgiIG4lR0wB7en1z6Lf3UJEbCRljZ0WV5QTiMNgj8uM/T605e9LyKtd+RFfDV2eS3hNjpwYCUTSuNwUkj7gyS2B9Peq0MWnWwxEslzeOSqXczhmY5ww2jsQoGcdCR7G94nsIY9Xe6NxJG0y7pNh5wAEAGFPqf8A64zWZceXf6lC9vqjF2HmeXJgonJyAuM/3RgjJyTVQ96KfQul78U+j7CXOsCzvWzZRSRhihmuOjgDHyhQFUnC87fTPFQ308LRwz6fHA9vtEOyZiSA53MSoJA6E5xxg8DAo+wT3Lk3E0csu4KttENqoOcA9AwHfByBUtxBbynUHguPlEm1UZYkjhUYG4Kx5GCeRgg+uTWnuK39I1Sgml/wxHd6lthZ4IjNpM8ARGt5TH5MgABDMQcjjIDdulXbeDbpvlxvHex58wmNhI0gxgkgkjjb9PlHFZ9pbQW1wLKznd7Z8T7XjykqFcfPySOeOmMngDrVjw6JdKhdDFPCGRtiTMBEw3HbkkZ5DkZB4xyBxSna3ukzdo+7/wAP/XUytRsHfVVSJmstRY747pJMRSIORlcjaTg9Sec8dxckmv2jtZLi6MZ3Ze2kZUcr6qygKQcH5T168g1ZslurKZyXa42MqKtxlNxQlsqckHG7ue/aqdpNaajdyOyvNLETslTKEDG3JUHrwRnp7HNVe/ml/X9fgXv5pf112N21vSkc1zOjLGFRBHM4UD+EKMHgnI45/DnKW0MdpEbe2ulib5m3SgMPm77uB1PfPpmksrrz4bHOJ7maMSSNFsBQEEEnJ6bsjj0NWrbBcyNGzW4IkQoxyh53HBwQOuR3Gc+lc8tLnNN8raMPV7nWrYCU6Fp+q20Kh1aOVobgnHOcLycjpgCrFt4nFwlrNe6FJZRMzeYLqPe3ABGG4GOT19PpWiJm1BikkkkCqxj2qwG8eoYH/DrVbTtQnXKyGKYRlkY28ZbDDGcAE/iPf6ZrRrWOq9SfZp7r8SIXekTSpNZW0hIb5o1bCsWPIJI565xkHrz6Fx9lEMiXEUduBMI7ZYcqVxnB+8echsY2n2qxZDUbm4ddStLUWAjZAOCxcSYHy9gVwcc8nFUbnQUad3W78pQWkCMMcYGCejHkDqewpxcb2b/UqCg3va3zLdrNbtZQ32oRbZ9oJY5UydcEAdc9dvqelPv9TCqqpaeXtJz5wUbeD3yQOnOcVRaN7i0FslsI5o/3uwtuTGSOpxnIwecZPpU9pqti9lLbXdnK5jj2SusB2gHqCFzjA9aHHra5Ukm+aMb6/cUkjkNlNc2lwvmyEh9w3gOOQB6ZGADjBHbgVdtdZ1Wxt3gjtrSV4wGeKCbeybug2j5hR4dsxbaZI9vB5iGfdGuwHcgAAI3cDoT69qiu7uKDUJbdmtbeBz88zbsHPvxg49uv4021JtWuDtPSSvbclfxNqxtwDYwvKxBCZ/eLzyWUdsemcVn6LpuqT6vZX96GjhicOqODE3soXg4z/e9a7QWNmrhpLl3BxgO2QN2APl6fj71yjXs9va3cCF4ltZ/LQsgbcmAf73HXqOmOlRCakmoKxlCUZp+zjb7+pWZ9Stp3mmSKRpHEccRdkBYsBuyTx1/+t6WBc3hGQLUD0EUrY/EDB+tRT+ZqNzbi4dUO7zCwf5Aqc556cZ6dyO1ZwsNcYApC6qeQqscAeg+bpV8ilu7GnLGSu7f16mnJqtpa3V1Ld74IbdlDKpZ0Bbgc45JyQRjp37VdN7pzZuZzBJvOwM4Unk7cAk888fWmwpDOkQknF1DNnJkYkAg5Vec5Iz+OelP1OFzEzS3sMkTZDlU8w7QORllO0AgHgjpQ7XsVJu4xJGjuGIuZPs4H7yNQFRcnjHGR0I6//X1lmxBF5jFzGu0/uht3DjJwvUfhWBaeZ9stoZbsR7MxxxxCNxJ8o5ck/MRyRgZ65A7yJaxnZBDdQxxqSRCIhIko65IIIyOpOcnJ61MopkSjd6mwJzJIslo43uq5Ztu0Dj19z/8ArxTbK68y7fFo0ckw3ysHLLuAwMcYwR/d/rVbT7SG3KmN2nfBd5HA5BPQgnI6/pz2q55SPMjrGJNuRvRgcegweKiXLsKSiPuEikZHmg3OzbNrNgY9cZwf1qB1FmzNFJGjMNuSiqvUZ4x79eeM+laCqXQYT5vvYPb16Z5qjd/6XbobeQAfcBG5cnjg4HTpUxetmTF99iO9WxvYf3TBnbAZssDnoQG4P0xTWL6gUsvPgzCw8xWtyXdeQrBw2ATg8/pTo4rZ4wqwnaPmJG4CRv4iT+dSsl2kAJkSVs/N8pAII45BH9Ac9qq9tByS2/MrXvn29s84is1WIEiWUBgEA/4Dj8/xqSRmhhZ5Yo45pAd5Usc4/AEev+NSTfaYbFgdjEJjcqnOR3wOB+o/nWVZsztGZZrtZI0L7pCVQk55LDCngE4xxxVJXVykrq4+PUJxL5LXHlSpEMKsTeW4yM43feOO2SOfarIvLpXhACmVBuId2jQDGCWwCpIx04I61K8s0aq1tHaXG4hS8km1lAPUAZB6Z6jrUQjNwqGGcYiwvlsu4uAMD73Tr70Oz6Bo+hSuo0vHJilinW4ICkvkRtnn5TzwCe3PGcVZ0+8gkuVZGCKIjtGxVVxnBPIyBlc8YH14qyhESusckLSFMFN5Q57ZI4HOenaqGpWYaZ1iMLyOAkl6SVVAoJ343dRng59OcU7p6Mbs3Ymu3Lmfcs6PJEqsMfIwBOD+oBwPSqf2uZYHt4ISHTKO5j7n3JOAfb3wBUxkmSNZIf3w53hYuXGOCAP4uAMEdO/XNdHj/tRbRI5ZJpdzvIWYRwjnG7sSSOnPPWritC42S1RoWsYtrMJFGXDDKtnAbnoOcHrxUN5cXd1cqbYoGXbDKtzGcNkj7jfdOV44HUGq2ZLi8+0efMYpJAoRc7MgZ3NxjbhuSM9AcjBpguYZL6Vbl0uDASttJ9n2+X8hJbJJJ+YHrjn26Lld7kuLetrluwkA1CSGSOFbgSM/yyABcqRwONvy+oxknrVi2M8aGIsHgihwZDnmQ8kqOgXGfrnNQWdmkcrRxlWlkkzPIqkbznJ5JOcZ69/wpZLiD7SIsz/63zDgnI4OPz45PPT3pWT2BQvsQ3Vr/aVwZgoEVpF5i4c8t0UDIIPf1/Co7mX7VGrBJFY4B24Ylhwf5n8zT7/X7Wa2kt4psLjO04DuO3HQf1pljLaW1uLiWadIA3yB5cDjPQE8HHOatcyWqNdbWkvkb5dvLUzhNzAAb+MnBz9OPYdajuNtyjPhHEw24UgFs55DDtjP4ZoNxuVCscwLAEqE+Ybjg8kgcdeueAaqAW5CRbJsnlY2VV2noB+ePX1ArnSOdb3JJbySazeA2wudato/Mi8wfNLGGHIx/EOhA56464rKNlNb6zLJFNHBLLNskEdsWLA8bQQTtXO3B4PetGf93EJRMYLqGJWTzf8Alnye/Hpg9sEjvSfYmvx9uihjkWPezoibD5vzZBAPPUcn0X3rSLUb9ioyUU1sn/X3GfBHML2S0cLM1wq+W8AIKKDjcAOTg8duhzmq+lwwaa97PNcTygI0brGVVvmIyeTjIOR0HUn2E2mWt1Hc6j5oghTYEEUr8yISCAn8X8J7HJ4IzSzeRdRmAzC3u9oW4SHy5EYEDO0MwAOOdw6YPWtW90dLluun9f1oRRfYrXUo49NlmmupQFVkWNTgDOdxBHbP19Kt29zHcDdNIbiwHyXJVR5kRz8rttyrHIPK9QSDnjMGuW0lpBDcWsMCQxEoiNMrZ4VcEknggHgZ+lVL6+0+xs3axhmaaUcXEO9djseVZiM54JyMA8ZFFuezRKj7RJ7/ANd/y/UsX+oXGnSLctFJLYud73iFXikOMZXA+uR1OMVEZLpZo1idEW5kTHybSgeIkPweWG1hznkHvnNy8aW0tUh09NySIJCZlB/dLgqTx1LuTkc9Dxmotj3UETfZneSJyIVgCByyHHLnkcqTgLwPakmrXsCkkuZrT+uhosrRWdpaafE0cMTiNjImJFAycqDwedvI7GsnV2ku3YyvG0QfMJUsxVFxkMq8k9f1HNXdfvlsbxS4aSd8rGsTbHZRyRycNuIA2jPA/KwtrYG3hsn2DAOYgwBfgFgVI7e2PX1qIvl959TFO2r6mdcaXZWf2LyneYs7ucSbkVdqqM5wc4XgAevSriXlwYT5E6qD8gAf7uO+TnHHeh/JaRBu+SNGO0x7yyjA6NyMewx0FJLZwGS1uvtUrGbCIyxs+4nJG8jIUdeT059KfNdWkC5YqzFS4vY9LjZEwh2sjbCpXP8ACxA7n09faql69rbX0bzb5JozmMsN0qjnoQCfUfz71KVkkhhtWM2xGACSLt8s5654B47+5GDVZYgsxaARQi2B2rsVN47KuRgnHf8ApVRS3ZUEnfQ1TqEBilFyDNkFgyRkYQ5xwSCCR6Y5HaoLeOORPIt/Ogj2mVoTMys/y4APGCCO+6orVZpMx28M4EY+cFVCqcAgls9uRjvjPcVn+RqEF4BeJDFbgZS58/zJTkcDDZ2jg+3FSorZMnkVrX/r0NxpYkAguCttMVOxy+xnwfUdT+OeelMvIhdOslndW033SYCC8hx3BGOe3K496qyzwwxql2085UhTI3ycnockAEjnnFNgmRZ5JLRDLE+35HDAADqccgge35ilytah7Pljf/hivLDLa3IWZEinKnbKiJGxUYIJVjswM++eehrRjvEgZ2l8t5FcBQkQBVj03BeCeCciqNy63ME8N3A0JGVikRztkz0I64OR9ais9NnSKeMRLB/qyrwMDuHVgTtyo/zxVSs17xMtS3o9xALi9vb93mu0l8mOEsBHskAwQuOCR/hVyK5iWJALa0AAAA81f8ao2kMe3UpWe6NuqiUTMMlXXI2gngnBxj27VTjurZo1bfqhyAc/ZV/wrNxTbCrFTd5f1obgEcDFIQV3EttiAAVR7g84B7dM02GSPygsdjJIGOzawHyjHIxu+bAI4HrUtvtuJZGuYrR7mMkK6EnIBIO5SM9eMe/tWRqV7LazTSbzLbxuqOqtiONMcBi6A5+mTj3qorm0Ra97Yvx6bDvmkhWfyWZlMPlBgx4wRkkYBXIBAPPPFWrlbh7JA9t9plgZdpDISQO/VQOp4Oen0NQ6fIjpLdm7aZS20GGVjEMcYwcHIx27++abNeSRBVOyZgAQfLkG1ck/NgkAgcc9c9u0tu5FiJXSe588WlwXhUqWjYptJC8jKYPQnrjp61ZtppzETp0nmISqs87AgnoeRjHbjtjjFEeoPcJJLcnIXY42IVB4ySGzgjBHAGR3NWra/hmZxCyPs4Z9+UBHYHPX/wCtnBob02G210H25ufN2SjHlqDIpIceobPHoeeenNXXZzGEQ55zuPK8euMeh6VAs6kMMoBHgnkYHHbjpQ17F91ZF3kHoeM/Xt/+usnqzJ3fQdJ5qxhQY0xwrbf6Z/XNVImnikZHjErElshmBI9c5wD7Y/CiORPs7QySSPIxBwRnHQZ/3cjOfrVmF4opUhXO9gFCncc4GOOMU720Htcx2hjgjHkzXNvOHG7Ywfpx82cbuBjv9ehqwLmOe2nQwy3LxOsUvlRtk5Aw2GI459+vpVjUooJcwb40nb5miLAEjoSSM4/zxVO8F9AoSXVIohEGCuIS+R/c3FgDnHcdOMdDWiakl3LbTStuXohC8BSVW8tBllLHC8HjcOp/ln8KiQxRu5hlZ4lJ4EjnoehxnIHPGO3pUFzcuAy2wkHmMuDG+11+mR9AKi066imM8dxcXM0BfBkfCOgwMKSMkj3OOoGO9K1lcOVpXL7XlopWFZozPKm8KOeMYJ4xj9KrwRyGOEyTeZJGwRowhijfjJYDJ4yQRjp69Qaj3KWMLzXLRC3LFNqr5SOwXKgljnI+bjpznrVWVJLieTyY18x4ty+ZcKol2kfKFAJwAc5Hft60o9gUUaE0BxLLH5UASLy8tjA5GOCSoBI5AA9+agivI/siy3t5tjZ9u5xuLEgkbVHbk4yR25PFZd5dXsF+qyQoUmcCMq+9XfGMEZwAM8kEnA+6c8WJ4pHuI0jTfLHFn7KkW3Ay2NpI54GCBzxjkVcY6amkIq9myK6vUu/OMO+KIjHzEbmXrzzgA8fKDjjpkUzSk8uGa+RQEhO1G/vNx2APcgYHXJ69oobG6gjWe4AtEVWJeY4YHb8u5Tyvr06VrLBFaWluloJpbYnY0sRGXc5Jcljnnk5GTzjkVpKSS5YnTOpGMeSHUuRSurQ+U7NLn5RgsFGMEYxz78D+lO1OJ3v1MSQxB+ZWHODn+EcEnA7evPvHpssBmCW4ThQCSpwpweA3PYDnmp7zyXmYuZXkKAIQMbTgncM8A4PXpXO3aRyXtLQo2drDDfNdxGSRvLEaKw6DJGFUDI65yTnr25qREKSoWVZ5dxWNpU27SD0Xdx/EOuT+lTNeXFrb3MrIJo4Y90aqMsG6ZzyDxz+BqnpwQwPeXKzQxRghRK/ytkY4wSQBz0XA98VV27tj1d2XZPOSYPdmQIFyNmCzcnOBngY7nj9KaGtguEFyZ3UsSmBhc7egznkHjPpUYxGElFqrhm2KJZTGXHQLjGDwD159u1W5r2zsrfzLxra3iiUEMAue3AGBn61D0I3IYpTGJIdUilaEMXEsmCck8AAc8euP0rEWzmiil1CznnhZRthTcUyAcKW5C52gDOSSD6AVsTy6beqk+1pInQutwkrQgAjhxuxj5T1xjnHeqmkaZBbXtzbJcyCTaxlto8rGFJ4baoAySDz1OFHpVxlypvYtSUU3YsWmo3bvHFcRASsv+sR2w/ByNo3dwDkDj0xkiRbaOXUZL+1k+3RBQjm2CTknjqR3GBwQSe+e2Neaa93rdrJZ3ks6WnAM6KeOflOME8ge9Sz3SyyoX0u0uQNyS7h85bI6ZBPcEEnv3xw3HrEqUUtY9SWPSLCS8kluory3uWG+ON3Vi/J58sD5RnHp1x3q7qDxwQxLcXqWpnceW0cEgy3sm7H5+1RItqqG2lj+yeaNqojCNQRydrDksMc5GSB0x1q30iLmWznmju1j8o3UciopbHVl3HP4jjOaNZPf+vxKTc5b/wBfj+pBc6hcSadLPp2hX821Ht0mZt7KEwCQm37xwO/XIHSqUdhdS26qtxF8pDt8hQKwGSFGAWGP4l6Feh60hnu5p0Mlw9zc7fL+aZZh0wGAJCgn6dcn1rYtdTErxfale3IXAIcS7+cYBQ9c9cenbNaawWhaUqS9239ev6WMixnjgINy17cXW/8Adwqww7kD5i+4k8c4+oOOlXdOlvbkpbyeX9oi+aQSu7MgKLj5lOFIB+b1zgGt/TzZzRyMjeZEz4811ZirdzlhuHXufb6259Nt7dpZN8TiTO5txzwcHI78cc1lKur2aMZ109JLVmEbO68t7hdQCpk7PMLx5yD/ABMc9eefyqo+rBb9LhoEWR0EXyq0vmYJZgg3AfxckAk+gxmrepIs93E32ny+qwxMpK7jyS/XBOT2579cVV01bO5hzcWhDq52pKGKpgdV39Acnoo6mqi01dhdSSuW11i3kk8qNj55VlGxWVIxgkbmABUcAcE9enWoLZTd3U4+13Ac4KMhP+qGMgknBJOepGcdu+pZSjy9qJLEwjOBt2lT/dz+fb0+lQyywtKGeNBPuwq7uHbIJ3L0JGOTgkdvaU0noiU7PRFMXD+fHCkMDISRtnJwp/vbU+QDt19cmlmnhnka3tYkaPA3eWTs/Fhn8m5pDG97eKGhWSOIbdwZMDB6ZHIHvn3I71NL9mjljX7NEjjJ3LK4B45+6fm/H8qd0i7+9f8Ar8zPtkt7SVUvPsbWwBKrKzNgdDzwFHXqBWlI9vakPbqCZOXjZVCnGeSDjjp0IHtSo8TMJJp9iH+EMWCjk4Pzbh+J/Diq+o6VZvbFpXkkVCX/AHK4DD6kdePxPXNNyUn7we7KSU2yLSmguYgmntBE4ZndCuCScY5HykcdeD70xLrzbGWS7MVvArEMwEgLAEYHOCAeBjHY880ltC7XKTW15EYGiChDDhgOGAIA69c4weDU8k0dlHi7u4zIw+R5X+YAkgDBPPbmnJq+gTUU/dej1/r5jluP7Oje3ngV9OmkWTcGx5QJHT6Nzio00u42jZbaeFxwGL5x789aguLcLGrb2l2tt2zr8pB/2uhPWpl+0gALFq4UcARSuEx/s89PSs/NMyaT12vudXFo1hFL5iQfNIgLhnYhuB1BOKmfSbEzIFt1jDMQ3lkpuHzAA7SMgDpnp160UVwucr7nn+0m92zzfxPBHpOtQQacvkQqigRqTtAxnoeOozW0iqt8s4H7yWMiTPIYbh1Xoe/bufWiivR3jFvsezLWnBvsiG+uZRqEYDDDEKRtHQ+YT/6CP5VZWJIomMahWZVLNjknKjk/jRRUvQh6PQ0bdmZraMsxUn1OehHXrWVezyh32uU2xtIuz5cMDgdPaiis47kU1qbGnj7RqIExLBQSBnH8ZHb2Fc34nu7hBI8c0iMXERKHb8vPHFFFaUFeZphEnVSZyuh311aasvkXEoDMoIdi4PQdDntXe662zUfMQKJAzRB9o3BcZxnrRRW1de+n/XQ6sZGKnGy6P9BupRLFLB5e5QZWiIDHBUkjGP69a5P+0Lu51fU0nuJHS1RGhXPCkuV6d+FA59KKKzpbXOKO69f1Op14C1066eBVV2tzKWxkltvUk1S0Syh1HQbGe8Ekks0jiRvNYbh6HB6cnjpRRUp2hf0/UzbajEzPFUaaRf2Z05RBuDREDkFUjcqMHjjA59q0tMu7me10uGSeXy5QjyBGKlyY2JyRgnpRRWz1pJs23hqQ64fK0dbpMeefMJJGQeSOh46cVb0KeS6gHntuEccgTAAxjb6UUVL+Al/Z+Zb0eNW0axkIIkeFXLA4JJxk/qaZr91NbyO0L7S0zqTgHjymPf3AoorJa1H8xR1eouoSuLzTUDYVyUYDuoRyB+grTicuAHwVb5SpAxgcjjp1oopyXuA9it4jQWejWl5bM6XEq73O8kMSM5Kk4/Tiqt5CieGbK4XcJr6WFbhtx+cDdgdeB9MZ70UUQ+GL8y6etKDf8z/Ux9MvJr29uPPMe7y2uN6RrG5cDOSygEjjkZwe4NdFqdvHbWGitbho3lYSO6sQxJiyfm64yBx04ooqqqtNJf1oGIXLiFFbW/Qr+HJZJtOtpJJHLCRlGGIGBnHA4qxppMd9Mqs2Cqk5YnJGMdaKKzn8ckZy3kUvE6ATWhXKmQFWKkg4weBjp0HT0FReGLG2vcy3cKTSMzEl+e6j+Rooq037IuH8KTN/w9oemz20ZktVw6gsqsVUnb1wDjPPWs+aZ7HVLuC1IjSN0RTtBYAgE/Mee570UVlTblUalqRRbnWlGWqN1LeL7TJF5alQrDJGW565bqfzqpeD5ypyVxnBOc/eFFFYx3RjDcxdGxc3eqyTJGz28jiNggBACqe3XqetV/Dl1Ld6XJJcMHdrh1J2gcLIygceyqPwoorpktPu/I6ZdSrdzS/2ta24kdYWdgUViAcRZ7e4qKC7mh1SzjjcCOUSSOpUEM3TOCPc0UVvZcvy/wAzVJNalPVtVvLS2umtpQjJcMqkIpwN2PSr/iCNYNJ+1RZE4XhixOOnY8dzRRWdX3XC3UJaOCXU5KDxBqjhka8cqqEjgcfpWVoninWPscl39qTzyzAt5EeDz6bcZ96KKqromRVWqRSvvGOuWb3jWt3HE0uNxS2iGen+zxXNX/j3xLuAbUi45+/BG2PTGV4PvRRWCbOWcmloZcvxK8XQSusOtSxrjB2xRjI/75pg+J3jEDA1yf8A79x//E0UUXZg5ye7P//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power light micrograph in chronic rejection reveals marked tubular dropout and interstitial fibrosis (in the area between the glomeruli). These findings represent the end-stage of a process induced by ischemia from the associated vascular lesions and repeated episodes of interstitial inflammation (acute cellular rejection).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_40_34442=[""].join("\n");
var outline_f33_40_34442=null;
var title_f33_40_34443="Treatment Graves";
var content_f33_40_34443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of Graves' hyperthyroidism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Therapy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thionamides",
"       </td>",
"       <td>",
"        <p>",
"         Chance of permanent remission",
"        </p>",
"        <p>",
"         Some patients avoid permanent hypothyroidism",
"        </p>",
"        <p>",
"         Lower cost",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Minor side effects: rash, hives, arthralgias, transient granulocytopenia, gastrointestinal symptoms",
"        </p>",
"        <p>",
"         Major side effects: agranulocytosis, vasculitis (lupus-like syndrome), hepatitis",
"        </p>",
"        <p>",
"         Risk of fetal goiter and hypothyroidism if pregnant",
"        </p>",
"        <p>",
"         Requires more frequent monitoring",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radioiodine",
"       </td>",
"       <td>",
"        Permanent resolution of hyperthyroidism",
"       </td>",
"       <td>",
"        <p>",
"         Permanent hypothyroidism",
"        </p>",
"        <p>",
"         Patient must take radiation precautions for several days after treatment, avoiding contact with young children and pregnant women",
"        </p>",
"        <p>",
"         Rare radiation thyroiditis",
"        </p>",
"        <p>",
"         Patient concerns about long-term oncogenic effects of radiation",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Surgery",
"       </td>",
"       <td>",
"        Rapid, permanent cure of hyperthyroidism",
"       </td>",
"       <td>",
"        <p>",
"         Permanent hypothyroidism",
"        </p>",
"        <p>",
"         Risk of hypoparathyroidism, recurrent laryngeal nerve damage, and general anesthesia",
"        </p>",
"        <p>",
"         High cost",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Summary of the advantages and disadvantages of the three major therapeutic modalities used in the treatment of Graves' hyperthyroidism.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_40_34443=[""].join("\n");
var outline_f33_40_34443=null;
var title_f33_40_34444="Electrodiagnostic criteria CIDP";
var content_f33_40_34444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F71475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F71475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Electrodiagnostic criteria for CIDP",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        These criteria are applied by testing the median, ulnar (stimulated below the elbow), peroneal (stimulated below the fibular head), and tibial nerves on one side of the body. During testing, limb temperature should be no less than 33&deg;C at the palm and no less than 30&deg;C at the external malleolus.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Definite CIDP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At least one of the following demyelinating parameters are necessary:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;50 percent prolongation of motor distal latency above the ULN in two nerves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;30 percent reduction of motor conduction velocity below the LLN in two nerves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;20 percent prolongation of F-wave latency above the ULN in two nerves, or &gt;50 percent if the amplitude of the distal negative peak CMAP is &lt;80 percent of the LLN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Absence of F-waves in two nerves, if these nerves have amplitudes of distal negative peak CMAPs &ge;20 percent of the LLN, plus at least one other demyelinating parameter (meeting any of the definite criteria) in at least one other nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Partial motor conduction block, defined by a &ge;50 percent amplitude reduction of the proximal negative peak CMAP relative to distal, if distal negative peak CMAP is &ge;20 percent of the LLN, in two nerves, or in one nerve plus at least one other demyelinating parameter (meeting any of the definite criteria) in at least one other nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abnormal temporal dispersion, defined by a &gt;30 percent duration increase between the proximal and distal negative peak CMAP in at least two nerves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Distal CMAP duration (interval between onset of the first negative peak and return to baseline of the last negative peak) increase in at least one nerve (median &ge;6.6 ms, ulnar &ge;6.7 ms, peroneal &ge;7.6 ms, tibial &ge;8.8 ms) plus at least one other demyelinating parameter (meeting any of the definite criteria) in at least one other nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Probable CIDP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;30 percent amplitude reduction of the proximal negative peak CMAP relative to the distal, excluding the posterior tibial nerve, if the distal negative peak CMAP is &ge;20 percent of LLN, in two nerves, or in one nerve plus at least one other demyelinating parameter (meeting any of the definite criteria) in at least one other nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Possible CIDP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        As in \"Definite CIDP\" but in only one nerve",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CMAP: compound muscle action potential; ULN: upper limit of normal; LLN: lower limit of normal.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society--First Revision. J Peripher Nerv Syst 2010; 15:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_40_34444=[""].join("\n");
var outline_f33_40_34444=null;
var title_f33_40_34445="PROSTQA probabilities of erection after brachytherapy";
var content_f33_40_34445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F82368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F82368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    PROSTQA model-predicted probabilities of men having functional erections suitable for intercourse two years after brachytherapy for prostate cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Age, y",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Race/ethnicity*",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        BMI",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Predicted functional erections after treatment, percent (95% CI) (by pretreatment sexual HRQOL score)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        67",
"       </td>",
"       <td class=\"subtitle2\">",
"        83",
"       </td>",
"       <td class=\"subtitle2\">",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        60",
"       </td>",
"       <td rowspan=\"3\">",
"        African American",
"       </td>",
"       <td>",
"        &lt;25",
"       </td>",
"       <td>",
"        78 (48-94)",
"       </td>",
"       <td>",
"        92 (73-98)",
"       </td>",
"       <td>",
"        98 (89-99)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25-&lt;35",
"       </td>",
"       <td>",
"        61 (35-83)",
"       </td>",
"       <td>",
"        83 (62-94)",
"       </td>",
"       <td>",
"        94 (83-98)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;35",
"       </td>",
"       <td>",
"        28 (7-69)",
"       </td>",
"       <td>",
"        56 (18-88)",
"       </td>",
"       <td>",
"        81 (41-96)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        White/other",
"       </td>",
"       <td>",
"        &lt;25",
"       </td>",
"       <td>",
"        54 (33-74)",
"       </td>",
"       <td>",
"        79 (61-90)",
"       </td>",
"       <td>",
"        93 (83-97)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25-&lt;35",
"       </td>",
"       <td>",
"        34 (22-48)",
"       </td>",
"       <td>",
"        62 (50-73)",
"       </td>",
"       <td>",
"        85 (75-91)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;35",
"       </td>",
"       <td>",
"        11 (3-37)",
"       </td>",
"       <td>",
"        29 (9-63)",
"       </td>",
"       <td>",
"        58 (24-86)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        65",
"       </td>",
"       <td rowspan=\"3\">",
"        African American",
"       </td>",
"       <td>",
"        &lt;25",
"       </td>",
"       <td>",
"        73 (41-91)",
"       </td>",
"       <td>",
"        89 (67-97)",
"       </td>",
"       <td>",
"        97 (86-99)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25-&lt;35",
"       </td>",
"       <td>",
"        54 (28-77)",
"       </td>",
"       <td>",
"        79 (54-92)",
"       </td>",
"       <td>",
"        93 (77-98)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;35",
"       </td>",
"       <td>",
"        22 (5-62)",
"       </td>",
"       <td>",
"        48 (14-84)",
"       </td>",
"       <td>",
"        76 (33-95)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        White/other",
"       </td>",
"       <td>",
"        &lt;25",
"       </td>",
"       <td>",
"        46 (28-66)",
"       </td>",
"       <td>",
"        73 (55-86)",
"       </td>",
"       <td>",
"        90 (79-96)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25-&lt;35",
"       </td>",
"       <td>",
"        27 (18-39)",
"       </td>",
"       <td>",
"        54 (44-65)",
"       </td>",
"       <td>",
"        80 (69-88)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;35",
"       </td>",
"       <td>",
"        9 (2-30)",
"       </td>",
"       <td>",
"        23 (6-56)",
"       </td>",
"       <td>",
"        50 (18-82)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"6\">",
"        70",
"       </td>",
"       <td rowspan=\"3\">",
"        African American",
"       </td>",
"       <td>",
"        &lt;25",
"       </td>",
"       <td>",
"        66 (34-88)",
"       </td>",
"       <td>",
"        86 (60-96)",
"       </td>",
"       <td>",
"        95 (81-99)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25-&lt;35",
"       </td>",
"       <td>",
"        46 (21-73)",
"       </td>",
"       <td>",
"        73 (45-90)",
"       </td>",
"       <td>",
"        90 (70-97)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;35",
"       </td>",
"       <td>",
"        17 (3-56)",
"       </td>",
"       <td>",
"        40 (10-80)",
"       </td>",
"       <td>",
"        69 (25-94)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        White/other",
"       </td>",
"       <td>",
"        &lt;25",
"       </td>",
"       <td>",
"        39 (22-58)",
"       </td>",
"       <td>",
"        67 (47-82)",
"       </td>",
"       <td>",
"        87 (72-95)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25-&lt;35",
"       </td>",
"       <td>",
"        22 (13-33)",
"       </td>",
"       <td>",
"        47 (34-60)",
"       </td>",
"       <td>",
"        75 (60-86)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;35",
"       </td>",
"       <td>",
"        6 (1-25)",
"       </td>",
"       <td>",
"        18 (4-50)",
"       </td>",
"       <td>",
"        42 (13-78)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PROSTQA: Prostate Cancer Outcomes and Satisfaction With Treatment Quality Assessment; BMI: body mass index; HRQOL: health-related quality of life.",
"     <br>",
"      * White race/ethnicity included 3 percent of patients of other (non-African American) or unknown races/ethnicities.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Calculated as weight in kilograms divided by height in meters squared.",
"       <br>",
"        &Delta; Specific values of pretreatment sexual functioning (Expanded Prostate Cancer Index Composite scores of 67, 83, and 100; range of 0-100, with a higher score representing better function) are tabulated to represent cohort distribution (25th, 50th, and 75th percentiles of scores among prostatectomy-treated patients) as well as to reflect a clinically relevant set of possible pretreatment sexual functioning. These values correspond to the 45th, 60th, and 85th percentiles among patients treated with brachytherapy. Across all treatment groups, these percentiles correspond to 358 patients (36 percent) with pretreatment sexual HRQOL scores of 67 or less, 441 (45 percent) with scores of 68-99, and 186 (19 percent) with scores of 100.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306:1205. Copyright &copy; 2011 American Medical Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_40_34445=[""].join("\n");
var outline_f33_40_34445=null;
var title_f33_40_34446="Vacuolated uroepithelial cells";
var content_f33_40_34446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54906&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vacuolated uroepithelial cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine showing vacuolated urinary epithelial cells (oval fat bodies) in a Fabry patient (Papanicolaou stain, original magnification X160).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine 2002; 81:122. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_40_34446=[""].join("\n");
var outline_f33_40_34446=null;
var title_f33_40_34447="Common bile duct stone on MRCP";
var content_f33_40_34447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Common bile duct stone on MRCP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 299px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal thick slab MRCP demonstrates distal common bile duct stone (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Leyendecker, JR, Brown, JJ. Practical Guide to Abdominal and Pelvic MRI. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_40_34447=[""].join("\n");
var outline_f33_40_34447=null;
